-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 HEHe7MgW+IQa2bNbPK5O3mACF3dI6cWwWicfaBFhpRu6mlcvTmsIeyekH7yKeWVW
 KLXr+SsCHZ5yc0Ko6ID/1g==

<SEC-DOCUMENT>0000950136-04-000214.txt : 20040129
<SEC-HEADER>0000950136-04-000214.hdr.sgml : 20040129
<ACCEPTANCE-DATETIME>20040129173013
ACCESSION NUMBER:		0000950136-04-000214
CONFORMED SUBMISSION TYPE:	S-2/A
PUBLIC DOCUMENT COUNT:		18
FILED AS OF DATE:		20040129

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MILESTONE SCIENTIFIC INC/NJ
		CENTRAL INDEX KEY:			0000855683
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		IRS NUMBER:				133545623
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-2/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-110376
		FILM NUMBER:		04553537

	BUSINESS ADDRESS:	
		STREET 1:		220 S ORANGE AVE
		STREET 2:		LIVINGSTON CORPORATE PARK
		CITY:			LIVINGSTON
		STATE:			NJ
		ZIP:			07039
		BUSINESS PHONE:		2013793171

	MAIL ADDRESS:	
		STREET 1:		44 KEAN ROAD
		STREET 2:		220 SOUTH ORANGE AVE
		CITY:			LIVINGSTON
		STATE:			NJ
		ZIP:			07039

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	U S OPPORTUNITY SEARCH INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-2/A
<SEQUENCE>1
<FILENAME>file001.txt
<DESCRIPTION>AMENDMENT NO. 2 TO FORM S-2
<TEXT>
<PAGE>


   AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JANUARY 29, 2004


                                                     REGISTRATION NO. 333-110376
================================================================================
                UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
                               -----------------

                                 AMENDMENT NO. 2

                                       TO
                                    FORM S-2
                             REGISTRATION STATEMENT
                                      UNDER
                           THE SECURITIES ACT OF 1933
                               -----------------
                            MILESTONE SCIENTIFIC INC.
             (Exact name of Registrant as specified in its charter)

<TABLE>
<S>                                                       <C>
        DELAWARE                                               13-3545623
(State or Other Jurisdiction of                             (I.R.S. Employer
 Incorporation or Organization)                           Identification No.)
                             220 SOUTH ORANGE AVENUE
                            LIVINGSTON CORPORATE PARK
                              LIVINGSTON, NJ 07039
                                 (973) 535-2717
               (Address, including zip code, and telephone number,
             including area code, of Registrant's executive offices)
</TABLE>

                                -----------------
                                  LEONARD OSSER
                             CHIEF EXECUTIVE OFFICER
                            MILESTONE SCIENTIFIC INC.
                             220 SOUTH ORANGE AVENUE
                            LIVINGSTON CORPORATE PARK
                              LIVINGSTON, NJ 07039
                                 (973) 535-2717
            (Name, address, including zip code, and telephone number,
                   including area code, of agent for service)
                                -----------------
                                   Copies to:

<TABLE>
<S>                                         <C>
      STEPHEN A. ZELNICK, ESQ.                MARK A. VON BERGEN, ESQ.
 MORSE, ZELNICK, ROSE & LANDER, LLP              DAVID C. WANG, ESQ.
        405 PARK AVENUE                         HOLLAND & KNIGHT LLP
       NEW YORK, NY 10022                     2300 U.S. BANCORP TOWER
         (212) 838-8040                        111 S.W. FIFTH AVENUE
    (212) 838-9190 FACSIMILE                    PORTLAND, OR 97204
                                                  (503) 243-2300
                                             (503) 241-8014 FACSIMILE
</TABLE>

                                -----------------
     APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC: AS SOON
AS PRACTICABLE AFTER THIS REGISTRATION STATEMENT BECOMES EFFECTIVE.

     If any of the securities being registered on this Form are to be offered
on a delayed or continuous basis pursuant to Rule 415 under the Securities Act
of 1933, as amended (the "Securities Act"), check the following box. [X]

     If the registrant elects to deliver its annual report to security holders,
or a complete and legible facsimile thereof, pursuant to item 11(a)(1) of this
form, check the following box. [ ]

     If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, check the following box and
list the Securities Act registration statement number of the earlier effective
registration statement for the same offering. [ ]

     If this Form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. [ ]

     If this Form is a post-effective amendment filed pursuant to Rule 462(d)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. [ ]

     If delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box. [ ]
                               -----------------
THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES
AS MAY BE NECESSARY TO RELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE
A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT
SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF THE
SECURITIES ACT OF 1933 OR UNTIL THIS REGISTRATION STATEMENT SHALL BECOME
<PAGE>

EFFECTIVE ON SUCH DATE AS THE SECURITIES AND EXCHANGE COMMISSION, ACTING
PURSUANT TO SAID SECTION 8(a), MAY DETERMINE.
================================================================================


<PAGE>


[sidebar]
The information in this prospectus is not complete and may be changed. We may
not sell these securities until the registration statement filed with the
Securities and Exchange Commission is effective. This prospectus is not an
offer to sell these securities and is not soliciting an offer to buy these
securities in any jurisdiction where the offer or sale is not permitted.
[end sidebar]

PROSPECTUS (SUBJECT TO COMPLETION)
DATED JANUARY 29, 2004


                                 1,200,000 UNITS

                      [MILESTONE SCIENTIFIC LOGO OMITTED]


           EACH UNIT CONSISTING OF TWO SHARES OF COMMON STOCK AND ONE
            REDEEMABLE WARRANT TO PURCHASE ONE SHARE OF COMMON STOCK

     This is a public offering on a firm commitment basis of [1,200,000] units,
each unit consisting of two shares of common stock and one warrant. Each
warrant entitles its holder to purchase one share of common stock at an
exercise price of $   [150% of the closing market price of our common stock on
the pricing date of this offering]. The warrants are exercisable at any time
after they become separately tradable until their expiration date, five years
after the effective date of this prospectus. The exercise of the warrants will
be conditional upon the underlying shares being covered by an effective
registration statement at that time. We cannot assure that an effective
registration statement will be in effect at the time when the investors may
seek to exercise their warrants. Beginning six months from the effective date
of this offering, we may redeem some or all of the warrants at a price of $.25
per warrant, by giving not less than 30 days' notice to the holders of the
warrants, which we may do at any time after the closing price for our stock on
the principal exchange on which the stock trades, equals or exceeds $    [200%
of the closing price of our common stock on The American Stock Exchange on the
pricing date of this offering] for any five consecutive trading days. The
common stock and the warrants will trade only as a unit for 30 calendar days
following the date the units begin trading. After that date, the common stock
and the warrants will both trade separately and trading in the units will
cease.

     We expect to offer units at an aggregate offering price of $8,000,000,
excluding units that may be sold on exercise of the representative's
over-allotment option. The price of the units is expected to be two times the
last closing price of our common stock on The American Stock Exchange.

     Our common stock is currently traded on American Stock Exchange under the
symbol "MS." On [January 28], 2004, the last reported sale price of our common
stock on the American Stock Exchange was $[3.17] per share. We are applying to
the American Stock Exchange to also list the units and warrants under the
symbols "MSU" and "MSW," respectively.

     INVESTING IN THESE UNITS INVOLVES SIGNIFICANT RISKS. SEE "RISK FACTORS"
BEGINNING ON PAGE 9 TO READ ABOUT RISKS YOU SHOULD CONSIDER BEFORE BUYING THESE
UNITS.


     NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY OTHER REGULATORY
BODY HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE
ADEQUACY OR ACCURACY OF THE DISCLOSURES IN THIS PROSPECTUS. ANY REPRESENTATION
TO THE CONTRARY IS A CRIMINAL OFFENSE.

<TABLE>
<CAPTION>
================================================================================
                                                PER UNIT         TOTAL
- --------------------------------------------------------------------------------
<S>                                          <C>             <C>
Public offering price ....................    $               $
- --------------------------------------------------------------------------------
Underwriting discount ....................    $               $
- --------------------------------------------------------------------------------
Proceeds to us, before expenses ..........    $               $
================================================================================
</TABLE>

*    In addition we will issue to the representative of the underwriters, 5-year
     warrants to purchase 120,000 units, commencing one year after the effective
     date of the offering at price of [120% of the unit offering price].

     Paulson Investment Company, Inc. is the representative of the underwriters
of this offering. We have granted the representative a 45-day option to
purchase up to additional 180,000 units to cover over-allotments.



PAULSON INVESTMENT COMPANY, INC.
                                                            S.W. BACH & COMPANY


                  The date of this Prospectus is        , 2004

<PAGE>

                              [Inside Front Cover]



                      Computer controlled local anesthetic
                         delivery system with handpiece







               [Picture of CompuDent Unit with The Wand handpiece]











     We have rights to the following trademarks: CompuDent (Registered
Trademark) , CompuMed (Registered Trademark) , The Wand (Registered
Trademark) , The WandPlus (Registered Trademark) , CompuFlo (Trade Mark) ,
SafetyWand (Trade Mark) , and CoolBlue Wand (Trade Mark) . We have also used
trademarks, tradenames and service marks owned by others in this prospectus.


     All references in this prospectus to Milestone, "we," "us," or "our" refer
to Milestone Scientific Inc., its wholly owned subsidiary, Sagacity I, Inc. and
its 88.65% owned subsidiary, Spintech, Inc. ("Spintech"), unless the context
otherwise indicates.


     Our web address is www.milesci.com. Information contained on our website
is not part of this prospectus.
<PAGE>

                               PROSPECTUS SUMMARY


     This summary provides a brief overview of the key aspects of the offering.
However, it is a summary and may not contain all of the information that is
important to you. For a more complete understanding of this offering, we
encourage you to read this entire prospectus, including our financial
statements and the notes to those statements. All information in this
prospectus has been retroactively adjusted to reflect a 1-for-3 reverse stock
split effective in January 2004.


                            MILESTONE SCIENTIFIC INC.

OVERVIEW

     Milestone is a leader in advanced subcutaneous injection technology for
dental and medical applications. Its principal product, CompuDent, a computer
controlled, precision metered, local anesthetic injection system, together with
its ergonomically designed, single patient use, disposable handpiece, The Wand,
enables a dentist to consistently administer safe, effective and less painful
injections. Since January 1998, Milestone has sold more than 24,000 CompuDent
units and over 13 million single use handpieces in the United States and in
over 25 other countries. CompuDent has been favorably evaluated in 18 peer
reviewed, published clinical studies and over 25 other evaluative articles. The
system provides these specific benefits:

     o    CompuDent minimizes the pain associated with palatal and other
          injections, resulting in a more comfortable injection experience for
          the patient;

     o    the pencil grip used with CompuDent's handpieces provides enhanced
          tactile sense and more accurate control;

     o    new injections made possible with CompuDent eliminate collateral
          numbness of the tongue, lips and facial muscles;

     o    bidirectional rotation of The Wand handpiece results in greater
          precision and more rapid onset of anesthesia by eliminating needle
          deflection in mandibular block injections;

     o    the single patient use, disposable handpiece minimizes the risk of
          cross contamination;

     o    the ergonomic design of The Wand makes an injection easier and less
          stressful to administer and lowers the risk of carpal tunnel syndrome
          to the dentist or hygienist; and

     o    CompuDent can increase productivity in many dental procedures by
          eliminating the need for preliminary pain blocking injections, and
          reducing the waiting time required to see if the injection has taken
          effect.

SAFETYWAND


     In September 2003, Milestone received FDA approval for a newly developed
and patented disposable handpiece, the SafetyWand, that incorporates safety
engineered sharps protection features to aid in the prevention of inadvertent
needlesticks. The SafetyWand was designed to conform with the regulations of
the Occupational Safety and Health Administration of the U.S. Department of
Labor ("OSHA") promulgated under the federal Needlestick Safety and Prevention
Act ("the Needlestick Safety Act"), while also meeting the clinical needs of
dentists. To date, these OSHA regulations have generally not been enforced
against dentists by OSHA and similar local and state authorities due to lack of
commercially available products that meet the special needs of dentistry.
Milestone believes that the commercial availability of the SafetyWand will
enable OSHA, and similar local and state authorities, to begin enforcement, or
stricter enforcement, of the Needlestick Safety Act against dentists. Since the
SafetyWand can only be used with the CompuDent system, enforcement by OSHA
could promote increased handpiece sales to current CompuDent users, while also
providing impetus for the purchase of these systems by new users. In October
2003, we launched the SafetyWand at the American Dental Association Annual
Meeting in California. The SafetyWand became commercially available in January
2004.



                                       3
<PAGE>

NEW MARKETING APPROACH

     In early 2003, Milestone began building a national sales force of highly
trained independent representatives to provide sales coverage in urban areas in
12 states. To increase its ability to retain this sales force and to enhance
its performance, Milestone:

     o    increased its base price of CompuDent to new customers to provide
          sufficient gross profit to recruit and adequately compensate its sales
          force;

     o    established a sales support staff to generate leads, set appointments,
          provide technical support and customer service and foster increased
          handpiece use; and

     o    began distributing a new product used in repairing and whitening
          teeth, the CoolBlue Wand, to assist its sales force in gaining access
          to dental offices for sales of CompuDent.


     Milestone's sales force currently includes one full time sales manager, 6
full time sales support staff and 12 independent sales representatives. With a
growing new sales force and the acquisition of rights to new products to
facilitate access to dental offices, Milestone intends to direct its marketing
efforts to capturing new customers, particularly from specialty practitioners,
including periodontists, pedodontists, endodontists and cosmetic/restorative
dentists.



OTHER PRODUCTS AND TECHNOLOGIES

     To broaden the use of its anesthetic injection technology, in 2001
Milestone launched CompuMed, a system similar to CompuDent, for the medical
market. To date, sales and marketing of CompuMed have been limited by financial
constraints. Milestone is currently seeking distribution partners in a variety
of discrete medical disciplines.


     Milestone has also developed CompuFlo, a prototype product embodying an
advanced pressure sensing technology for subcutaneous injection of liquid
medications and local anesthetics. CompuFlo enables health care practitioners
to monitor and precisely control pressure, rate and volume during subcutaneous
injections. Due to cash constraints, to date Milestone has conducted only
limited research as to potential medical applications for this technology and
has not yet begun development of commercial devices embodying this technology.
Recently, a major medical center has commenced two clinical pilot studies using
the CompuFlo pressure sensing technology. The first study is to evaluate
identification of the epidural space during epidural anesthesia commonly used
for postoperative pain management and pain relief during childbirth. The second
study is designed to determine whether measuring and controlling injection
pressures of local anesthetics may aid in reducing the risk of peripheral nerve
injury while increasing patient safety. No assurances can be given that these
clinical studies will prove CompuFlo efficacious for these purposes.



CORPORATE INFORMATION

     Milestone was organized in August 1989 as a Delaware corporation under the
name U.S. Opportunity Search, Inc. In 1996 we changed our name to Milestone
Scientific Inc. Our executive office is located at 220 South Orange Avenue,
Livingston Corporate Park, Livingston, New Jersey 07039. Our telephone number
is (973) 535-2717.


                                       4
<PAGE>

                                 THE OFFERING

Securities offered............   1,200,000 units, each unit consisting of two
                                 shares of common stock and one redeemable
                                 warrant to purchase one share of common stock.
                                 The common stock and the warrants will not
                                 trade separately until the 31st calendar day
                                 following the date the units begin trading.
                                 After that date the common stock and the
                                 warrants will both trade separately and trading
                                 in the units will cease.


Shares of common stock to be
  outstanding after this
  offering.....................  9,166,271(1)

Warrants:

  Number to be outstanding after
  this offering................   1,200,000

  Exercise terms...............  The warrants are exercisable at any time
                                 after they become separately tradable, which
                                 will be the 31st calendar day following the
                                 date the units begin trading, until the
                                 expiration date. Each warrant entitles its
                                 holder to purchase one share of common stock at
                                 an exercise price equal to 150% of the closing
                                 market price of the common stock on the pricing
                                 date of this offering. The exercise of the
                                 warrants will be conditional upon the
                                 underlying shares being covered by an effective
                                 registration statement at that time. We cannot
                                 assure that an effective registration statement
                                 will be in effect at the time when investors
                                 may seek to exercise their warrants.

  Expiration date...........             , 2009

  Redemption..................   Beginning six months from the effective date
                                 of this offering, we may redeem some or all of
                                 the warrants, at a price of $0.25 per warrant,
                                 on 30 days notice to the holders. However, we
                                 may only redeem the warrants if the closing
                                 price for our stock, as reported on the
                                 principal exchange on which our stock trades,
                                 for any five consecutive trading days has
                                 equaled or exceeded 200% of the closing price
                                 of the common stock on the American Stock
                                 Exchange on the pricing date of this offering.
                                 For example, if we seek to exercise our right
                                 to redeem the warrants, the potential loss of
                                 appreciation, or difference between the warrant
                                 exercise price and the stock price on the date
                                 of exercise, to investors from their failure to
                                 exercise or sell a warrant during the 30 days
                                 notice period, would be as follows:


- ----------

(1)  Including an estimated 653,594 shares constituting part of the units to be
     issued, at the price of the units offered hereby, to satisfy $2,179,734 of
     indebtedness, accrued interest, accounts payable and accrued compensation
     on the date of this Prospectus or, for 29,985 units to be issued, at that
     price, ten days after the closing of this offering.




                                       5
<PAGE>



<TABLE>
<CAPTION>
   ASSUMED CLOSING                       ASSUMED MARKET                     POTENTIAL LOSS OF
 PRICE OF OUR STOCK   ASSUMED WARRANT   PRICE AT TIME OF   POTENTIAL GAIN      APPRECIATION
   ON PRICING DATE     EXERCISE PRICE      REDEMPTION       FROM EXERCISE    FROM REDEMPTION
- -------------------- ----------------- ------------------ ---------------- -------------------
<S>                  <C>               <C>                <C>              <C>
$  3.20                    $ 4.80            $ 6.40            $ 1.60           $   1.35
                                             $ 7.40            $ 2.60           $   2.35
                                             $ 8.40            $ 3.60           $   3.35

$  3.40                    $ 5.20            $ 6.80            $ 1.70           $   1.45
                                             $ 7.80            $ 2.70           $   2.45
                                             $ 8.80            $ 3.70           $   3.35

$  3.60                    $ 5.40            $ 7.20            $ 1.80           $   1.55
                                             $ 8.20            $ 2.80           $   2.55
                                             $ 9.20            $ 3.80           $   3.55
</TABLE>



                                 The Company may not give a notice of
                                 redemption of the Warrants unless the
                                 underlying shares are covered by an effective
                                 registration statement. Additionally, an
                                 effective registration statement must be in
                                 place for at least 30 calendar days after
                                 mailing of the notice of redemption before the
                                 redemption may be effected. Consequently, if
                                 an effective registration statement covering
                                 the underlying shares is in place at the time
                                 that the Company mails its notice of
                                 redemption, but, during the notice period, the
                                 registration statement ceases to be in effect
                                 (or is suspended), then the notice period will
                                 automatically be extended for that number of
                                 calendar days equal to the number of calendar
                                 days of cessation (or suspension), unless
                                 waived in writing by the warrant holder.




AMEX symbols:
  Existing....................  Common Stock     MS
  Proposed....................  Units            MSU
                                Warrants         MSW

Risk factors..................  Please refer to "Risk Factors" for a
                                description of the risk factors you should
                                consider.


     Unless otherwise stated, the information contained in this prospectus
assumes no exercise of:


     o    the warrants;

     o    the over-allotment option to purchase up to 180,000 units;

     o    warrants to purchase 120,000 units granted to the representative in
          connection with this offering;

     o    outstanding compensatory options for 437,948 shares of common stock,
          exercisable at a weighted average price of $5.55 per share and
          outstanding warrants for 799,730 shares of common stock exercisable at
          a weighted average exercise price of $4.48 per share; or


     o    conversion rights relating to convertible notes in the aggregate
          principal amount of $100,000 convertible into 70,709 shares of common
          stock and shares of series A convertible preferred stock convertible
          into 4,381 shares of common stock.



                                       6
<PAGE>

                         SUMMARY FINANCIAL INFORMATION

<TABLE>
<CAPTION>

                                                YEARS ENDED DECEMBER 31,     NINE MONTHS ENDED SEPTEMBER 30,
                                               ---------------------------   -------------------------------
                                                   2002           2001            2003             2002
                                               ------------   ------------   -------------   ---------------
                                                                                       (UNAUDITED)
                                                    (IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
<S>                                            <C>            <C>            <C>             <C>
STATEMENT OF OPERATIONS DATA:
Revenues ...................................   $   4,074      $   4,094       $    3,101     $   3,216
Gross profit ...............................   $   2,093      $   2,120       $    1,541     $   1,717
Operating expenses .........................   $   3,763      $   5,321       $    2,683     $   2,777
Net loss ...................................   $  (2,440)     $  (3,991)      $   (1,787)    $  (1,604)
Net loss per share--basic and
 diluted(1) ................................   $    (.59)     $   (1.07)      $     (.42)    $    (.39)
Weighted average number of shares
 outstanding--basic and diluted(1) .........   4,156,558      3,714,197        4,217,185     4,084,342
</TABLE>

- ----------
(1)   The effect of options, warrants and convertible debt instruments has been
      excluded, as their effect is anti-dilutive.


     The table below sets forth a summary of our balance sheet data as of
December 31, 2002 and as of September 30, 2003 on an actual basis, pro forma
and pro forma as adjusted for this offering.

     Pro forma balance sheet data takes into account the following events
occurring after September 30, 2003:

     o    The issuance of additional 94,327 shares of common stock to the
          various noteholders mentioned above, as consideration for previously
          extending the maturity date on the notes, out of which 13,526 common
          shares were issued to Leonard Osser, our Chairman and Chief Executive
          Officer;

     o    The issuance of 102,195 shares of common stock to vendors in payment
          of outstanding trade payables in the amount of approximately $503,000;

     o    The issuance of 2,333 shares of common stock upon the exercise of
          options for an aggregate exercise price of $7,750;

     o    The payment of $50,000 of outstanding debt due to the Chairman & Chief
          Executive Officer.

     o    The issuance of 39,613 shares of common stock for a consideration, net
          of commissions and closing costs, of $217,485 under an equity put
          agreement;

     o    The issuance of 16,667 shares of common stock to Leonard Osser, our
          Chairman and Chief Executive Officer, upon the exercise of options for
          an aggregate exercise price of $50,000;

     o    The issuance of 25,365 preferred shares in payment of $25,365 of
          outstanding debt, including principal and interest to a non-affiliate
          noteholder;


     o    The expected issuance, on the date this offering becomes effective, of
          an estimated 239,241 units (assuming a unit price of $6.67), in
          payment of $1,595,734 of debt, including interest, to Leonard Osser,
          our Chairman and Chief Executive Officer and to a major stockholder;
          and

     o    The expected issuance, on the date this offering becomes effective, of
          an estimated 57,571 units (assuming a unit price of $6.67), in payment
          of $384,000 of accrued compensation to Leonard Osser, our Chairman and
          Chief Executive Officer.

     o    The expected issuance, ten days after the closing of this offering, of
          an estimated 29,985 units (assuming a unit price of $6.67) in payment
          of $200,000 of accrued liabilities for legal services.



                                       7
<PAGE>

     Pro forma as adjusted for this offering takes into account the pro forma
data as well as the receipt of $6,500,000 of estimated net proceeds from this
offering, the deduction of underwriting discounts and commissions and other
estimated offering expenses to be paid by us.

<TABLE>
<CAPTION>
                                               DECEMBER 31, 2002               SEPTEMBER 30, 2003
                                                 (IN THOUSANDS)            (UNAUDITED, IN THOUSANDS)
                                              -------------------   ----------------------------------------
                                                                                                 PRO FORMA,
                                                                       ACTUAL      PRO FORMA     AS ADJUSTED
                                                                    -----------   -----------   ------------
<S>                                           <C>                   <C>           <C>           <C>
BALANCE SHEET DATA:
Current assets ............................        $    893          $  1,275        $1,500        $8,000
Working capital (deficiency) ..............          (5,214)           (1,449)          640         7,140
Total assets ..............................           1,241             1,514         1,739         8,239
Total liabilities .........................           7,347             4,391         1,500         1,500
Stockholders' equity (deficiency) .........          (6,106)           (2,877)          239         6,739
</TABLE>



                                       8
<PAGE>

                                 RISK FACTORS

     This offering involves a high degree of risk. You should carefully
consider the risks described below and the other information in this
prospectus, including our financial statements and the notes to those
statements, before you purchase any units.


                         RISKS RELATED TO OUR BUSINESS

WE HAVE NO HISTORY OF PROFITABLE OPERATIONS. CONTINUING LOSSES COULD EXHAUST
OUR CAPITAL RESOURCES AND FORCE US TO DISCONTINUE OPERATIONS.

     Although our operations commenced in November 1995, until 1998 we had
limited revenues. For the years ended December 31, 1998, 1999, 2000, 2001 and
2002, our revenues were approximately $8.8 million, $2.9 million, $5.7 million,
$4.1 million and $4.1 million, respectively. In addition, we have had losses
for each year since the commencement of operations, including net losses of
approximately $2.5 million for 2002 and $1.8 million for the nine months ended
September 30, 2003. At September 30, 2003, we had an accumulated deficit of
approximately $43.6 million. Unless we can significantly increase sales of our
CompuDent units, handpieces or other injection devices, we expect to incur
losses for the foreseeable future.

WE HAVE A SIGNIFICANT WORKING CAPITAL DEFICIT. AS A RESULT, WE HAVE NOT BEEN
ABLE TO SUFFICIENTLY EXPAND OUR SALES AND MARKETING FORCE AND INCREASE OUR
REVENUES.

     Our working capital deficit at September 30, 2003, after adjustment to
reflect the subsequent repayment of $503,000 of trade payables through the
issuance of common stock in October 2003, was approximately $946,000. This has
impaired our ability to expand marketing and sales promotion and develop an
adequate sales force, which in turn, had a negative impact on revenue growth.

WE HAVE LIMITED FINANCIAL RESOURCES AND WE MAY NEED ADDITIONAL CAPITAL IN THE
FUTURE.

     Our capital requirements have been and may continue to be significant. In
the future, we may need to borrow funds or sell equity securities, or else
curtail or reduce our activities. We have no current arrangements for future
additional financing, except as disclosed herein. We cannot assure you that any
sources of additional financing will be available on acceptable terms, or at
all. To the extent that any future financing involves the sale of our equity
securities, the ownership interest of our stockholders could be substantially
diluted.

WE CANNOT BECOME SUCCESSFUL UNLESS WE GAIN GREATER MARKET ACCEPTANCE FOR OUR
PRODUCTS AND TECHNOLOGY.

     As with any new technology, there is substantial risk that the marketplace
will not accept the potential benefits of this technology or be unwilling to
pay for any cost differential with the existing technologies. Market acceptance
of CompuDent, the SafetyWand, CompuMed and CompuFlo depends, in large part,
upon our ability to educate potential customers of their distinctive
characteristics and benefits and will require substantial marketing efforts and
expense. More than 24,000 units of the CompuDent or its predecessor have been
sold worldwide since 1998. Sales of disposable handpieces in 2002 reflect a
moderate increase in usage of our dental and medical systems. We cannot assure
you that our current or proposed products will be accepted by practitioners or
that any of the current or proposed products will be able to compete
effectively against current and alternative products.

OUR LIMITED DISTRIBUTION CHANNELS MUST BE EXPANDED FOR US TO BECOME SUCCESSFUL.

     Our future revenues depend on our ability to market and distribute our
anesthetic injection technology successfully. In the United States, we rely on
a limited number of independent representatives and in-house sales people.
Abroad, we lack distributors in many markets. To be successful we will need to
retain and hire additional sales personnel, provide for their proper training
and ensure adequate customer support. We cannot assure you that we will be able
to hire and retain an adequate sales force or engage suitable distributors, or
that our sales force or distributors will be able to successfully market and
sell our products.


                                       9
<PAGE>

WE DEPEND ON TWO PRINCIPAL MANUFACTURERS. IF WE CANNOT MAINTAIN OUR EXISTING
RELATIONSHIPS OR DEVELOP NEW ONES, WE MAY HAVE TO CEASE OUR OPERATIONS.

     We have informal arrangements with the manufacturer of our CompuDent and
CompuMed units and the principal manufacturer of our handpieces for those units
pursuant to which they manufacture these products under specific purchase
orders but without any long-term contract or minimum purchase commitment. We
have been supplied by these manufacturers since the commencement of production
in 1998. However, termination of the manufacturing relationship with any of
these manufacturers could significantly and adversely affect our ability to
produce and sell our products. Though we have established an alternate source
of supply for our handpieces in China and other alternate sources of supply
exist, we would need to recover our existing tools or have new tools produced
to establish relationships with new suppliers. Establishing new manufacturing
relationships could involve significant expense and delay. Any curtailment or
interruptions of the supply, whether or not as a result or termination of the
relationship, would adversely affect us.

WE MAY BE SUBJECT TO PRODUCT LIABILITY CLAIMS THAT ARE NOT FULLY COVERED BY OUR
INSURANCE AND THAT COULD PUT US UNDER A TREMENDOUS FINANCIAL STRAIN.

     We could be subject to claims for personal injury from the alleged
malfunction or misuse of our dental and medical products. While we carry
liability insurance that we believe is adequate, we cannot assure you that the
insurance coverage will be sufficient to pay such claims should they be
successful. A partially or completely uninsured claim, if successful and of
significant magnitude, could have a material adverse effect on us.

WE RELY ON THE CONTINUING SERVICES OF OUR CHAIRMAN AND CHIEF EXECUTIVE OFFICER,
PRESIDENT AND DIRECTOR OF CLINICAL AFFAIRS.

     We depend on the personal efforts and abilities of our Chairman and Chief
Executive Officer, our President who was promoted to this position from that of
Senior Vice President in September 2003, and our Director of Clinical Affairs.
We maintain a key man life insurance policy in the amount of $1,000,000 on the
life of our Chairman and Chief Executive Officer. However, the loss of his
services or the services of each of our President or Director of Clinical
Affairs, on whom we maintain no insurance, could have a materially adverse
effect on our business.


                        RISKS RELATED TO THIS OFFERING

IF WE ARE UNABLE TO SATISFY THE AMERICAN STOCK EXCHANGE MAINTENANCE
REQUIREMENTS, OUR COMMON STOCK MAY BE DELISTED FROM THE AMERICAN STOCK EXCHANGE
AND, AS A RESULT, OUR LIQUIDITY AND THE VALUE OF OUR COMMON STOCK MAY BE
IMPAIRED.

     Shares of our common stock are currently listed on the American Stock
Exchange. Continued listing on the American Stock Exchange requires that we
maintain at least $6,000,000 in stockholders' equity since we have sustained
losses in our five most recent fiscal years. At December 31, 2002, Milestone
had a total stockholders' deficit of approximately $6.1 million. On May 2,
2002, we received a letter from the American Stock Exchange advising us that we
had fallen below the stockholders' equity criterion and requesting that we
submit a recovery plan detailing any actions taken, or planned to be taken
within the next 18 months, to bring us into compliance. On June 10, 2002, we
submitted a detailed recovery plan to the American Stock Exchange, which, as
supplemented on August 14, 2002, showed how we expect to achieve stockholders'
equity of $6,000,000 by December 31, 2003. On August 23, 2002, the American
Stock Exchange advised us that they had determined that the plan makes a
reasonable demonstration of Milestone's ability to regain compliance with the
continued listing standards by the conclusion of the plan period at the end of
2003. Since that date the continued listing of our securities on the American
Stock Exchange has been subject to periodic review by the Exchange and the
Exchange has accepted supplemental submissions by Milestone showing continued
progress towards regaining compliance. However, on December 18, 2003 the
Exchange informally advised Milestone that it had not demonstrated sufficient
progress towards regaining compliance by the end of the plan period and further
advised that it would shortly begin delisting proceedings. If such proceedings
are initiated by the Exchange, Milestone intends to appeal such action and
request


                                       10
<PAGE>


an oral hearing. At such hearing, Milestone would present the fact that at the
conclusion of the offering covered by this prospectus, Milestone would again be
in compliance with the Exchange's stockholder equity criterion with expected
stockholders' equity exceeding the minimum amount required by the American
Stock Exchange by $739.000. While we believe that completion of this offering
is necessary to maintain our listing on the American Stock Exchange, no
assurance can be given that listing will be continued until that time. If our
securities are delisted from the American Stock Exchange, trading, if any, in
the common stock and warrants would be conducted in the over the counter market
in the so-called "pink sheets" or on the NASD's "OTC Bulletin Board."
Consequently, the liquidity of our securities could be impaired, not only in
the number of securities that could be bought and sold, but also through delays
in the timing of transactions, reduction in security analysts and new media
coverage of Milestone, and lower prices for our securities than might otherwise
be obtained.


IF OUR SHARES OF COMMON STOCK ARE REMOVED OR DELISTED FROM THE AMERICAN STOCK
EXCHANGE, THE ABILITY OF STOCKHOLDERS TO SELL OUR COMMON STOCK AND WARRANTS IN
THE SECONDARY MARKET COULD BE RESTRICTED.

     The Securities and Exchange Commission has adopted regulations which
generally define "penny stock" to be an equity security that has a market
price, as defined, of less than $5.00 per share or an exercise price of less
than $5.00 per share, subject to certain exceptions, including an exception of
an equity security that is quoted on the American Stock Exchange. If our shares
of common stock are removed or delisted from the American Stock Exchange, they
may become subject to rules that impose additional sales practice requirements
on broker-dealers who sell these securities. For transactions covered by these
rules, the broker-dealer must make a special suitability determination for the
purchaser of such securities and have received the purchaser's written consent
to the transactions prior to the purchase. Additionally, for any transaction
involving a penny stock, unless exempt, the rules require the delivery, prior
to the transaction, of a disclosure schedule prepared by the Securities and
Exchange Commission relating to the penny stock market. The broker-dealer also
must disclose the commissions payable to both the broker-dealer and the
registered underwriter, and current quotations for the securities, and, if the
broker-dealer is the sole market maker, the broker-dealer must disclose this
fact and the broker-dealer's presumed control over the market. Finally, among
other requirements, monthly statements must be sent disclosing recent price
information for the penny stock held in the account and information on the
limited market in penny stocks. As such, the "penny stock" rules, if our
securities are delisted from the American Stock Exchange, may restrict the
ability to sell our common stock and warrants in the secondary market.

THE MARKET PRICE OF OUR COMMON STOCK HAS BEEN VOLATILE AND MAY CONTINUE TO
FLUCTUATE SIGNIFICANTLY BECAUSE OF VARIOUS FACTORS, SOME OF WHICH ARE BEYOND
OUR CONTROL.

     Our stock price has been extremely volatile, fluctuating over the last
three years between closing prices of $.42 and $7.77. These fluctuations have
been unrelated to or disproportionately affected by our operating performance.
The market price of our common shares could continue to fluctuate significantly
after this offering in response to a variety of factors, some of which may be
beyond our control.

THE EXISTENCE OF OUTSTANDING OPTIONS, WARRANTS AND CONVERTIBLE SECURITIES MAY
PRECLUDE US FROM OBTAINING ADDITIONAL EQUITY FINANCING.


     We currently have outstanding options, warrants,convertible debentures and
series A convertible preferred stock to purchase 1,233,392 shares of our common
stock at prices ranging from $.87 to $18.00 per share with a weighted average
exercise or conversion price of $4.55. Holders of these warrants and options
are given the opportunity to profit from a rise in the market price of our
common stock and are likely to exercise their securities at a time when we
would be able to obtain additional equity capital on more favorable terms.
Thus, the terms upon which we will be able to obtain additional equity capital
may be adversely affected, since the holders of outstanding options and
warrants can be expected to exercise them at a time when we would, in all
likelihood, be able to obtain any needed capital on terms more favorable to us
than the exercise terms provided by such outstanding securities. We have
granted registration rights with respect to shares of our common stock



                                       11
<PAGE>

covered by the warrants. The market price of our common shares has been
volatile and may continue to fluctuate significantly because of various
factors, some of which are beyond our control.

OUR STOCKHOLDERS MAY EXPERIENCE SIGNIFICANT DILUTION AND THE PRICE OF OUR
COMMON STOCK MAY BE ADVERSELY AFFECTED BY THE ISSUANCE OF SHARES OF OUR COMMON
STOCK UNDER AN EQUITY PUT AGREEMENT.

     After taking into account 39,613 shares sold in October and through
December 15, 2003, under an equity put agreement expiring on May 10, 2004, we
may sell up to an additional 660,387 shares of our common stock under that
agreement. The price of our common stock may decrease as a result of the actual
or potential sale of these shares into the market. We may sell shares of our
common stock under the equity put agreement at a price that is below the market
price of our stock at the time of the sale. These sales will dilute the
interests of our existing stockholders. In that event, not only would you lose
a portion of your investment, but we would probably find it more difficult to
obtain additional financing. The more shares that are issued under the equity
put, the more our shares will be diluted and the more our stock price may
decrease. This may encourage short sales, which could place further downward
pressure on the price of our common stock.

WE ARE CONTROLLED BY A LIMITED NUMBER OF SHAREHOLDERS.

     Immediately after this offering (including an estimated 593,624 shares
forming part of units to be issued to them in satisfaction of debt and accrued
compensation), our principal shareholders, Leonard Osser and K. Tucker
Andersen, will own 32.9% of the issued and outstanding shares of our common
stock (31.7% if the over-allotment option is exercised in full). As a result,
they will have the ability to exercise substantial control over our affairs and
corporate actions requiring shareholder approval, including electing directors,
selling all or substantially all of our assets, merging with another entity or
amending our certificate of incorporation. This de facto control could delay,
deter or prevent a change in control and could adversely affect the price that
investors might be willing to pay in the future for our securities.

IF WE DO NOT MAINTAIN AN EFFECTIVE REGISTRATION STATEMENT COVERING THE WARRANTS
OR COMPLY WITH APPLICABLE STATE SECURITIES LAWS, YOU MAY NOT BE ABLE TO
EXERCISE THEM.

     In order for you to exercise the warrants, the shares of common stock
underlying them must be covered by an effective registration statement and, if
the issuance of shares is not exempt under state securities laws, must be
properly registered with state securities regulators. At present, we plan to
have a registration statement current when the warrants are exercised and, to
the extent that the underlying shares do not qualify for one or more exemptions
under state securities laws, we intend to register the shares with the relevant
authorities. However, we cannot provide absolute assurances that state
exemptions will be available, the state authorities will permit us to register
the underlying shares, or that an effective registration statement will be in
place at the relevant time(s). These factors may have an adverse effect on the
demand for the warrants and the prices that can be obtained from reselling
them.

THE WARRANTS MAY BE REDEEMED ON SHORT NOTICE. THIS MAY HAVE AN ADVERSE IMPACT
ON THEIR PRICE.

     Beginning six months from the effective date of the offering, we may
redeem the warrants for $0.25 per warrant on 30 days notice at any time after
the closing price for our stock, as reported on its principal trading market,
has, for any five consecutive trading days, equaled or exceeded 200% of the
closing price of the common stock on the effective date of this offering. If we
give notice of redemption, you will be forced to sell or exercise your warrants
or accept the redemption price. The notice of redemption could come at a time
when, under your personal circumstances, it is not advisable or possible for
you to exercise the warrants or a current prospectus or exemption does not
exist.

FUTURE SALES OR THE POTENTIAL FOR SALE OF A SUBSTANTIAL NUMBER OF SHARES OF OUR
COMMON STOCK COULD CAUSE THE TRADING PRICE OF OUR COMMON STOCK AND WARRANTS TO
DECLINE AND COULD IMPAIR OUR ABILITY TO RAISE CAPITAL THROUGH SUBSEQUENT EQUITY
OFFERINGS.

     Sales of a substantial number of shares of our common stock in the public
markets, or the perception that these sales may occur, could cause the market
price of our stock to decline and could


                                       12
<PAGE>


materially impair our ability to raise capital through the sale of additional
equity securities. Once this offering is completed, in addition to the
6,146,011 shares of common stock actually issued and the 6,112,678 outstanding,
there will be another 4,378,706 shares of common stock reserved for future
issuance as follows:


     o    up to 1,200,000 shares underlying the warrants;

     o    up to 540,000 shares underlying the over-allotment option, including
          the shares underlying the warrants included in that option;

     o    up to 360,000 shares underlying the representative's warrants,
          including the shares underlying the warrants included in the
          representative's warrants;

     o    up to 314,333 shares underlying stock options previously granted, or
          to be granted, under our Stock Option Plan;

     o    up to 1,028,896 shares underlying other stock options and warrants
          that were granted and remained outstanding as of October 31, 2003;

     o    up to 70,709 shares underlying 6% convertible notes in the aggregate
          principal amount of $100,000 and up to 4,381 shares of common stock
          underlying our series A convertible preferred stock;

     o    up to 660,387 shares reserved for issuance, at our option, under an
          equity put agreement; and

     o    up to 200,000 shares underlying other stock options approved to be
          granted on December 22, 2003.

     The common stock included in the units as well as the common stock
underlying the warrants will be freely tradable without restriction. Before
this offering, we had 6,112,678 shares of common stock outstanding, of which
2,762,934 are freely tradable. The remaining 3,349,744 shares are either held
by "affiliates", as defined by the rules and regulations promulgated under the
Securities Act of 1933, or are "restricted securities" as defined in Rule 144
promulgated under the Securities Act of 1933. Of this amount, 102,195
restricted shares not held by affiliates and 3,084,884 restricted or non-
restricted shares held by "affiliates," can only be sold in compliance with the
timing and volume limitations of Rule 144 promulgated under the Securities Act
of 1933. The other 162,665 restricted shares may be sold without limitation
under Rule 144(k). We have granted demand registration rights to holders of
155,614 shares of common stock including shares underlying warrants and
piggyback registration rights to holders of convertible notes covering an
aggregate of 70,709 shares of common stock. The holders of these shares can
require us to register the shares for resale. While we, our executive officers
and directors and stockholders holding 5% or more of our outstanding shares
have agreed not to sell any shares of stock for a period of 90 days after this
offering without the consent of the representative of the underwriters, the
representative may waive that restriction at its sole discretion.


THE DECREASE OF OUR OUTSTANDING SHARES AS A RESULT OF THE REVERSE STOCK SPLIT,
WITHOUT CHANGE TO OUR AUTHORIZED CAPITALIZATION, INCREASES THE ABILITY OF OUR
BOARD OF DIRECTORS TO ISSUE SHARES WITHOUT STOCKHOLDER APPROVAL. ISSUANCE OF
SHARES MAY DILUTE THE VALUE OF OUR OUTSTANDING SHARES OR HAVE A NEGATIVE IMPACT
ON THE TRADING PRICE OF THE COMMON STOCK.

     The 1-for-3 stock split effected in January 2004 reduced our outstanding
shares from 18,338,033 to 6,112,677 (9,166,271 shares after giving effect to
the consummation of this transaction and related issuances of units). Since the
reverse stock split was effected without change in our authorized shares, the
differential between outstanding shares and authorized shares increased, thus
providing the Board of Directors with increased ability to effect issuances of
stock without stockholder authorization. For example, shares may be issued in
capital raising transactions, mergers or acquisitions for compensatory reasons
where other governing rules or statutes do not separately require stockholder
approval. The issuance of these shares for less than their book value or for
less than value paid by purchasers in this offering could have a dilutive
effective on purchasers in this offering. Further the issuance of the shares
could also have a negative impact on the trading price of our then outstanding
common stock, including the stock issued in this offering.



                                       13
<PAGE>

MANAGEMENT HAS BROAD DISCRETION OVER THE USE OF PROCEEDS FROM THIS OFFERING. WE
MAY USE THE PROCEEDS OF THIS OFFERING IN WAYS THAT DO NOT IMPROVE OUR OPERATING
RESULTS OR THE MARKET VALUE OF OUR SECURITIES.

     While we have general expectations as to the allocation of the net
proceeds of this offering, that allocation may change in response to a variety
of unanticipated events, such as differences between our expected and actual
revenues from operations or availability of commercial financing opportunities,
unexpected expenses or expense overruns or unanticipated opportunities
requiring cash expenditures. We have significant flexibility as to the timing
and the use of the proceeds. You will rely on our judgment with only limited
information about our specific intentions regarding the use of proceeds. We may
spend most of the net proceeds of this offering in ways with which you may not
agree. If we fail to apply these funds effectively, our business, results of
operations and financial condition may be materially and adversely affected.


                          FORWARD-LOOKING STATEMENTS

     Some of the statements made in this prospectus discuss future events and
developments, including our future business strategy and our ability to
generate revenue, income and cash flow and possible stricter enforcement of the
Needlestick Safety Act. In some cases, you can identify forward-looking
statements by words or phrases such as "may," "will," "should," "expects,"
"plans," "anticipates," "believes," "estimates," "predicts," "potential,"
"continue," "our future success depends," "seek to continue," or the negative
of these words or phrases, or comparable words or phrases. These statements are
only predictions that are based, in part, on assumptions involving judgments
about future economic, competitive and market conditions, regulatory
enforcement and future business decisions, all of which are difficult or
impossible to predict accurately and many of which are beyond our control.
Actual events or results may differ materially. In evaluating these statements,
you should specifically consider various facts, including the risks outlined in
this "Risk Factors" section. Although we believe that the expectations
reflected in the forward-looking statements are reasonable, we cannot guarantee
future results, levels of activity, performance or achievements. You are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date on which they are made. We do not undertake to
update any of the forward-looking statements after the date of this prospectus
to conform these statements to actual results.


                              RECENT DEVELOPMENTS

     Since October 1, 2003, we have entered into the following financing
transactions:

     On October 2, 2003 we issued 1,646,419 shares of common stock in
satisfaction of 6% / 12% Secured and Senior Secured Notes and other secured
notes in the aggregate amount of approximately $5 million. We also committed to
issue 25,365 shares of 8% convertible preferred stock in satisfaction of
$25,365 of principal and accrued interest. The preferred stock will be
convertible into common stock at the average closing price of our common stock
in October 2003. Subsequently, we issued 94,327 additional shares of common
stock to these former noteholders as consideration for their previous consent
to extend the maturity date of these notes.

     On October 9, 2003 we reached an agreement to satisfy $1,192,873 of debt
and accrued interest due to a major investor, K. Tucker Andersen, and $402,861
of debt and accrued interest and $384,000 of deferred compensation due to our
Chief Executive Officer and Chairman, Leonard Osser, through the issuance of
units, similar to the units offered in this offering, on the later of January
2, 2004 or the effective date of this offering. The units will be issued at the
same price as offered in this offering.

     On October 21, 2003 we received $7,750 upon the exercise of options for
2,333 shares of common stock.

     On October 31, 2003 we issued 102,195 shares of our common stock to
principal vendors, in satisfaction of trade payables in the aggregate amount of
approximately $503,000.

     During October and through December 15, 2003 we issued an aggregate of
39,613 shares of common stock in consideration for a total of $217,500, after
brokerage commissions and closing costs, under an equity put agreement.


                                       14
<PAGE>

     On December 15, 2003 we issued 16,666 shares of common stock upon the
exercise of options by the CEO for an aggregate price of $50,000.

     In December 2003 we reached an agreement to satisfy $200,000 of accounts
payable through the issuance of 29,985 units ten days after the closing of this
offering. The units will be issued at the same terms and price as offered in
this offering.

                                USE OF PROCEEDS

     The principal purpose of this offering is to raise a sufficient amount of
capital that will allow us to:

     o    expand significantly our independent sales force and our sales support
          staff and provide for their proper training;

     o    implement marketing and advertising campaigns directed at the dental
          market;

     o    support the launch of the SafetyWand, including manufacturing and
          marketing costs;

     o    expand our international sales including the hiring of three sales
          managers for Asia, Europe and South America;

     o    develop and commercialize our Periodontal Ligament or PDL Injector
          project;

     o    to reestablish our dental and hygiene school program;

     o    respond quickly to new competitive and business developments in the
          industries and markets in which we operate and compete;

     o    qualify for continued listing on the American Stock Exchange;

     o    repay a portion of the outstanding debt to two of our major
          shareholders; and

     o    pay a portion of the accrued compensation to our Chief Executive
          Officer.

     Based on gross proceeds of $8 million, and after deducting $800,000
reflecting the estimated underwriting discount, a non-accountable expense
allowance of $240,000, and other estimated offering expenses of $460,000
payable by us, the net proceeds to us from this offering will be approximately
$6.5 million, or $7.54 million if the representative exercises the
over-allotment option in full.

     The table below lists the specific uses of proceeds:


<TABLE>
<CAPTION>
                                                     APPROXIMATE     APPROXIMATE
USE OF CAPITAL                                          AMOUNT       PERCENTAGE
- -------------------------------------------------   -------------   ------------
<S>                                                 <C>             <C>
   Sales and marketing ..........................    $2,770,000          42.6%
   Product development ..........................    $1,095,000          16.8%
   Production tooling ...........................    $  250,000           3.8%
   Non-sales personnel expense ..................    $  235,000           3.6%
   Repayment of debt and accrued compensation ...    $  525,000           8.0%
   Miscellaneous working capital ................    $1,625,000          25.0%
                                                     ----------         -----
      Total .....................................    $6,500,000         100.0%
                                                     ==========         =====
</TABLE>


     Sales and marketing expenses. This amount consists of the costs we expect
to incur to expand our independent and sales supportstaff, in the U.S. and
internationally. It includes expenses relating to hiring and training
additional sales and marketing personnel, consultant fees, and expenses
relating to attending trade shows and conventions and producing marketing
materials.

     Product development. This amount is required for further development of
our PDL Injector Device and to develop additional clinical applications of the
CompuFlo technology including epidural injections.


     Production tooling. This amount represents the estimated costs for the
development of molds and dies for the commercial production of the SafetyWand.


     Non-sales personnel expense. Prior to this offering, we have been
operating with cash conservation as a dominant business objective. We expect
that additional personnel will be required,


                                       15
<PAGE>

primarily in financial, administrative and customer service areas, both to
provide adequate support to operations on an ongoing basis and to support
growth.

     Repayment of debt and accrued compensation. This amount includes repayment
in cash of $91,680 out of $1,595,734 outstanding debt to two of our major
shareholders, Leonard Osser, our Chairman and Chief Executive Officer, and K.
Tucker Andersen, the beneficial owner of 20.7% of our outstanding shares of
common stock, and the payment of $256,000 out of $640,000 of accrued
compensation to our Chairman and Chief Executive Officer. The balance of the
debt and accrued compensation will be paid by issuance of units on the
effective date of this offering, valued at the same price as is offered to the
public. The cash amounts represent estimated tax amounts due by these
individuals for accrued interest on the debt and on payment of the accrued
compensation.

     Miscellaneous working capital. These costs include general and
administrative costs, including the cost of increasing our inventory, acquiring
and enhancing our operating, support and management systems and capital
expenditures for computers and other equipment. We may use the portion of the
amount currently allocated to working capital and general corporate purposes to
reduce our current liabilities. We may also use a portion of the net proceeds
to license or acquire new products, technologies or intellectual property or to
acquire or invest in businesses complementary to ours. If the representative
exercises the over-allotment option, the additional net proceeds, approximately
$1.2 million, will be added to working capital.

     The above information represents our best estimate of our capital
requirements based upon the current status of our business. We will retain
broad discretion in the allocation of the net proceeds within the categories
listed above. The amounts actually expended for these purposes may vary
significantly and will depend on a number of factors, including our rate of
revenue growth, cash generated by operations, evolving business needs and the
other factors described in "Risk Factors."

     Pending their use, we intend to invest the net proceeds of this offering
in interest bearing, investment grade securities.

     We expect that the net proceeds from this offering, when combined with the
proceeds of other financing transactions and revenue from operations, will be
sufficient to fund our operations and capital requirements for at least 12
months following this offering. We may be required to raise additional capital
through the sale of equity or other securities sooner if our operating
assumptions change or prove to be inaccurate. We cannot assure you that any
financing of this type would be available. In the event of a capital
inadequacy, we would be required to limit our growth and the expenditures
described above.
                                DIVIDEND POLICY

     We have not declared or paid any dividends and do not intend to pay any
dividends in the foreseeable future. We intend to retain any future earnings
for use in the operation and expansion of our business. Any future decision to
pay dividends on common stock will be at the discretion of our board of
directors and will be dependent upon our fiscal condition, results of
operations capital requirements and other factors our board of directors may
deem relevant.

                                CAPITALIZATION

     The following table sets forth our capitalization as of September 30, 2003
on an actual basis, pro forma and pro forma as adjusted for this offering. Pro
forma data takes into account the following events occurring after September
30, 2003:

     o    The issuance of 94,327 additional shares of common stock to these
          debtholders as agreed remuneration for previously extending the
          maturity date of the notes, out of which 13,526 were issued to Leonard
          Osser, our Chairman and Chief Executive Officer;

     o    The issuance of 102,195 shares of common stock as payment of
          approximately $503,000 due to principal vendors;

     o    The issuance of 39,613 shares of common stock for a consideration, net
          of commission and closing costs of $217,075 under an equity put
          agreement;

     o    The issuance of 2,333 shares of common stock upon the exercise of
          options for a total consideration of $7,750;


                                       16
<PAGE>

     o    the payment of $50,000 of outstanding debt due to our Chairman and
          Chairman and Chief Executive Officer.

     o    The issuance of 25,365 preferred shares in repayment of $25,365 of
          outstanding debt, including principal and interest amounts to a
          noteholder.

     o    The issuance of 16,667 shares of common stock to Leonard Osser, our
          Chairman and Chief Executive Officer, upon the exercise of options for
          an aggregate exercise price of $50,000.

     o    The expected issuance, on the later of January 2, 2004 or the date
          this offering becomes effective, of 239,214 units, in payment of
          $1,595,734 of debt, including interest, to Leonard Osser, our Chairman
          and Chief Executive Officer and to a major stockholder; and

     o    The expected issuance, on the later of January 2, 2004 or the date
          this offering becomes effective, of 57,571 units, in payment of
          $384,000 of accrued compensation to Leonard Osser, our Chairman and
          Chief Executive Officer.

     o    The expected issuance, ten days after the closing of this offering, of
          an estimated 29,985 units (assuming a unit price of $6.67) in payment
          of $200,000 of accrued liabilities for legal services.

     Pro forma as adjusted for this offering takes into account the pro forma
data as well as the receipt of $6.5 million of estimated net proceeds from this
offering, the deduction of underwriting discounts and commissions and other
estimated offering expenses to be paid by us.



<TABLE>
<CAPTION>
                                                                         SEPTEMBER 30, 2003
                                                                -------------------------------------
                                                                                           PRO FORMA
                                                                 ACTUAL     PRO FORMA     AS ADJUSTED
                                                                --------   -----------   ------------
                                                                           (IN THOUSANDS)
<S>                                                             <C>        <C>           <C>
 Accounts payable and accrued expenses ......................     $1,726       $1,125        $1,125
 Notes payable including interest ...........................      2,105          151           151
 Accrued compensation .......................................        560          224           224
                                                                  ------       ------        ------
   Total debt ...............................................      4,391        1,500         1,500
                                                                  ------       ------        ------
Stockholders' equity (deficiency):
 Common stock, $0.001 par value, 50,000,000 shares
   authorized, 5,890,875 shares issued and 5,857,542
   outstanding, actual; 6,799,604 shares issued and 6,766,271
   outstanding, pro forma; and 9,199,604 shares issued and
   9,166,271 outstanding, pro forma as adjusted .............          6            7             9

 Preferred Stock, $.001 par value 5,000,000 shares authorized,
   no shares issued and outstanding, actual; 25,365 shares
   issued and outstanding, pro forma; and 25,365 shares issued
   and outstanding, pro forma as adjusted ....................
 Additional paid-in capital ..................................    41,623      44,738         51,236
 Retained earnings (deficit) .................................   (43,574)    (43,574)       (43,574)
 Unearned compensation .......................................       (20)        (20)           (20)
 Treasury stock, at cost, 33 shares ..........................      (912)       (912)          (912)
                                                                 -------     -------        -------
   Total stockholders' equity (deficiency) ...................    (2,877)        239          6,739
                                                                 -------     -------        -------
   Total capitalization ...................................... $   1,514   $   1,739      $   8,239
                                                               =========   =========      =========
</TABLE>

                       PRICE RANGES OF OUR COMMON STOCK

     The principal market on which our common stock is traded is the American
Stock Exchange. The ticker symbol for our common stock is MS. The following
table sets forth the high and low closing sales prices of our common stock, as
quoted by the American Stock Exchange.


                                       17
<PAGE>



                                                           HIGH          LOW
                                                        ----------   ----------
   2002
   First Quarter ....................................     $ 2.04       $ 1.56
   Second Quarter ...................................     $ 3.00       $ 1.74
   Third Quarter ....................................     $ 2.04       $  .87
   Fourth Quarter ...................................     $ 1.20       $  .63

   2003
   First Quarter ....................................     $ 1.02       $  .42
   Second Quarter ...................................     $ 1.20       $  .54
   Third Quarter ....................................     $ 4.98       $  .81
   Fourth Quarter ...................................     $ 7.77       $ 3.09

   2004
   First Quarter (through January 27, 2004) .........     $ 4.20       $ 3.13



     According to the records of our transfer agent, there were approximately
3,000 holders of record of our common stock as of December 31, 2003.

     We have applied to the American Stock Exchange to list the units offered
by this prospectus, as well as the warrants and common stock underlying those
units.



                     SELECTED CONSOLIDATED FINANCIAL DATA

     The selected consolidated financial data set forth below should be read
together with "Management's Discussion and Analysis or Plan of Operations"
included elsewhere in this prospectus. The statement of operations data for
each of the years in the two-year period ended December 31, 2002 and the
balance sheet data at December 31, 2002 are derived from our financial
statements, which have been audited by J.H. Cohn LLP, independent public
accountants, and are included elsewhere in this prospectus. The statement of
operations data for the nine-month periods ended September 30, 2003 and 2002
and the balance sheet data for September 30, 2003 are derived from our
unaudited financial statements. The unaudited financial statements have been
prepared on substantially the same basis as the audited financial statements
and, in the opinion of management, include all adjustments, consisting only of
normal recurring adjustments, necessary for the fair presentation of the
results of operations for these periods. Historical results are not necessarily
indicative of the results to be expected in the future, and the results of
interim periods are not necessarily indicative of results for the entire year.


STATEMENT OF OPERATIONS DATA:


<TABLE>
<CAPTION>
                                                                                     NINE MONTHS ENDED SEPTEMBER
                                                      YEARS ENDED DECEMBER 31,                   30,
                                                    -----------------------------   -----------------------------
                                                         2001            2002            2002            2003
                                                    -------------   -------------   -------------   -------------
                                                                                             (UNAUDITED)
                                                           (IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
<S>                                                 <C>             <C>             <C>             <C>
Revenues ........................................    $    4,094      $    4,074      $    3,216      $    3,101
Cost of sales ...................................         1,973           1,980           1,499           1,560
                                                     ----------      ----------      ----------      ----------
Gross profit ....................................         2,121           2,094           1,717           1,541
Selling, general and administrative
 expenses .......................................         5,271           3,589           2,713           2,492
Research and development ........................            50             148              64             112
Closing of Deerfield, IL facility ...............            --              26              --              79
                                                     ----------      ----------      ----------      ----------
Loss from operations ............................        (3,200)         (1,669)         (1,060)         (1,142)
Sale of prophy angle business and related
 consulting income ..............................            64              80              --              --
Other income ....................................            --              --              72              --
Interest expense, net ...........................          (855)           (851)           (616)           (645)
                                                     ----------      ----------      ----------      ----------
Net loss ........................................    $   (3,991)     $   (2,440)     $   (1,604)     $   (1,787)
                                                     ==========      ==========      ==========      ==========
Net loss per share -- basic and diluted .........    $    (1.07)     $     (.59)     $     (.39)     $     (.42)
                                                     ==========      ==========      ==========      ==========
Weighted average number of shares
 outstanding -- basic and diluted ...............     3,714,197       4,156,558       4,084,341       4,217,185
                                                     ==========      ==========      ==========      ==========
</TABLE>


                                       18
<PAGE>

BALANCE SHEET DATA:


                                                   (IN THOUSANDS)
                                            DECEMBER 31,     SEPTEMBER 30,
                                                2002             2003
                                           --------------   --------------
Current assets .........................     $     893         $  1,275
Working capital ........................     $  (5,214)        $ (1,449)
Total assets ...........................     $   1,241         $  1,514
Total liabilities ......................     $   7,347         $  4,391
Stockholders' equity (deficit) .........     $  (6,106)        $ (2,877)


                     MANAGEMENT'S DISCUSSION AND ANALYSIS
                             OR PLAN OF OPERATIONS

     You should read the following discussions of our financial condition and
results of operations in conjunction with the financial statements and the
notes to those statements included elsewhere in this prospectus. This
discussion may contain forward-looking statements that involve risks and
uncertainties. Our actual results may differ materially from those anticipated
in these forward-looking statements as a result of certain factors, such as
those set forth under "Risk Factors" and elsewhere in this prospectus.


OVERVIEW

     We have generated most of our revenues during our last two fiscal years
and the interim period this year through sales of our CompuDent system and The
Wand disposable handpiece used with that system. Revenues have been earned
domestically and internationally through sales in more than 25 countries.
During this period handpiece sales have provided a growing portion of our
revenues, reflecting a growing base of new customers for our systems
internationally and more intensive use of their systems by a relatively
stagnant base of customers domestically. Though we have continued to sell new
systems domestically, a large part of our domestic sales during this period
represented the sale of upgraded units or additional units to our existing
customer base. Our limited domestic sale of new systems reflects our limited
sales and marketing efforts as a result of cash constraints. We expect to use a
portion of the proceeds of this offering to increase sales and marketing
expense and believe these increases should generate additional revenue. The
following table shows a breakdown of our revenues, domestically and
internationally, by product category, and the percentage of total revenue by
each product category.


<TABLE>
<CAPTION>
                                         NINE MONTHS ENDED SEPTEMBER 30,
                                -------------------------------------------------
                                          2003                     2002
                                ------------------------ ------------------------
<S>                             <C>           <C>        <C>           <C>
DOMESTIC
CompuDent .....................  $  524,566       25.4%   $  799,671       32.8%
Handpieces ....................   1,398,347       67.7%    1,461,607       59.9%
Other .........................     141,417        6.9%      176,923        7.3%
                                 ----------      -----    ----------      -----
Total Domestic ................  $2,064,330      100.0%   $2,438,201      100.0%
                                 ==========      =====    ==========      =====
INTERNATIONAL
CompuDent .....................  $  574,225       55.4%   $  436,228       56.1%
Handpieces ....................     460,152       44.4%      337,714       43.4%
Other .........................       2,574        0.2%        3,764        0.5%
                                 ----------      -----    ----------      -----
Total International ...........  $1,036,951      100.0%   $  777,706      100.0%
                                 ==========      =====    ==========      =====
DOMESTIC/INTERNATIONAL ANALYSIS

Domestic ......................  $2,064,330       66.6    $2,438,201       75.8
International .................   1,036,951       33.4       777,706       24.2
                                 ----------      -----    ----------      -----
                                 $3,101,281      100.0%   $3,215,907      100.0%
                                 ==========      =====    ==========      =====

<CAPTION>
                                             YEAR ENDED DECEMBER 31,
                                -------------------------------------------------
                                          2002                     2001
                                ------------------------ ------------------------
<S>                             <C>           <C>        <C>           <C>
DOMESTIC
CompuDent .....................  $  956,275       30.1%   $1,309,712       39.0%
Handpieces ....................   1,999,050       63.0%    1,756,498       52.4%
Other .........................     219,605        6.9%      288,092        8.6%
                                 ----------      -----    ----------      -----
Total Domestic ................  $3,174,930      100.0%   $3,354,302      100.0%
                                 ==========      =====    ==========      =====
INTERNATIONAL
CompuDent .....................  $  495,730       55.1%   $  519,089       70.2%
Handpieces ....................     403,346       44.9%      192,271       26.0%
Other .........................           0        0.0%       28,048        3.8%
                                 ----------      -----    ----------      -----
Total International ...........  $  899,076      100.0%   $  739,408      100.0%
                                 ==========      =====    ==========      =====
DOMESTIC/INTERNATIONAL ANALYSIS

Domestic ......................  $3,174,930       77.9%   $3,354,302       81.9%
International .................     899,076       22.1%      739,408       18.1%
                                 ----------      -----    ----------      -----
                                 $4,074,006      100.0%   $4,093,710      100.0%
                                 ==========      =====    ==========      =====
</TABLE>


                                       19
<PAGE>

     We have earned gross profits of 51.8% and 51.4% in the years ended
December 31, 2001 and 2002, respectively, and 53.4% and 49.7% in the nine-month
periods ended September 30, 2002 and 2003, respectively. However, our revenues
have been too low to support our overhead, research and development expense and
interest on our debt. We have therefore reported substantial, though declining,
losses for each of those periods. We have taken steps to cut our overhead,
increase sales and reduce our interest expense.

     We took the following steps to reduce our operating overhead and improve
our utilization of cash:

     o    We reconfigured our sales force, commencing in 2001 and continuing
          through 2003, from a large internal force to independent sales
          representatives, distributors and a small sales support staff;

     o    We closed our Deerfield, Illinois facility on January 31, 2003,
          resulting in a reduction of ten employees. Customer support, technical
          service and other back-office functions previously conducted at this
          location were consolidated into our New Jersey location;

     o    We outsourced to an independent warehouse located in Pennsylvania
          receiving, shipping and storage functions previously conducted at
          Deerfield; and

     o    We cut marketing expense and limited our participation in trade shows,
          even though this had a further negative effect on sales.

     Next, we took steps to reduce our debt burden. We cut the interest rate on
our Senior Secured and Secured Notes (after negotiation with our noteholders)
from 20% per year to 12% per year (6% if we paid interest in cash) and extended
the previously extended maturity date until July and August 2003. Then, in
October 2003, we paid $5,014,014 of debt by issuing 1,646,419 shares of common
stock and 25,365 shares of convertible preferred stock and satisfied
approximately $503,000 of trade payable by issuing 102,195 shares of common
stock. In October we also reached an agreement to satisfy, on the later of
January 2, 2004 or the closing of this offering, an additional $1,979,734 of
debt, accrued interest and accrued compensation through issuance of 296,812
units. In December 2003 we reached an agreement to satisfy, ten days after the
closing of this offering, $200,000 of accounts payable through issuance of
29,895 units.

     Finally, at the beginning of 2003, we took steps to increase our revenues.
In early 2003 we completed development of the SafetyWand, which incorporates
safety engineered sharps protection features to aid in the prevention of
inadvertent needlesticks. We believe that the SafetyWand is one of the first
safety engineered injection devices that conforms with OSHA regulations under
the federal Needlestick Safety Act, while also meeting the clinical needs of
dentists. To date, these regulations have generally not been enforced against
dentists by OSHA and similar local and state authorities due to lack of
commercially available products that meet the special needs of dentistry.
Milestone believes that the commercial availability of the SafetyWand will
enable OSHA, and similar local and state authorities to begin enforcement, or
stricter enforcement, of the Needlestick Safety Act against dentists. Since the
SafetyWand can only be used with the CompuDent system, enforcement by OSHA
could promote increased handpiece sales to current CompuDent users, while also
providing impetus for the purchase of these systems by new users. In September
2003, we obtained FDA approval for SafetyWand. In October 2003, we launched the
SafetyWand at the American Dental Association Annual Meeting in California.
SafetyWand will be commercially available before the end of 2003.

     In early 2003, we adopted a new marketing approach and began building a
national sales force of highly trained independent representatives to provide
sales coverage in urban areas in 12 states. To increase our ability to retain
this sales force and to enhance its performance, we:

     o    increased the base price of our CompuDent unit to new customers to
          provide sufficient gross profit to recruit and adequately compensate
          our sales force;

     o    established a sales support staff to generate leads, set appointments,
          provide technical support and customer service and foster increased
          handpiece use; and

     o    began distributing a new product used in repairing and whitening
          teeth, the CoolBlue Wand, which also helps gaining access to dental
          offices.


                                       20
<PAGE>

     With a growing new sales force and the acquisition of rights to new
products to facilitate access to dental offices, we intend to direct our
marketing efforts to capturing new customers, particularly from specialty
practitioners, including periodontists, pedodontists, endodontists and
cosmetic/restorative dentists.


     The technology underlying our SafetyWand, the CompuFlo and an improvement
to the controls for CompuDent were developed by our Director of Clinical
Affairs and assigned to us. Upon sale of products using any such technology we
will owe him a 5% royalty on the total sales price, or, if technology covered
by other patents is also used by the product, on an allocated part of the sales
price. In addition, he is granted, pursuant to the agreement, an option to
purchase, at fair market value on the date of the grant, 25,000 of our common
stock upon the issuance of each additional patent relating to these
technologies.



SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

     Our discussion and analysis of our financial condition and results of
operations are based upon our consolidated financial statements, which have
been prepared in accordance with accounting principles generally accepted in
the United States of America. The preparation of these consolidated financial
statements requires us to make estimates and judgments that affect the reported
amounts of assets, liabilities, revenues and expenses, and related disclosure
of contingent assets and liabilities. On an on-going basis, we evaluate our
estimates, including those related to accounts receivable, inventories,
advances to our contract manufacturer, stock based compensation and
contingencies. We base our estimates on historical experience and on various
other assumptions that are believed to be reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying
values of assets and liabilities that are not readily apparent from other
sources. Actual results may differ from those estimates under different
assumptions or conditions.


 Inventory

     Inventories principally consist of finished goods and component parts
stated at the lower of cost (first-in, first-out method) or market.


 Impairment of Long-Lived Assets

     We review long-lived assets for impairment whenever circumstances and
situations change such that there is an indication that the carrying amounts
may not be recovered.


 Revenue Recognition

     Revenue is recognized when title passes at the time of shipment and
collectibility is deemed probable.


RESULTS OF OPERATIONS

     The results of operations for the year ended December 31, 2002, and nine
months ended September 30, 2003, reflect our concentrated effort to reduce our
overhead while slowly growing our user base in the dental market domestically
and abroad. The loss for the year 2002, approximately $2.5 million, represents
a 39% reduction from the same period in 2001. However, the net loss for the
nine months ended September 30, 2003 was approximately $183,000 greater than
the loss reported for the nine months ended September 30, 2002 as a result of a
decline in sales volume and gross profit, coupled with increases in research
and development expenses and interest expense.


                                       21
<PAGE>

     The following table sets forth for the periods presented, statement of
operations data as a percentage of revenues. The trends suggested by this table
may not be indicative of future operating results.

<TABLE>
<CAPTION>
                                                                 NINE-MONTH
                                                         PERIODS ENDED SEPTEMBER 30,
                                           -------------------------------------------------------
                                                      2003                        2002
                                           --------------------------- ---------------------------
<S>                                        <C>             <C>         <C>             <C>
Net sales ................................  $   3,101,281     100.0%    $   3,215,907     100.0%
Cost of sales ............................      1,560,288      50.3%        1,499,063      46.6%
Gross profit .............................      1,540,993      49.7%        1,716,844      53.4%
Selling, general & administrative
 expense .................................      2,491,737      80.3%        2,712,649      84.4%
Closing of Deerfield, Il facility ........         79,023       2.5%                        0.0%
Research and development .................        112,158       3.6%           63,928       1.9%
Loss from operations .....................     (1,141,925)    (36.8)%      (1,059,733)    (32.9)%

<CAPTION>
                                                          YEARS ENDED DECEMBER 31,
                                           -------------------------------------------------------
                                                      2002                        2001
                                           --------------------------- ---------------------------
<S>                                        <C>             <C>         <C>             <C>
Net sales ................................  $   4,074,006     100.0%    $   4,093,710     100.0%
Cost of sales ............................      1,980,949      48.6%        1,973,156      48.2%
Gross profit .............................      2,093,057      51.4%        2,120,554      51.8%
Selling, general & administrative
 expense .................................      3,588,836      88.1%        5,271,032     128.8%
Closing of Deerfield, Il facility ........         26,067       0.6%                        0.0%
Research and development .................        147,709       3.6%           49,943       1.2%
Loss from operations .....................     (1,669,555)    (41.0)%      (3,200,421)    (78.2)%
</TABLE>

     Fiscal year ended December 31, 2002 compared to fiscal year ended
December 31, 2001

     Net sales for the years ended December 31, 2002 and 2001 were $4,074,006
and $4,093,710, respectively. The $19,704 decrease is attributable primarily to
a decrease in domestic sales of CompuDent, $71,592 generated from prophy angle
sales in 2001 before the sale of this product line in November 2001, and our
decision to consolidate a $94,500 shipment to our South African distributor
with its January 2003 order to lower freight charges. The decrease was
partially offset by a 13% or $229,183 increase in domestic dental sales of The
Wand handpieces, $207,000 increase in The Wand handpiece sales to foreign
distributors, and CompuMed sales of approximately $163,000. The reduction in
CompuDent sales domestically are the direct result of the downsizing of our
sales and marketing effort in the U.S.

     Cost of sales for the years ended December 31, 2002 and 2001 were
$1,980,949 and $1,973,156 respectively. The $7,793 increase is attributable
primarily to product mix.

     For the year ended December 31, 2002, we generated a gross profit of
$2,093,057 or 51.4% as compared to a gross profit of $2,120,554 or 51.8% for
the year ended December 31, 2001. The decrease in gross profit is mainly
attributable to an increase in sales revenue generated from sales to foreign
distributors. The gross profit from these sales is lower than the aggregate
gross profit generated from domestic sales.

     Selling, general and administrative expenses for the years ended December
31, 2002 and 2001 were $3,588,836 and $5,271,032, respectively. The $1,682,196
decrease is attributable primarily to an approximate $858,000 decrease in
expenses associated with the sale and marketing of CompuDent units and The Wand
handpieces due to the transitioning of its sales force to independent
representatives and an approximate $293,700 decrease in legal fees. In
addition, during 2001, we issued 242,308 shares as payment for services
rendered in the amount of $247,649. We had incurred higher legal expenses in
2001 related to advertising agreements and patent registrations.

     In 2002, we incurred costs totaling $26,067 associated with the closing
down of our Illinois facility.

     Research and development expenses for the years ended December 31, 2002
and 2001 were $147,709 and $49,943, respectively. The $97,766 increase is
attributed to the development of the SafetyWand.

     Other income for the years ended December 31, 2002 and 2001, $80,000 and
$64,487, respectively reflect the sale of our prophy angle business in 2001 and
consulting services we provided during 2002, in connection with this sale.

     The loss from operations for the years ended December 31, 2002 and 2001
were $1,669,555 and $3,200,421, respectively. The $1,530,866 decrease in loss
from operations is explained above.

     We incurred interest expense of $850,642 for the year ended December 31,
2002 as compared to $858,582 for the year ended December 31, 2001. The decrease
of $7,940 is attributable to a lower average interest rate, which was partially
offset by an increase in outstanding principal debt obligations.


                                       22
<PAGE>

     The net loss for the years ended December 31, 2002 was $2,440,197 as
compared to a net loss of $3,991,580 for 2001. The $1,551,383 decrease in net
loss is primarily attributable to a sharp decrease in selling and
administrative expenses, including reduction in personnel.

     Nine months ended September 30, 2003 compared to nine months ended
September 30, 2002

     Net sales for the nine months ended September 30, 2003 and 2002 were
$3,101,281 and $3,215,907, respectively. The $114,626 or 3.6% decrease is
primarily related to an approximate $175,000 decrease in CompuDent and CompuMed
domestic sales, a $63,000 decrease in domestic sales of the Wand handpieces.
These decreases were partially offset by a $122,000 increase in foreign sales
of the Wand handpiece. The decrease in Wand handpiece sales is the result of
changing the primary vendor of the Wand handpiece, resulting in inconsistent
inventory levels. Those transition issues have been resolved and are resulting
in improved supply chain management.

     Cost of sales for the nine months ended September 30, 2003 and 2002 were
$1,560,288 and $1,499,063, respectively. The $61,225 increase is attributable
primarily to higher sales volume to foreign distributors.

     For the nine months ended September 30, 2003, Milestone generated a gross
profit of $1,540,993 or 49.7% as compared to a gross profit of $1,716,844 or
53.4% for the nine months ended September 30, 2002. The decrease in gross
profit percentage is primarily attributable to increased sales to foreign
distributors. Sales to foreign distributors are of higher volume but at a
reduced margin.

     Selling, general and administrative expenses for the nine months ended
September 30, 2003 and 2002 were $2,491,737 and $2,712,649, respectively. The
$220,912 decrease is attributable primarily to an approximate $241,000 decrease
in expenses associated with the sale and marketing of the Wand. An approximate
$63,000 expense associated with the independent sales representative start up
costs, was primarily offset by a commensurate amount of commissions earned
during the similar period in the previous year.

     Milestone incurred costs totaling $79,023 relating to the closure of its
Deerfield, IL facility.

     Research and development expenses for the nine months ended September 30,
2003 and 2002 were $112,158 and $63,928, respectively. These costs were related
to the development of Milestone's SafetyWand.

     The loss from operations for the nine months ended September 30, 2003 and
2002 was $1,141,925 and $1,059,733, respectively. The $82,192 increase in loss
from operations is explained above.

     Milestone generated $72,000 in income for the nine months ended September
30, 2002 as a result of a consulting contract which expired in October 2002.

     Interest expense of $645,457 was incurred for the nine months ended
September 30, 2003 as compared to $616,519 for the nine months ended September
30, 2002. The increase is attributable to higher average borrowings in 2003.

     The net loss for the nine months ended September 30, 2003 was $1,787,382
as compared to a net loss of $1,604,252 for the nine months ended September 30,
2002. The $183,130 increase in net loss is explained above.


LIQUIDITY AND CAPITAL RESOURCES

     At December 31, 2002, as shown in the accompanying consolidated financial
statements, we incurred net losses of approximately $2,440,000 and $3,992,000
and negative cash flows from operating activities of approximately $676,000 and
$1,385,000 during 2002 and 2001, respectively. As a result, we had a cash
balance of approximately $10,000, a working capital deficiency of approximately
$5,214,000 and a stockholders' deficiency of approximately $6,106,000 as of
December 31, 2002. These matters raise substantial doubt about our ability to
continue as a going concern.

     At September 30, 2003, the accompanying condensed consolidated financial
statements have been prepared assuming Milestone will continue as a going
concern. However, as shown in the


                                       23
<PAGE>

accompanying condensed consolidated financial statements, Milestone incurred
net losses of approximately $1,787,000 and $1,604,000 and negative cash flows
from operating activities of $861,000 and $418,000 during the nine months ended
September 30, 2003 and 2002, respectively. As a result, Milestone had a cash
balance of approximately $96,000, a working capital deficiency of approximately
$1,449,000 and a stockholders' deficit of approximately $2,877,000 as of
September 30, 2003. These matters raised substantial doubt about Milestone's
ability to continue as a going concern. Management believes that its initial
concerns about the Company's ability to continue as a going concern have been
alleviated through the subsequent satisfaction of a substantial portion of its
outstanding obligations, the introduction of new products and continuing
efforts to reduce operating overhead. Nevertheless, management believes that it
is probable that Milestone will continue to incur losses and negative cash
flows from operating activities through at least September 30, 2004.

     During the year ended December 31, 2002, we reduced our average monthly
cash used in operations to less than $60,000, completed a $4.1 million debt
restructuring program, and obtained $785,000 in additional financing. This
program included debt to equity conversions, deferring payment on a portion of
our payables, restructuring our debt and outsourcing our sales force.


 Satisfaction of certain liabilities

     Agreements reached by Milestone in October 2003 will effectively eliminate
the current stockholders' deficiency upon the later of completion of this
offering or January 2, 2004. During the month, Milestone satisfied $5,014,000
of secured debt including interest, through the issuance of 1,646,419 shares of
common stock and $25,365 face amount of 8% cumulative convertible preferred
stock. Also, approximately $503,000 of trade payables to principal vendors was
satisfied through issuance of 102,195 shares of common stock valued at $4.92
per share, the approximate fair market value.

     Additionally, we reached agreements to satisfy, an aggregate amount of
$1,963,000 of debt, accrued interest, and accrued compensation through the
issuance of equity securities. Satisfaction of the secured debt for borrowed
money to a major investor and to our Chairman and CEO and accrued compensation
to our CEO will be on the later of January 2, 2004 or the effective date of the
next public offering of our securities through the issuance of common stock and
warrants at the same price as offered to the public. This settlement is
contingent upon there being a public offering. Payment of this debt, following
the conversion to equity in September 2003 of additional $5 million of debt
will eliminate most of Milestone's funded debt and will remove almost all liens
on its assets.


     Milestone has no commitments for future capital expenditures, but expects
to spend $1,095,000 for product development and $250,000 for production tooling
for the SafetyWand. Milestone expects that the proceeds of this offering will
be sufficient to meet its needs for capital resources for working capital and
for capital expenditures for at least 12 months.



 Reduction of operating overhead

     To date, we have taken certain steps in order to reduce our operating
overhead and use of cash. These steps includethe following:

     o    Commencing in 2001 and continuing through 2003, we reconfigured our
          sales force from a large internal sales force to independent sales
          representatives, distributors and a small sales support staff;

     o    On January 31, 2003, we completed the closing of the Deerfield,
          Illinois facility, resulting in the termination of ten employees. The
          customer support, technical service and other back-office functions
          previously conducted, in whole or in part, at this location were
          consolidated into our New Jersey location. The receiving, shipping and
          storage functions, which were also previously done at this location,
          are now outsourced to an independent warehouse located in
          Pennsylvania.

     On June 4, 2003, we borrowed $50,000 pursuant to a 6% secured convertible
promissory note due November 27, 2004. At the option of the noteholder, the
principal and interest are payable on the


                                       24
<PAGE>

maturity date in common stock at a rate of one share of common stock for every
$.936 of indebtedness. Additionally, we granted the investor warrants to
purchase 53,419 of our common stock at a per share price of $1.56 with an
estimated fair value of $14,423 at any time or from time to time during the
period commencing June 4, 2003 and ending June 3, 2005. This resulted in an
initial increase to debt discount and to additional paid-in capital.


 Cash flow results

     For the nine months ended September 30, 2003, the Company's net cash used
in operating activities was $860,990. This was attributable primarily to a net
loss of $1,787,382 adjusted for noncash items of $280,494 (of which $242,628
was for amortization of debt discount and deferred financing costs); a $372,167
increase in accounts receivable; an $135,997 increase in inventories; a
$137,575 decrease in advances to contract manufacturer; a $3,341 decrease in
prepaid expenses; an increase in accounts payable of $399,731 a $402,827
increase in accrued interest; a $29,412 decrease in accrued expenses; and an
$240,000 increase in deferred compensation.

     For the nine months ended September 30, 2003, the Company used $15,817 in
investing activities for capital expenditures.

     For the nine months ended September 30, 2003, the Company generated
$962,994 from financing activities as it issued promissory notes to existing
investors totaling $900,000, incurred $108,537 of net borrowings from its Chief
Executive Officer, recorded $22,721 in deferred financing activities and
incurred $22,500 in expenses in registering shares.


RECENT ACCOUNTING PRONOUNCEMENT

     In December 2002, SFAS No.148, "Accounting for Stock-Based
Compensation-Transition and Disclosure, an Amendment of SFAS No. 123" was
issued. SFAS No. 148 amends SFAS No. 123, to provide alternative methods of
transition for a voluntary change to the fair value method of accounting for
stock-based employee compensation. In addition, SFAS No. 148 amends the
disclosure requirements of SFAS No. 123 to require prominent disclosures in
both annual and interim financial statements about the method of accounting for
stock-based employee compensation and the effects of the method used on
reporting results. Milestone adopted SFAS No. 148, effective January 1, 2003
and it did not have any material impact on its consolidated financial
statements.


     In May 2003, SFAS No. 150, "Accounting for Certain Financial Instruments
with Characteristics of both Liabilities and Equity" was issued. The statement
requires that an issuer classify financial instruments that are within its
scope as a liability. Many of those instruments were classified as equity under
previous guidance. Most of the guidance in SFAS No. 150 is effective for all
financial instruments entered into or modified after May 31, 2003, and
otherwise effective at the beginning of the first interim period beginning
after June 15, 2003. We are currently evaluating the provisions of this
statement, and do not believe that it will have an impact on our consolidated
financial statements.



                                       25
<PAGE>

                                    BUSINESS


BACKGROUND

     Milestone is a leader in advanced subcutaneous injection technology for
dental and medical applications. Its products improve the quality of patient
care and comfort, while also addressing the health and safety needs of the
practitioner. Milestone's principal product, CompuDent, was developed to
replace the hypodermic syringe in dentistry. The hypodermic syringe has been
little changed since its invention more than 150 years ago. A dentist using a
syringe can generally administer an adequate volume of anesthetic to the
intended target area to achieve the desired level of anesthesia. However, use
of a syringe for this purpose, may result in a number of unintended
consequences or collateral problems including:

     o    high levels of patient pain in some procedures;

     o    post-operative pain as a result of tissue tearing or distension;

     o    necrosis as a consequence of tissue tearing and other damage;

     o    failure to hit the intended nerve target because of needle deflection
          and the awkward manner in which the syringe must be held;

     o    temporary paralysis of adjacent tissue such as the tongue, lips, and
          facial muscles;

     o    fear reactions by the patient to the syringe;

     o    carpal tunnel syndrome to the dentist or hygienist;

     o    inability to inject sufficient anesthetic into dense tissue or tight
          spaces; and

     o    use of unnecessarily high levels of anesthetic.


DENTAL PRODUCTS


 CompuDent and the Wand

     Milestone's principal product, CompuDent, is a computer controlled,
precision metered, local anesthetic injection system. The system, including its
ergonomically designed, single patient use, disposable handpiece, The Wand,
enables a dentist to consistently administer safe, effective and less painful
injections. Since January 1998, Milestone has sold more than 24,000 CompuDent
units and over 13 million single use handpieces in the United States and in
over 25 other countries. CompuDent has been favorably evaluated in 18 peer
reviewed, published clinical studies and over 25 other evaluative articles. The
system provides these benefits:

     o    minimizes the pain associated with palatal and other injections,
          resulting in a more comfortable injection experience for the patient;

     o    the pencil grip used with The Wand handpiece provides enhanced tactile
          sense and more accurate control;

     o    new injections made possible with CompuDent minimize collateral
          numbness of the tongue, lips and facial muscles;

     o    bidirectional rotation of The Wand handpiece results in greater
          precision and more rapid onset of anesthesia by eliminating needle
          deflection in mandibular block injections;

     o    the single patient use disposable handpiece minimizes the risk of
          cross contamination;

     o    the ergonomic design of The Wand makes an injection easier, less
          stressful to administer and reduces the risk of carpal tunnel syndrome
          to the dentist or hygienist; and

     o    CompuDent can increase productivity in many dental procedures by
          eliminating the need for preliminary pain blocking injections, and
          reducing the waiting time required to see if the injection has taken
          effect.


                                       26
<PAGE>

     The system design allows a drop of anesthetic to always precede the needle
tip, thus creating a pathway of already anesthetized tissue for the needle to
penetrate. The system also eliminates the "bee-sting" effect, that is, the
painful effect associated with a surge of fluid into a confined tissue area.
Syringes do not allow sufficient control of the flow rate to achieve these
benefits. With a syringe, the needle often enters tissue that has not yet been
anesthetized. Further, dentists using a syringe do not have a solid resting
point against which they may guide their hand while administering the
injection, often resulting in uncontrolled and movement of the needle that
causes pain for the patient.

     The slim, pencil-like, shape of The Wand handpiece is also more functional
for the user and less ominous in appearance to the patient. The pencil grip
provides enhanced tactile sense, more accurate control, and a greater level of
stability for the user by preventing antagonistic movements. As a single
patient use device, the handpiece also offers protection against patient
cross-contamination.

     The design of The Wand handpiece allows the practitioner to use a new
needle insertion technique called bidirectional rotational insertion that
minimizes needle deflection. Contemporary dental anesthesia textbooks indicate
that needle deflection is a source of anesthetic failures in mandibular blocks,
the most common dental injection. Anesthetic blocks are missed 15% to 20% of
the time because of needle deflection associated with hypodermic syringes. The
bidirectional rotational insertion technique associated with The Wand handpiece
addresses these failures. Further, the new technique also requires two to three
times less force to penetrate tissue, which may lead to a less painful
injection experience for the patient.

     We sell CompuDent units, together with an initial supply of 50 handpieces,
in the U.S. for $1,995. However, discounts are offered for purchases of
multiple units and on sales of additional units to existing customers. We sell
The Wand for $75 and The Wand with bonded needle handpieces for $62.50, for a
box of 50 handpieces, but offer discounts for participants in the Milestone
Savings Plan and other periodic buying programs.

     Our international master distributors and direct distributors to whom we
sell in a number of countries purchase units at a range of generally lower
prices, depending upon the extent of the marketing, promotional, training and
repair obligations which they assume.


 The SafetyWand

     In September 2003, we received FDA approval for the SafetyWand, an
injection handpiece device that incorporates safety engineered sharps
protection features. The SafetyWand was developed to address requirements of
the Needlestick Safety Act, mandating the use of a safety engineered sharps
device to eliminate inadvertent needle sticks. The Act was adopted in 2000
after it was found that U.S. healthcare workers suffer from an estimated
800,000 needle-stick injuries each year, some of which resulted in cases of
HIV, Hepatitis B, Hepatitis C and other illnesses, costing taxpayers in excess
of $2 billion annually, in testing and treatment.

     OSHA promulgates regulations under the Needlestick Safety Act. OSHA and
corresponding authorities in some states are responsible for enforcing the Act
and its regulations. OSHA and similar state and local authorities conduct
enforcement actions on a state-by-state basis. While OSHA and these state and
local authorities are empowered to levy substantial fines for failure to use
these devices, we believe that they have largely been unable to enforce the law
against dentists because of the inadequacy of existing devices to meet both the
requirements of the law and the unique clinical needs of dentists. The
SafetyWand is one of the first safety engineered injection devices that
conforms with more than 30 parameters published by OSHA to be met by safety
engineered products while also meeting the clinical needs of dental
practitioners. It provides the practitioner with a safer retractable needle
device, with single hand activation, which is reusable multiple times during a
single patient visit, yet small and sleek enough not to obscure the dentist's
often limited field of view.

     We believe that the commercial availability of the SafetyWand will enable
OSHA and similar state and local authorities to begin enforcement, or stricter
enforcement, of the Needlestick Safety Act against dentists. Since the
SafetyWand can only be used with CompuDent, enforcement by OSHA could promote
increased handpiece sales to current CompuDent users, while also providing
significant


                                       27
<PAGE>


impetus for the purchase of these systems by new users. However, there are no
assurances that the Act or related regulations will be strictly or consistently
enforced or that this enforcement will result in increased sales of our
products. We launched the SafetyWand at the American Dental Association Annual
Meeting in California in October 2003 and began initial shipments of the
SafetyWand in January 2004.



 The Wand Handpiece with Needle

     This handpiece was designed to eliminate the re-use of handpieces on
multiple patients, a problem occurring primarily outside the United States.
This product is The Wand handpiece with a needle permanently attached. The
benefits of this product are three-fold: for the patient, the risk of
contamination from a previously used needle is eliminated, for the
practitioner, there is less preparation time needed, and for Milestone, it
should increase overall handpiece sales as customers will now stock handpieces
with different sized needles. In June 2003 we received our CE mark to sell The
Wand Handpiece with Needle in Europe. Since June we have generated $130,000 in
Wand Handpiece with Needle sales.


 CoolBlue Wand Dental Enhancement System

     In August 2003, we entered into an agreement with DaVinci Systems,
granting us non-exclusive distribution rights for the CoolBlue Wand,
manufactured by DaVinci. The CoolBlue Wand is a dental enhancement system that
uses advanced blue light emitting diodes for faster curing of dental repair
amalgams, trans-illumination of teeth and activation of whitening gels and
pastes. The agreement also granted us exclusive worldwide distribution rights
for a whitening head. Under a further understanding with DaVinci, these rights
were expanded to include products for the consumer home market. We began
selling the CoolBlue Wand at a dental trade show in late October 2003. Through
December 15, 2003 we have sold $23,025 of these units and have received orders
for an additional $20,130.

     Curing. Technological advances have allowed the introduction of a
composite material that is soft and malleable and generally matches the color
of teeth. Once applied, this composite is hardened through the use of a curing
light. The first generation of curing lights used halogen lamps, which require
several minutes of curing time and emitted a great deal of heat in the mouth.
Newer curing lights use light emitting diodes ("LEDs") that reduce curing time
and emit less heat. DaVinci's curing light uses shorter wavelength blue LEDs
that cure faster, deeper and cooler than products using halogen lamps. Further,
the design is versatile and allows optional attachments for trans-illumination
to identify cracks in a tooth and for activating whitening gels and pastes.

     Whitening. The curing light may also be used as the base device for a
whitening system employing a proprietary whitening head developed by DaVinci
for Milestone, a dental office treatment kit, a take home kit provided by the
dentist for follow-up, and a unique whitening rinse for long term maintenance.
DaVinci will supply all components of the system to Milestone. Milestone is the
exclusive worldwide distributor of the whitening head. All gels, pastes and
rinse to be used with the whitening head will be supplied to Milestone by
DaVinci at the lowest price provided to its customers.

     We are currently working with a manufacturer to complete development of
packaging for the system. Concurrently, Milestone has engaged a creative firm
to assist in the development of the launch materials, including naming, logo
creation and promotional materials. We expect to launch the whitening system
and to begin shipments of the product in the first quarter of 2004. We believe
this product has an array of practitioner and patient benefits including lower
cost and safety and which will allow the dentist to market take home
consumables.

     For its assistance in arranging our distribution agreement with DaVinci,
we agreed to pay Strider Inc., a commission of 5% of our gross revenues on all
products purchased from DaVinci and resold to the professional dental market,
and a commission of 2% of our gross revenues on all products purchased from
DaVinci and resold to markets other than the professional dental market.


                                       28
<PAGE>

 The Proposed PDL Injector Device

     The periodontal ligament injection, or PDL injection, is a site specific
injection which is highly effective for single tooth anesthesia. During a PDL
procedure, a dentist anesthetizes a single tooth without causing collateral
anesthesia to the tongue, lip and cheek. However, due to the pain elicited from
the high volume of drug required and the associated pressure, a PDL can only be
used as a secondary injection once the patient has already been anesthetized.

     The traditional PDL injection is typically administered using a spring
loaded, high pressure, trigger-activated injector, known as a PDL Injector.
Using this device, anesthetic must be delivered into the PDL under extremely
high pressure and force over a short period of time, resulting in rapid flow
rates and high interstitial pressures in the PDL. A successful injection is
only possible if the needle placement allows the proper flow of anesthetic into
the PDL. If the needle is obstructed in any way, proper flow of the drug cannot
occur and excessive pressure will result, possibly leading to persistent post
operative pain and potential tissue necrosis.

     An independent clinical study conducted by the NYU College of Dentistry in
2000, demonstrated that when lower pressures are used over a longer period of
time, larger volumes of anesthetic can be effectively delivered into the PDL
space. These lower pressures are very difficult to produce with any handheld
syringe and impossible to consistently produce with a PDL Injector. Our
modified PDL injection, administered with the CompuDent, can be used on any
tooth and differs significantly from the traditional PDL injection as
administered with the PDL Injector or syringe. Using these devices requires the
delivery of a relatively small volume of anesthetic solution under tremendous
pressure while the CompuDent allows the operator to deliver a larger volume,
under controlled pressure using a slow, controlled flow rate. The modified PDL
injection can be used for primary anesthesia as well as the traditional
supplementary injection to a mandibular block. Successful administration of the
PDL also reduced the number of visits and time required for many procedures.

     While CompuDent has enhanced the practitioners' ability to perform a
successful PDL injection, there is still one component missing -- the ability
to know for certain that the needle is in the PDL. By using pressure/force
feedback to control the flow rate, one could predictably produce successful PDL
injections.

     We have reduced to practice the use of pressure/force feedback and control
in our CompuFlo device discussed below. The proposed PDL Injector combines our
computer controlled injection system from CompuDent with our patented pressure
sensing technology to scientifically ensure a successful PDL injection. This
pressure sensing technology provides real-time measurement during an injection
that we believe will allow the practitioner to properly position the needle and
inject a sufficient volume of anesthetic. We have begun discussions with a
major international manufacturer of dental equipment for their distribution, on
an exclusive worldwide basis of our proposed PDL Injector. Marketing of the
proposed PDL Injector Device can begin once we obtain a 510(k) clearance the
FDA, which we expect to apply for during the first half of 2004.

MEDICAL PRODUCTS

 CompuMed

     In 2001 Milestone introduced CompuMed, an anesthetic injection system
designed to meet the needs of the medical market. CompuMed provides benefits
similar to CompuDent. CompuMed allows a number of medical procedures, now
requiring IV sedation, to be performed with only local anesthesia because of
the significantly reduced pain. Also, dosages of local anesthetic can often be
significantly reduced, thus reducing side effects, accelerating recovery times,
lowering costs and minimizing complications. CompuMed is now gaining acceptance
in a variety of discrete medical applications including colorectal surgery,
podiatry, dermatology, including Moh's surgery for the removal of basal cell
carcinomas and other oncological dermatologic procedures, nasal and sinus
surgery, including rhinoplasty, hair transplantation and plastic surgery.

     An independent clinical study conducted by researchers at the University
of Southern California and published in May 2001, in colorectal surgery,
confirmed that patients experienced significantly less


                                       29
<PAGE>

pain when the CompuMed system was used. The study was terminated before
accruing its initial target number of patients because the researchers
considered it unethical not to use CompuMed exclusively. In another clinical
study conducted in 2001 by researchers at Scholl College of Podiatric Medicine
in Chicago Illinois, which was presented as an abstract in the field of
podiatry, CompuMed was compared with the traditional hypodermic syringe for
obtaining regional anesthetics in the hallux. The results stated that the
moderate pain associated with the traditional syringe decreased to nearly
non-existent when using the CompuMed.

     Also, in 2002, we sold 21 units of CompuMed to a national hair restoration
provider.

PROPOSED PRODUCTS

 CompuFlo


     Milestone has developed CompuFlo, a prototype injection, perfusion and
aspiration device, that embodies a new technology that Milestone believes, will
provide it with entry into new markets, specifically the large hospital sector.
CompuFlo provides a real time readout of pressures, fluid densities and flow
rates in the delivery and removal of a wide array of liquid drugs and other
fluids, including bodily fluids. Due to cash constraints, Milestone has not yet
developed devices embodying this technology for specific applications. A major
medical center has commenced two clinical pilot studies using the CompuFlo
pressure sensing technology. The first study is to evaluate identification of
the epidural space during epidural anesthesia commonly used for postoperative
pain management and pain relief during childbirth. The second study is designed
to determine whether measuring and controlling injection pressures of local
anesthetics may aid in reducing the risk of peripheral nerve injury while
increasing patient safety. No assurances can be given that these clinical
studies will prove CompuFlo efficacious for these purposes.


 SafetyInfuse Wand

     Milestone has also developed SafetyInfuse Wand, a safety engineered IV
catheter introducer. This product is designed to allow a practitioner to
introduce an IV catheter into a vein using a single-handed, automatic safety
engineered device. Protraction and retraction can be accomplished with a single
hand, further enhancing the safety feature. It is a fail-safe device; that is,
if the safety components break or fail to operate, then the needle moves into
its protected state thus ensuring optimal safety to the end user. A major
advantage of the SafetyInfuse Wand is that it can be used multiple times on a
single patient, following a failure to introduce the catheter into the vein.
Due to cash constraints, Milestone has not yet applied for 510(k) FDA marketing
clearance for the SafetyInfuse Wand, but we expect to do so in 2004.

MANUFACTURING

     CompuDent and CompuMed units are manufactured for us by Tricor Systems,
Inc. ("Tricor") pursuant to specific purchase orders. In order to fund certain
expenses of Tricor, we have advanced funds to Tricor. These advances are
reduced as Tricor makes shipments to us. Net advances to Tricor as of December
31, 2001 and 2002 and September 30, 2003 were approximately $690,000, $398,000,
and $250,000, respectively. The Wand disposable handpiece is manufactured for
us in Mexico by Nypro Precision Assemblies ("NPA"), a subsidiary of Nypro Inc.
Pursuant to scheduled production requirements. NPA utilizes molds,
semi-automated assembly equipment and packaging equipment purchased by us.
These products are sterilized in California and shipped to our fulfillment
center in Pennsylvania. The Wand Handpiece with Needle is supplied to us by
United Systems, which arranges for its manufacture by manufacturers in China.
We may expand our relationship with this supplier to include production of
other types of handpieces. All of the manufacturers for our products, including
those supplying United Systems, are ISO compliant.

MARKETING

 Marketing Background

     When we launched CompuDent in 1997, we relied on four major dental dealers
to distribute our products. While this achieved broad access to dental offices,
the nature of a typical sales visit by these


                                       30
<PAGE>

dealers' representatives proved to be counterproductive to the training
requirements of CompuDent. Though more than 15,000 units were sold in the first
quarter following launch, this distribution method distanced us from our
customers and made it impossible to provide customer support and adequate
clinical training. These factors, coupled with introduction problems typically
associated with new technology and early product design problems, now resolved,
led to disgruntled customers and limited handpiece use. Therefore, in 2000 we
began selling directly to customers. We hired a sales manager and eleven direct
sales representatives to cover major metropolitan areas. However, the then
sales price for CompuDent was inadequate to cover our direct expenses,
including compensation to our representatives. We also experienced difficulty
gaining access to dental offices because the representatives had a single
product and the technology was still new to the market.


 New Marketing Plan -- Dentistry -- Domestic

     In January 2003, we developed a new sales and marketing plan, which
reflected five years of lessons learned in the marketplace. We increased the
base price of CompuDent from $1,495 to $1,995 that allowed us to recruit and
adequately compensate our sales force and support staff. We developed a
comprehensive training plan to enable our reps to provide orientation and
training to new customers, and to foster increased usage of disposable
handpieces. By September 30, 2003, we had a force of 12 sales representatives
providing sales coverage in urban areas in 12 states. The typical independent
rep manages a territory of approximately 3,500 to 5,000 dentists within a large
metropolitan area. We support these independent sales reps in several important
ways:

     o    our sales support staff set appointments to help the reps gain access
          to dental offices;

     o    we generate sales leads for them through our attendance at an average
          of 20 trade shows a year and through limited advertising and direct
          mail campaigns;

     o    we provide technical and service support;

     o    we provide them with access to our existing customer base for the
          purpose of increasing utilization of handpieces as well as converting
          customers to a subscription program, the Milestone Saving Plan, under
          which they commit to the monthly purchase of handpieces at a discount
          from our regular prices; and

     o    in September 2003, we began distributing the CoolBlue Wand which helps
          our sales force gain access to dental offices for sales of CompuDent.

     Also, in 2002 we entered into a non-exclusive distribution agreement with
Benco Dental, granting them rights to distribute CompuDent and its handpieces
in designated portions of the eastern U.S. Benco failed to achieve specified
minimum purchase requirements and we now have the right to terminate the
agreement upon notice to Benco. However, we continue to sell limited amounts of
units and handpieces to Benco at a discount to our direct customers.

     With a growing new sales force and the acquisition of rights to new
products to facilitate access to dental offices, we intend to direct our
marketing efforts to capturing new customers from specialty practitioners,
including periodontists, pedodontists, endodontists and cosmetic/restorative
dentists.


 Dentistry -- International Marketing

     We manage the sales and marketing support for Canada, Mexico, Brazil and
Japan. Throughout the rest of the world, we distribute our products through two
master distributors who manage an extensive network of independent dealers. The
role of these principal distributors, Milestone Medical Technologies ("MMT")
and United Systems, Inc ("United"), includes identification of suitable local
distributors, establishment of distribution arrangements, supporting local
marketing efforts and acting as liaison with the parent company. International
sales represented 18%, 22% and 33% of sales in 2001 and 2002, and the first six
months of 2003, respectively.

     MMT is our principal distributor for Europe, Africa and the Middle East.
MMT is our largest customer, representing 55%, 63% and 77% of our international
revenues in 2001, 2002 and the first nine months of 2003, respectively, and
10%, 14% and 26% of total sales in those periods, respectively.


                                       31
<PAGE>

     United Systems is our principal distributor in China, Taiwan, and South
Korea. Handpiece use for these territories is less than in Europe and the US.
In 2001, 2002 and the first nine months of 2003, respectively, sales to these
territories represented fewer than 1% of our total revenues, for all those
periods.

     In addition, sales to Yoshida Dental Manufacturing Company of Japan, Synca
(our distributor in Canada) and Moyco (our distributor in Mexico) in 2001, 2002
and the first nine months of 2003, represented collectively, 7%, 8% and 6%,
respectively.

     After this offering, we plan to hire a dedicated sales manager for each of
the three major regions -- Europe, Asia and Latin America, to oversee the
implementation of this sales and marketing strategy and to ensure that the
distributors are provided with adequate training and technical support. We also
plan to assist our master distributors to engage new distributors in major
markets, to train existing and new distributors and to replace poor performing
distributors.


     Proposed Expanded Marketing Program for Dental and Hygiene Schools

     More than 5,000 students graduate annually from dental schools in the U.S.
We believe this presents a key opportunity for us to cultivate use of CompuDent
early in the dentists' training. We expect to use a portion of the proceeds of
this offering to offer special educational assistance programs to dental and
hygiene schools in the U.S. and Canada. Our hope is that training in the use of
CompuDent will be incorporated into the curriculum of the schools and that
students will use the products throughout their training.

     As of September 30, 2003, CompuDent has been added to the curriculum of 8
U.S. and Canadian dental schools and 13 schools providing degrees in dental
hygiene. Through our international distribution partners, training in the use
of CompuDent systems has also become part of the curriculum in several
international dental programs. To properly implement a program of this
magnitude and potential importance, we may need to hire a dedicated Academic
Director. This Academic Director, ideally either a retired dentist or
hygienist, would be responsible for working with the staffs of the chosen
institutions on incorporating the product into their curricula.


COMPETITION

     Our anesthetic delivery systems compete with disposable and reusable
syringes that generally sell at lower prices and that use established and
well-understood methodologies and other local anesthetic delivery systems, in
both the dental and medical marketplaces.

     Our systems compete on the basis of their performance characteristics and
the benefits provided to both the practitioner and the patient. Clinical
studies have shown that our systems reduce fear, pain and anxiety for some
patients, and we believe that they can also reduce practitioner stress levels.
CompuDent can be used for all local anesthesia techniques that can be performed
with a syringe. CompuDent can also be used for new and modified techniques that
cannot be performed with traditional syringes. These new techniques allow
faster procedures, shorten chair time, while minimizing numbing of the lips and
facial muscles, enhance productivity, reduce stress and virtually eliminate
pain and anxiety.

     The Luer Lock needle, sold by Milestone, competes with dental needles
produced and distributed by a number of major manufacturers and distributors
and other producers or distributors of dental products, many of whom have
significant competitive advantages because of their size, strength in the
marketplace, financial and other resources and broad product lines. Milestone
competes on the basis of convenience since it can package the product with an
order for disposable handpieces.

     We face intense competition from many companies in the medical and dental
device industry, including well-established academic institutions, possessing
substantially greater financial, marketing, personnel, and other resources.
Most of our competitors have established reputations, stemming from their
success in the development, sale, and service of competing dental products.
Further, rapid technological change and research may affect our products.
Current or new competitors could, at any time, introduce new or enhanced
products with features that render our products less marketable or


                                       32
<PAGE>

even obsolete. Therefore, we must devote substantial efforts and financial
resources to improve our existing products, bring our products to market
quickly, and develop new products for related markets. In addition, our ability
to compete successfully requires that we establish an effective distribution
network. New products must be approved by regulatory authorities before they
may be marketed. We cannot assure you that we can compete successfully, that
our competitors will not develop technologies or products that render our
products less marketable or obsolete, or that we will succeed in improving our
existing products, effectively develop new products, or obtain required
regulatory approval for those products.

PATENTS AND INTELLECTUAL PROPERTY

     We hold the following U.S. utility and design patents:

<TABLE>
<CAPTION>
                                                                               U.S. PATENT       DATE OF
                                                                                  NUMBER          ISSUE
                                                                             ---------------   ----------
<S>                                                                          <C>               <C>
                                 COMPUDENT
Hypodermic Anesthetic Injection Method ...................................      4,747,824        5/31/88
Hypodermic Anesthetic Injection Apparatus & Method .......................      5,180,371        1/19/93
 (CompuFlo, CompuMed, and CompuDent) .....................................
Dental Anesthetic and Delivery Injection Unit ............................      6,022,337         2/8/00
Dental Anesthetic Delivery Injection Unit (continuation of No. 6,022,337)       6,152,734       11/28/00
Dental Anesthetic Delivery Injection Unit (continuation of No. 6,022,337)       6,132,414       10/17/00
Design for a Dental Anesthetic Delivery System Handle ....................       D427,314        6/27/00
Design for a Dental Anesthetic Delivery System Holder ....................       D422,361         4/4/00
Design for a Dental Anesthetic Delivery System Housing ...................       D423,665        4/25/00
Handpiece for Injection Device with a Retractable and Rotating Needle ....      6,428,517         8/6/02

                                SAFETYWAND
Dental Anesthetic and Delivery Injection Unit with Automated Rate
 Control .................................................................      6,652,482       11/25/03

                                 COMPUFLO
Pressure/Force Computer Controlled Drug Delivery System ..................      6,200,289        3/13/01

                                   OTHER
Hypodermic Syringe and Method ............................................      4,877,934       12/19/88
Apparatus and Method for Sterilizing, Destroying and Encapsulating
 Medical Implement Wastes ................................................      4,992,217        2/12/91
Apparatus and Method for Verifiably Sterilizing Destroying and
 Encapsulating Regulated Medical Wastes ..................................      5,078,924         1/7/92
Apparatus and Method for Verifiably Sterilizing, Destroying and
 Encapsulating Regulated Medical Wastes ..................................      5,401,444        3/28/95
Self-Sterilizing Hypodermic Syringe and Method ...........................      5,512,730        4/30/96
Self-Sterilizing Hypodermic Syringe and Method ...........................      5,693,026        12/2/97
</TABLE>


     In addition, we have recently received a Notice of Allowance for patent
protection on a safety intravenous catheter introduction device from the U.S.
Patent Office.


     We also have several patent applications pending before the U.S. Patent
and Trademark Office, and hold a number of corresponding patents in Europe and
other major markets.

     During the 2002 and 2001 fiscal years, we expensed $147,709 and $49,943,
respectively, on research and development activities. The higher costs incurred
during 2002 were primarily associated with the development of the SafetyWand.

     We rely on a combination of patent, copyright, trade secret, and trademark
laws and employee and third party nondisclosure agreements to protect our
intellectual property rights. Despite the precautions taken by us to protect
our products, unauthorized parties may attempt to reverse


                                       33
<PAGE>

engineer, copy, or obtain and use products and information that we regard as
proprietary, or may design products serving similar purposes that do not
infringe on our patents. Litigation may be necessary to protect our
intellectual property rights and could result in substantial cost to us and
diversion of our efforts by with no guarantee of success. Our failure to
protect our proprietary information and the expenses of doing so could have a
material adverse effect on our operating results and financial condition.

     While there are no current claims that our products infringe the
proprietary rights of third parties, there can be no assurance that third
parties will not assert infringement claims against us in the future with
respect to current or future products or that any such assertion may not
require us to cease selling such products, or to enter into arrangements that
require us to pay royalties, or to engage in costly litigation. Although we
have received no claims of infringement, it is possible that infringement of
existing or future patents or proprietary rights of others may occur. In the
event that our products infringe upon patent or proprietary rights of others,
we may be required to modify our processes or to obtain a license. There can be
no assurance that we would be able to do so in a timely manner, upon acceptable
terms and conditions, or at all. The failure to do so would have a material
adverse effect on us.

GOVERNMENT REGULATION

     The FDA cleared CompuDent system and its disposable handpiece for
marketing in the U.S., for dental applications in July 1996, the CompuMed
system for marketing in the U.S. for medical applications in May 2001 and the
SafetyWand for marketing in the U.S. for dental applications in September 2003.
For us to commercialize our other products in the United States, we will have
to submit additional 510(k) applications with the FDA.

     The manufacture and sale of medical devices and other medical products are
subject to extensive regulation by the FDA pursuant to the FDC Act, and by
other federal, state and foreign authorities. Under the FDC Act, medical
devices must receive FDA clearance before they can be marketed commercially in
the United States. Some medical products must undergo rigorous pre-clinical and
clinical testing and an extensive FDA approval process before they can be
marketed. These processes can take a number of years and require the
expenditure of substantial resources. The time required for completing such
testing and obtaining such approvals is uncertain, and FDA clearance may never
be obtained. Delays or rejections may be encountered based upon changes in FDA
policy during the period of product development and FDA regulatory review of
each product submitted. Similar delays also may be encountered in other
countries. Following the enactment of the Medical Device Amendments to the FDC
Act in May 1976, the FDA classified medical devices in commercial distribution
into one of three classes. This classification is based on the controls
necessary to reasonably ensure the safety and effectiveness of the medical
device. Class I devices are those devices whose safety and effectiveness can
reasonably be ensured through general controls, such as adequate labeling,
premarket notification, and adherence to the FDA's Quality System Regulation
("QSR"), also referred to as "Good Manufacturing Practices" ("GMP")
regulations. Some Class I devices are further exempted from some of the general
controls. Class II devices are those devices whose safety and effectiveness
reasonably can be ensured through the use of special controls, such as
performance standards, post-market surveillance, patient registries, and FDA
guidelines. Class III devices are those which must receive premarket approval
by the FDA to ensure their safety and effectiveness. Generally, Class III
devices are limited to life-sustaining, life-supporting or implantable devices.

     If a manufacturer or distributor can establish that a proposed device is
"substantially equivalent" to a legally marketed Class I or Class II medical
device or to a Class III medical device for which the FDA has not required
premarket approval, the manufacturer or distributor may seek FDA marketing
clearance for the device by filing a 510(k) Premarket Notification. The 510(k)
Premarket Notification and the claim of substantial equivalence may have to be
supported by various types of data and materials, including test results
indicating that the device is as safe and effective for its intended use as a
legally marketed predicate device. Following submission of the 510(k) Premarket
Notification, the manufacturer or distributor may not place the device into
commercial distribution until an order is issued by the FDA. By regulation, the
FDA has no specific time limit by which it must respond to a


                                       34
<PAGE>

510(k) Premarket Notification. At this time, the FDA typically responds to the
submission of a 510(k) Premarket Notification within 90 days. The FDA response
may declare that the device is substantially equivalent to another legally
marketed device and allow the proposed device to be marketed in the United
States. However, the FDA may determine that the proposed device is not
substantially equivalent or may require further information, such as additional
test data, before the FDA is able to make a determination regarding substantial
equivalence. Such determination or request for additional information could
delay market introduction of our products and could have a material adverse
effect on us. If a device that has obtained 510(k) Premarket Notification
clearance is changed or modified in design, components, method of manufacture,
or intended use, such that the safety or effectiveness of the device could be
significantly affected, separate 510(k) Premarket Notification clearance must
be obtained before the modified device can be marketed in the United States. If
a manufacturer or distributor cannot establish that a proposed device is
substantially equivalent to a legally marketed device, the manufacturer or
distributor will have to seek premarket approval of the proposed device a more
difficult procedure requiring extensive data, including pre-clinical and human
clinical trial data, as well as extensive literature, to prove the safety and
efficacy of the device.

     Though CompuDent, the SafetyWand and CompuMed have received FDA marketing
clearance, there can be no assurance that any of our other products under
development will obtain the required regulatory clearance on a timely basis, or
at all. If regulatory clearance of a product is granted, such clearance may
entail limitations on the indicated uses for which the product may be marketed.
In addition, modifications may be made to our products to incorporate and
enhance their functionality and performance based upon new data and design
review. There can be no assurance that the FDA will not request additional
information relating to product improvements, that any such improvements would
not require further regulatory review thereby delaying the testing, approval
and commercialization of our development products or that ultimately any such
improvements will receive FDA clearance.

     Compliance with applicable regulatory requirements is subject to continual
review and will be monitored through periodic inspections by the FDA. Later
discovery of previously unknown problems with a product, manufacturer, or
facility may result in restrictions on such product or manufacturer, including
fines, delays or suspensions of regulatory clearances, seizures or recalls of
products, operating restrictions and criminal prosecution and could have a
material adverse effect on us.

     We are subject to pervasive and continuing regulation by the FDA, whose
regulations require manufacturers of medical devices to adhere to certain QSR
requirements as defined by the FDC Act. QSR compliance requires testing,
quality control and documentation procedures. Failure to comply with QSR
requirements can result in the suspension or termination of production, product
recall or fines and penalties. Products also must be manufactured in registered
establishments. In addition, labeling and promotional activities are subject to
scrutiny by the FDA and, in certain circumstances, by the Federal Trade
Commission. The export of devices is also subject to regulation in certain
instances.

     The Medical Device Reporting ("MDR") regulation obligates us to provide
information to the FDA on product malfunctions or injuries alleged to have been
associated with the use of the product or in connection with certain product
failures that could cause serious injury. If, as a result of FDA inspections,
MDR reports or other information, the FDA believes that we are not in
compliance with the law, the FDA can institute proceedings to detain or seize
products, enjoin future violations, or assess civil and/or criminal penalties
against us, its officers or employees. Any action by the FDA could result in
disruption of our operations for an undetermined time.

     In June 2003 we received CE mark in the European Common Market for
marketing in Europe of the SafetyWand and the Wand Handpiece with Needle. In
July 2003, we obtained regulatory approval to sell CompuDent and its handpieces
in Australia and New Zealand.

PRODUCT LIABILITY

     Failure to use any of our products in accordance with recommended
operating procedures potentially could result in subjecting users to health
hazards or injury. Failures of our products to


                                       35
<PAGE>

function properly could subject us to claims of liability. We maintain
liability insurance in an amount that we believe is adequate. However, there
can be no assurance that our insurance coverage will be sufficient to pay
product liability claims brought against us. A partially or completely
uninsured claim, if successful and of significant magnitude, could have a
material adverse effect on us.


EMPLOYEES


     On January 26, 2004 Milestone had 10 full-time employees, including three
executive officers, six sales support staff, a national sales manager, and two
part time employees. In addition, 12 independent sales representatives provide
us with their services on an independent basis.



FACILITIES

     Our offices are located in Livingston Corporate Park in Livingston, New
Jersey. We lease approximately 2,693 square feet of office space under a lease
through March 2007, at a cost that we believe to be competitive. We may have to
increase our office space in the future, and we believe that we will be able to
find adequate premises at reasonable terms. A third party distribution and
logistics center in Pennsylvania handles shipping and order fulfillment.


                                       36
<PAGE>

                                  MANAGEMENT

     The current executive officers, directors and key personnel of Milestone
and their respective ages as of September 30, 2003 are as follows:

<TABLE>
<CAPTION>
                                                                                             DIRECTOR
NAME                                   AGE                      POSITION                      SINCE
- -----------------------------------   ----    -------------------------------------------   ---------
<S>                                   <C>     <C>                                           <C>
Leonard A. Osser ..................    56     Chairman and Chief Executive Officer            1991
Stuart J. Wildhorn ................    46     President
Thomas M. Stuckey .................    49     Vice President and Chief Financial Officer
Mark Hochman, D.D.S. ..............    45     Director of Clinical Affairs
Eugene Casagrande, D.D.S. .........    60     Director of Professional Relations
Paul Gregory (2) ..................    68     Director                                        1997
Leonard M. Schiller(1)(2) .........    62     Director                                        1997
Jeffrey Fuller(1) .................    57     Director                                        2003
Leslie Bernhard(1) ................    59     Director                                        2003
</TABLE>

- ------------
(1)   Member of the Audit Committee

(2)   Member of the Compensation Committee


     Leonard A. Osser has been our Chairman and Chief Executive Officer since
July 1991. From 1980 until the consummation of Milestone's public offering in
November 1995, he was engaged primarily as the principal owner and Chief
Executive of U.S. Asian Consulting Group, Inc., a New Jersey based provider of
consulting services in "work-out" and "turnaround" situations for publicly and
privately owned companies in financial difficulty.

     Stuart J. Wildhorn has been our President since September 2003 and prior
to that he had been our Senior Vice President since April 2001. From 1990 until
April 2001, Mr. Wildhorn held progressive senior management positions with
Datex-Ohmeda, a leading manufacturer of anesthesia and patient monitoring
products.

     Thomas M. Stuckey has been our Vice President and Chief Financial Officer
since May 1998. Mr. Stuckey is a CPA and CMA and holds a MS degree in
Accounting from Syracuse University.

     Dr. Mark Hochman has been a clinical consultant to Milestone since 1997
and has served as the Director of Clinical Affairs and Director of Research and
Development since 1999. He has a doctorate of dental surgery with advanced
training in the specialties of periodontics and orthodontics from New York
University College of Dentistry and has been practicing dentistry since 1984.
He holds a faculty appointment as a clinical associate professor at NYU School
of Dental Surgery. Dr. Hochman is a recognized world authority on advanced
subcutaneous drug delivery systems, has published numerous articles in this
area and is personally responsible for inventing much of the technology
currently available from Milestone.

     Dr. Eugene Casagrande has been the Director of Professional Relations for
Milestone since September 1998. In his capacity, Dr. Casagrande represents
Milestone in a variety of clinical and industry related opportunities. Dr.
Casagrande is the President and founder of Casagrande Consulting Services, an
entity devoted to quality management to the dental industry.

     Paul Gregory has been a director of Milestone since April 1997. Mr.
Gregory has been a business and insurance consultant at Innovative Programs
Associates Inc. and Paul Gregory Associates Inc. since January 1995 and January
1986, respectively, where he services, among other entities, foreign and
domestic insurance groups, law and accounting firms and international
corporations.

     Leonard M. Schiller has been a director of Milestone since April 1997. Mr.
Schiller has been a partner in the Chicago law firm of Schiller, Klein &
McElroy, P.C. since 1977. He has also been President of The Dearborn Group, a
residential property management and real estate acquisition company since 1980.


                                       37
<PAGE>

     Jeffrey Fuller has been a director of Milestone since January 2003. Mr.
Fuller has been president and owner of two municipal water supply systems,
Hudson Valley Water Co. and Lake Lenape Water Co. since 1983 and in addition
has been an executive recruiter since 1995.

     Leslie Bernhard has been a director of Milestone since May 2003. Ms.
Bernhard co-founded AdStar, Inc., and since 1986 has been its president, chief
executive officer and a director. AdStar is an application service provider for
the newspaper classified advertising industry.

     All directors hold office until the next annual meeting of stockholders
and until their successors are duly elected and qualified. Officers are elected
to serve, subject to the discretion of the Board of Directors, until their
successors are appointed.

     Milestone's Board of Directors has established compensation and audit
committees. The Compensation Committee reviews and recommends to the Board of
Directors the compensation and benefits of all the officers of Milestone,
reviews general policy matters relating to compensation and benefits of
employees of Milestone, and administers the issuance of stock options to
Milestone's officers, employees, directors and consultants. All compensation
arrangements between Milestone and its directors, officers and affiliates are
reviewed by the compensation committee, the majority of which is made up of
independent directors. The Audit Committee meets with management and
Milestone's independent auditors to determine the adequacy of internal controls
and other financial reporting matters.


            LIMITATION OF DIRECTORS' LIABILITY AND INDEMNIFICATION

     Our certificate of incorporation provides that a director will not be
personally liable to us or to our stockholders for monetary damages for breach
of the fiduciary duty of care as a director, including breaches which
constitute gross negligence. This provision does not eliminate or limit the
liability of a director:

     o    for breach of his or her duty of loyalty to us or to our stockholders;

     o    for acts or omissions not in good faith or which involve intentional
          misconduct or a knowing violation of law;

     o    under Section 174 of the Delaware General Corporation Law (relating to
          unlawful payments or dividends or unlawful stock repurchases or
          redemptions);

     o    for any improper benefit; or

     o    for breaches of a director's responsibilities under the Federal
          securities laws.

     Our certificate of incorporation also provides that we indemnify and hold
harmless each of our directors and officers to the fullest extent authorized by
the Delaware General Corporation Law, against all expense, liability and loss
(including attorney's fees, judgments, fines, ERISA excise taxes or penalties
and amounts paid or to be paid in settlement) reasonably incurred or suffered
by such person in connection therewith.

     Insofar as indemnification for liabilities arising under the Securities
Act may be permitted to directors, officers and controlling persons pursuant to
our certificate of incorporation, Bylaws and the Delaware General Corporation
Law, we have been advised that in the opinion of the Securities and Exchange
Commission such indemnification is against public policy and is, therefore,
unenforceable.

     Insofar as indemnification for liabilities arising under the Securities
Act may be permitted to directors, officers or controlling persons under our
certificate of incorporation, we have been informed that, in the opinion of the
SEC, indemnification is against public policy as expressed in the Securities
Act and is unenforceable.


                                       38
<PAGE>

                            EXECUTIVE COMPENSATION


     The following Summary Compensation Table sets forth all compensation
earned, in all capacities, during the fiscal years ended December 31, 2003,
2002, and 2001 by (i) Milestone's Chief Executive Officer and (ii) the most
highly compensated executive officers, other than the CEO, who were serving as
executive officers at the end of the 2003 fiscal year and whose salary as
determined by Regulation S-B, Item 402, exceeded $100,000 (the individuals
falling within categories (i) and (ii) are collectively referred to as the
"Named Executives").



                          SUMMARY COMPENSATION TABLE


                                                                AWARDS
                                              ANNUAL         COMMON STOCK
                                           COMPENSATION       UNDERLYING
                                              SALARY           OPTIONS
NAME AND PRINCIPAL POSITION      YEAR           ($)              (#)
- -----------------------------   ------   ----------------   -------------
Leonard A. Osser ............    2003        351,770(1)         16,667
   Chief Executive               2002        351,800(2)         16,667
   Officer and Chairman          2001        350,967(3)         16,667

Stuart J. Wildhorn ..........    2003        163,207
   President                     2002        155,400             2,333
                                 2001         93,750            16,667

Thomas A. Stuckey ...........    2003        144,835
   Chief Financial               2002        136,267(4)          2,333
   Officer and Vice President    2001        116,905             3,333




- ------------
(1)   Includes $320,000 in deferred compensation but excludes $51,928 paid by
      Milestone to Marilyn Elson, a certified public accountant, in payment of
      tax services and assistance with preparation of this registration
      statement. Ms. Elson is the wife of Mr. Osser.

(2)   Includes $320,000 in deferred compensation but excludes $19,049 paid by
      Milestone to Marilyn Elson, Mr. Osser's wife, in payment of professional
      tax services.

(3)   Includes $350,000 in deferred compensation. The deferred compensation was
      paid subsequent to year end through the issuance of 208,333 units, each
      consisting of one share and one six-year warrant to purchase one share at
      prices ranging from $2.40-$6.00. It excludes $20,850 paid by Milestone to
      Marilyn Elson.

(4)   Includes a $20,000 bonus paid in 2002.



STOCK OPTIONS


     The following tables show certain information with respect to incentive
and non-qualified stock options granted in 2003 to Named Executives under
Milestone's 1997 Stock Option Plan and the aggregate value at December 31, 2003
of such options. In general, the per share exercise price of all options is
equal to the fair market value of a share of Common Stock on the date of grant.

              OPTION GRANTS IN 2003 INDIVIDUAL GRANTS OF OPTIONS



<TABLE>
<CAPTION>
                                  NUMBER OF        PERCENT OF TOTAL
                              SHARES OF COMMON     OPTIONS GRANTED
                              STOCK UNDERLYING       TO EMPLOYEES      EXERCISE PRICE
NAME                               OPTIONS             IN 2002             ($/SH)        EXPIRATION DATE
- --------------------------   ------------------   -----------------   ---------------   ----------------
<S>                          <C>                  <C>                 <C>               <C>
Leonard A. Osser .........   16,667 (1)           100%                     $ .87        01-01-08
</TABLE>


- ------------

(1)   Options vest December 1, 2007



                                       39
<PAGE>


                    AGGREGATED 2003 YEAR END OPTIONS VALUES
                 FOR OPTIONS GRANTED PRIOR TO AND DURING 2003



<TABLE>
<CAPTION>
                                      NUMBER OF SHARES OF
                                             COMMON
                                        STOCK UNDERLYING       VALUE OF UNEXERCISED
                                          UNEXERCISED          IN-THE-MONEY OPTIONS
                                     OPTIONS AT 12-31-2002       AT 12-31-2002(1)
                                          EXERCISABLE              EXERCISABLE
               NAME                      UNEXERCISABLE            UNEXERCISABLE
     ----------------------------   -----------------------   ---------------------
<S>                                 <C>                       <C>
     Leonard A. Osser ...........         0 / 66,667              $0 / $28,583
     Stuart J. Wildhorn .........       12,667 / 6,333            $1,167 / $583
     Thomas M. Stuckey ..........        20,222 / 778             $1,167 / $583
</TABLE>


- ------------

(1)   Based on the closing price on December 31, 2003 of $3.09 as quoted on the
      American Stock Exchange.



EMPLOYMENT CONTRACTS

     As of January 1, 1998 Milestone entered into an Employment Agreement with
Mr. Osser, which provides for an initial term expiring on December 31, 2002,
with a two-year non-competition period at the end of the term. The term is
automatically extended for successive one-year periods, unless prior to
December 1 of any year either party notifies the other of its election not to
extend the term. Neither party has given notice to the other. Under the
Agreement Mr. Osser serves as our full-time Chief Executive Officer and
receives annual base pay of $350,000, increasing to reflect cost of living
adjustments commencing on January 1, 2001. In addition, during January 1998 and
each of the next four Januarys Milestone shall grant Mr. Osser an option to
purchase 16,667 shares of Common Stock exercisable only during the last 30 days
of the five-year option term unless Milestone achieves certain financial goals
to be specified annually by the Compensation Committee. Additionally, as soon
as financial statements for each year commencing with 1998 are completed,
Milestone shall grant the executive an additional option to purchase up to
16,667 shares depending upon the achievement of specified performance goals.
Further, Mr. Osser shall receive the opportunity to earn cash bonuses of up to
$200,000 per year depending upon the achievement of performance targets to be
specified by the Option Committee.

     On July 7, 1998, at his sole discretion, Mr. Osser implemented a voluntary
reduction of his annual base salary, reducing his annual base pay from $350,000
to $188,462. The voluntary reduction has been described by Mr. Osser as being
both temporary and having no effect upon his rights under his employment
agreement with Milestone. Such reduction remained in effect until August 5,
2000. At that time, Mr. Osser began to defer his salary at the $350,000 annual
base. At December 31, 2000, his deferred compensation was $141,346. In December
2001, Milestone reached an agreement with Mr. Osser to satisfy the $491,346 of
unpaid salary. The agreement calls for the issuance of 204,728 units. Each unit
consists of one share of Milestone common stock and one warrant to purchase an
additional share of such common stock. The warrants will be exercisable at
$2.40 per share through January 31, 2003, thereafter at $3.00 per share through
January 31, 2004, and thereafter at $6.00 per share through January 31, 2007,
at which time they will expire. On March 31, 2003, Mr. Osser signed an
agreement deferring $640,000 of his annual salary until April 1, 2004. On
October 9, 2003 Mr. Osser signed an agreement according to which he will
receive, on the later of January 2, 2004 or the date this offering becomes
effective, an estimated 50,375 units, in payment of $336,000 of accrued
compensation.

     In December 2003 Milestone entered into a new employment agreement with
Mr. Osser for a five-year term commencing January 1, 2004. Under the new
agreement Mr. Osser will receive base compensation of $300,000 per year,
payable one half in cash and one half in common stock valued at the average
closing price of the common stock during the first 15 trading days in the month
of December during each year of the term. While the number of shares to be
issued will be determined each year, the stock will not be issuable until the
end of the term of the agreement. In addition, Mr. Osser may earn annual
bonuses up to an aggregate of $300,000, payable one half in cash and one


                                       40
<PAGE>

half in common stock, contingent upon Milestone achieving predetermined annual
operating cash flow, revenue and earnings targets. For 2004 he can earn a
$150,000 bonus based on Milestone achieving break-even cash flow from
operations, a $100,000 bonus based on Milestone achieving net revenues of
$6,250,000 and a $50,000 bonus based on Milestone achieving break-even
earnings, determined in accordance with generally accepted accounting
principles. The cash flow bonus and the earnings bonus will not be payable to
the extent that the payment thereof will reduce operating cash flow or earnings
below break-even, respectively. For purposes of the agreement operating cash
flow shall mean cash flow from operations adjusted for financing transactions
plus accounts receivable increases and less accounts payable increases. Shares
of common stock issued in partial payment of bonuses will be valued at the
average closing price of the common stock during the first 15 trading days in
the month of March during each year of the term. The stock portion of the bonus
awards, if any, will be paid at the end of the term of the agreement.


COMPENSATION OF DIRECTORS

     In 2003, each non-employee director was granted a five-year option to
purchase 6,667 shares of our Common Stock at an exercise price of $1.50, a
price above the fair market value of a share of our Common Stock on the date of
grant. Directors receive no cash compensation.


                           EQUITY COMPENSATION PLANS


<TABLE>
<CAPTION>
                                                         NUMBER OF
                                                     SECURITIES TO BE                                NUMBER OF
                                                        ISSUED UPON        WEIGHTED AVERAGE         SECURITIES
                                                        EXERCISE OF       EXERCISE PRICE OF     REMAINING AVAILABLE
                                                        OUTSTANDING          OUTSTANDING        FOR FUTURE ISSUANCE
                                                        OPTIONS AND          OPTIONS AND           UNDER EQUITY
                                                         WARRANTS              WARRANTS         COMPENSATION PLANS
                                                    ------------------   -------------------   --------------------
<S>                                                 <C>                  <C>                   <C>
Equity compensation plans approved by
 stockholders (1):
Grants under our 1997 Stock Option Plan .........         200,115              $ 3.12                114,218

Equity compensation plans not approved by
 stockholders(2)
 Aggregate Individual Option Grants .............         229,167              $ 6.00             Not Applicable

   Total ........................................         429,282              $ 4.66
</TABLE>


- ------------
(1)   Consisting of our 1997 stock option plan covering a total of 333,333
      common shares underlying options issuable to officers and other key
      employees and excluding 2,333 options which were exercised in October
      2003 and 16,667 options which were exercised in December 2003. The plan
      has a term of 10 years and is administered by a committee appointed by
      the board of directors. The committee, in its sole discretion, determines
      who is eligible to receive these incentive stock options, how many
      options they will receive, the term of the options, the exercise price
      and other conditions relating to the exercise of the options. Stock
      options granted under the plan must be exercised within a maximum of 10
      years from the date of grant at an exercise price that is not less than
      the fair market value of the common shares on the date of the grant.
      Options granted to shareholders owning more than 10% of our outstanding
      common shares must be exercised within five years from the date of grant
      and the exercise price must be at least 110% of the fair market value of
      the common shares on the date of the grant.

(2)   The aggregate individual option grants outside the Stock Option Plan
      referred to in the table above include options issued as payment for
      services rendered to us by outside consultants and providers of certain
      services. The aggregate individual warrant grants referred to in the
      table above include warrants granted to investors in Milestone as part of
      private placements and credit line arrangements.


                                       41
<PAGE>

             CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS


     In December 2001, we reached an agreement with Mr. Osser to satisfy
$491,346 of his deferred compensation through the issuance of 204,728 units,
each unit consisted of one share of Milestone common stock and one warrant to
purchase an additional share of common stock. These units were issued to Mr.
Osser in January 2002.

     In January 2002, we issued 108,333 units to K. Tucker Andersen, a 5% or
greater stockholder, each comprised of one share of common stock and one
five-year warrant to purchase one share of common stock at prices increasing
from $2.40 to $6.00, in consideration for $250,000. We also issued to Mr.
Andersen, in January 2002, 11,280 additional units in repayment of interest in
the amount of $27,072 accrued under a $500,000 line of credit.

     As of September 30 and November 10, 2003 we issued an aggregate of 147,011
shares of common stock to Mr. Osser in repayment of $404,638 of principal and
accrued interest on the 6%/12% notes and the prior extension of these notes and
an aggregate of 779,184 shares of common stock to K. Tucker Andersen, in
satisfaction of $2,345,304 of principal and accrued interest on the 6%/12%, 8%
and 10% notes and the prior extension of these notes. The shares issued to
Messrs. Osser and Andersen represented their share of common stock issued to
the holders of that debt in the aggregate amount of approximately $5 million,
including accrued interest, and Messrs. Osser and Andersen received no extra or
special benefit that was not shared on a pro rata basis by all of the holders
of that debt.

     On October 9, 2003 we reached an agreement with Messrs. Osser and Andersen
to satisfy $1,595,734 of debt, including interest, out of which approximately
$402,861 is due to Mr. Osser and $1,192,873 is due to Mr. Andersen. In
addition, $384,000 of deferred compensation is due to Mr. Osser because of his
deferral of salary under his employment agreement. The debt of Messrs. Osser
and Andersen and the deferred compensation to Mr. Osser will be paid through
the issuance of units identical to those offered in this offering, on the later
of January 2, 2004 or the effective date of this offering. The units will be
valued at the initial unit price in this offering.

     We have adopted a policy that, in the future, the audit committee must
review all transactions with any officer, director or 5% shareholder.


                                       42
<PAGE>

        SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

     The following table sets forth information regarding the beneficial
ownership of our common shares as of the date of this prospectus by:

     o    each person, or group of affiliated persons, known by us to be the
          beneficial owner of more than 5% of our outstanding common shares;

     o    each of our directors;

     o    each Named Executive above; and

     o    all of our directors and executive officers as a group.

     The following table does not take into account any common shares sold as a
result of the exercise of the over-allotment option granted to the
representative. Except as otherwise indicated, the persons listed below have
sole voting and investment power with respect to all of the common shares owned
by them. The individual shareholders have furnished all information concerning
their respective beneficial ownership to us.


<TABLE>
<CAPTION>
                                                     SHARES OF
                                                   COMMON STOCK
                                                   BENEFICIALLY        PERCENTAGE OF
NAME OF BENEFICIAL OWNER (1)                         OWNED (2)           OWNERSHIP
- --------------------------------------------   --------------------   --------------
<S>                                            <C>                    <C>
     EXECUTIVE OFFICERS AND DIRECTORS

     Leonard Osser .........................         1,322,058(3)          20.89%
     Stuart J. Wildhorn ....................            13,444(4)              *
     Thomas M. Stuckey .....................            13,989(5)              *
     Paul Gregory ..........................            10,858(6)              *
     Leonard M. Schiller ...................            30,339(7)              *
     Jeffrey Fuller ........................             6,667(8)              *
     Leslie Bernhard .......................             6,667(9)              *
     All directors & executive officers as a
       group (7 persons) ...................         1,404,022(10)         21.90%
     5% AND GREATER STOCKHOLDERS
     K. Tucker Andersen ....................         1,316,717(11)         21.54%
     Cumberland Associates, LLC ............           660,258(12)         10.80%
</TABLE>


- ------------
*     Less than 1%

(1)   The addresses of the persons named in this table are as follows: Leonard
      A. Osser, Stuart Wildhorn and Thomas M. Stuckey are all at 220 South
      Orange Avenue, Livingston Corporate Park, Livingston, NJ 07039; Paul
      Gregory, Innovative Programs Associates Inc., 370 E. 76th Street, New
      York, New York 10021; Leonard M. Schiller, Schiller, Klein & McElroy,
      P.C., 33 North Dearborn Street, Suite 1030, Chicago, Illinois 60602;
      Jeffrey Fuller, Eagle Chase, Woodbury, NY 11797; Leslie Bernhard, AdStar,
      Inc., 4553 Glencoe Avenue, Suite 325, Marina del Rey, California 90292;
      K. Tucker Anderson, c/o Cumberland Associates LLC, 1114 Avenue of the
      Americas, New York, New York 10036; and Cumberland Associates, LLC, 1114
      Avenue of the Americas, New York, New York.

(2)   A person is deemed to be a beneficial owner of securities that can be
      acquired by such person within 60 days from the filing of this proxy
      statement upon the exercise of options and warrants or conversion of
      convertible securities. Each beneficial owner's percentage ownership is
      determined by assuming that options, warrants and convertible securities
      that are held by such person (but not held by any other person) and that
      are exercisable or convertible within 60 days from the filing of this
      report have been exercise or converted. Except as otherwise indicated,
      and subject to applicable community property and similar laws, each of
      the persons named has sole voting and investment power with respect to
      the shares shown as beneficially owned. All percentages are determined
      based on the number of all shares, including those underlying


                                       43
<PAGE>

    options exercisable within 60 days from the filing of this proxy statement
    held by the named individual, divided by 6,112,678 outstanding shares on
    December 15, 2003 and those shares underlying options exercisable within
    60 days from the filing of this proxy statement, held by the named
    individual.


(3)   Includes (i) 204,728 shares issuable upon exercise of stock options
      within 60 days of the date hereof, which until January 31 are exercisable
      at $3.00, and beginning February 1, 2004 will be exercisable at $6.00 and
      (ii) warrants immediately exercisable to purchase 11,904 shares at $5.25
      per share.


(4)   Includes 11,111 shares subject to stock options, exercisable within 60
      days of the date hereof at $7.50 per share and 2,333 shares subject to
      stock options, exercisable within 60 days of the date hereof at $2.25 per
      share.


(5)   Includes 8,333 shares subject to stock options, exercisable within 60
      days of the date hereof at $6.5625 per share, 2,222 shares subject to
      stock options exercisable within 60 days of the date hereof at $7.50 per
      share and 2,333 shares subject to stock options exercisable within 60
      days of the date hereof at $2.25 per share. Mr. Stuckey disclaims
      beneficial ownership of (i) 3,333 shares which are held by his wife as
      custodian for their children, and (ii) 567 shares which are owned by his
      wife in her IRA.


(6)   Includes 50 shares held by Mr. Gregory's wife, 4,141 shares subject to
      stock options, exercisable within 60 days of the date hereof at $6.5625
      per share, and 6,667 subject to stock options, exercisable within 60 days
      of the date hereof at $1.50 per share.

(7)   Includes 4,141 shares subject to stock options, exercisable within 60
      days of the date hereof at $6.5625 per share, 6,667 shares subject to
      stock options, exercisable within 60 days of the date hereof at $1.50 per
      share and 19,531 shares subject to stock options exercisable within 60
      days of the date hereof at $9.00 per share.

(8)   Includes 6,667 shares subject to stock options, exercisable within 60
      days of the date hereof at $1.50 per share.

(9)   Includes 6,667 shares subject to stock options, exercisable within 60
      days of the date hereof at $1.50 per share


(10)  Includes 285,541 shares subject to stock options, 11,904 shares subject
      to warrants all of which are exercisable within sixty (60) days of the
      date hereof and 30,667 shares to which he has shared voting and
      dispositive power.


(11)  Based solely upon an amendment to Schedule 13D filed by K. Tucker
      Andersen with the Securities and Exchange Commission on November 13,
      2003.

(12)  Based solely upon Form 4 filed by Cumberland Associates, LLC with the
      Securities and Exchange Commission on November 5, 2003.

     All of the common shares set forth in the above table are covered by
lock-up agreements prohibiting their sale, assignment or transfer for 90 days
following the date of this prospectus without the prior written consent of the
representative.


                                       44
<PAGE>

                           DESCRIPTION OF SECURITIES

     As of the date of this prospectus, our authorized capital stock consists
of 55,000,000 shares consisting of 50,000,000 of common stock, par value $.001
per share and 5,000,000 shares of preferred stock par value $.001 per share.
After this offering, we will have 9,199,604 shares of common stock issued and
9,166,271 outstanding (9,526,271 outstanding if the over-allotment option is
exercised in full) and 25,356 shares of series A preferred stock. As of the
date of this prospectus, we have 6,112,678 shares of common stock outstanding.


UNITS

     Each unit consists of two shares of common stock and one warrant to
purchase one share of common stock. The shares and the warrants included in the
units will not trade separately until the 31st day following the effective date
of this offering, unless the representative of the underwriters determines that
separate trading of the public warrants shall occur earlier. At closing, we
will deliver only unit certificates. An investor can request physical delivery
of the certificate and can immediately request that the unit certificate can be
exchanged for stock and unit certificates. If the investor does so before the
stock and warrants trade separately, trades based on the stock and warrant
certificates will mot clear until trading in those securities commences.


COMMON STOCK

     The holders of outstanding shares of common stock are entitled to receive
dividends out of legally available assets when and to the extent determined by
our board of directors from time to time. Each stockholder is entitled to one
vote for each share held by him on each matter submitted to a vote of
stockholders. At an election of directors, each director is elected by a
plurality of the voting shares of common stock. The shares of common stock are
not entitled to preemptive rights and are not convertible or redeemable. In the
case of a liquidation, dissolution or other termination of our business, the
holders of common stock are entitled to share ratably in the distribution of
all of our assets remaining available for distribution after all of our
liabilities have been satisfied. Each outstanding share of common stock is, and
all shares of common stock to be outstanding after this offering is completed
will be, fully paid and nonassessable.


WARRANTS


     General. The warrants issued in this offering may be exercised at any time
beginning on the 31st calendar day after this offering and ending on     ,
2005. Each warrant entitles the holder to purchase one share of common stock at
an exercise price of $   per share [150%] of the closing market price of our
common stock on the pricing date of this offering]. This exercise price will be
adjusted if specific events, summarized below, occur. A holder of warrants will
not be deemed a holder of the underlying stock for any purpose until the
warrant is exercised.

     Redemption. Beginning six months after the effective date of this
offering, we will have the right to redeem the warrants at a price of $0.25 per
warrant, after providing 30 days' prior written notice to the warrantholders,
at any time after the closing price for our common stock, as reported on the
principal exchange on which our stock trades, was at or above [200% of the
price of our common stock on the effective date of this offering] for any five
consecutive trading days. We will send a written notice of redemption by first
class mail to holders of the warrants at their last known addresses appearing
on the registration records maintained by the transfer agent. No other form of
notice or publication or otherwise will be required. If we call the warrants
for redemption, the holders of the warrants will then have to decide whether to
sell the warrants, exercise them before the close of business on the business
day preceding the specified redemption date or hold them for redemption.

     We may not give a notice of redemption of the warrants unless the
underlying shares are covered by an effective registration statement.
Additionally, an effective registration statement must be in place for at least
30 calendar days after mailing of the notice of redemption before the
redemption may be effected. Consequently, if an effective registration
statement covering the underlying shares is in place at the time that we mail
our notice of redemption, but, during the notice period, the



                                       45
<PAGE>


registration statement ceases to be in effect (or is suspended), then the
notice period will automatically be extended for that number of calendar days
equal to the number of calendar days of cessation (or suspension), unless
waived in writing by the warrant holder.


     Exercise. The holders of the warrants may exercise them only if an
appropriate registration statement is then in effect and if the common stock
issuable upon their exercise are qualified for sale under the securities laws
of the state in which the holder resides. To exercise a warrant, the holder
must deliver to our transfer agent the warrant certificate on or before the
expiration date or the redemption date, as applicable, with the form on the
reverse side of the certificate executed as indicated, accompanied by payment
of the full exercise price for the number of warrants being exercised.
Fractional shares of common stock will not be issued upon exercise of the
warrants.

     Adjustments of exercise price. The exercise price of the warrants will be
adjusted if we declare any stock dividend to stockholders or effect any split
or share combination with regard to our common stock. If we effect any stock
split or stock combination with regard to our common stock, the exercise price
in effect immediately before the stock split or combination will be
proportionately reduced or increased, as the case may be. Any adjustment of the
exercise price will also result in an adjustment of the number of shares
underlying a unit warrant or, if we elect, an adjustment of the number of
warrants outstanding.

     In order for you to exercise the warrants, the shares of common stock
underlying them must be covered by an effective registration statement and, if
the issuance of shares is not exempt under state securities laws, must be
properly registered with state securities regulators. At present, we plan to
have a registration statement current when the warrants are exercised and, to
the extent that the underlying shares do not qualify for one or more exemptions
under state securities laws, we intend to register the shares with the relevant
authorities. However, we cannot provide absolute assurances that state
exemptions will be available, the state authorities will permit us to register
the underlying shares, or that an effective registration statement will be in
place at the relevant time(s). These factors may have an adverse effect on the
demand for the warrants and the prices that can be obtained from reselling
them.

PREFERRED STOCK

     Under our Certificate of Incorporation, our board of directors has the
authority, without further action by the stockholders, to issue from time to
time up to 5,000,000 shares of preferred stock in one or more series. The board
of directors may fix the number of shares, designations, preferences, powers
and other special rights of each series of the preferred stock. The issuance of
preferred stock could decrease the amount of earnings and assets available for
distribution to holders of common stock, affect adversely the rights and
powers, including voting rights, of the holders of common stock, or have the
effect of delaying, deferring or preventing a change in control in Milestone.

     No shares of the preferred stock have yet been issued or designated.
However, we are obligated to issue 25,356 shares of Series A convertible
preferred stock to a non-affiliate noteholder who agreed to take these shares
in exchange for his portion of approximately $5 million of secured debt.
Initially these shares of the Series A preferred stock will be convertible into
one share of common stock (three shares after giving effect to the proposed
one-for-three reverse stock split). The Series A preferred stock will vote
together with the common stock as a single class and will have one vote for
each share of common stock into which it is convertible. It will have a
liquidation preference of $1.00 per share and will be entitled to 8% cumulative
annual dividends on the amount of its liquidation preference, in cash or common
stock, at Milestone's option, until conversion. The Series A preferred stock
will become convertible into common stock six months after the closing of this
offering and unless converted earlier, will automatically convert to common
stock on November 1, 2005.

OPTIONS AND WARRANTS


     As of the date of this prospectus, we had outstanding 200,115 compensatory
stock options granted to employees and directors. These options have exercise
prices ranging from $.87 to $18.00 per share and expire between February 2005
and January 2008. Of these options, 70,337 are currently exercisable.



                                       46
<PAGE>


     As of the date of this prospectus, we had outstanding 229,167 compensatory
stock options granted to non-employees. These options have exercise prices
ranging from $1.50 to $13.50 per share and expire between July 2005 and May
2008. Of these options, 176,944 are currently exercisable.


     As of the date of this prospectus, we had outstanding 799,730 warrants.
These options have exercise prices ranging from $1.56 to $9.00 per share and
expire between February 2005 and January 2007. All of these options are
currently exercisable.

REGISTRATION RIGHTS

     As of the date of this prospectus, 226,323 shares of common stock,
including shares underlying warrants and convertible debentures are covered by
registration rights agreements with the holders of these securities. Regarding
102,195 shares of common stock, there is an informal understanding that we will
file a registration statement in connection with these shares. Regarding 53,419
shares, we have agreed to use our reasonable best efforts to file a
registration statement covering these shares. The remaining 70,709 are covered
by agreements according to which we will include them in the next Registration
Statement on Form S-3 that we file with the SEC, provided they have not yet
become eligible to sell their shares under Rule 144.

AUTHORIZED BUT UNISSUED SHARES

     The authorized but unissued shares of common and preferred stock are
available for future issuance without stockholder approval. These additional
shares may be utilized for a variety of corporate purposes, including future
public offerings to raise additional capital, corporate acquisitions and
employee benefit plans. The existence of authorized but unissued shares could
render more difficult or discourage an attempt to obtain control of us by means
of a proxy contest, tender offer, merger or otherwise.

     The Delaware General Corporation Law provides generally that the
affirmative vote of a majority of the shares entitled to vote on any matter is
required to amend a corporation's certificate of incorporation or bylaws,
unless the corporation's certificate of incorporation or bylaws, as the case
may be, requires a greater percentage. Our certificate of incorporation does
not impose any supermajority vote requirements.

TRANSFER AGENT, WARRANT AGENT AND REGISTRAR

     The transfer agent and registrar for our common stock and the warrant
agent for the warrants is Continental Stock Transfer & Trust Company, located
in New York, New York.


                                 UNDERWRITING

     The underwriters named below have severally agreed, subject to the terms
and conditions contained in an underwriting agreement with us, to purchase
[1,200,000] units, each unit consisting of two shares of common stock and one
public warrant to purchase one share of common stock from us at the price set
forth on the cover page of this prospectus, in accordance with the following
table:

                                                         NUMBER OF
           UNDERWRITER                                    SHARES
           -----------                                  ----------
           Paulson Investment Company, Inc. .........
           S.W. Bach & Company ......................
                                                        ----------
           Total ....................................
                                                        ==========

     Nature of Underwriting Commitment. The underwriting agreement provides
that the underwriters are committed to purchase all the units offered by this
prospectus if any units are purchased. This commitment does not apply to
180,000 units subject to the over-allotment option granted by us to the
representative to purchase additional units in this offering.

     Conduct of the Offering. We have been advised by Paulson Investment
Company, Inc., that the underwriters propose to offer the units to be sold in
this offering directly to the public at the public


                                       47
<PAGE>

offering price set forth on the cover page of this prospectus, and to certain
securities dealers at that price less a concession of not more than $0.   per
share. The underwriters may allow, and those dealers may reallow, a concession
not in excess of $0.   per share to certain other dealers. After the shares are
released for sale to the public, the underwriters may change the offering price
and other selling terms from time to time. No change in those terms will change
the amount of proceeds to be received by us as set forth on the cover page of
this prospectus.

     The underwriters have informed us that they do not expect to confirm sales
of units offered by this prospectus to accounts over which they exercise
discretionary authority without obtaining the specific approval of the account
holder.

     Over-allotment Option. We have granted the underwriters an option,
expiring 45 days after the date of this prospectus, to purchase up to 180,000
additional units from us on the same terms as set forth in this prospectus with
respect to the 1,200,000 units. The underwriters may exercise this option, in
whole or in part, only to cover over-allotments, if any, in the sale of the
units offered by this prospectus.

     Offering Discounts. The following table shows the per unit and total
underwriting discounts to be paid by us to the underwriters. These amounts are
shown assuming no exercise and full exercise, respectively, of the
underwriters' over-allotment option described above:

<TABLE>
<CAPTION>
                                                                          TOTAL WITHOUT       TOTAL WITH
                                                                         OVER-ALLOTMENT     OVER-ALLOTMENT
                                                           PER UNIT          OPTION             OPTION
                                                         ------------   ----------------   ---------------
<S>                                                      <C>            <C>                <C>
Total underwriting discount to be paid by us .........   $                  $                 $
</TABLE>

     Expense Allowance. We have agreed to pay to Paulson Investment Company,
Inc., a non-accountable expense allowance equal to three percent of the
aggregate public offering price of the units sold by us in this offering
(including units sold on exercise of the underwriters' over-allotment option).

     Representative's Warrants. On completion of this offering, we will issue
to the representative of the underwriters, Paulson Investment Company, Inc.,
warrants to purchase from us up to 120,000 units, for a price of $      per
unit (120%). These warrants are exercisable during the four-year period
beginning one year from the date of this prospectus. These warrants are not
transferable or assignable for one year following the effective date of this
prospectus, except to an individual who is an officer or partner of the
underwriters and members of the selling group, by will or by the laws of
descent and distribution, and are not redeemable.

     The holder of these warrants will have, in that capacity, no voting,
dividend or other shareholder rights. Any profit realized on the sale of the
units issuable upon exercise of these warrants may be deemed to be additional
underwriting compensation. The securities underlying these warrants are being
registered pursuant to the registration statement of which this prospectus is a
part. During the term of these warrants, the holder thereof is given the
opportunity to profit from a rise in the market price of our common stock. We
may find it more difficult to raise additional equity capital while these
warrants are outstanding. At any time at which these warrants are likely to be
exercised, we may be able to obtain additional equity capital on more favorable
terms.

     Indemnification. We have agreed to indemnify the underwriters against
certain liabilities, including liabilities under the Securities Act, or to
contribute to payments that the underwriters may be required to make in respect
thereof.

     Lock-up Agreements. Our officers, directors and the holders of 5% or more
of our securities have agreed not to sell or transfer any shares of our common
stock or equity securities for ninety days after the date of this public
offering, without first obtaining the written consent of Paulson Investment
Company, Inc. Specifically, these officers and directors have agreed not to,
directly or indirectly:

     o    sell or offer to sell any shares of our common stock or equity
          securities;

     o    grant any option to sell any shares of our common stock or equity
          securities;


                                       48
<PAGE>

     o    engage in any short sale of our common stock or equity securities;

     o    pledge or otherwise transfer or dispose of any shares of our common
          stock or equity securities; or

     o    publicly announce an intention to do any of the foregoing.

     These lock-up agreements presently apply to 3,084,884 shares of our common
stock, 379,800 options or warrants to acquire shares of our common stock and
379,800 shares of common stock underlying these options and warrants. These
lock-up agreements apply to all such securities that are currently owned or
later acquired either of record or beneficially by the persons executing the
agreements. However, Paulson Investment Company, Inc. may, in its sole
discretion and without notice, release some or all of the securities subject to
these agreements at any time during the ninety-day period. Currently, there are
no agreements by Paulson Investment Company, Inc. to release any of the
securities from the lock-up agreements.


     Our officers, directors and the holders of 5% or more of our securities
have agreed that, for a period of one year from the date of this prospectus,
they will notify Paulson Investment Company, Inc. before they sell our common
stock under Rule 144.


     Stabilization and Other Transactions. The rules of the SEC generally
prohibit the underwriters from trading in our securities on the open market
during this offering. However, the underwriters are allowed to engage in some
open market transactions and other activities during this offering that may
cause the market price of our securities to be above or below that which would
otherwise prevail in the open market. These activities may include
stabilization, short sales and over-allotments, syndicate covering transactions
and penalty bids.

     o    Stabilizing transactions consist of bids or purchases made by the
          managing underwriter for the purpose of preventing or slowing a
          decline in the market price of our securities while this offering is
          in progress.

     o    Short sales and over-allotments occur when the managing underwriter,
          on behalf of the underwriting syndicate, sells more of our shares than
          they purchase from us in this offering. In order to cover the
          resulting short position, the managing underwriter may exercise the
          over-allotment option described above and/or may engage in syndicate
          covering transactions. There is no contractual limit on the size of
          any syndicate covering transaction. The underwriters will deliver a
          prospectus in connection with any such short sales. Purchasers of
          shares sold short by the underwriters are entitled to the same
          remedies under the federal securities laws as any other purchaser of
          units covered by the registration statement.

     o    Syndicate covering transactions are bids for or purchases of our
          securities on the open market by the managing underwriter on behalf of
          the underwriters in order to reduce a short position incurred by the
          managing underwriter on behalf of the underwriters.

     o    A penalty bid is an arrangement permitting the managing underwriter to
          reclaim the selling concession that would otherwise accrue to an
          underwriter if the common stock originally sold by the underwriter was
          later repurchased by the managing underwriter and therefore was not
          effectively sold to the public by such underwriter.

     If the underwriters commence these activities, they may discontinue them
at any time without notice. The underwriters may carry out these transactions
on the American Stock Exchange, in the over-the-counter market or otherwise.


                                 LEGAL MATTERS


     The validity of the common shares offered by this prospectus will be
passed upon for us by Morse, Zelnick, Rose & Lander LLP, New York, New York.
Holland & Knight LLP will pass upon certain matters for the underwriters named
in this prospectus in connection with this offering. Morse, Zelnick, Rose and
Lander, LLP, legal counsel to Milestone, and its affiliates are the holders of
158,463 shares of common stock and options to purchase 71,873 shares of Common
Stock.



                                       49
<PAGE>

     In addition, Morse, Zelnick, Rose & Lander LLP will receive 29,985 units
following ten days from the closing of this offering in payment of accrued
legal fees pursuant to a March 2003 commitment.


                                    EXPERTS

     The Consolidated Financial Statements as of December 31, 2002 and for the
years ended December 31, 2001 and 2002, have been audited by J. H. Cohn LLP,
independent public accountants, as set forth in their report. We have included
these financial statements in the prospectus and elsewhere in the registration
statement in reliance on J. H. Cohn LLP's report, given on their authority as
experts in accounting and auditing.


                      WHERE YOU CAN FIND MORE INFORMATION

     In connection with the units offered by this prospectus, we have filed a
registration statement on Form S-2 under the Securities Act with the SEC. This
prospectus, filed as part of the registration statement, does not contain all
of the information included in the registration statement and the accompanying
exhibits and schedules. For further information with respect to our units,
shares and warrants, and us you should refer to the registration statement and
the accompanying exhibits and schedules. Statements contained in this
prospectus regarding the contents of any contract or any other document are not
necessarily complete, and you should refer to the copy of the contract or other
document filed as an exhibit to the registration statement, each statement
being qualified in all respects by the actual contents of the contract or other
document referred to. You may inspect a copy of the registration statement and
the accompanying exhibits and schedules without charge at the Securities and
Exchange Commission's public reference facilities, Room 1024, 450 Fifth Street,
N.W., Washington, D.C. 20549, and at its regional offices located at 233
Broadway, 16th Flr., New York, NY 10279, and you may obtain copies of all or
any part of the registration statement from those offices for a fee. You may
obtain information on the operation of the Public Reference Room by calling the
Securities and Exchange Commission at 1-800-SEC-0330. The SEC maintains a web
site that contains reports, proxy and information statements and other
information regarding registrants that file electronically. The address of the
site is http://www.sec.gov.

     We are registered under the Securities and Exchange Act of 1934 and we
file with the SEC annual reports on Form 10-KSB and quarterly reports on Form
10-QSB. The following documents filed by us with the Securities and Exchange
Commission are incorporated in this prospectus by reference:

     (1)  Annual Report on Form 10-KSB for the fiscal year ended December 31,
          2002;


     (2)  Quarterly Report on Form 10-QSB for the fiscal quarters ended March
          31, 2003, June 30, 2003 and September 30, 2003 including the amendment
          to Form 10-QSB for the fiscal quarter ended September 30, 2003, as
          filed with the Commission on November 14, 2003.;

     (3)  Current Reports on Form 8-K filed on April 17, 2003, July 3, 2003 and
          July 23, 2003; and



     Upon written or oral request, we will provide, without charge, to each
person to whom a copy of this prospectus is delivered, a copy of any document
incorporated by reference in this prospectus (other than exhibits, unless such
exhibits are specifically incorporated by reference in such documents).
Requests should be directed to Milestone Scientific Inc., 220 South Orange
Avenue, Livingston, NJ 07039, (973) 535-2717 Attention: Leonard Osser, Chairman
and Chief Executive Officer.

     We intend to furnish our shareholders with annual reports containing
financial statements audited by our independent public accountants. This
prospectus will not be accompanied by our latest annual report to shareholders.



                                       50
<PAGE>

                  MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES

                                     INDEX

<TABLE>
<CAPTION>
                                                                                         PAGE
                                                                                         -----
<S>                                                                                       <C>
Interim Financial Statements for the Nine Months Ended September 30, 2003
   -- Condensed Consolidated Balance Sheets
      September 30, 2003 (Unaudited) and December 31, 2002 ............................   F-2
   -- Condensed Consolidated Statements of Operations
      Nine Months Ended September 30, 2003 and 2002 (Unaudited) .......................   F-3
   -- Condensed Consolidated Statements of Cash Flows
      Nine Months Ended September 30, 2003 and 2002 (Unaudited) .......................   F-4
   -- Notes to Condensed Consolidated Financial Statements (Unaudited) ................   F-6
Financial Statements for the Year Ended December 31, 2002
   -- Report of Independent Public Accountants ........................................   F-14
   -- Consolidated Balance Sheet at December 31, 2002 .................................   F-15
   -- Consolidated Statements of Operations years ended December 31, 2002 and 2001 ....   F-16
   -- Consolidated Statements of Changes in Stockholders' Deficiency years ended
      December 31, 2002 and 2001 ......................................................   F-17
   -- Consolidated Statements of Cash Flows years ended December 31, 2002 and 2001 ....   F-19
   -- Notes to Consolidated Financial Statements ......................................   F-21
</TABLE>



                                      F-1
<PAGE>

                  MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES


                     CONDENSED CONSOLIDATED BALANCE SHEETS
                   SEPTEMBER 30, 2003 AND DECEMBER 31, 2002



<TABLE>
<CAPTION>
                                                                         SEPTEMBER 30,      DECEMBER 31,
                                                                              2003              2002
                                                                        ---------------   ----------------
                                                                          (UNAUDITED)
<S>                                                                     <C>               <C>
                                ASSETS
Current Assets:
 Cash ................................................................. $    95,870       $     9,683
 Accounts receivable, net .............................................     611,602           239,435
 Inventories ..........................................................     255,288           119,291
 Advances to contract manufacturer ....................................     250,360           300,000
 Deferred debt financing costs, net ...................................          --           159,877
 Prepaid expenses .....................................................      61,611            64,952
                                                                        -----------       -----------
       Total current assets ...........................................   1,274,731           893,238
Equipment, net ........................................................     205,158           227,207
Advances to Contract Manufacturer -- Long term ........................          --            87,935
Deferred Debt Financing -- Long term ..................................       1,964                --
Other Assets ..........................................................      32,333            32,333
                                                                        -----------       -----------
       Totals ......................................................... $ 1,514,186       $ 1,240,713
                                                                        ===========       ===========
                 LIABILITIES AND STOCKHOLDERS' DEFICIENCY
Current Liabilities:
 Account payable, including $32,000 to related parties................. $ 1,177,061       $ 1,269,523
 Accrued expenses .....................................................      57,080            86,492
 Accrued interest .....................................................     197,585           169,519
 Note payable net of debt discount ....................................     915,485         4,581,708
 Notes payable-officer/stockholder ....................................     376,215                --
                                                                        -----------       -----------
       Total current liabilities ......................................   2,723,426         6,107,242
Accounts payable, including $160,000 to related parties................     492,193                --
Accrued interest ......................................................       1,042           139,323
Deferred compensation payable to officer/stockholder ..................     560,000           320,000
Notes payable, net of debt discount ...................................     582,514           480,091
Notes payable -- officer/stockholder ..................................      32,000           300,000
                                                                        -----------       -----------
       Total liabilities ..............................................   4,391,175         7,346,656
                                                                        -----------       -----------
Commitments and Contingencies
Stockholders' Deficiency:
 Preferred stock, par value $.001; authorized 5,000,000 shares.........          --                --
 8% Cumulative convertible preferred par value $.001; authorized and
   issued 25,365 shares; ..............................................          25                --
 Common stock, par value $.001; authorized, 50,000,000 shares;
   5,890,875 shares and 4,244,457 shares issued, at September 30, 2003
   and December 31, 2002, respectively ................................       5,891             4,244
 Additional paid-in capital ...........................................  41,622,760        36,608,096
 Accumulated deficit .................................................. (43,574,149)      (41,786,767)
 Unearned compensation ................................................     (20,000)          (20,000)
 Treasury stock, at cost, 33,333 shares ...............................    (911,516)         (911,516)
                                                                        -----------       -----------
       Total stockholders' deficiency .................................  (2,876,989)       (6,105,943)
                                                                        -----------       -----------
         Totals ....................................................... $ 1,514,186       $ 1,240,713
                                                                        ===========       ===========
</TABLE>

            See Notes to Condensed Consolidated Financial Statements.

                                      F-2
<PAGE>

                  MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES

                CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                 NINE MONTHS ENDED SEPTEMBER 30, 2003 AND 2002
                                  (UNAUDITED)

<TABLE>
<CAPTION>
                                                                                     2003                2002
                                                                              -----------------   -----------------
<S>                                                                           <C>                 <C>
Net sales .................................................................     $   3,101,281       $   3,215,907
Cost of sales .............................................................         1,560,288           1,499,063
                                                                                -------------       -------------
Gross profit ..............................................................         1,540,993           1,716,844
                                                                                -------------       -------------
Selling, general and administrative expenses ..............................         2,491,737           2,712,649
Charge in connection with the closing of the Deerfield, IL facility .......            79,023                  --
Research and development expenses .........................................           112,158              63,928
                                                                                -------------       -------------
   Totals .................................................................         2,682,918           2,776,577
                                                                                -------------       -------------
Loss from operations ......................................................        (1,141,925)         (1,059,733)
Other income ..............................................................                --              72,000
Interest, net .............................................................          (645,457)           (616,519)
                                                                                -------------       -------------
Net loss ..................................................................     $  (1,787,382)      $  (1,604,252)
                                                                                =============       =============
Loss per share -- basic and diluted .......................................     $        (.42)      $        (.39)
                                                                                =============       =============
Weighted average shares outstanding -- basic and diluted ..................         4,217,185           4,084,341
                                                                                =============       =============
</TABLE>

            See Notes to Condensed Consolidated Financial Statements.

                                      F-3
<PAGE>

                  MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES

                CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                 NINE MONTHS ENDED SEPTEMBER 30, 2003 AND 2002
                                  (UNAUDITED)



<TABLE>
<CAPTION>
                                                                                 2003               2002
                                                                           ----------------   ----------------
<S>                                                                        <C>                <C>
Cash flows from operating activities:
 Net loss ..............................................................     $ (1,787,382)      $ (1,604,252)
 Adjustments to reconcile net loss to net cash used in operating
   activities:
   Depreciation ........................................................           26,618             41,672
   Amortization of debt discount and deferred financing costs ..........          242,628            234,837
   Loss on disposal of fixed assets ....................................           11,248                 --
   Amortization of advertising cost ....................................               --             24,803
   Stock options issued for services ...................................               --              2,500
   Changes in operating assets and liabilities:
    Increase in accounts receivable ....................................         (372,167)          (153,015)
    (Increase) decrease in inventories .................................         (135,997)            80,614
    Decrease in advances to contract manufacturer ......................          137,575            174,449
    (Increase) decrease in prepaid expenses ............................            3,341            (10,378)
    Increase in other assets ...........................................               --            (19,971)
    Increase in accounts payable .......................................          399,731            169,465
    Increase in accrued interest .......................................          402,827            381,682
    Increase (decrease) in accrued expenses ............................          (29,412)            19,829
    Increase in deferred compensation ..................................          240,000            240,000
                                                                             ------------       ------------
      Net cash used in operating activities ............................         (860,990)          (417,765)
                                                                             ------------       ------------
Cash flows from investing activities-payment for capital expenditures ..          (15,817)           (69,691)
                                                                             ------------       ------------
Cash flows from financing activities:
 Expenses related to registering shares ................................          (22,500)                --
 Proceeds from note payable -- officer/stockholder .....................          180,537                 --
 Payments to note payable -- officer/stockholder .......................          (72,322)                --
 Proceeds from issuance of notes payable ...............................          900,000            525,000
 Payments for deferred financing costs .................................          (22,721)           (40,538)
                                                                             ------------       ------------
      Net cash provided by financing activities ........................          962,994            484,462
                                                                             ------------       ------------
Net Increase (Decrease) in Cash ........................................           86,187             (2,994)
Cash, beginning of period ..............................................            9,683             15,742
                                                                             ------------       ------------
Cash, end of period ....................................................     $     95,870       $     12,748
                                                                             ============       ============
</TABLE>

            See Notes to Condensed Consolidated Financial Statements.

                                      F-4
<PAGE>

                   MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES

                 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                  NINE MONTHS ENDED SEPTEMBER 30, 2003 AND 2002
                                   (UNAUDITED)


Supplemental schedule of noncash financing activities:

     In September 2003, the Company granted warrants to purchase 5,000 shares
of common stock (with an estimated fair value of $10,400) in connection with a
$50,000 credit facility provided by an existing investor. This resulted in an
initial increase to debt discount and to additional paid-in capital.

     On September 30, 2003, in consideration for payment of $5,014,267 of
aggregate debt and interest, the Company issued 1,646,419 shares of common
stock and $25,365 face amount of 8% cumulative convertible preferred stock.

     In June 2003, we granted warrants to purchase 53,419 shares of common
stock (with an estimated fair value of $14,423) in connection with a $50,000
credit facility provided by a major existing investor. This resulted in an
initial increase to debt discount and to additional paid-in capital.

     During the nine months ended September 30, 2003, pursuant to the 6%/12%
promissory note agreements, we converted $206,989 of accrued interest into
additional principal.

     In January 2002, we issued 11,280 units consisting of one share of common
stock and one warrant to purchase an additional share of common stock in
exchange for payment of accrued interest totaling $27,072.

     In January 2002, in consideration for payment of $491,346 in deferred
compensation, we issued 204,728 units (consisting of one share of common stock
and one warrant to purchase an additional share of common stock).The warrants
are exercisable at $2.40 per share through January 31, 2003; at $3.00 per share
through January 31, 2004 and thereafter at $6.00 per share through January 31,
2007.

     In January 2002, pursuant to the 20% promissory note agreements, we
converted $63,377 of accrued interest into additional principal.

     In April 2002, pursuant to the 20% promissory note agreements, we
converted $65,168 of accrued interest into additional principal.

     In April 2002, pursuant to the debt restructuring, we recorded a deferred
financing charge of $329,572. This resulted in an increase to notes payable of
$140,203 and accrued interest of $189,369.

     In September 2002, pursuant to the 6%/12% promissory note agreements, the
Company converted $41,512 of accrued interest into additional principal.

     In August 2002, the Company issued 66,667 shares of common stock in
exchange for payment of $90,000 of outstanding legal fees.

     In July 2002, the Company issued 62,500 units consisting of one share of
common stock and one warrant to purchase an additional share of common stock to
a vendor as consideration for services rendered in accordance with the
agreement valued at $150,000.


                                      F-5
<PAGE>

                  MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES

              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                  (UNAUDITED)


NOTE 1 -- SUMMARY OF ACCOUNTING POLICIES

     The unaudited condensed consolidated financial statements of Milestone
Scientific Inc. and Subsidiaries (the "Company" or "Milestone") have been
prepared in accordance with accounting principles generally accepted in the
United States of America for interim financial information. Accordingly, they
do not include all of the information and footnotes required by accounting
principles generally accepted in the United States of America for complete
financial statements.

     These unaudited condensed consolidated financial statements should be read
in conjunction with the consolidated financial statements and notes thereto for
the year ended December 31, 2002 included in our Annual Report on Form 10-KSB.
The accounting policies used in preparing these unaudited condensed
consolidated financial statements are the same as those described in the
December 31, 2002 consolidated financial statements.

     In the opinion of Milestone, the accompanying unaudited condensed
consolidated financial statements contain all adjustments (consisting of normal
recurring entries) necessary to present fairly the financial position as of
September 30, 2003 and the results of operations for the nine months ended
September 30, 2003 and 2002.

     The results reported for the nine months ended September 30, 2003 and 2002
are not necessarily indicative of the results of operations which may be
expected for a full year.


NOTE 2 -- BASIS OF PRESENTATION

     The accompanying condensed consolidated financial statements have been
prepared assuming Milestone will continue as a going concern. However, as shown
in the accompanying condensed consolidated financial statements, Milestone
incurred net losses of approximately $1,787,000 and $1,604,000 and negative
cash flows from operating activities of approximately $861,000 and $418,000
during the nine months ended September 30, 2003 and 2002, respectively. As a
result, Milestone had a cash balance of only approximately $96,000, a working
capital deficiency of approximately $1,449,000 and a stockholders' deficiency
of approximately $2,877,000 as of September 30, 2003. These matters raise
substantial doubt about Milestone's ability to continue as a going concern.
Management believes that its initial concerns about Milestone's ability to
continue as a going concern have been alleviated by recent actions taken by
Milestone as well as management's plans which are discussed below.

     Further, management believes that, in the absence of substantial increase
in revenue, it is probable that Milestone will continue to incur losses and
negative cash flows from operating activities through at least September 30,
2004 and that Milestone will need to obtain additional equity or debt
financing, as well as to continue its ability to defer its obligations, to
sustain its operations until it can expand its customer base and achieve
profitability, if ever.


REDUCTION OF OPERATING OVERHEAD

     To date, the Company has taken certain steps in order to reduce its
operating overhead and utilization of cash. These steps include, amongst
others, the following:

     o    Commencing in 2001 and continuing through 2003, the Company
          reconfigured its sales force. The Company went from maintaining a
          large internal sales force to utilizing independent sales
          representatives and distributors.

     o    The Company reduced administrative personnel and telemarketers by
          approximately ten people.


                                      F-6
<PAGE>

                   MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES

       NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
                                   (UNAUDITED)

NOTE 2 -- BASIS OF PRESENTATION -- (CONTINUED)

     o    On January 31, 2003, the Company completed the closing of the
          Deerfield, IL facility. The customer support, service and other
          back-office functions previously conducted, in whole or in part, at
          this location were consolidated into the Company's New Jersey
          location. The receiving, shipping and storage functions, which were
          also previously done at this location, are now outsourced to an
          independent warehouse located in Pennsylvania.

RESTRUCTURING LIABILITIES AND PROFORMA IMPACT

     On September 30, 2003, the Company satisfied approximately $5,014,000 of
secured debt including interest, through the issuance of 1,646,419 shares of
Common Stock and $25,365 face amount of 8% cumulative convertible preferred
stock. In addition, during October and November 2003, the Company took the
following additional steps to restructure its liabilities and raise equity.

     o    On October 31, 2003, the Company issued 102,195 shares of common stock
          to certain of its principal vendors having a fair value of
          approximately $502,800, in satisfaction of trade payables and future
          services in the aggregate amount of $502,800.

     o    The Company has agreed to issue 94,327 shares of common stock having a
          fair value of $329,572 in satisfaction of $329,572 of deferred
          financing costs incurred in extending certain of its outstanding
          loans.

     o    The Company issued 33,943 shares of common stock upon the receipt of
          approximately $189,000 upon exercising its rights to draw upon a
          private equity put facility.

     o    The Company issued 2,333 shares of its common stock upon the exercise
          of options by an employee and the receipt of $7,750.

     o    Additionally, the Company reached agreements with a major investor and
          the Company's chairman and chief executive officer to satisfy in the
          aggregate, an approximate $1,961,000 of debt, accrued interest and
          deferred compensation through the issuance of securities at fair value
          at the later of (i) the effective date of a public offering or (ii)
          January 2, 2004.

     These transactions have had or will have a significant impact on the
Company's net worth. Presented below on a proforma basis is selected financial
data, which gives effect to the aforementioned transactions as if they occurred
on September 30, 2003.

                                                     SEPTEMBER 30, 2003
                                                   -----------------------
                                                      ACTUAL      PROFORMA
                                                   -----------   ---------
                                                       (IN THOUSANDS)
Total current assets ...........................    $  1,275      $1,643
Total current liabilities ......................       2,724       1,301
Working capital (deficiency) ...................      (1,449)        342
Total liabilities ..............................       4,391       1,768
Total stockholders equity (deficiency) .........      (2,877)        114

ADDITIONAL RESOURCES

     In April 2003, the Company received an additional $900,000 8% line of
credit from a major investor which is scheduled to mature on January 1, 2005.
As of September 30, 2003, $600,000 was outstanding on the aforementioned line
of credit.

EQUITY PUT FACILITY

     During October 2003 and through November 4, 2003, Milestone exercised its
right to draw upon a private equity facility. In exchange of net proceeds of
$189,440 the Company issued 33,943 shares of


                                      F-7
<PAGE>

                  MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES


      NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
                                  (UNAUDITED)

NOTE 2 -- BASIS OF PRESENTATION -- (CONTINUED)

common stock. The put facility was arranged in January 2001 under the terms of
a three-year private equity line agreement with Hillgreen Investments Limited
("Hillgreen"), a British Virgin Islands corporation. Hillgreen is obligated to
purchase, subject to the fulfillment of specified conditions, up to 700,000
shares of Milestone's common stock. Hillgreen has allocated $20,000,000 to fund
its purchase obligations. The transaction was arranged by Jesup & Lamont
Securities Corporation, a New York based investment banking firm. Milestone's
right to draw upon this facility is subject to a number of limitations and
conditions, including a limitation on the amounts sold to Hillgreen within
specified periods. Subject to these and other conditions and limitations,
Milestone will have full control over the timing of any financing under the
equity line and is under no obligation to sell any shares to Hillgreen. All
shares that are sold are priced at 87.5% of the volume weighted average market
price of Milestone common stock during a fixed period prior to the sale.
Milestone has discretion to establish a floor price below which shares will not
be sold by Milestone to Hillgreen.

EQUITY OFFERING

     On November 10, 2003, the Company filed with the Securities Exchange
Commission a registration statement on Form S-2 (the "Registration Statement").
The Registration Statement covers the sale of units of common stock and
warrants for an aggregate firm commitment gross offering price of $8,000,000 to
$10,000,000. The warrants included in the units are exercisable at any time
after they become separately tradable until their expiration date, five years
after the date of the closing of the offering of an exercise price equal to
150% of the closing market price of our common stock on the pricing date of
this offering. Some or all of the warrants may be redeemed by us at a price of
$0.01 per warrant, by giving not less than 30 days notice to the holders of the
warrants, which the Company may do at any time, beginning 6 months from the
effective date of this offering after the closing price for the Company's
common stock on the principal exchange on which it trades (i.e. AMEX) has
equaled or exceeded 200% of the price of the Company's common stock on the
effective date of this offering. The common stock included in the units and the
warrants will trade only as a unit for 30 days following the closing date of
the offering, unless the underwriter determines that separate trading should
occur earlier.

     After that date, the common stock included in the units and the warrants
will trade separately. The size of the offering, the number of units to be
sold, the price per unit, the securities included in the units and the exercise
price of the warrants are all subject to change.

     As currently contemplated, the gross proceeds of an $8,000,000 offering
are expected to yield net proceeds, of $6,500,000 after taking into account
underwriting discounts and commissions and estimated offering expenses. As set
forth in the Registration Statement the net proceeds of the offering will be
used primarily to expand and support sales and marketing efforts for CompuDent
in the United States, including new marketing and advertising campaigns,
support the launch of the recently announced SafetyWand product line, expand
international sales efforts and develop commercial models of products using
other new subcutaneous injection technology. We will retain broad discretion in
the allocation of the net proceeds within the categories set forth above. The
amounts actually expended within these categories may vary significantly and
will depend on a number of factors, including our rate of revenue growth, cash
generated by operations, evolving business needs and other factors. There are
no assurances that the Company will be successful in raising the aforementioned
amount of capital or any other amount.

     The accompanying unaudited condensed consolidated financial statements do
not include any adjustments relating to the recoverability and classification
of recorded asset amounts or the amounts and classifications of liabilities
that might be necessary should the Company be unable to continue as a going
concern.


                                      F-8
<PAGE>

                  MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES


      NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
                                  (UNAUDITED)
NOTE 3 -- LOSS PER SHARE

     The rights of the Company's preferred and common stockholders are
substantially equivalent. The Company has included the 25,365 outstanding
preferred shares from the date of issuance in the weighted average number of
shares outstanding in the computation of basic loss per share for the three and
nine months ended September 30, 2002 and 2003, in accordance with the "two
class" method of computing earnings (loss) per share.

     Options and warrants to purchase 1,100,271 and 1,584,452 shares of common
stock were outstanding as of September 30, 2003 and 2002, respectively, but
were not included in September the computation of diluted loss per share
because the effect would have been anti-dilutive.


NOTE 4 -- SIGNIFICANT CUSTOMER

     We had one foreign customer who accounted for approximately 25% of our net
sales for the nine months ended September 30, 2003 and approximately 18% for
the nine months ended September 30, 2002. At June 30, 2003, receivables from
this customer were approximately 70% of our total accounts receivable.


NOTE 5 -- NOTES PAYABLE TO OFFICER/STOCKHOLDER

     Notes payable to officer/stockholder represent six obligations payable to
our Chief Executive Officer ("CEO"), consisting of (i) $200,000 note payable,
with interest payable at 9% per annum and having an original due date of
January 2, 2003, (ii) a $100,000 line of credit with interest payable at 6% per
annum having an original due date of April 2, 2003, and (iii) a $108,215 of
notes payable on demand with interest payable at 6% per annum.

     The $108,215 arose when the Company's CEO provided the Company with a
$57,322 short term loan on January 17, 2003 for the express purpose of
purchasing Wand(R) handpieces from the Company's supplier. The Company repaid
the loan in full by February 7, 2003. On February 12, 2003, April 7 and
September 30, 2003, the Company's CEO provided additional demand loans of
$38,215, $35,000 and $50,000, respectively. The loans for $38,215 and $35,000
were provided to fund operations. The loan for $50,000 was provided for the
purpose of covering expenses relating to the further exploration of equity
financing alternatives. As of September 30, 2003 and November 4, 2003, $108,215
remains outstanding.

     On April 1, 2003, the $200,000 and $100,000 notes were extended to
April 1, 2004. On April 15, 2003, $32,000 of the $108,215 notes payable was
extended to January 2, 2005.


NOTE 6 -- NOTES PAYABLE

6%/12% PROMISSORY NOTES

     On September 30, 2003, the Company satisfied $5,014,014 of secured debt
obligations including interest through the issuance of 1,646,419 shares of its
Common stock and 25,365 of its Preferred Stock. These obligations consisted of
the following:

     o    6%/12% Promissory Notes with an aggregate value of $2,822,959

     o    8% Promissory Notes with an aggregate value of $1,604,315

     o    $500,000 line of credit and $86,740 of accrued interest


                                      F-9
<PAGE>

                   MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES

       NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
                                   (UNAUDITED)

NOTE 6 -- NOTES PAYABLE -- (CONTINUED)

     As of September 30, 2003, short term notes payable, net of a $9,955 debt
discount, consist of the following:

     $329,572 of additional consideration given to the original noteholder of
the 6%/12% of promissory notes when they agreed to extend the obligations on
April 15, 2002 until July 1, 2003. The $329,572 of the additional consideration
was subsequently satisfied through the issuance of 94,327 shares of the
Company's Common stock during October and November 2003 valued at $3.48 per
share, the fair value.

     o    $500,000 borrowed under the $1,000,000 6% credit facility.

     o    $600,000 borrowed under the $900,000 8% credit facility.

     Agreements reached in October 2003 provide for the satisfaction of the
obligations through the issuance of equity securities by January 2004. (See
Note 2)

     Long term notes payables consist of $100,000 in 6% promissory notes and
$500,000 of the 8% promissory note.

     Descriptions of the above obligations follow.

(A) THE 6%/12% PROMISSORY NOTES CONSIST OF THE FOLLOWING ISSUANCES

     (i)  On September 16, 2001, we restructured our obligations to the holders
          of its 10% Senior Secured Promissory Notes. Under the terms of the
          agreement, each of the noteholders agreed to exchange their 10% Notes
          for a new, zero coupon note (the "Zero Coupon Note").

          As a result of us initially restructuring our obligations, the
          unamortized portion of the debt discount and deferred financing costs
          were amortized through June 30, 2002. The significant terms of the
          Restructuring Debt were (i) modification of the interest rate (ii)
          granting us the option to pay the debt with shares of common stock and
          (iii) repricing the warrants which were previously issued to the
          shareholders back to the initial exercise price of $5.25 per share.

          Subsequently, on April 15, 2002, the holders additionally agreed to
          extend the promissory notes to July 1, 2003 and to lower the interest
          rate to 6% if paid in cash or to 12% if paid in common stock. In
          connection with the extension, we recorded $16,215 in deferred
          financing charges relating to professional fees and $140,203 of
          deferred financing costs relating to consideration to the noteholders
          valued at $120 per share of our common stock for each $1,000 face
          amount outstanding at maturity which increased the aggregate carry
          value of the notes by $140,203. We were accruing interest expense at
          12%. These deferred financing costs were being amortized through July
          1, 2003. These obligations were satisfied as described above through
          the issuance of 390,374 shares of common stock and 25,365 of
          convertible preferred stock. To date and subsequent to September 30,
          2003, the Company issued 40,262 shares of the common stock in
          satisfaction of the $140,212 of deferred financing costs.

     (ii) In August 2000, we borrowed $1,000,000 which consists of two loans
          from two funds managed by Cumberland Associates LLC, and bear interest
          at 20% per year and payable in cash or through the issuance of
          additional 20% notes on which both interest and principal are payable.
          The loans are secured by substantially all of our assets and are
          subordinated to the 6%/12% senior secured promissory notes that were
          amended April 15, 2002. We can prepay the loans in cash at any time.
          We can prepay the notes and accrued interest with common stock at its
          option. Stock issued in lieu of payment of the debt will be valued at
          85% of the then market price.


                                      F-10
<PAGE>

                   MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES

       NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
                                   (UNAUDITED)

NOTE 6 -- NOTES PAYABLE -- (CONTINUED)

          For the nine months ended September 30, 2003 and 2002, we converted
          into principal, accrued interest of $206,989 and $171,785,
          respectively.

          On April 12, 2002, Cumberland Associates LLC agreed to extend the
          maturity date of these loans through July 1, 2003 and to lower the
          interest rate from 20% to 6%, if paid in cash, or 12% if paid in
          common stock. We recorded $16,215 of deferred financing charges
          relating to professional fees and $189,369 relating to consideration
          issued to the noteholders valued at $120 per share of our common stock
          for each $1,000 face amount outstanding at maturity. We are currently
          accruing interest expense at 12%. Accordingly, the deferred financing
          costs and the unamortized financing charges were being amortized
          through July 1, 2003.

          These obligations were satisfied as described above through the
          issuance of 532,924 shares of common stock. From October 10, 2003
          through November 10, 2003, the Company issued 54,066 shares of common
          stock in satisfaction of the $189,360 of deferred financing costs.


(B) 8% PROMISSORY NOTES

   The 8% promissory notes consist of the following:

     On July 31, 2000, we established a $1,000,000 credit facility with a major
existing investor. Initially, $500,000 was borrowed under the line, which was
due on June 30, 2003. In December 2000 and January 2001, we borrowed under the
credit facility an additional $400,000 and $100,000, respectively, due on
December 31, 2003. In connection with the initial $500,000, the investor
received five-year warrants to purchase 23,333 shares of our common stock,
exercisable at $9.00 per share. In connection with the $400,000, the investor
received five-year warrants to purchase 26,667 shares of our common stock
exercisable at $3.75 per share. In connection with the $100,000, the investor
received five-year warrants to purchase 6,667 shares of our common stock at
$3.75 per share. On April 12, 2002, the investor agreed to extend the maturity
date of the $500,000 to August 1, 2003. At our option, this $500,000 can be
convertible into common stock. Accordingly, in connection with the extension,
the unamortized debt discount is being amortized to August 1, 2003. On April
15, 2003, the investor agreed to extend the maturity date of the $500,000 and
interest originally due December 31, 2003 to January 2, 2005. Accordingly, only
$500,000 of loans have been recorded as long term debt in the accompanying
consolidated financial statements. On July 1, 2003, the investor agreed to
extend the maturity date of notes due August 1, 2003 until September 20, 2003.
At the option of the Company, this $500,000 can be convertible into common
stock. On September 30, 2003, the Company satisfied $500,000 of the obligation
and $120,644 of related interest through the issuance of 204,833 shares of the
Company common stock.

     During 2002 and through February 2003, we issued a total of $1,385,000
promissory notes to an existing investor. The notes bear interest at 8% if paid
in cash and 10% if paid in stock and mature on September 30, 2003. At our
option, the principal and interest are payable on the maturity date in common
stock.

     During 2002 and through February 2003, the Company issued a total of
$1,385,000 promissory notes to an existing investor maturing on September 30,
2003. At the option of the company, the notes bear interest of 8% if paid in
cash and 10% if paid in stock.

     During the nine months ended September 30, 2003, the Company borrowed
$600,000 under an $800,000, 8% credit facility from an existing investor. In
October 2003, agreements were reached providing for the issuance of equity
securities in satisfaction of these obligations and related interest.

     On September 30, 2003, the Company issued 324,644 shares of its common
stock in consideration for payment of these promissory notes including
interest.


                                      F-11
<PAGE>

                   MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES

       NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
                                   (UNAUDITED)

NOTE 6 -- NOTES PAYABLE -- (CONTINUED)

(C) $500,000 LINE OF CREDIT

     On March 9, 2001 the Company obtained from a major existing investor, a
10% $500,000 line of credit, which was to mature on August 31, 2002.
Additionally, the Company pays a 2% facility fee on the line outstanding
balance.

     In connection with obtaining the line of credit, the lender received
warrants to purchase 33,333 shares of common stock at an exercise price of
$3.30. The estimated fair value of the warrants, which amounted to $40,000 was
recorded as a debt discount. In addition, the Company incurred deferred
financing fees of $28,384 which was being amortized to August 31, 2002. On
April 12, 2002 the investor agreed to extend the line of credit and payment for
interest to August 1, 2003. Furthermore in July 2003, the investor agreed to
extend the line of credit and payment for interest until September 30, 2003. In
connection with each extension, amortization of unamortized debt discount and
deferred financing costs were also extended. These obligations were satisfied
as described above through the issuance of 193,644 shares of Common Stock.


(D) 6% CONVERTIBLE PROMISSORY NOTES

     During June 2003 and September 2003, we issued $50,000 promissory notes to
existing investors. The June note bears interest at 6% and matures on November
27, 2004. At our option, the principal and interest are payable on the maturity
date in common stock at a rate of one share of our common stock for every $.936
of indebtedness. Additionally, Milestone granted the investor warrants to
purchase 53,419 shares of our common stock at a per share price of $1.56 with
an estimate fair value of $14,423 at any time or from time to time during the
period commencing of June 4, 2003 and ending June 3, 2005. This resulted in an
initial increase to debt discount and to additional paid-in capital of $14,423
equal to the estimated fair market value of the warrants. The note dated
September 25, 2003 bears interest at 6% and matures on March 24, 2005. At the
option of the Company, the principal and interest are payable on the maturity
date in common stock at a rate of one share of common stock for every $3.30 of
indebtedness. Additionally, Milestone granted the investor warrants to purchase
5,000 of common stock at a per share price of $6.00 with an estimate fair value
of $14,423 at any time or from time to time during the period of June 4, 2003
through June 5, 2005. This resulted in an initial increase to debt discount and
to additional paid-in capital.


NOTE 7 -- ACCOUNTS PAYABLE -- LONG TERM

     In addition to the $160,000 of trade payables which had been previously
extended to January 2005, the Company on October 3, 2003, reached agreements to
satisfy $502,800 of trade payables including $187,000 of services not yet
completed or billed through the issuance of 102,285 shares of Common stock
valued at $4.92 per share.


NOTE 8 -- LEGAL PROCEEDINGS

     On June 10, 2002, a former distributor, Henry Schein, Inc., sued Milestone
in the Supreme Court of the State of New York for $110,851 claimed to be due
them for returned merchandise. Milestone denies any liability. The parties are
currently engaged in discovery. Milestone believes it has a meritorious defense
to this complaint based, in part, on its position that the plaintiff had no
right to return the goods.

     On May 9, 2003, Milestone was served with a Breach of Contract Complaint.
In the complaint, the plaintiff, Korman/Lender Management (landlord of the
facility in Deerfield, IL) seeks damages of $17,755 plus costs, including
attorney's fees, interest and continuing rental obligation. We are in the
process of preparing a response.


                                      F-12
<PAGE>

                   MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES

       NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
                                   (UNAUDITED)

NOTE 9 -- EMPLOYEE STOCK OPTION PLAN

     As of September 30, 2003, there were 221,115 outstanding options granted
under the Milestone 1997 Stock Option Plan. We account for these plans under
the recognition and measurement principles of APB Opinion No. 25, Accounting
for Stock Issued to Employees, and related Interpretations. No stock-based
employee compensation cost is reflected in net loss, as all options granted
under those plans had an exercise price equal to the market value of the
underlying common stock on the date of grant. The following table illustrates
the effect on net loss and loss per share if we had applied the fair value
recognition provisions of FASB Statement No. 123, Accounting for Stock-Based
Compensation, to stock-based employee compensation.

<TABLE>
<CAPTION>
                                                                       NINE MONTHS ENDED SEPTEMBER 30
                                                                     -----------------------------------
                                                                           2003               2002
                                                                     ----------------   ----------------
<S>                                                                  <C>                <C>
Net loss, as reported ............................................     $(1,787,382)       $(1,604,252)
Deduct: Total stock-based employee compensation expenses
 determined under fair value based method for all awards .........
                                                                          (168,462)          (369,365)
                                                                       -----------        -----------
Net loss, pro forma ..............................................     $(1,955,844)       $(1,973,617)
                                                                       -----------        ===========
Loss per share: Basic and diluted
 As reported .....................................................           $(.42)             $(.39)
                                                                             =====              =====
 Basic-pro forma .................................................           $(.45)             $(.48)
                                                                             =====              =====
</TABLE>

NOTE 10 -- CLOSING OF DEERFIELD, IL FACILITY


     In December 2002, Milestone initiated the transition of its customer
service office to its corporate headquarters in Livingston, New Jersey and its
distribution and logistics center to a third party, Design Centre of York,
Pennsylvania. The resulting closing of the Deerfield location was completed
during January 2003. The net book value of the facility's fixed assets
transferred or disposed during January 2003 was $41,425 and $11,248,
respectively.


NOTE 11 -- SUBSEQUENT EVENTS


REVERSE STOCK SPLIT

     The Board of Directors adopted a resolution, which was approved by the
shareholders on December 9, 2003, of an amendment to the Company's Certificate
of Incorporation to effect a reverse stock split of its common stock. The ratio
would be no greater than one-for-ten, at the sole discretion of the Company's
board of directors, in connection with an underwritten public offering by the
Company.

     On December 22, 2003, the Company formed a committee to determine the
amount of the split. On January 6, 2004, the committee approved a 1-for-3
reverse stock split of its common stock and the Company filed an amendment to
its Certificate of Incorporation effecting that reverse split. Accordingly, all
share and per share information in these unaudited condensed consolidated
financial statements have been restated to retroactively reflect the 1-for-3
combination.



                                      F-13
<PAGE>

                   REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS


To the Board of Directors
Milestone Scientific, Inc.

We have audited the accompanying consolidated balance sheet of MILESTONE
SCIENTIFIC, INC. AND SUBSIDIARIES as of December 31, 2002, and the related
consolidated statements of operations, changes in stockholders' deficiency and
cash flows for the years ended December 31, 2002 and 2001. These consolidated
financial statements are the responsibility of our management. Our
responsibility is to express an opinion on these consolidated financial
statements based on our audits.


We conducted our audits in accordance with auditing standards generally
accepted in the United States of America. Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements. An audit also includes assessing the accounting
principles used and significant estimates made by management, as well as
evaluating the overall financial statement presentation. We believe that our
audits provide a reasonable basis for our opinion.


In our opinion, the consolidated financial statements referred to above present
fairly, in all material respects, the financial position of Milestone
Scientific, Inc. and Subsidiaries as of December 31, 2002, and their results of
operations and cash flows for the years ended December 31, 2002 and 2001, in
conformity with accounting principles generally accepted in the United States
of America.


                                          /s/ J.H. Cohn LLP

Roseland, New Jersey
April 1, 2003, except for Notes B and H which are as of April 15, 2003
and Note Q which is as of January 6, 2004.



                                      F-14
<PAGE>

                   MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES

                           CONSOLIDATED BALANCE SHEET

                              AT DECEMBER 31, 2002

<TABLE>
<CAPTION>
<S>                                                                               <C>
                                     ASSETS
Current Assets:
 Cash .........................................................................    $       9,683
 Accounts receivable, net of allowance for doubtful accounts of $46,152........          239,435
 Inventories ..................................................................          119,291
 Advances to contract manufacturer ............................................          300,000
 Deferred debt financing, net .................................................          159,877
 Prepaid expenses .............................................................           64,952
                                                                                   -------------
   Total current assets .......................................................          893,238
Equipment, net ................................................................          227,207
Advances to Contract Manufacturer -- Long term ................................           87,935
Other Assets ..................................................................           32,333
                                                                                   -------------
   Total ......................................................................    $   1,240,713
                                                                                   =============
                        LIABILITIES AND STOCKHOLDERS DEFICIENCY
Current Liabilities:
 Account payable, including $32,000 to related parties.........................    $   1,269,523
 Accrued expenses .............................................................           86,492
 Accrued interest .............................................................          169,519
 Notes payable ................................................................        4,581,708
                                                                                   -------------
   Total current liabilities ..................................................        6,107,242
Accrued interest ..............................................................          139,323
Deferred compensation payable to officer/stockholder ..........................          320,000
Notes payable .................................................................          480,091
Notes payable -- officer/stockholder ..........................................          300,000
                                                                                   -------------
   Total liabilities ..........................................................        7,346,656
                                                                                   -------------
Commitments and Contingencies
Stockholders Deficiency:
 Common stock, par value $.001; authorized, 50,000,000 shares; 4,244,457 shares
   issued .....................................................................            4,244
 Additional paid-in capital ...................................................       36,608,096
 Accumulated deficit ..........................................................      (41,786,767)
 Unearned compensation ........................................................          (20,000)
 Treasury stock, at cost, 33,333 shares .......................................         (911,516)
                                                                                   -------------
   Total stockholders' deficiency .............................................       (6,105,943)
                                                                                   -------------
   Total ......................................................................    $   1,240,713
                                                                                   =============
</TABLE>

        The accompanying notes are an integral part of these statements.

                                      F-15
<PAGE>

                   MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES

                      CONSOLIDATED STATEMENTS OF OPERATIONS

                            YEARS ENDED DECEMBER 31,

<TABLE>
<CAPTION>
                                                                                2002                2001
                                                                         -----------------   -----------------
<S>                                                                      <C>                 <C>
Net Sales ............................................................     $   4,074,006       $   4,093,710
Cost of sales ........................................................         1,980,949           1,973,156
                                                                           -------------       -------------
Gross profit .........................................................         2,093,057           2,120,554
                                                                           -------------       -------------
Selling, general and administrative expenses .........................         3,588,836           5,271,032
Research and development expenses ....................................           147,709              49,943
Closing of Deerfield, IL facility ....................................            26,067                  --
                                                                           -------------       -------------
   Totals ............................................................         3,762,612           5,320,975
                                                                           -------------       -------------
Loss from operations .................................................        (1,669,555)         (3,200,421)
Interest income ......................................................                --               2,936
Interest expense .....................................................          (850,642)           (858,582)
Sale of prophy angle business and related consulting income ..........            80,000              64,487
                                                                           -------------       -------------
   Net Loss ..........................................................     $  (2,440,197)      $  (3,991,580)
                                                                           =============       =============
Loss per common share -- basic and diluted ...........................     $        (.59)      $       (1.07)
                                                                           =============       =============
Weighted-average shares outstanding -- basic and diluted .............         4,156,558           3,714,197
                                                                           =============       =============
</TABLE>

        The accompanying notes are an integral part of these statements.

                                      F-16
<PAGE>

                   MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES

         CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIENCY

                     YEARS ENDED DECEMBER 31, 2002 AND 2001

<TABLE>
<CAPTION>
                                                     COMMON STOCK          ADDITIONAL
                                                ----------------------       PAID IN         ACCUMULATED        UNEARNED
                                                   SHARES      AMOUNT        CAPITAL           DEFICIT         ADVERTISING
                                                -----------   --------   --------------   -----------------   ------------
<S>                                             <C>           <C>        <C>              <C>                 <C>
Balance, January 1, 2001 ....................    3,584,299     $3,584     $34,591,642       $ (35,354,990)     $       --
Warrants issued with draw-down on
 credit facility ............................                                  23,400
Common stock issued for consideration
 for payment of accrued interest ............        9,214          9          36,270
Warrants issued pursuant to a $500,000
 line of credit .............................                                  40,000
Common stock issued for services
 rendered ...................................       30,769         31         149,969
Warrants issued for unearned
 advertising fees ...........................                                 324,218                            (324,218)
Proceeds from sale of common stock,
 net of expenses ............................      166,667        167         491,833
Warrants issued to consultants ..............                                 100,000
Stock options issued for services
 rendered ...................................                                  97,649
Amortization of unearned advertising
 expense ....................................                                                                      21,398
Amortization of deferred compensation........
Proceeds from sale of common stock yet
 to be issued, net of expenses ..............                                 243,167
Net loss ....................................                                                  (3,991,580)
                                                 ---------     ------     -----------       -------------      ----------
Balance, December 31, 2001 ..................    3,790,949      3,791      36,098,148         (39,346,570)       (302,820)
Common stock issued from the sale of
 common stock in 2001 .......................      108,333        108            (108)
Common stock issued for accrued
 interest ...................................       11,280         11          27,061
Common stock issued for deferred
 compensation ...............................      204,728        205         491,141
Common stock issued for payment of
 accounts payable ...........................       62,500         62         149,938
Amortization of unearned advertising
 expense ....................................                                                                      24,803
Expired warrants for unearned
 advertising ................................                                (278,017)                            278,017
Stock options issued for future services.....                                  30,000
Common stock issued for payment of
 accounts payable ...........................       66,667         67          89,933
Net loss ....................................                                                  (2,440,197)
                                                 ---------     ------     -----------       -------------      ----------
Balance, December 31, 2002 ..................    4,244,457     $4,244     $36,608,096       $ (41,786,767)     $       --
                                                 =========     ======     ===========       =============      ==========
</TABLE>


                                      F-17
<PAGE>

                   MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES

         CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIENCY

                     YEARS ENDED DECEMBER 31, 2002 AND 2001




<TABLE>
<CAPTION>
                                                   DEFERRED         UNEARNED         TREASURY
                                                 COMPENSATION     COMPENSATION         STOCK             TOTAL
                                                --------------   --------------   --------------   ----------------
<S>                                             <C>              <C>              <C>              <C>
Balance, January 1, 2001 ....................     $ (31,055)       $      --        $ (911,516)      $ (1,702,335)
Warrants issued with draw- down on
 credit facility ............................                                                              23,400
Common stock issued for consideration
 for payment of accrued interest ............                                                              36,279
Warrants issued pursuant to a $500,000
 line of credit .............................                                                              40,000
Common stock issued for services
 rendered ...................................                                                             150,000
Warrants issued for unearned
 advertising fees ...........................                                                                   0
Proceeds from sale of common stock,
 net of expenses ............................                                                             492,000
Warrants issued to consultants ..............                                                             100,000
Stock options issued for services
 rendered ...................................                                                              97,649
Amortization of unearned advertising
 expense ....................................                                                              21,398
Amortization of deferred compensation........        31,055                                                31,055
Proceeds from sale of common stock yet
 to be issued, net of expenses ..............                                                             243,167
Net loss ....................................                                                          (3,991,580)
                                                  ---------        ---------        ----------       ------------
Balance, December 31, 2001 ..................            --               --          (911,516)        (4,458,967)
Common stock issued from the sale of
 common stock in 2001
Common stock issued for accrued
 interest ...................................                                                              27,072
Common stock issued for deferred
 compensation ...............................                                                             491,346
Common stock issued for payment of
 accounts payable ...........................                                                             150,000
Amortization of unearned advertising
 expense ....................................                                                              24,803
Expired warrants for unearned
 advertising ................................                                                                   0
Stock options issued for future services.....                        (20,000)                              10,000
Common stock issued for payment of
 accounts payable ...........................                                                              90,000
Net loss ....................................                                                          (2,440,197)
                                                  ---------        ---------        ----------       ------------
Balance, December 31, 2002 ..................     $      --        $ (20,000)       $ (911,516)      $ (6,105,943)
                                                  =========        =========        ==========       ============
</TABLE>

       The accompanying notes are an integral part of these statements.

                                      F-18
<PAGE>

                   MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES

                      CONSOLIDATED STATEMENTS OF CASH FLOWS

                            YEARS ENDED DECEMBER 31,

<TABLE>
<CAPTION>
                                                                               2002               2001
                                                                         ----------------   ----------------
<S>                                                                      <C>                <C>
Cash flows from operating activities:
Net loss .............................................................     $ (2,440,197)      $ (3,991,580)
Adjustments to reconcile net loss to net cash used in operating
 activities:
 Depreciation ........................................................           53,052             75,990
 Amortization of unearned advertising cost ...........................           24,803             21,398
 Amortization of debt discount and deferred financing costs ..........          340,133            306,734
 Common stock issued for services ....................................               --            150,000
 Amortization of deferred compensation ...............................               --             31,055
 Stock options and warrants issued to consultants ....................           10,000            197,649
 Loss on disposal of fixed asset .....................................            1,909                 --
 Changes in operating assets and liabilities:
   Decrease in accounts receivable ...................................          124,308            165,801
   Decrease in inventories ...........................................           43,349             13,533
   Decrease in advances to contract manufacturer .....................          301,594            315,000
   (Increase) decrease in prepaid expenses ...........................          (33,967)           121,727
   Decrease in other assets ..........................................          (19,971)            (2,044)
   Increase in accounts payable ......................................          107,220            253,776
   Increase in accrued interest ......................................          510,508            551,847
   Increase (decrease) in accrued expenses ...........................          (18,918)            54,178
   Increase in deferred compensation .................................          320,000            350,000
                                                                           ------------       ------------
 Net cash used in operating activities: ..............................         (676,177)        (1,384,936)
                                                                           ------------       ------------
Cash flows from investing activities-payment for capital expenditures           (74,344)           (10,672)
                                                                           ------------       ------------
Cash flows from financing activities:
 Proceeds from sale of common stock, net of expenses .................               --            492,000
 Proceeds from note payable-- officer/stockholder ....................          100,000                 --
 Proceeds from line of credit ........................................               --            500,000
 Proceeds from issuance of notes payable .............................          685,000            100,000
 Proceeds from the sale of common stock yet to be issued .............               --            243,167
 Payments for deferred financing costs ...............................          (40,538)           (96,684)
                                                                           ------------       ------------
 Net cash provided by financing activities ...........................          744,462          1,238,483
                                                                           ------------       ------------
 Net Decrease in Cash ................................................           (6,059)          (157,125)
Cash at beginning of year ............................................           15,742            172,867
                                                                           ------------       ------------
Cash at end of year ..................................................     $      9,683       $     15,742
                                                                           ============       ============
Supplemental disclosures of cash flow information:
 Cash paid during the year for interest ..............................     $          0       $          0
                                                                           ============       ============
 Cash paid during the year for taxes .................................     $          0       $          0
                                                                           ============       ============
</TABLE>


                                      F-19
<PAGE>

                   MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES


               CONSOLIDATED STATEMENTS OF CASH FLOWS--(CONTINUED)


Supplemental schedule of noncash financing activities:

     In January 2002, we issued 11,280 units consisting of one share of common
stock and one warrant to purchase an additional share of common stock in
exchange for payment of accrued interest totaling $27,072.

     In January 2002, we issued 204,728 units (consisting of one share of
common stock and one warrant to purchase an additional share of common stock)
for payment of $491,346 in deferred compensation. The warrants are exercisable
at $2.40 per share through January 31, 2003; at $3.00 per share through January
31, 2004 and thereafter at $6.00 per share through January 31, 2007.

     In January 2002, pursuant to the 20% promissory note agreements, we
converted $63,377 of accrued interest into additional principal.

     In April 2002, pursuant to the 6%/12% promissory note agreements, we
converted $65,168 of accrued interest into additional principal.

     In April 2002, pursuant to the debt restructuring, we recorded a deferred
financing charge of $329,572. This resulted in an increase to notes payable of
$140,203 and accrued interest of $189,369.

     In July 2002, we issued 62,500 units consisting of one share of common
stock and one warrant to purchase an additional share of common stock to a
vendor in accordance with the agreement valued at $150,000 for payment of
accounts payable.

     In August 2002, we issued 66,667 shares of common stock in exchange for
payment of $90,000 of accounts payable.

     In September 2002, pursuant to the 6%/12% promissory note agreements, we
converted $41,512 of accrued interest into additional principal.

     In January 2001, pursuant to the 20% promissory note agreements, we
converted $51,111 of accrued interest into additional principal.

     In January 2001, we granted warrants to purchase 6,667 shares of common
stock (with an estimated fair value of $23,400) in connection with $100,000
drawn from a $1,000,000 credit facility provided by a major existing investor.
This resulted in an initial increase to debt discount and to additional paid-in
capital.

     In February 2001, we issued 9,214 shares of common stock in exchange for
payment of accrued interest totaling $36,279.

     In February 2001, we issued 30,769 shares of common stock with a value of
$150,000 for services rendered.

     In March 2001, pursuant to a $500,000 line of credit agreement, we granted
warrants to purchase 33,333 shares of common stock (with an estimated fair
value of $80,000). This resulted in an initial increase to debt discount and in
additional paid-in capital.

     In March 2001, we granted warrants to purchase 130,208 shares of common
stock with an estimated fair value of $324,418 for advertising services. This
amount was recorded in stockholders' deficiency as an increase to unearned
advertising and to additional paid-in capital.

     In April 2001, pursuant to the 20% promissory note agreements, we
converted $53,472 of accrued interest into additional principal.


                                      F-20
<PAGE>

                 MILESTONE SCIENTIFIC INC. AND ITS SUBSIDIARIES

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


NOTE A -- ORGANIZATION

     Milestone Scientific Inc. (the "Company" or "Milestone") was incorporated
in the State of Delaware in August 1989. Milestone has developed a proprietary,
computer-controlled anesthetic delivery system, through the use of the Wand
(Registered Trademark) , a single use disposable handpiece. The system is
marketed in dentistry under the trademark CompuDent (Trade Mark)  and Wand Plus
(Registered Trademark)  and in medicine under the trademark CompuMed (Trade
Mark) . CompuDent (Trade Mark)  is suitable for all dental procedures that
requires local anesthetic. CompuMed (Trade Mark)  and Wand Plus (Registered
Trademark)  are suitable for many medical procedures regularly performed in
Plastic Surgery, Hair Restoration Surgery, Podiatry, Colorectal Surgery,
Dermatology, Orthopedics and a number of other disciplines. The systems are
sold in the United States and in over 25 countries abroad. Our products are
manufactured by third-party contract manufacturers.


NOTE B -- BASIS OF PRESENTATION

     The accompanying consolidated financial statements have been prepared
assuming that the Company will continue as a going concern. However, as shown
in the accompanying consolidated financial statements, the Company incurred net
losses of approximately $2,440,000 and $3,992,000 and negative cash flows from
operating activities of approximately $676,000 and $1,385,000 during 2002 and
2001, respectively. As a result, the Company had a cash balance of
approximately $10,000, a working capital deficiency of approximately $5,214,000
and a stockholders' deficiency of approximately $6,106,000 as of December 31,
2002. These matters raise substantial doubt about the Company's ability to
continue as a going concern.

     Management believes that, in the absence of a substantial increase in
revenue, it is probable that the Company will continue to incur losses and
negative cash flows from operating activities through at least December 31,
2003 and that the Company will need to obtain additional equity or debt
financing, as well as to continue its ability to defer its obligations, to
sustain its operations until it can expand its customer base and achieve
profitability.

     To date, the Company has taken certain steps in order to reduce its
operating expenses and utilization of cash. These steps include, amongst
others, the following:

     o    Commencing in 2001 and continuing through 2002, the Company
          reconfigured its sales force. The Company went from maintaining a
          large internal sales force to utilizing independent sales
          representatives and distributors.

     o    The Company reduced administrative personnel and telemarketers by
          approximately ten people.

     o    On January 31, 2003, the Company completed the closing of the
          Deerfield, IL facility. The customer support, service and other
          back-office functions previously conducted, in whole or in part, at
          this location were consolidated into the Company's New Jersey
          location. The receiving, shipping and storage functions, which were
          also previously done at this location, will be outsourced at an
          independent warehouse located in Pennsylvania. The closure of the
          Illinois facility will result in reductions in overhead and other
          costs, while improving operational efficiencies.

     o    Obtained an agreement from its Chief Executive Officer/Stockholder to
          defer 2002 and 2003 compensation, aggregating $640,000 until April
          2004.

     o    Restructured and extended the maturity dates of its debt obligations
          (see Note H). Further, as part of the debt restructuring, the Company
          obtained agreements from certain of its note holders enabling it to
          convert debt and related interest aggregating approximately $4,751,000
          into shares of common stock. It is the Company's intention to have
          this conversion completed sometime during the third quarter 2003.


                                      F-21
<PAGE>

                 MILESTONE SCIENTIFIC INC. AND ITS SUBSIDIARIES

            NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

NOTE B -- BASIS OF PRESENTATION -- (CONCLUDED)

     o    Obtained an agreement from one of its attorneys to convert an
          additional $160,000 of the amount owed into shares of common stock.

     In addition, during February 2003, the Company received a $200,000 note
payable from an existing investor. The note is convertible into shares of
common stock, at the Company's option, which it plans to do during the third
quarter of 2003. During April 2003, the Company received an additional $900,000
line of credit from the same investor, which is scheduled to mature on January
1, 2005, unless extended.

     The accompanying consolidated financial statements do not include any
adjustments relating to the recoverability and classification of recorded asset
amounts or the amounts and classifications of liabilities that might be
necessary should the Company be unable to continue as a going concern.


NOTE C -- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES


1. PRINCIPLES OF CONSOLIDATION

     The consolidated financial statements include the accounts of the Company
and of its wholly-owned subsidiary and its majority-owned subsidiary, Spintech.
All significant intercompany balances and transactions have been eliminated in
consolidation.


2. CASH AND CASH EQUIVALENTS

     For purposes of the statements of cash flows, the Company considers all
highly liquid investments purchased with a maturity of three months or less to
be cash equivalents. At December 31, 2002 and 2001, the Company did not have
any cash equivalents.


3. INVENTORIES

     Inventories principally consist of finished goods and component parts
stated at the lower of cost (first-in, first-out method) or market.


4. EQUIPMENT

     Equipment is recorded at cost, less accumulated depreciation. Depreciation
expense is computed using the straight-line method over the estimated useful
lives of the assets, which range from 3 to 7 years. The costs of maintenance
and repairs are charged to operations as incurred.


5. DEBT ISSUE COST AND DEBT DISCOUNT

     Debt issue costs are deferred and amortized to interest expense over the
term of the related loan on a straight-line method, which approximates the
interest method. Debt discounts are offset against the principal balance and
amortized using the straight-line method over the term of the related loan.


6. IMPAIRMENT OF LONG-LIVED ASSETS

     The Company reviews long-lived assets for impairment whenever
circumstances and situations change such that there is an indication that the
carrying amounts may not be recovered.


7. REVENUE RECOGNITION

     Revenue is recognized when title passes at the time of shipment and
collectibility is reasonably assured.


                                      F-22
<PAGE>

                 MILESTONE SCIENTIFIC INC. AND ITS SUBSIDIARIES

            NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

NOTE C -- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -- (CONTINUED)

8.   RESEARCH AND DEVELOPMENT

     Research and development costs are expensed as incurred.


9.   INCOME TAXES

     The Company uses the liability method of accounting for income taxes, as
set forth in SFAS No. 109, "Accounting for Income Taxes." Under this method,
deferred income taxes, when required, are provided on the basis of the
difference between the financial reporting and income tax bases of assets and
liabilities at the statutory rates enacted for future periods.


10.  BASIC AND DILUTED NET LOSS PER COMMON SHARE

     Basic and diluted net loss per share are computed using the
weighted-average number of shares of common stock outstanding during the
period. Potentially dilutive securities have been excluded from the computation
of diluted earnings per share, as their effect is antidilutive. If the Company
had reported net income, diluted earnings per share would have included the
shares used in the computation of net loss per share plus common equivalent
shares related to 1,614,785 and 1,108,611 outstanding options and warrants for
the years ended December 31, 2002 and 2001, respectively and the payment of the
notes payable with shares of common stock.


11.  USE OF ESTIMATES

     The preparation of financial statements in conformity with accounting
principles generally accepted in the United States of America requires
management to make estimates and assumptions in determining the reported
amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and reported amounts of
revenues and expenses during the reporting period. The most significant
estimates relate to the allowance for doubtful accounts, advances to contract
manufacturer, inventory valuation allowances, and valuation allowances on
deferred tax assets. Actual results could differ from those estimates.


12.  FAIR VALUE OF FINANCIAL INSTRUMENTS

     The carrying amounts reported in the consolidated balance sheet for cash,
accounts receivable, accounts payable and accrued expenses approximate fair
value based on the short-term maturity of these instruments. Notes payable to
officer/stockholder and long-term notes payable approximate fair value due to
the fact that the effective interest rates are comparable among the various
noteholders.


13.  ACCOUNTING FOR STOCK-BASED COMPENSATION

     The Company has adopted the disclosure provisions of Statements of
Financial Accounting Standards No. 123 ("SFAS No. 123"), "Accounting for Stock
Based Compensation," and therefore applies the intrinsic value method of
accounting for employee stock options as prescribed under Accounting Principles
Board Opinion No. 25 ("APB No. 25"), "Accounting for Stock Issued to
Employees." Under APB No. 25, when the exercise price of an employee stock
option granted by the Company is equal to or greater than the market price of
the underlying stock on the date of grant, no compensation expense is
recognized.


14.  CONCENTRATION OF CREDIT RISK

     The Company's financial instruments that are exposed to concentrations of
credit risk consist primarily of cash and trade accounts receivable. The
Company places its cash with high quality credit institutions. At times, such
investments may be in excess of the Federal Deposit Insurance


                                      F-23
<PAGE>

                 MILESTONE SCIENTIFIC INC. AND ITS SUBSIDIARIES

            NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

NOTE C -- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -- (CONTINUED)

Corporation insurance limit. the Company has not experienced any losses in such
accounts and believes it is not exposed to any significant credit risks.
Financial instruments which potentially subject the Company to concentrations
of credit risk consist principally of trade accounts receivable, as the Company
does not require collateral or other securities to support customer
receivables.


NOTE D -- INVENTORIES

     Inventories consist of the following:


The Wand (Registered Trademark)  units and handpieces .........  $125,214
Component parts and other materials ...........................   104,558
                                                                 --------
                                                                  229,772
Reserve .......................................................   110,481
                                                                 --------
                                                                 $119,291
                                                                 ========

NOTE E -- ADVANCES TO CONTRACT MANFACTURER


     Advances to contract manufacturer represents deposits to the Company's
contract manufacturer to fund future inventory commitments. The aggregate
amount of the advances amounted to $387,935 of which approximately $300,000 is
estimated to be used in 2003.


NOTE F -- EQUIPMENT


     Equipment consists of the following:


Furniture and fixtures ................  $  194,656
Office equipment ......................     148,797
Tooling equipment .....................      64,079
Trade show displays ...................      81,800
Computer servers and software .........     125,341
                                         ----------
                                            614,673
Less accumulated depreciation .........    (387,466)
                                         ----------
                                         $  227,207
                                         ==========

NOTE G -- NOTES PAYABLE TO OFFICER/STOCKHOLDER


     Notes payable to officer/stockholder represent two obligations payable to
the Company's Chief Executive Officer ("CEO"), consisting of (i) $200,000 note
payable, with interest payable at 9% per annum having an original due date of
January 2, 2003; and (ii) a $100,000 line of credit with interest payable at 6%
per annum having an original due date of April 2, 2003. On April 1, 2003, the
notes were extended to April 1, 2004. Interest expense for the years ended
December 31, 2002 and 2001 amounted to $19,701 and $18,250, respectively.


                                      F-24
<PAGE>

                MILESTONE SCIENTIFIC INC. AND ITS SUBSIDIARIES


           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

NOTE H -- NOTES PAYABLE

     Notes payable consist of the following:

     Short term

<TABLE>
<S>                                                                                       <C>
6%/12% Promissory notes, due on August 1, 2003 (A) ......................................  $2,945,542
8% Line of credit for $500,000, originally due on August 31, 2002, extended to August 1,
 2003, net of debt discount of $7,024 (B)................................................     492,976
8% Promissory notes payable, $500,000 originally due June 30, 2003, extended to August 1,
 2003 and $685,000 due August 1, 2003, net of debt discount of $41,810 (C)...............   1,143,190
                                                                                           ----------
   Total ................................................................................  $4,581,708
                                                                                           ==========
</TABLE>

     Long Term (B)

       8% Promissory note payable for $500,000 originally due December 31,
       2003, extended to January 2, 2005, net of a debt discount of $19,909
       totaling $480,091.

     (A) 6%/12%PROMISSORY NOTES

     The 6%/12% Promissory Notes consist of the following issuances:

          (i)  On March 16, 2001, the Company restructured its obligations to
               the holders of its 10% Senior Secured Promissory Notes. Under the
               terms of the agreement, each of the noteholders agreed to
               exchange their 10% Notes for a new, zero coupon note (the "Zero
               Coupon Note").

               As a result of the Company initially restructuring its
               obligations, the unamortized portion of the debt discount and
               deferred financing costs were amortized through March 31, 2002.
               The significant terms of the Restructuring Debt were (i)
               modification of the interest rate, (ii) granting the company the
               option to pay the debt with shares of common stock and (iii)
               repricing the warrants which were previously issued to the
               shareholders back to the initial exercise price of $5.25 per
               share.

               Subsequently, on April 15, 2002, the holders additionally agreed
               to extend the promissory notes to July 1, 2003 and to lower the
               interest rate to 6% if paid in cash or to 12% if paid in common
               stock. In connection with the extension, the Company recorded
               $16,215 in deferred financing charges relating to professional
               fees and $140,203 of deferred financing costs relating to
               consideration to the noteholders valued at $120 per share of the
               Company's common stock for each $1,000 face amount outstanding at
               maturity which increased the aggregate carry value of the notes
               by $140,203. The Company is accruing interest expense at 12%.
               These deferred financing costs are being amortized through
               July 1, 2003.

         (iii) In August 2000, the Company borrowed $1,000,000 which consists
               of two loans from two funds managed by Cumberland Associates LLC,
               and bear interest at 20% per year and payable in cash or through
               the issuance of additional 20% notes on which both interest and
               principal are payable. The loans are secured by substantially all
               assets of the Company and are subordinated to the 6%/12% senior
               secured promissory notes that were amended April 15, 2002. The
               Company can prepay the loans in cash at any time. The Company can
               prepay the notes and accrued interest with common stock at its
               option after March 31, 2001. Stock issued in lieu of payment of
               the debt will be valued at 85% of the then market price. For the
               year ended December 31, 2002, the Company converted $257,865 of
               accrued interest into


                                      F-25
<PAGE>

                MILESTONE SCIENTIFIC INC. AND ITS SUBSIDIARIES


           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

NOTE H -- NOTES PAYABLE -- (CONTINUED)

              principal. During 2001, the Company had previously converted
              $222,417 of accrued interest into principal. On April 12, 2002,
              Cumberland Associates LLC agreed to extend the maturity date of
              these loans through July 1, 2003 and to lower the interest rate
              from 20% to 6%, if paid in cash, or 12% if paid in common stock.
              The Company recorded $16,215 of deferred financing charges
              relating to professional fees and $189,369 relating to
              consideration issued to the noteholders valued at $120 per share
              of the Company's common stock for each $1,000 face amount
              outstanding at maturity. The Company is currently accruing
              interest expense at 12%. Accordingly, the deferred financing
              costs and the unamortized financing charges are being amortized
              through July 1, 2003.

              It is currently the Company's intention to satisfy these
              obligations with shares of common stock upon their maturity.


   (B) 8% PROMISSORY NOTES

     The 8% promissory notes consist of the following:

       On July 31, 2000, the Company established a $1,000,000 credit facility
       with a major existing investor. Initially, $500,000 was borrowed under
       the line, which was due on June 30, 2003. In December 2000, and January
       2001, the Company borrowed under the credit facility an additional
       $400,000 and $100,000, respectively, due on December 31, 2003. In
       connection with the initial $500,000, the investor received five-year
       warrants to purchase 23,333 shares of the Company's common stock,
       exercisable at $9.00 per share. In connection with the $400,000, the
       investor received five-year warrants to purchase 26,667 shares of the
       Company's common stock exercisable at $3.75 per share. In connection
       with the $100,000, the investor received five-year warrants to purchase
       6,667 shares of the Company's common stock at $3.75 per share. On April
       12, 2002, the investor agreed to extend the maturity date of the
       $500,000 to August 1, 2003. At the option of the Company, this $500,000
       can be convertible into common stock. Accordingly, in connection with
       the extension, the unamortized debt discount is being amortized to
       August 1, 2003. On April 15, 2003, the investor agreed to extend the
       maturity date of the $500,000 and interest originally due December 31,
       2003 to January 2, 2005. Accordingly, only $500,000 of loans have been
       recorded as long term debt in the accompanying consolidated financial
       statements.

   (C) During 2002, the Company issued a total of $1,185,000 promissory notes
       to an existing investor. The notes bear interest at 8% if paid in cash
       and 10% if paid in stock and mature on August 1, 2003. At the option of
       the Company, the principal and interest are payable on the maturity date
       in common stock. Additionally, the note will automatically convert into
       the Company's common stock if the Company issues 333,333 shares or
       raises at least $1,000,000 from the sale of equities prior to August 1,
       2003, at the market price in that transaction but not less than $.50 per
       common share, or more than $6.00 per share. The Company is accruing
       interest at 10%.


NOTE I -- STOCK OPTION PLAN

     In 1997, the Board of Directors approved the adoption of the 1997 Stock
Option Plan. The 1997 Stock Option Plan provides for the grant of options to
purchase up to 166,667 shares of the Company's common stock. In 1999, the Plan
was amended, providing for the grant of options to purchase up to 333,333
shares of the Company's common stock. Options may be granted to employees,
officers, directors and consultants of the Company for the purchase of common
stock of


                                      F-26
<PAGE>

                MILESTONE SCIENTIFIC INC. AND ITS SUBSIDIARIES


           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

NOTE I -- STOCK OPTION PLAN -- (CONTINUED)
the Company at a price not less than the fair market value of the common stock
on the date of the grant. In general, options become exercisable over a
three-year period from the grant date and expire five years after the date of
grant.

     The Company has adopted the disclosure provisions of Statement of
Financial Accounting Standards No. 123 ("SFAS No. 123"), "Accounting for
Stock-Based Compensation." SFAS No. 123 establishes financial accounting and
reporting standards for stock-based employee compensation plans. The Company
applies the intrinsic value method prescribed under Accounting Principles Board
Opinion No. 25 and related interpretations in accounting for its stock-based
compensation plans.

     If the Company had elected to recognize compensation expense based upon
the fair value at the grant date, consistent with the methodology prescribed by
SFAS No. 123, pro forma net loss and net loss per share to common stockholders
for the years ended December 31, 2002 and 2001 would have increased to the
following pro forma amounts:


                                               DECEMBER 31,
                                     ---------------------------------
                                           2002             2001
                                     ---------------- ----------------
Net loss as reported ...............   $ (2,440,197)    $ (3,991,580)
                                       ============     ============
Pro forma net loss .................   $ (2,664,814)    $ (4,484,067)
                                       ============     ============
Loss per share as reported .........          $(.59)          $(1.07)
                                              =====           ======
Pro forma loss per share ...........          $(.64)          $(1.21)
                                              =====     ============

     The weighted-average fair value of the individual options granted during
2002 and 2001 was estimated as $.66 and $5.37, respectively, on the date of
grant. The fair value for 2002 and 2001 was determined using a Black-Scholes
option-pricing model with the following assumptions:

<TABLE>
<CAPTION>
                                         DECEMBER 31,
                                    ----------------------
                                       2002        2001
                                    ---------   ----------
<S>                                 <C>         <C>
Volatility ......................      71%       92.0%
Risk-free interest rate .........     4.5%         5.7%
Expected life ...................   5 years     5 years
</TABLE>

     Stock option activity during 2002 and 2001 is summarized below:




<TABLE>
<CAPTION>
                                                       SHARES OF         WEIGHTED
                                                     COMMON STOCK        AVERAGE
                                                     ATTRIBUTABLE        EXERCISE
                                                      TO OPTIONS     PRICE OF OPTIONS
                                                    --------------  -----------------
<S>                                                 <C>             <C>
Options outstanding at January 1, 2001 ...........      309,703         $  15.33
Granted ..........................................       46,667             6.96
Forfeited ........................................      (46,615)            9.06
                                                        -------
Options outstanding at December 31, 2001 .........      309,755            15.48
Granted ..........................................       57,667             2.37
Forfeited ........................................     (120,141)           14.97
                                                       --------
Options outstanding at December 31, 2002 .........      247,281         $  12.24
                                                       ========         ========
</TABLE>


                                      F-27
<PAGE>

                 MILESTONE SCIENTIFIC INC. AND ITS SUBSIDIARIES

            NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

NOTE I -- STOCK OPTION PLAN -- (CONTINUED)

     The following table summarizes information concerning outstanding and
exercisable options at December 31, 2002.

<TABLE>
<CAPTION>
                                       REMAINING
                        NUMBER        CONTRACTUAL       NUMBER
EXERCISE PRICES      OUTSTANDING     LIFE (YEARS)     EXERCISABLE
- -----------------   -------------   --------------   ------------
<S>                 <C>             <C>              <C>
$1.6500..........       16,667            4.0                 0
 2.2500 .........       20,333            4.0             6,778
 2.6250 .........       16,667            2.0                 0
 3.0000 .........       16,667            1.0                 0
 3.6000 .........        8,333            4.5                 0
 3.7500 .........        1,667            1.7             1,667
 3.7500 .........        3,333            4.8                 0
 4.6875 .........        1,667            0.7             1,667
 4.8300 .........        8,281            2.5             5,521
 5.4375 .........        2,333            2.1             1,555
 6.0000 .........       16,667            3.0                 0
 6.5625 .........       27,000            2.5            18,000
 7.5000 .........       33,333            1.8            33,333
 7.5000 .........       26,667            3.6             8,889
 9.0000 .........        9,667            1.0             9,667
 9.0000 .........        1,500            1.5             1,500
12.0000 .........          500            1.5               500
15.0000 .........          500            1.5               500
18.0000 .........          500            1.5               500
48.0000 .........       16,666            0.0                 0
47.5000 .........        8,333            0.3             8,333
69.0000 .........       10,000            0.2            10,000
                        ------                           ------
                       247,281                          108,410
                       =======                          =======
</TABLE>

     The weighted-average exercise price of options exercisable at December 31,
2002 is $15.90.

     The Company charged $10,000 to operations during the year ended December
31, 2002, representing the fair market value of 50,000 stock options issued to
a customer. Furthermore, the Company charged $197,649 to operations during the
year ended December 31, 2001, representing the fair market value of 110,000
common stock purchase warrants issued to consultants.

NOTE J -- EMPLOYMENT CONTRACT AND DEFERRED COMPENSATION

     In January 1998, the Company entered into a five-year employment contract
with its CEO providing for an annual base compensation of up to $350,000, plus
stock options and cash bonuses based upon attaining certain earnings levels,
which the Company has not yet achieved.

     In July 1998, the CEO agreed to a voluntary reduction of his annual base
salary from $350,000 to approximately $188,000 that remained in effect through
August 2000. At that time, the CEO agreed to defer his annual salary on a
discretionary basis. Accordingly, the Company has recorded deferred
compensation payable to the CEO in the amount of $491,346 at December 31, 2001.


     In January 2002, in consideration for payment of the deferred
compensation, the Company issued 208,333 units. Each unit consisted of one
share of the Company's common stock and one warrant to purchase an additional
share of common stock. The warrants are exercisable at $2.40 per share


                                      F-28
<PAGE>

                MILESTONE SCIENTIFIC INC. AND ITS SUBSIDIARIES

           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

NOTE J -- EMPLOYMENT CONTRACT AND DEFERRED COMPENSATION (CONTINUED)

through January 31, 2003 and then at $3.00 per share through January 31, 2004
and thereafter at $6.00 per share through January 31, 2007. Furthermore, on
April 1, 2003, the CEO has agreed to defer payment on $640,000 of additional
compensation relating to his salary for 2002 and 2003 until January 2, 2005.


NOTE K -- SALES OF PROPHY ANGLES AND RELATED CONSULTING INCOME

     In November 2001, the Company sold certain tangible and intangible assets,
rights and properties (which were fully amortized) relating to the
SplatrFree(Trade Mark) prophy angle to Smart Health, Inc. for $55,000. In
addition, the Company entered into a 12 month consulting agreement with Smart
Health for $96,000. The Company recorded consulting income of $80,000 for the
year ended December 31, 2002.


NOTE L -- INCOME TAXES

     Deferred tax attributes resulting from differences between financial
accounting amounts and tax bases of assets and liabilities at December 31, 2002
and 2001 are as follows:


<TABLE>
<CAPTION>
                                                                2002               2001
                                                          ----------------   ----------------
<S>                                                       <C>                <C>
Current assets and liabilities
   Allowance for doubtful accounts ....................    $      18,000      $      22,000
   Inventory allowance ................................           44,000             60,000
   Warrants issued to consultants .....................               --                 --
   Other ..............................................               --                 --
Valuation allowance ...................................          (62,000)           (82,000)
                                                           -------------      -------------
Current deferred tax asset ............................    $          --      $          --
                                                           =============      =============
Non-current assets and liabilities
   Depreciation .......................................    $     (60,000)     $    (540,000)
   Asset impairment charge ............................               --                 --
   Net operating loss carryforward ....................       14,000,000         13,600,000
   Warrants and options issued to consultants .........          598,000            423,000
   Accrued interest ...................................          347,000            177,000
   Deferred compensation ..............................          128,000                 --
                                                           -------------      -------------
                                                              15,013,000         13,660,000
Valuation allowance ...................................      (15,013,000)       (13,660,000)
                                                           -------------      -------------
   Non-current deferred tax asset (liability) .........    $          --      $          --
                                                           =============      =============
</TABLE>

     For the years ended December 31, 2002 and 2001 the valuation allowance
increased by $1,353,000 and $2,038,000 respectively.

     As of December 31, 2002, the Company has Federal and State net operating
loss carryforwards of approximately $36,000,000 that will be available to
offset future taxable income, if any through December 2022. The utilization of
the Company's net operating losses may be subject to a substantial limitation
due to the "change of ownership provisions" under Section 382 of the Internal
Revenue Code and similar state provisions. Such limitation may result in the
expiration of the net operating loss carryforwards before their utilization.
The Company has established a 100% valuation allowance to reserve for all of
its net deferred tax assets due to the significant uncertainty that their
benefit will be realized in the future.


                                      F-29
<PAGE>

                MILESTONE SCIENTIFIC INC. AND ITS SUBSIDIARIES

           NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

NOTE M -- PRODUCT SALES AND SIGNIFICANT CUSTOMERS

     The Company's sales by product and by geographical region are as follows:


                                            DECEMBER 31,
                                    -----------------------------
                                         2002            2001
                                    -------------   -------------
The Wand system kits ............    $1,452,005      $1,828,801
The Wand handpieces . ...........     2,402,396       1,948,769
Prophy angles ...................            --          71,592
Dental needles ..................       181,236         168,169
Other ...........................        38,369          76,379
                                     ----------      ----------
                                     $4,074,006      $4,093,710
                                     ==========      ==========
Dental division .................    $3,892,069      $4,093,710
Medical division ................       181,937              --
                                     ----------      ----------
                                     $4,074,006      $4,093,710
                                     ==========      ==========
United States ...................    $3,174,930      $3,354,302
Canada ..........................       215,722         173,729
Other foreign countries .........       683,354         565,679
                                     ----------      ----------
                                     $4,074,006      $4,093,710
                                     ==========      ==========

     During the years ended December 31, 2002 and 2001, the Company had sales
to one customer (a worldwide distributor of the Company's products based in
South Africa) of approximately $566,000 and $410,000, respectively. This
represented 14% and 10% the total net sales for 2002 and 2001, respectively.
Accounts receivable from this customer amounted to approximately $157,000,
representing 65% of net accounts receivable at December 31, 2002.

NOTE N -- COMMITMENTS AND CONTINGENCIES

      Lease Commitments

     The Company leases office space and warehouse facilities under
noncancelable operating leases. These leases also provide for escalations of
the Company's share of utilities and operating expenses, which expire through
2007.

     Aggregate minimum rental commitments under noncancelable operating leases
are as follows:


YEAR ENDING
DECEMBER 31,
- --------------
2003 .............          $123,000
2004 .............           104,000
2005 .............            72,000
2006 .............            66,000
2007 .............            21,000
                            --------
                            $386,000
                            ========

     For the years ended December 31, 2002 and 2001, rent expense amounted to
approximately $108,000 and $103,000 respectively.

      Contract Manufacturing Agreement

     The Company has informal arrangements for the manufacture of The Wand unit
and system kit with Tricor Systems, Inc. ("Tricor") and for the manufacture of
The Wand disposable handpiece by Nypro Inc.


                                      F-30
<PAGE>

                 MILESTONE SCIENTIFIC INC. AND ITS SUBSIDIARIES

            NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

NOTE N -- COMMITMENTS AND CONTINGENCIES -- (CONTINUED)

     The termination of the manufacturing relationship with any of the above
manufacturers could have a material adverse effect on the Company's ability to
produce and sell its products. Although alternate sources of supply exist and
new manufacturing relationships could be established, the Company would need to
recover its existing tools or have new tools produced. Establishment of new
manufacturing relationships could involve significant expense and delay. Any
curtailment or interruption of the supply, whether or not as a result of
termination of such a relationship, would adversely affect the Company.


      Contingencies

     In March 2001, the Company entered into an advertising agreement with News
USA, Inc. and Vested Media Partners, Inc. (the "Agreement") to increase the
awareness of healthcare professionals and the public to the benefits of The
Wand and the CompuFlo technologies.

     Under the Agreement, News USA is required to prepare articles and
advertisements for the Company's products and technologies and place them in
newspapers and on radio stations.

     News USA had guaranteed 72,000 media placements during the 18-month term
of the Agreement. In exchange for these services, the Company granted warrants
to purchase 390,625 shares of common stock exercisable on the following dates
and prices over the life of the Agreement: (1) $3.84 during the first 18
months, (2) $6.75 during the next year and (3) $9.00 during the next year.

     The Agreement provided for a termination clause in the fourth month if the
Company's average closing stock price does not exceed $6.75 during the first
ten days of the fourth month provided that the Company has received 24,000
publications. Accordingly, the remaining two-thirds of the warrants to purchase
the Company's common stock would not become exercisable. However, the vendor
can recommence producing the publications whenever the Company's average
closing stock price for a ten day period exceeds $6.75. At the end of the ninth
month, the vendors have the option to terminate the Agreement if the Company's
stock price has not averaged $6.75 for a ten day period.

     Upon termination, two-thirds of the warrants remaining to purchase the
Company's common stock will be forfeited unless the vendors resume fulfilling
one-half of their obligation in three months and the remaining obligation in
the next six months.

     In March 2001, the Company initially recorded unearned advertising cost of
$324,218 which represents the estimated fair value of the 130,208 of the
warrants for one-third of the total warrants granted based on the 24,000
minimum placements. The unearned advertising cost is being amortized as
publications are received by the Company over the minimum placements. As of
December 31, 2002, unearned advertising cost was $278,017 and during the year
ended December 31, 2002, the Company recorded $24,803 in advertising expenses
relating to placements during the year. The estimated fair value of the
remaining warrants to purchase 260,417 of the Company's common stock have not
been recorded in the Company's consolidated financial statements due to the
likelihood that the Agreement will not be fulfilled.

     As of December 31, 2002, News USA did not meet the guaranteed media
placements and accordingly the unearned advertising cost of $278,017 was
reversed.


NOTE O -- RELATED PARTY TRANSACTIONS

     The Company paid $137,500 and $72,500 during the years ended December 31,
2002 and December 31, 2001, respectively, to a law firm where one of the
partners was previously on the Company's Board of Directors. At December 31,
2002 and 2001, the Company had accounts payable to the law firm of $389,181 and
$302,866, respectively. On March 29, 2002, the Company entered into an
agreement with the law firm deferring $272,866 of the accounts payable to
January 2, 2003. The


                                      F-31
<PAGE>

                 MILESTONE SCIENTIFIC INC. AND ITS SUBSIDIARIES

            NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

NOTE O -- RELATED PARTY TRANSACTIONS -- (CONTINUED)

law firm and the former Director also participated in the February 2001 private
placement, each purchasing $50,000 of 10% Senior Secured Promissory Notes and
warrants to purchase 2,381 shares of the Company's Common Stock. The notes were
extended to July 1, 2003.

     For the years ended December 31, 2002 and 2001, the Company paid $19,049
and $20,850 to the wife of Milestone's CEO. She was employed by Milestone to
render professional services. At December 31, 2002, the Company had accounts
payable totaling $32,000 to the Company's CEO and his wife.


NOTE P -- STOCKHOLDERS' DEFICIENCY

     In January 2001, Milestone entered into a three-year private equity line
agreement with Hillgreen Investments Limited ("Hillgreen"), a British Virgin
Islands corporation, pursuant to which Hillgreen is obligated to purchase,
subject to the fulfillment of specified conditions, up to 700,000 shares of
Milestone common stock over the next 36 months. Hillgreen has allocated
$20,000,000 to fund its purchase obligations. The transaction was arranged by
Jesup & Lamont Securities Corporation, a New York based investment banking
firm. Milestone's right to draw upon this facility is subject to a number of
limitations and conditions, including a limitation on the amounts sold to
Hillgreen within specified periods. Subject to these and other conditions and
limitations, Milestone will have full control over the timing of any financing
under the equity line and is under no obligation to sell any shares to
Hillgreen. Any shares that are sold will be priced at 87.5% of the volume
weighted average market price of Milestone common stock during a fixed period
prior to the sale. Milestone has discretion to establish a floor price below
which shares will not be sold by Milestone to Hillgreen. At April 11, 2003,
without any restrictions and based on the closing stock price, the maximum
proceeds that the Company could receive would be approximately $478,000.

     In August 2002, the Company issued 66,667 shares of common stock in
exchange for payment of $90,000 of outstanding legal fees.


NOTE Q -- SUBSEQUENT EVENTS

     On January 17, 2003, the Company's CEO provided the Company with a $57,322
short term loan for the express purpose of purchasing Wand handpieces from the
Company's supplier. The Company repaid the loan in full by February 7, 2003. On
February 12, 2003, the CEO provided the Company with a $38,215 loan for the
same purposes as above. The loan is payable on demand and $33,215 remains
outstanding as of March 31, 2003.

     On February 13, 2003, the Company received $200,000 from an existing
investor that matures on August 1, 2003. At the option of the Company, the note
and interest can be paid in common stock.

     On April 7, 2003, the CEO provided the Company with an additional $35,000
to use for the express purpose of contributing towards the Company's increased
insurance premium.


     The Board of Directors adopted a resolution, which was approved by the
shareholders on December 9, 2003, of an amendment to the Company's Certificate
of Incorporation to effect a reverse stock split of its common stock. The ratio
would be no greater than one-for-ten, at the sole discretion of the Company's
board of directors, in connection with an underwritten public offering by the
Company.

     On December 22, 2003, the Company formed a committee to determine the
amount of the split. On January 6, 2004 the committee approved a 1-for-3
reverse stock split of its common stock and the Company filed an amendment to
its Certificate of Incorporation effecting that reverse split. Accordingly, all
share and per share information in these consolidated financial statements have
been restated to retroactively reflect the 1-for-3 combination.



                                      F-32
<PAGE>


                               INSIDE BACK COVER


                                 COMPANY LOGO







<TABLE>
<S>                                                 <C>
                   SAFETYWAND(TM)                                       SAFETYWAND(TM)

                                                            [PICTURE OF SAFETYWAND WITH NEEDLE
 [PICTURE OF SAFETYWAND WITH NEEDLE RETRACTED.]                        PROTRACTED.]

       SAFETYWAND(TM) HANDPIECE WITH NEEDLE,             SAFETYWAND (TM) HANDPIECE WITH NEEDLE,
        IN THE RETRACTED SAFE POSITION.                 IN THE PROTRACTED POSITION, READY FOR USE.
</TABLE>








                   COOLBLUEWAND(TM) DENTAL ENHANCEMENT SYSTEM.










               [PICTURE OF COOLBLUEWAND WITH BLUE LIGHT EMITTING]

<PAGE>
================================================================================

       YOU MAY RELY ON THE INFORMATION CONTAINED IN THIS PROSPECTUS. WE HAVE
NOT AUTHORIZED ANYONE TO PROVIDE INFORMATION DIFFERENT FROM THAT CONTAINED IN
THIS PROSPECTUS. NEITHER THE DELIVERY OF THIS PROSPECTUS NOR SALE OF COMMON
SHARES MEANS THAT INFORMATION CONTAINED IN THIS PROSPECTUS IS CORRECT AFTER THE
DATE OF THIS PROSPECTUS. THIS PROSPECTUS IS NOT AN OFFER TO SELL OR
SOLICITATION OF AN OFFER TO BUY OUR COMMON SHARES IN ANY CIRCUMSTANCES UNDER
WHICH THE OFFER OR SOLICITATION IS UNLAWFUL.


                      -----------------------------------
                               TABLE OF CONTENTS


                                                 PAGE
                                                 ----
Prospectus Summary ............................    3
Risk Factors ..................................    9
Forward Looking Statements ....................   14
Recent Developments ...........................   14
Use of Proceeds ...............................   15
Dividend Policy ...............................   16
Capitalization ................................   16
Price Ranges of Our Common Stock ..............   17
Selected Consolidated Financial Data ..........   18
Management's Discussion and Analysis
   or Plan of Operations ......................   19
Business ......................................   26
Management ....................................   37
Limitation of Directors' Liability and
   Indemnification ............................   38
Executive Compensation ........................   39
Certain Relationships and Related Party
   Transactions ...............................   42
Security Ownership of Certain
   Beneficial Owners and Management ...........   43
Description of Securities .....................   45
Underwriting ..................................   47
Legal Matters .................................   49
Experts .......................................   50
Where You Can Find More
   Information ................................   50
Index to Financial Statements .................   F-1



                                1,200,000 UNITS



                      [MILESTONE SCIENTIFIC LOGO OMITTED]


                                -----------------

                                   PROSPECTUS

                                -----------------



                              PAULSON INVESTMENT
                                 COMPANY, INC.




                              S.W. BACH & COMPANY




                                        , 2004


================================================================================
<PAGE>

                                     PART II


                     INFORMATION NOT REQUIRED IN PROSPECTUS


LIMITATION OF DIRECTOR LIABILITY; INDEMNIFICATION


     Our Certificate of Incorporation provides that a director will not be
personally liable to us or to our stockholders for monetary damages for breach
of the fiduciary duty of care as a director, including breaches which
constitute gross negligence. This provision does not eliminate or limit the
liability of a director:

     o    for breach of his or her duty of loyalty to us or to our stockholders;

     o    for acts or omissions not in good faith or which involve intentional
          misconduct or a knowing violation of law;

     o    under Section 174 of the Delaware General Corporation Law (relating to
          unlawful payments or dividends or unlawful stock repurchases or
          redemptions),

     o    for any improper benefit, or

     o    for breaches of a director's responsibilities under the Federal
          securities laws.

     Our Certificate of Incorporation also provides that we indemnify and hold
harmless each of our directors and officers to the fullest extent authorized by
the Delaware General Corporation Law, against all expense, liability and loss
(including attorney's fees, judgments, fines, ERISA excise taxes or penalties
and amounts paid or to be paid in settlement) reasonably incurred or suffered
by such person in connection therewith.

     Insofar as indemnification for liabilities arising under the Securities
Act may be permitted to directors, officers and controlling persons pursuant to
our Certificate of Incorporation, Bylaws and the Delaware General Corporation
Law, we have been advised that in the opinion of the Securities and Exchange
Commission such indemnification is against public policy and is, therefore,
unenforceable.

     The Underwriting Agreement provides for reciprocal indemnification between
us and our controlling persons, on the one hand, and the underwriters and their
respective controlling persons, on the other hand, against certain liabilities
in connection with this offering, including liabilities under the Securities
Act of 1933, as amended.


OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION.

     The following are the expenses of the issuance and distribution of the
securities being registered, other than underwriting commissions and expenses,
all of which will be paid by the Company. Other than the SEC registration fee
and the NASD filing fees all of such expenses are estimated.

Registration fee .......................................    $  1,625
NASD fee ...............................................    $  2,266
American Stock Exchange listing fee ....................    $  3,000
Printing expenses ......................................    $ 75,000
Accounting fees and expenses ...........................    $100,000
Legal fees and expenses ................................    $250,000
Transfer agent and registrar fees and expenses .........    $ 10,000
Miscellaneous ..........................................    $ 18,109
                                                            --------
Total ..................................................    $460,000
                                                            ========


                                      II-1
<PAGE>

RECENT SALES OF UNREGISTERED SECURITIES.

     On January 31, 2000, Milestone issued five-year warrants to purchase an
aggregate of 47,619 shares of Common Stock to holders of Milestone's 10%
Secured Promissory Notes, including Cumberland Associates LLC, Strategic
Restructuring Partnership L.P., a former principal of Cumberland Associates,
two officers of the Corporation, an affiliate of one of its directors and six
other individuals. The warrants were issued as consideration for the loans made
by these investors to Milestone at the time of issuance. Each of the warrants,
as originally issued, contained a provision gradually escalating its exercise
price from $5.25 in 2000 to a maximum of $21.00 in 2004. However, in March
2001, the exercise price of these warrants was amended by agreement between
Milestone and the warrant holders to provide for an exercise price of $5.25 per
share up to the date of maturity. The warrants were issued pursuant to the
exemption from registration under the Securities Act of 1933, as amended (the
"Act"), provided by Sections 4(2) and 4(6) of the Act.

     Morse, Zelnick, Rose and Lander, LLP, legal counsel to Milestone, and its
affiliates, are the holders of warrants to purchase 10,044 shares of Common
Stock. On February 3, 2000, Milestone reduced the exercise price of all these
warrants to $3.75 and extended their exercise period to February 2, 2005.
Consideration for the amendments were legal services rendered to Milestone by
Morse, Zelnick, Rose & Lander, LLP. The warrants originally were issued
pursuant to the exemption from registration under the Act provided by Sections
4(2) and 4(6) of the Act.

     On December 7, 2000, and January 26, 2001, Milestone issued to K. Tucker
Andersen, a major existing investor, warrants to purchase 26,667 and 6,667
shares of Common Stock, respectively, at an exercise price of $3.75 and $5.625
per share, respectively. Each of the aforementioned warrants are exercisable
for five years from the date of issuance and were issued as consideration for
loans of a total of $1,000,000 that the investor made to Milestone. The loans,
which are evidenced by a senior secured promissory note, bear an 8% interest
that is payable quarterly in arrears. Principal payments, in the amount of
$500,000 each, are due on June 30, 2003, and December 31, 2003, respectively.
The warrants were issued pursuant to the exemptions from registration under the
Act provided by Sections 4(2) and 4(6) of the Act.

     On January 22, 2001, Milestone entered into an agreement to grant to
Hillgreen Investments Limited ("Hillgreen") warrants to purchase 33,333 shares
of Common Stock as consideration for opening an equity put agreement with
Milestone. In addition, as consideration for the services rendered by Jesup &
Lamont Securities Corporation ("Jesup & Lamont") as placement agent in
connection with the equity put, Milestone granted to Jesup & Lamont warrants to
purchase 25,000 shares of Common Stock. The warrants issued to Hillgreen and
Jesup & Lamont are exercisable at any time prior to January 22, 2004 at a price
of $5.58 per share, and were issued pursuant to the exemptions from
registration under the Act provided by Sections 4(2) and 4(6) of the Act.

     On January 30, 2001, Milestone issued to Shaul Koren 30,769 shares of
Common Stock, as payment for consulting services performed by Mr. Koren,
pursuant to exemptions from registration under the Act provided by Sections
4(2) and 4(6) of the Act.

     On February 8, 2001, Milestone issued to Cumberland Associates LLC,
Strategic Restructuring Partnership L.P., a former principal of Cumberland
Associates, two officers of the Corporation, an affiliate of one of its
directors and six other individuals, an aggregate of 9,214 shares of Common
Stock in payment of interest on the 10% Secured Promissory Notes issued to
these investors on January 31, 2000. The stock was issued pursuant to the
exemption from registration under the Act provided by Sections 4(2) and 4(6) of
the Act.

     On March 9, 2001, Milestone issued to K. Tucker Andersen, a major existing
investor a warrant to purchase 33,333 shares of Common Stock, exercisable at
any time for five years from the date of issuance at $3.30 per share, as
consideration for opening a $500,000 line of credit. Milestone pays a 2%
facility fee on the line of credit and interest at a rate of 10% per annum on
monies borrowed. On December 28, 2001, Milestone signed an agreement to issue
11,280 units, consisting of one share and one warrant to purchase one share in
payment of the $27,072 accrued interest through December 31, 2001. The warrants
are exercisable at $2.40 per share through January 31, 2003, thereafter at
$3.00 per


                                      II-2
<PAGE>

share through January 31, 2004, and thereafter at $6.00 per share through
January 31, 2007, at which time they will expire. All of these units and
warrants were issued in January 2002 pursuant to the exemptions from
registration under the Act provided by Sections 4(2) and 4(6) of the Act.

     In March 2001, Milestone signed an agreement with News USA, Inc. and
Vested Media Partners, Inc. to increase the awareness of healthcare
professionals and the public to the benefits of CompuDent(TM), CompuMed(TM),
The Wand(R) and CompuFlo(TM) technologies. Under the agreement, News USA, Inc.
is required to prepare, write and seek to place in newspapers and other media,
articles about Milestone's products and technologies. As consideration for
their services, Milestone granted to News USA, Inc. and Vested Media Partners,
Inc. warrants to purchase an aggregate of approximately 390,667 shares of
Milestone's Common Stock at prices increasing from $3.84, to $9.00 per share
during the 3-year warrant term. The warrants were issued pursuant to the
exemptions from registration under the Act provided by Sections 4(2) and 4(6)
of the Act.

     On December 28, 2001, Milestone entered into an agreement with its CEO,
Leonard Osser, to issue to him 204,728 units in payment of $491,346 in
compensation, specifically, his salary as Chief Executive Officer of Milestone,
which he voluntarily has deferred since August 5, 2000. In January 2002, the
units were issued and each unit consists of one share of Milestone's common
stock and one warrant to purchase an additional share of such common stock. The
warrants are exercisable at $2.40 per share through January 31, 2003,
thereafter at $3.00 per share through January 31, 2004, and thereafter at $6.00
per share through January 31, 2007, at which time they will expire. The
warrants were issued pursuant to the exemptions from registration under the Act
provided by Sections 4(2) and 4(6) of the Act.

     In December 2001, Milestone entered into an agreement with K. Tucker
Andersen, an existing investor, to issue 108,333 units. The units, which were
issued in January 2002, consist of one share of Milestone common stock and one
warrant to purchase an additional share of such common stock. The warrants are
exercisable at $2.40 per share through January 31, 2003, thereafter at $3.00
per share through January 31, 2004, and thereafter at $6.00 per share through
January 31, 2007, at which time they will expire. The units were issued in
exchange for $185,000 and the cancellation of a 10% convertible promissory note
issued in October 2001, under which an amount of $75,000 was due at that time.

     In July 2002, we issued 62,500 units consisting of one share of common
stock and one warrant to purchase an additional share of common stock to a
vendor in accordance with the agreement valued at $150,000.

     In August 2002, we issued 66,667 shares of common stock in exchange for
payment of $90,000 of outstanding legal fees.

     In June 2003 we issued a 6% convertible note in the amount of $50,000 and
an 18 months warrant to purchase 53,419 shares of our common stock at $1.56 per
share, in consideration for a $50,000 loan from an accredited investor.

     In September 2003 we issued a 6% convertible note in the amount of $50,000
and an 18 months warrant to purchase 5,000 shares of our common stock at $6.00
per share, in consideration for a $50,000 loan from an accredited investor.

     In October 2003 we issued 1,646,419 shares of common stock in satisfaction
of 6% / 12% Secured and Senior Secured Notes in the aggregate amount of
approximately $5 million. We also committed to issue 25,365 shares of 8%
convertible preferred stock in satisfaction of $25,365 of principal and accrued
interest. The preferred stock will be convertible into 4,381 common stock at
$5.79. Subsequently, we issued 94,327 additional shares of common stock to
these former noteholders as consideration for their previous consent to extend
the maturity date of these notes.

     On October 31, 2003 we issued 102,195 shares of our common stock to
principal vendors, in satisfaction of trade payables in the aggregate amount of
approximately $503,000.

     The foregoing securities were issued in reliance upon the exemption from
the registration requirements of the Securities Act of 1933, as amended,
provided in Section 4(2) thereof, as a


                                      II-3
<PAGE>

transaction by an issuer not involving a public offering. The registrant
reasonably believed that each purchaser had such knowledge and experience in
financial and business matters to be capable of valuating the merits and risks
of the investment, each purchaser represented an intention to acquire the
securities for investment only and not with a view to distribution thereof and
appropriate legends were affixed to the stock certificates or warrants. No
commissions were paid in connection with such issuances.


EXHIBITS


<TABLE>
<CAPTION>
  EXHIBIT
    NO.                             DESCRIPTION
- ----------                          -----------
<S>          <C>
    1        Form of Underwriting Agreement
  3.1        Certificate of Incorporation of Milestone (1)
  3.2        Certificate of Amendment filed July 13, 1995 (2)
  3.3        Certificate of Amendment filed December 6, 1996 (3)
  3.4        Certificate of Amendment filed December 17, 1997 (6)
  3.5        Certificate of Amendment filed July 23, 2003
  3.6        Certificate of Amendment filed January 8, 2004.
  3.7        Certificate of Designation filed January 15, 2004
  3.8        By-laws of Milestone (1)
  4.1        Specimen Stock Certificate (2)
  4.2        Form of unit certificate (9)
  4.3        Form of warrant agreement, including form of warrant
  4.4        Form of representative's warrant
 10.1        Lease dated November 25, 1996 between Livingston Corporate Park Associates, L.L.C. and
             Milestone. (3)
 10.2        Intentionally Left Blank
 10.5        Intentionally Left Blank
 10.8        Agreement for The Wand Product dated December 1, 1996, between Spintech and Princeton
             PMC. (3)
 10.10       Agreement between Milestone and Spintech dated December 21, 1994, and Amendment No.
             1 thereto. (2)
 10.11       Employment Agreement between Milestone and Leonard Osser dated January 1, 1998. (6)
 10.12       Intentionally Left Blank
 10.13       Intentionally Left Blank
 10.14       Intentionally Left Blank
 10.15       Private Equity Line of Credit Agreement between Milestone and Hillgreen Investments
             Limited dated January 22, 2001. (5)
 10.16       Registration Rights Agreement, dated January 22, 2001, between Registrant and Hillgreen
             Investments Limited. (5)
 10.17       Intentionally Left Blank
 10.18       Intentionally Left Blank
 10.19       Intentionally Left Blank
 10.20       Intentionally Left Blank
 10.21       Intentionally Left Blank
 10.22       Intentionally Left Blank
 10.23       Letter from Leonard Osser and Morse, Zelnick, Rose & Lander, LLP, dated April 9, 2000. (7)
</TABLE>


                                      II-4
<PAGE>



<TABLE>
<CAPTION>
  EXHIBIT
    NO.                             DESCRIPTION
- ----------                          -----------
<S>          <C>
 10.24        Intentionally left blank.
 10.25        Letter from Morse, Zelnick, Rose & Lander LLP, dated March 29, 2002, re-deferral of
              payment.
 10.26        Letter from Leonard Osser, dated April 15, 2003 deferring payment. (9)
 10.27        Letter from Morse, Zelnick, Rose & Lander LLP, dated April 2003 deferring payment. (9)
 10.28        Line of Credit for $900,000 and extension of $500,000 line of credit, dated April 15, 2003.
 10.29        Agreement with DaVinci Systems dated July 30, 2003.
 10.30        Agreement with Mark Hochman and amendments thereto dated April 9, 1998, December 16,
              1999, November 28, 2001, October 10, 2002 and December 19, 2003.
 10.31        Agreement with Strider dated September 2003.
 10.32        Agreement with Len Osser and K. Tucker Andersen, dated October 9, 2003.
 10.33        Agreement with Morse, Zelnick, Rose & Lander dated December 22, 2003.
 10.34        Employment Agreement with Leonard Osser dated December 20, 2003.
 21.1         Subsidiaries of the Registrant. (3)
 23.1         Consent of J. H. Cohn LLP
</TABLE>


- ----------
(1)   Incorporated by reference to Milestone's Registration Statement on Form
      SB-2 No. 333-92324.

(2)   Incorporated by reference to Amendment No. 1 to Milestone's Registration
      Statement on Form SB-2 No. 333-92324.

(3)   Incorporated by reference to Milestone's Form 10-KSB for the year ended
      December 31, 1996.

(4)   Incorporated by reference to Milestone's Registration Statement on Form
      S-3 No. 333-39784.

(5)   Incorporated by reference to Milestone's Registration Statement on Form
      S-2 No. 333-54732.

(6)   Incorporated by reference to Milestone's Form 10-KSB for the year ended
      December 31, 1999.

(7)   Incorporated by reference to Milestone's Form 10-KSB for the year ended
      December 31, 2000.

(8)   Incorporated by reference to Milestone's Form 10-KSB for the year ended
      December 31, 2001.

(9)   Previously filed in Amendment No. 1 to this Registration Statement.

UNDERTAKINGS

     A.   The undersigned Registrant hereby undertakes:

          (1) to file, during any period in which offers or sales are being
     made, a post-effective amendment to this Registration Statement:

               (i) to include any prospectus required by Section 10(a)(3) of the
          Securities Act;

               (ii) to reflect in the prospectus any facts or events arising
          after the effective date of the Registration Statement (or the most
          recent post-effective amendment thereof) which, individually or in the
          aggregate, represent a fundamental change in the information set forth
          in the Registration Statement; and

               (iii) to include any additional or changed material information
          with respect to the plan of distribution disclosed in the Registration
          Statement.

          (2) That, for the purpose of determining any liability under the
     Securities Act, each such post-effective amendment shall be deemed to be a
     new Registration Statement relating to the securities offered therein, and
     the offering of such securities at that time shall be deemed to be the
     initial bona fide offering thereof.

          (3) To remove from registration by means of a post-effective amendment
     any of the securities being registered which remain unsold at the
     termination of the offering.


                                      II-5
<PAGE>

          (4) For purposes of determining any liability under the Securities
     Act, the information omitted from the form of prospectus filed as part of a
     registration statement in reliance upon Rule 430A and contained in the form
     of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or
     497(h) under the Securities Act shall be deemed to be part of the
     registration statement as of the time it was declared effective.

          (5) For the purpose of determining any liability under the Securities
     Act, each post-effective amendment that contains a form of prospectus shall
     be deemed to be a new registration statement relating to the securities
     offered therein, and the offering of such securities at that time shall be
     deemed to be the initial bona fide offering thereof.

     B. Insofar as indemnification for liabilities arising under the Securities
Act may be permitted to directors, officers and controlling persons of the
small business issuer pursuant to the foregoing provisions, or otherwise, the
small business issuer has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as
expressed in the Act and is, therefore, unenforceable. In the event that a
claim for indemnification against such liabilities (other than the payment by
the small business issuer of expenses incurred or paid by a director, officer
or controlling person of the small business issuer in the successful defense of
any action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the
small business issuer will, unless in the opinion of its counsel the matter has
been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public
policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue.


                                      II-6
<PAGE>

                                  SIGNATURES


     In accordance with the requirements of the Securities Act of 1933, as
amended, the registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form S-2 and authorized
this Registration Statement to be signed on its behalf by the undersigned, in
the City of New York, State of New York on January 29, 2004.



                                     MILESTONE SCIENTIFIC INC.

                                     By: /s/ Leonard Osser
                                        ---------------------------------
                                        Leonard Osser, Chief Executive Officer


     ALL MEN BY THESE PRESENTS, that each person whose signature appears below
constitutes and appoints Leonard Osser his true and lawful attorney-in-fact and
agent, with full power of substitution and resubstitution, for him and in his
name, place and stead, in any and all capacities, to sign any and all pre- or
post-effective amendments to this Registration Statement, and to file the same
with all exhibits thereto, and other documents in connection therewith, with
the Securities and Exchange Commission, granting unto said attorneys-in-fact
and agents, and each of them, full power and authority to do and perform each
and every act and thing requisite or necessary to be done in and about the
premises, as fully to all intents and purposes as he might or could do in
person, hereby ratifying and confirming all that said attorneys-in-fact and
agents, or any one of them, or their or his substitutes, may lawfully do or
cause to be done by virtue hereof.


     In accordance with the requirements of the Securities Act of 1933, as
amended, this Registration Statement has been signed by the following persons
in the capacities indicated on January 29, 2004.



            SIGNATURE                                 TITLE
- --------------------------------      -------------------------------------
       /s/ Leonard Osser*             Chief Executive Officer and Chairman
- --------------------------------      of the Board of Directors
          Leonard Osser

     /s/ Thomas M. Stuckey*           Chief Financial Officer
- --------------------------------
        Thomas M. Stuckey

      /s/ Leonard Schiller*           Director
- --------------------------------
        Leonard Schiller

        /s/ Paul Gregory*             Director
- --------------------------------
          Paul Gregory

       /s/ Jeffrey Fuller*            Director
- --------------------------------
         Jeffrey Fuller

      /s/ Leslie Bernhard*            Director
- --------------------------------
         Leslie Bernhard

*By:     /s/ Leonard Osser
     --------------------------------
     Leonard Osser

                                      II-7
<PAGE>

                                 EXHIBIT INDEX




<TABLE>
<CAPTION>
  EXHIBIT
    NO.                                         DESCRIPTION
- ----------                                      ------------
<S>          <C>
 1           Form of Underwriting Agreement
 3.1         Certificate of Incorporation of Milestone (1)
 3.2         Certificate of Amendment filed July 13, 1995 (2)
 3.3         Certificate of Amendment filed December 6, 1996 (3)
 3.4         Certificate of Amendment filed December 17, 1997 (6)
 3.5         Certificate of Amendment filed July 23, 2003
 3.6         Certificate of Amendment filed January 8, 2004.
 3.7         Certificate of Designation filed January 15, 2004
 3.8         By-laws of Milestone (1)
 4.1         Specimen Stock Certificate (2)
 4.2         Form of unit certificate
 4.3         Form of warrant agreement, including form of warrant
 4.4         Form of representative's warrant
 10.1        Lease dated November 25, 1996 between Livingston Corporate Park Associates, L.L.C. and
             Milestone. (3)
 10.2        Intentionally Left Blank
 10.5        Intentionally Left Blank
 10.8        Agreement for The Wand Product dated December 1, 1996, between Spintech and Princeton
             PMC. (3)
 10.10       Agreement between Milestone and Spintech dated December 21, 1994, and Amendment No.
             1 thereto. (2)
 10.11       Employment Agreement between Milestone and Leonard Osser dated January 1, 1998. (6)
 10.12       Intentionally Left Blank
 10.13       Intentionally Left Blank
 10.14       Intentionally Left Blank
 10.15       Private Equity Line of Credit Agreement between Milestone and Hillgreen Investments
             Limited dated January 22, 2001. (5)
 10.16       Registration Rights Agreement, dated January 22, 2001, between Registrant and Hillgreen
             Investments Limited. (5)
 10.17       Intentionally Left Blank
 10.18       Intentionally Left Blank
 10.19       Intentionally Left Blank
 10.20       Intentionally Left Blank
 10.21       Intentionally Left Blank
 10.22       Intentionally Left Blank
 10.23       Letter from Leonard Osser and Morse, Zelnick, Rose & Lander, LLP, dated April 9, 2000. (7)
 10.24       Intentionally left blank.
 10.25       Letter from Morse, Zelnick, Rose & Lander LLP, dated March 29, 2002, re-deferral of
             payment.
 10.26       Letter from Leonard Osser, dated April 15, 2003 deferring payment. (9)
 10.27       Letter from Morse, Zelnick, Rose & Lander LLP, dated April 2003 deferring payment.
 10.28       Line of Credit for $900,000 and extension of $500,000 line of credit, dated April 15, 2003.
</TABLE>


<PAGE>



<TABLE>
<CAPTION>
  EXHIBIT
    NO.                                            DESCRIPTION
- -----------   -------------------------------------------------------------------------------------
<S>           <C>
 10.29        Agreement with DaVinci Systems dated July 30, 2003.
 10.30        Agreement with Mark Hochman and amendments thereto dated April 9, 1998, December 16,
              1999, November 28, 2001, October 10, 2002 and December 19, 2003.
 10.31        Agreement with Strider dated September 3, and December 19, 2003.
 10.32        Agreement with Len Osser and K. Tucker Andersen, dated October 9, 2003.
 10.33        Agreement with Morse, Zelnick, Rose & Lander dated December 22, 2003.
 10.34        Employment Agreement with Leonard Osser dated as of December 20, 2003.
 21.1         Subsidiaries of the Registrant. (3)
 23.1         Consent of J. H. Cohn LLP
</TABLE>


- ----------
(1)   Incorporated by reference to Milestone's Registration Statement on Form
      SB-2 No. 333-92324.

(2)   Incorporated by reference to Amendment No. 1 to Milestone's Registration
      Statement on Form SB-2 No. 333-92324.

(3)   Incorporated by reference to Milestone's Form 10-KSB for the year ended
      December 31, 1996.

(4)   Incorporated by reference to Milestone's Registration Statement on Form
      S-3 No. 333-39784.

(5)   Incorporated by reference to Milestone's Registration Statement on Form
      S-2 No. 333-54732.

(6)   Incorporated by reference to Milestone's Form 10-KSB for the year ended
      December 31, 1999.

(7)   Incorporated by reference to Milestone's Form 10-KSB for the year ended
      December 31, 2000.

(8)   Incorporated by reference to Milestone's Form 10-KSB for the year ended
      December 31, 2001.

(9)   Previously filed in Amendment No. 1 to this Registration Statement.

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1
<SEQUENCE>3
<FILENAME>file002.txt
<DESCRIPTION>FORM OF UNDERWRITING AGREEMENT
<TEXT>
<PAGE>


                                 1,200,000 Units


                            Milestone Scientific Inc.


                             UNDERWRITING AGREEMENT


                                                               ___________, 2004



Paulson Investment Company, Inc.
As Representative of the
  Several Underwriters
811 SW Naito Parkway, Suite 200
Portland, Oregon 97204

Gentlemen:

         Milestone Scientific Inc., a Delaware corporation (the "Company"),
proposes to sell to the several underwriters (the "Underwriters") named in
Schedule I hereto for whom you are acting as Representative (the
"Representative") an aggregate of 1,200,000 Units (the "Firm Units"). Each Unit
will consist of two shares ("Share") of the common stock, par value $0.001, of
the Company ("Common Stock") and one warrant (individually, a "Warrant" and,
collectively, the "Warrants") each to purchase one share of Common Stock. The
Warrants are to be issued under the terms of a Warrant Agreement (the "Warrant
Agreement") by and between the Company and Continental Stock Transfer & Trust
Company, as warrant agent (the "Warrant Agent"), in each case substantially in
the form most recently filed as an exhibit to the Registration Statement
(hereinafter defined). The respective number of the Firm Units to be so
purchased by the several Underwriters are set forth opposite their names in
Schedule I hereto. The Company also proposes to grant to the Representative an
option to purchase in aggregate up to 180,000 additional Units, identical to the
Firm Units (the "Option Units"), as set forth below.

         As the Representative, you have advised the Company (a) that you are
authorized to enter into this Agreement for yourself as Representative and on
behalf of the several Underwriters, and (b) that the several Underwriters are
willing, acting severally and not jointly, to purchase the numbers of Firm Units
set forth opposite their respective names in Schedule I. The Firm Units and the
Option Units (to the extent the aforementioned option is exercised) are herein
collectively called the "Units."

         In consideration of the mutual agreements contained herein and of the
interests of the parties in the transactions contemplated hereby, the parties
hereto agree as follows:


                                       1
<PAGE>

         1. Representations and Warranties of the Company. The Company
represents and warrants to each of the Underwriters as follows:

               (a) A registration statement on Form S-2 (File No. 110376) with
respect to the Units has been prepared by the Company in conformity with the
requirements of the Securities Act of 1933, as amended (the "Act"), and the
Rules and Regulations (the "Rules and Regulations") of the Securities and
Exchange Commission (the "Commission") thereunder and has been filed with the
Commission. Copies of such registration statement, including any amendments
thereto, the preliminary prospectuses (meeting the requirements of the Rules and
Regulations) contained therein and the exhibits, financial statements and
schedules, as finally amended and revised, have heretofore been delivered by the
Company to you. Such registration statement, together with any registration
statement filed by the Company pursuant to Rule 462(b) of the Act, herein
referred to as the "Registration Statement," which shall be deemed to include
all information omitted therefrom in reliance upon Rule 430A and contained in
the Prospectus referred to below, has become effective under the Act and no
post-effective amendment to the Registration Statement has been filed as of the
date of this Agreement. "Prospectus" means (i) the form of prospectus first
filed with the Commission pursuant to Rule 424(b) or (ii) the last preliminary
prospectus included in the Registration Statement filed prior to the time it
becomes effective or filed pursuant to Rule 424(a) under the Act that is
delivered by the Company to the Underwriters for delivery to purchasers of the
Units, together with the term sheet or abbreviated term sheet filed with the
Commission pursuant to Rule 424(b)(7) under the Act. Each preliminary prospectus
included in the Registration Statement prior to the time it becomes effective is
herein referred to as a "Preliminary Prospectus."

               (b) The Company has been duly organized and is validly existing
as a corporation in good standing under the laws of the State of Delaware, with
corporate power and authority to own or lease its properties and conduct its
business as described in the Registration Statement. Except as described in the
Registration Statement, the Company does not own a controlling interest in any
other corporation or other business entity that has any material assets,
liabilities or operations. Each entity that the Registration Statement discloses
as being controlled by the Company (each a "Subsidiary" and, collectively, the
"Subsidiaries") has been duly organized and is validly existing under the laws
of its jurisdiction of organization and has the necessary legal power and
authority to own or lease its properties and to conduct its business as
described in the Registration Statement. The Company and each Subsidiary is duly
qualified to transact business in all jurisdictions in which the conduct of its
business requires such qualification.

               (c) The outstanding shares of each class or series of capital
stock or other equity interests of the Company and each Subsidiary have been
duly authorized and validly issued and are fully paid and non-assessable and,
except as disclosed in the Registration Statement, have been issued and sold by
the Company or the Subsidiary in compliance in all material respects with
applicable securities laws; the issuance and sale of the Units have been duly
authorized by all necessary corporate action and, when issued and paid for as
contemplated herein, the Units will be validly issued, fully paid and
non-assessable; and no preemptive rights of shareholders exist with respect to
any security of the Company or the issue and sale thereof. Except as set forth
in the Registration Statement, neither the filing of the Registration Statement
nor the offering or sale of the Units as contemplated by this Agreement gives
rise to any rights,

                                       2
<PAGE>

other than those which have been waived or satisfied, for or relating to the
registration of any shares of Common Stock or other securities of the Company.
The Company has duly and validly reserved, out of its authorized and unissued
Common Stock, for issuance upon exercise of Warrants a number of shares
sufficient for such purposes, including Warrants included in the Option Units
and Units obtainable on exercise of the Representative's Warrants issuable as
described in Section 2(d) (the "Representative's Warrants").

               (d) The information set forth under the caption "Capitalization"
in the Prospectus is true and correct. The Common Stock conforms and the
Warrants and the Representative's Warrants will conform to the description
thereof contained in the Registration Statement. The forms of certificates for
the Common Stock, the Warrants and the Representative's Warrants conform to the
requirements of the corporate law of Delaware.

               (e) The Commission has not issued an order preventing or
suspending the use of any Prospectus relating to the proposed offering of the
Units nor instituted proceedings for that purpose. The Registration Statement
contains, and the Prospectus and any amendments or supplements thereto will
contain, all statements that are required to be stated therein by the Company
and will conform to the requirements of the Act and the Rules and Regulations.
The Registration Statement and any amendment thereto do not contain, and will
not contain, any untrue statement of a material fact and do not omit, and will
not omit, to state any material fact required to be stated therein or necessary
to make the statements therein not misleading. The Prospectus and any amendments
and supplements thereto do not contain, and will not contain, any untrue
statement of material fact; and do not omit, and will not omit, to state any
material fact required to be stated therein or necessary to make the statements
therein, in the light of the circumstances under which they were made, not
misleading; provided, however, that the Company makes no representations or
warranties as to information contained in or omitted from the Registration
Statement or the Prospectus, or any such amendment or supplement, in reliance
upon, and in conformity with, written information furnished to the Company by or
on behalf of any Underwriter through the Representative, specifically for use in
the preparation thereof.

               (f) The consolidated financial statements of the Company,
together with related notes and schedules as set forth in the Registration
Statement, present fairly the consolidated financial position and the results of
operations and cash flows of the Company and its consolidated subsidiaries at
the indicated dates and for the indicated periods. The impact of each material
accounting judgment made in the preparation of the financial statements included
in the Registration Statement has been fairly and adequately disclosed in the
notes thereto or elsewhere in the Registration Statement. Such financial
statements and related schedules have been prepared in accordance with generally
accepted principles of accounting, consistently applied throughout the periods
involved, except as disclosed herein and in the Registration Statement, and all
adjustments necessary for a fair presentation of results for such periods have
been made. The summary financial and statistical data of the Company included in
the Registration Statement presents fairly the information shown therein and
such data has been compiled on a basis consistent with the financial statements
presented therein and the books and records of the Company.

               (g) J.H. Cohn LLP, who have certified certain of the financial
statements filed with the Commission as part of the Registration Statement, are
independent public accountants

                                       3
<PAGE>

as required by the Act and the Rules and Regulations. There are no facts or
circumstances that would cause the selection and/or engagement of J.H. Cohn LLP
as auditors of the Company's financial statements included in the Registration
Statement or the Prospectus to constitute a violation of Title II of the
Sarbanes-Oxley Act of 2002 or any rules adopted or proposed to be adopted
pursuant thereto.

               (h) There is no action, suit, claim or proceeding pending or, to
the knowledge of the Company, threatened against the Company or any Subsidiary
before any court or administrative agency or otherwise which if determined
adversely to the Company or such Subsidiary might result in any material adverse
change in the earnings, business, management, properties, assets, rights,
operations, condition (financial or otherwise) or prospects of the Company or
prevent the consummation of the transactions contemplated hereby, except as set
forth in the Registration Statement.

               (i) The Company and each Subsidiary either has, or has disposed
of in the ordinary course of business since December 31, 2002, good and
marketable title to all of its properties and material assets, tangible and
intangible, reflected in the consolidated balance sheet of the Company and its
consolidated Subsidiaries as of that date that is a part of the financial
statements included in the Registration Statement, and has good and marketable
title to all other property described in the Registration Statement as owned by
the Company or a Subsidiary, subject to no lien, mortgage, pledge, charge or
encumbrance of any kind except those reflected in such financial statements (or
as described in the Registration Statement) or which are not material. All of
the leases and subleases under which the Company or any Subsidiary holds
properties are in full force and effect (with only such exceptions as are
commonly accepted by prudent companies engaged in the business of the Company or
such Subsidiary) and neither the Company nor any Subsidiary has received notice
of any claim that is materially adverse to the rights of the Company or any
Subsidiary under any of such leases or subleases.

               (j) The Company, for itself and its Subsidiaries that have been
consolidated for tax purposes, has filed all federal, state, local and foreign
income tax returns which have been required to be filed and has paid all taxes
indicated by said returns and all assessments received by it to the extent that
such taxes have become due and are not being contested in good faith. All tax
liabilities have been adequately provided for in the financial statements of the
Company. Except as described in the Registration Statement, all of the
Subsidiaries are consolidated with the Company for tax purposes.

               (k) Since the respective dates as of which information is given
in the Registration Statement, as it may have been amended or supplemented,
there has not been any material adverse change or any development involving a
prospective material adverse change in or affecting the earnings, business,
management, properties, assets, rights, operations, condition (financial or
otherwise), or prospects of the Company or any Subsidiary, whether or not
occurring in the ordinary course of business, and there has not been any
material transaction entered into or any material transaction that is probable
of being entered into by the Company or any Subsidiary, other than transactions
in the ordinary course of business and changes and transactions described in the
Registration Statement, as it may be amended or supplemented. Neither the
Company nor any Subsidiary has any material contingent obligations which are not

                                       4
<PAGE>

disclosed in the Company's financial statements included in the Registration
Statement or elsewhere in the Prospectus.

               (l) Neither the Company nor any Subsidiary is, nor, with the
giving of notice or lapse of time or both, will any such entity be, in violation
of or in default under its Certificate of Incorporation or Bylaws or other
charter documents or under any agreement, lease, contract, indenture or other
instrument or obligation to which it is a party or by which it, or any of its
properties, is bound and which default is of material significance in respect of
the condition, financial or otherwise of the Company or such Subsidiary or the
business, management, properties, assets, rights, operations, condition
(financial or otherwise) or prospects of the Company or such Subsidiary. The
execution and delivery of this Agreement and the consummation of the
transactions herein contemplated and the fulfillment of the terms hereof will
not conflict with or result in a breach of any of the terms or provisions of, or
constitute a default under, any indenture, mortgage, deed of trust or other
agreement or instrument to which any member of the Company is a party, or of the
Certificate of Incorporation or Bylaws of the Company or any order, rule or
regulation applicable to the Company of any court or of any regulatory body or
administrative agency or other governmental body having jurisdiction.

               (m) Each approval, consent, order, authorization, designation,
declaration or filing by or with any regulatory, administrative or other
governmental body necessary in connection with the execution and delivery by the
Company of this Agreement and the consummation of the transactions herein
contemplated (except such additional steps as may be required by the Commission,
the National Association of Securities Dealers, Inc. (the "NASD") or such
additional steps as may be necessary to qualify the Units for public offering by
the Underwriters under state securities or Blue Sky laws) has been obtained or
made and is in full force and effect.

               (n) The Company or a Subsidiary holds all patents, patent rights,
trademarks, trade names, copyrights, trade secrets and licenses of any of the
foregoing (collectively, "Intellectual Property Rights") that are necessary to
the conduct of its businesses; there is no claim pending or, to the best
knowledge of the Company, threatened against the Company or any Subsidiary or
any of their respective officers, directors or employees alleging any
infringement of Intellectual Property Rights, or any violation of the terms of
any license relating to Intellectual Property Rights, nor does the Company know
of any basis for any such claim. The Company knows of no infringement by others
of Intellectual Property Rights owned by or licensed to the Company or a
Subsidiary. The Company or a Subsidiary has obtained, is in compliance in all
material respect with and maintains in full force and effect all material
licenses, certificates, permits, orders or other, similar authorizations granted
or issued by any governmental agency (collectively "Government Permits")
required to conduct its business as it is presently conducted. No proceeding to
revoke, limit or otherwise materially change any Government Permit has been
commenced or, to the Company's best knowledge, is threatened against the Company
or any Subsidiary, and the Company has no reason to anticipate that any such
proceeding will be commenced against the Company or any Subsidiary. Except as
disclosed or contemplated in the Prospectus, the Company has no reason to
believe that any pending application for a Government Permit will be denied or
limited in a manner inconsistent with the Company's business plan as described
in the Prospectus.

                                       5
<PAGE>

               (o) The Company and each Subsidiary is in all material respects
in compliance with all applicable Environmental Laws. The Company has no
knowledge of any past, present or, as anticipated by the Company, future events,
conditions, activities, investigation, studies, plans or proposals that (i)
would interfere with or prevent compliance with any Environmental Law by the
Company or any Subsidiary or (ii) could reasonably be expected to give rise to
any common law or other liability, or otherwise form the basis of a claim,
action, suit, proceeding, hearing or investigation, involving the Company or any
Subsidiary and related to Hazardous Substances or Environmental Laws. Except for
the prudent and safe use and management of Hazardous Substances in the ordinary
course of the Company's business, (i) no Hazardous Substance is or has been
used, treated, stored, generated, manufactured or otherwise handled on or at any
Facility and (ii) to the Company's best knowledge, no Hazardous Substance has
otherwise come to be located in, on or under any Facility. No Hazardous
Substances are stored at any Facility except in quantities necessary to satisfy
the reasonably anticipated use or consumption by the Company. No litigation,
claim, proceeding or governmental investigation is pending regarding any
environmental matter for which the Company or any Subsidiary has been served or
otherwise notified or, to the knowledge of the Company, threatened or asserted
against the Company or any Subsidiary, or the officers or directors of the
Company or any Subsidiary in their capacities as such, or any Facility or the
Company's business. There are no orders, judgments or decrees of any court or of
any governmental agency or instrumentality under any Environmental Law which
specifically apply to the Company or any Subsidiary, any Facility or any of the
Company's or any Subsidiary's operations. Neither the Company nor any Subsidiary
has received from a governmental authority or other person (i) any notice that
it is a potentially responsible person for any Contaminated site or (ii) any
request for information about a site alleged to be Contaminated or regarding the
disposal of Hazardous Substances. There is no litigation or proceeding against
any other person by the Company or any Subsidiary regarding any environmental
matter. The Company has disclosed in the Prospectus or made available to the
Underwriters and their counsel true, complete and correct copies of any reports,
studies, investigations, audits, analyses, tests or monitoring in the possession
of or initiated by the Company or any Subsidiary pertaining to any environmental
matter relating to the Company, any Subsidiary, their past or present operations
or any Facility.

         For the purposes of the foregoing paragraph, "Environmental Laws" means
any applicable federal, state or local statute, regulation, code, rule,
ordinance, order, judgment, decree, injunction or common law pertaining in any
way to the protection of human health or the environment, including without
limitation, the Resource Conservation and Recovery Act, the Comprehensive
Environmental Response, Compensation and Liability Act, the Toxic Substances
Control Act, the Clean Air Act, the Federal Water Pollution Control Act and any
similar or comparable state or local law; "Hazardous Substance" means any
hazardous, toxic, radioactive or infectious substance, material or waste as
defined, listed or regulated under any Environmental Law; "Contaminated" means
the actual existence on or under any real property of Hazardous Substances, if
the existence of such Hazardous Substances triggers a requirement to perform any
investigatory, remedial, removal or other response action under any
Environmental Laws or if such response action legally could be required by any
governmental authority; "Facility" means any property currently owned, leased or
occupied by the Company.

               (p) Neither the Company, nor to the Company's best knowledge, any
of its affiliates, has taken or intends to take, directly or indirectly, any
action which is designed to

                                       6
<PAGE>

cause or result in, or which constitutes or might reasonably be expected to
constitute, the stabilization or manipulation of the price of the shares of
Common Stock or the Warrants to facilitate the sale or resale of the Units.

               (q) The Company is not an "investment company" within the meaning
of such term under the Investment Company Act of 1940 and the rules and
regulations of the Commission thereunder.

               (r) The Company maintains a system of internal accounting
controls sufficient to provide reasonable assurances that (i) transactions are
executed in accordance with management's general or specific authorization; (ii)
transactions are recorded as necessary to permit preparation of financial
statements in conformity with generally accepted accounting principles and to
maintain accountability for assets; (iii) access to assets is permitted only in
accordance with management's general or specific authorization; and (iv) the
recorded accountability for assets is compared with existing assets at
reasonable intervals and appropriate action is taken with respect to any
differences. The Company has adopted Disclosure Controls and Procedures, as
defined in Section 13a-14(c) of the rules and regulations adopted under the
Securities Exchange Act of 1934, as amended, (the "Exchange Act") and has
implemented such procedures as adopted and has evaluated the effectiveness of
such Disclosure Controls and Procedures.

               (s) The Company and each Subsidiary carries, or is covered by,
insurance in such amounts and covering such risks as is adequate for the conduct
of their respective businesses and the value of their respective properties and
as is customary for companies engaged in similar industries.

               (t) The Company and each Subsidiary is in compliance in all
material respects with all presently applicable provisions of the Employee
Retirement Income Security Act of 1974, as amended, including the regulations
and published interpretations thereunder ("ERISA"); no "reportable event" (as
defined in ERISA) has occurred with respect to any "pension plan" (as defined in
ERISA) for which the Company or any Subsidiary would have any liability; neither
the Company nor any Subsidiary has incurred and the Company does not expect that
it or any Subsidiary will incur liability under (i) Title IV of ERISA with
respect to termination of, or withdrawal from, any "pension plan" or (ii)
Sections 412 or 4971 of the Internal Revenue Code of 1986, as amended, including
the regulations and published interpretations thereunder (the "Code"); and each
"pension plan" for which the Company or any Subsidiary would have any liability
that is intended to be qualified under Section 401(a) of the Code is so
qualified in all material respects and nothing has occurred, whether by action
or by failure to act, which would cause the loss of such qualification.

               (u) The Company and each Subsidiary is in material compliance
with all laws, rules, regulations, orders of any court or administrative agency,
operating licenses or other requirements imposed by any governmental body
applicable to it, including, without limitation, all applicable laws, rules,
regulations, licenses or other governmental standards applicable to its
business; and the conduct of the business of the Company and each Subsidiary, as
described in the Prospectus, will not cause the Company or such Subsidiary to be
in violation of any such requirements.

                                       7
<PAGE>

               (v) Each of the Warrants and the Representative's Warrants have
been authorized for issuance to the purchasers thereof or to the Representative
or its designees, as the case may be, and will, when issued, possess rights,
privileges, and characteristics as represented in the most recent form of
Warrant Agreement or Representative's Warrants, as the case may be, filed as an
exhibit to the Registration Statement; the securities to be issued upon exercise
of the Warrants and the Representative's Warrants, when issued and delivered
against payment therefor in accordance with the terms thereof, will be duly and
validly issued, fully paid, nonassessable and free of preemptive rights, and all
corporate action required to be taken for the authorization and issuance of the
Warrants and the Representative's Warrants, and the securities to be issued upon
their exercise, have been validly and sufficiently taken. The execution by the
Company of the Warrant Agreement and the Representative's Warrants has been duly
authorized by all required action of the Company and, when so executed and
delivered (and assuming due and valid execution by the Warrant Agent, in the
case of the Warrant Agreement) will constitute the valid and binding obligations
of the Company, enforceable against the Company in accordance with their
respective terms, subject, as to enforcement, to bankruptcy, insolvency,
reorganization and other laws of general applicability relating to or affecting
creditors' rights and to general equity principles.

               (w) Except as disclosed in the Prospectus, neither the Company
nor any of its officers, directors or affiliates have caused any person, other
than the Underwriters, to be entitled to reimbursement of any kind, including,
without limitation, any compensation that would be includable as underwriter
compensation under the NASD's Corporate Financing Rule with respect to the
offering of the Units, as a result of the consummation of such offering based on
any activity of such person as a finder, agent, broker, investment adviser or
other financial service provider.

               (x) Except as described in the Prospectus, the Company does not
directly or indirectly control or have a material interest in any other business
entity.

               (y) The Units, the Common Stock and the Warrants have been
approved for listing on the American Stock Exchange ("AMEX") upon the
effectiveness of the Registration Statement and the Company has satisfied all of
the requirements of AMEX for such listing and for the trading of its Common
Stock, Units and Warrants on AMEX.

               (z) The Company has adopted organizational structures and
policies sufficient to comply with the requirements of the AMEX corporate
governance rules in effect as of the date hereof and as proposed to be amended
in accordance with any proposed rules of AMEX published for comment as of the
date hereof (collectively, the "AMEX Corporate Governance Rules"). Without
limiting the generality of the foregoing, the Company's Board of Directors has
validly appointed an Audit Committee and a Compensation Committee whose
composition satisfies the requirements of the AMEX Corporate Governance Rules.
The Board of Directors and/or the Audit Committee or Compensation Committee, as
the case may be, has adopted a charter governing the respective activities of
the Audit and Compensation Committees that satisfies the requirements of the
AMEX Corporate Governance Rules. The Audit Committee and the Compensation
Committee have each acted in accordance with the provisions of their respective
charters, as amended from time to time.

                                       8
<PAGE>

               (aa) Neither the Board of Directors nor the Audit Committee has
been informed, nor is any director of the Company aware, of (i) any significant
deficiencies in the design or operation of the Company's internal controls which
could adversely affect the Company's ability to record, process, summarize and
report financial data or any material weakness in the Company's internal
controls; or (ii) any fraud, whether or not material, that involves management
or other employees of the Company who have a significant role in the Company's
internal controls.

               (bb) Each of the certifications made by the principal executive
and principal financial officers of the Company pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002 and the rules and regulations adopted thereunder was
correct in all material respects when made.

               (cc) The Company and each Subsidiary has complied with all
provisions of Section 517.075 Florida Statutes, relating to doing business with
the Government of Cuba or with any person or affiliate located in Cuba.

         2. Purchase, Sale and Delivery of the Units.

               (a) On the basis of the representations, warranties and covenants
herein contained, and subject to the conditions herein set forth, the Company
agrees to sell to the Underwriters and each Underwriter agrees, severally and
not jointly, to purchase, at a price of [$____] per Unit, the number of Firm
Units set forth opposite the name of each Underwriter in Schedule I hereof,
subject to adjustments in accordance with Section 9 hereof.

               (b) Payment for the Firm Units to be sold hereunder is to be made
in New York Clearing House funds and, at the option of the Representative, by
bank wire to an account specified by the Company, certified or bank cashier's
checks drawn to the order of the Company, against either uncertificated delivery
of Firm Units or of certificates therefor (which delivery, if certificated,
shall take place in such location in New York, New York as may be specified by
the Representative) to the Representative for the several accounts of the
Underwriters. Such payment is to be made at the offices of the Representative at
the address set forth on the first page of this agreement, at 7:00 a.m., Pacific
time, on the third business day after the date of this Agreement or at such
other time and date not later than five business days thereafter as you and the
Company shall agree upon, such time and date being herein referred to as the
"Closing Date." (As used herein, "business day" means a day on which the New
York Stock Exchange is open for trading and on which banks in New York are open
for business and not permitted by law or executive order to be closed.) Except
to the extent uncertificated Firm Units are delivered at closing, the
certificates for the Firm Units will be delivered in such denominations and in
such registrations as the Representative requests in writing not later than the
second full business day prior to the Closing Date, and will be made available
for inspection by the Representative at least one business day prior to the
Closing Date.

               (c) In addition, on the basis of the representations and
warranties herein contained and subject to the terms and conditions herein set
forth, the Company hereby grants an option to the Underwriters to purchase the
Option Units at the price per Unit as set forth in Section 2(a). The option
granted hereby may be exercised in whole or in part by giving written notice (i)
at any time before the Closing Date and (ii) only once thereafter within 45 days
after

                                       9
<PAGE>

the date of this Agreement, by the Representative to the Company setting forth
the number of Option Units as to which the Underwriters are exercising the
option, the names and denominations in which the Option Units are to be
registered and the time and date at which certificates representing such Units
are to be delivered. The time and date at which certificates for Option Units
are to be delivered shall be determined by the Representative but shall not be
earlier than three nor later than 10 full business days after the exercise of
such option, nor in any event prior to the Closing Date (such time and date
being herein referred to as the "Option Closing Date"). If the date of exercise
of the option is three or more days before the Closing Date, the notice of
exercise shall set the Closing Date as the Option Closing Date. The option with
respect to the Option Units granted hereunder may be exercised only to cover
over-allotments in the sale of the Firm Units by the Underwriters. The
Representative may cancel such option at any time prior to its expiration by
giving written notice of such cancellation to the Company. To the extent, if
any, that the option is exercised, payment for the Option Units shall be made on
the Option Closing Date in New York Clearing House funds and, at the option of
the Representative, by bank wire to an account specified by the Company, or
certified or bank cashier's check drawn to the order of the Company for the
Option Units to be sold by the Company in consideration either of uncertificated
delivery of Option Units or delivery of certificates therefor (which delivery,
if certificated, shall take place in such location in New York, New York as may
be specified by the Representative) to the Representative for the several
accounts of the Underwriters. Except to the extent uncertificated Option Units
are delivered at closing, the certificates for the Option Units will be
delivered in such denominations and in such registrations as the Representative
requests in writing not later than the second full business day prior to the
Option Closing Date, and will be made available for inspection by the
Representative at least one business day prior to the Option Closing Date.

               (d) In addition to the sums payable to the Representative as
provided elsewhere herein, the Representative shall be entitled to receive at
the Closing, for itself alone and not as Representative of the Underwriters, as
additional compensation for its services, Representative's Warrants for the
purchase of up to 120,000 Units at a price of [$____] per Unit, upon the terms
and subject to adjustment and conversion as described in the form of
Representative's Warrants filed as an exhibit to the Registration Statement.

         3. Offering by the Underwriters.

               (a) It is understood that the several Underwriters are to make a
public offering of the Firm Units as soon as the Representative deems it
advisable to do so. The Firm Units are to be initially offered to the public at
the initial public offering price set forth in the Prospectus. The
Representative may from time to time thereafter change the public offering price
and other selling terms. To the extent, if at all, that any Option Units are
purchased pursuant to Section 2 hereof, the Representative will offer them to
the public on the foregoing terms.

         It is further understood that you will act as the Representative for
the Underwriters in the offering and sale of the Units in accordance with an
Agreement Among Underwriters entered into by you and the several other
Underwriters.

         4. Covenants of the Company. The Company covenants and agrees with the
several Underwriters that:

                                       10
<PAGE>

               (a) The Company will (i) use its best efforts to cause the
Registration Statement to become effective or, if the procedure in Rule 430A of
the Rules and Regulations is followed, to prepare and timely file with the
Commission under Rule 424(b) of the Rules and Regulations a Prospectus in a form
approved by the Representative containing information previously omitted at the
time of effectiveness of the Registration Statement in reliance on Rule 430A of
the Rules and Regulations, and (ii) not file any amendment to the Registration
Statement or supplement to the Prospectus of which the Representative shall not
previously have been advised and furnished with a copy or to which the
Representative shall have reasonably objected in writing or which is not in
compliance with the Rules and Regulations.

               (b) The Company will advise the Representative promptly (i) when
the Registration Statement or any post-effective amendment thereto shall have
become effective, (ii) of receipt of any comments from the Commission, (iii) of
any request of the Commission for amendment of the Registration Statement or for
supplement to the Prospectus or for any additional information, and (iv) of the
issuance by the Commission of any stop order suspending the effectiveness of the
Registration Statement or the use of the Prospectus or of the institution of any
proceedings for that purpose. The Company will use its best efforts to prevent
the issuance of any such stop order preventing or suspending the use of the
Prospectus and to obtain as soon as possible the lifting thereof, if issued.

               (c) The Company will cooperate with the Representative in
endeavoring to qualify the Units for sale under the securities laws of such
jurisdictions as the Representative may reasonably have designated in writing
and will make such applications, file such documents, and furnish such
information as may be reasonably required for that purpose, provided the Company
shall not be required to qualify as a foreign corporation or to file a general
consent to service of process in any jurisdiction where it is not now so
qualified or required to file such a consent. The Company will, from time to
time, prepare and file such statements, reports, and other documents, as are or
may be required to continue such qualifications in effect for so long a period
as the Representative may reasonably request for distribution of the Units.

               (d) The Company will deliver to, or upon the order of, the
Representative, from time to time, as many copies of any Preliminary Prospectus
as the Representative may reasonably request. The Company will deliver to, or
upon the order of, the Representative during the period when delivery of a
Prospectus is required under the Act, as many copies of the Prospectus in final
form, or as thereafter amended or supplemented, as the Representative may
reasonably request. The Company will deliver to the Representative at or before
the Closing Date, four signed copies of the Registration Statement and all
amendments thereto including all exhibits filed therewith, and will deliver to
the Representative such number of copies of the Registration Statement
(including such number of copies of the exhibits filed therewith that may
reasonably be requested), and of all amendments thereto, as the Representative
may reasonably request.

               (e) The Company will comply with the Act and the Rules and
Regulations, and the Exchange Act, and the rules and regulations of the
Commission thereunder, so as to permit the completion of the distribution of the
Units as contemplated in this Agreement and the Prospectus. If during the period
in which a prospectus is required by law to be delivered by an Underwriter or
dealer, any event shall occur as a result of which, in the judgment of the

                                       11
<PAGE>

Company or in the reasonable opinion of the Representative, it becomes necessary
to amend or supplement the Prospectus in order to make the statements therein,
in the light of the circumstances existing at the time the Prospectus is
delivered to a purchaser, not misleading, or, if it is necessary at any time to
amend or supplement the Prospectus to comply with any law, the Company promptly
will prepare and file with the Commission an appropriate amendment to the
Registration Statement or supplement to the Prospectus so that the Prospectus as
so amended or supplemented will not, in the light of the circumstances existing
at the time the Prospectus is so delivered, be misleading, or so that the
Prospectus will comply with the law.

               (f) The Company will make generally available to its security
holders, as soon as it is practicable to do so, but in any event not later than
15 months after the effective date of the Registration Statement, an earning
statement (which need not be audited) in reasonable detail, covering a period of
at least 12 consecutive months beginning after the effective date of the
Registration Statement, which earning statement shall satisfy the requirements
of Section 11(a) of the Act and Rule 158 of the Rules and Regulations and will
advise you in writing when such statement has been so made available.

               (g) The Company will, for a period of five years from the Closing
Date, deliver to the Representative copies of annual reports and copies of all
other documents, reports and information furnished by the Company to its
stockholders or filed with any securities exchange pursuant to the requirements
of such exchange or with the Commission pursuant to the Act or the Exchange Act.
The Company will deliver to the Representative similar reports with respect to
significant subsidiaries, as that term is defined in the Rules and Regulations,
which are not consolidated in the Company's financial statements.

               (h) The Company will make no offering, sale, short sale or other
disposition of any shares of Common Stock of the Company or other securities
convertible into or exchangeable or exercisable for shares of Common Stock or
derivatives of Common Stock (or agreement therefor), directly or indirectly, for
a period of ninety days after the date of this Agreement otherwise than
hereunder, or pursuant to contractual obligations existing on the date hereof or
pursuant to employee benefit plans in effect on the date hereof, or with the
prior written consent of the Representative, which consent will not be
unreasonably withheld.

               (i) The Company will use its best efforts to list, subject to
notice of issuance of the Units, the Common Stock and the Warrants on the AMEX
and to cause such listing to remain in effect with respect to each such security
unless and until (i) such security expires; (ii) such security is listed on
another exchange of at least comparable reputation; or (iii) the Company is no
longer required to file reports under Section 12 of the Exchange Act.

               (j) The Company has caused each officer and director and each
person who owns, beneficially or of record, shares of the Common Stock
constituting 5% or more of the Common Stock outstanding immediately prior to the
date hereof to furnish to you, on or prior to the date of this agreement, a
letter or letters, in form and substance satisfactory to the Underwriters
("Lock-up Agreements"), pursuant to which each such person has agreed not to
offer, sell, sell short or otherwise dispose of any shares of Common Stock or
other capital stock of the Company, or any other securities convertible,
exchangeable or exercisable for Common Stock or derivatives of Common Stock
owned by such person or request the registration for the

                                       12
<PAGE>

offer or sale of any of the foregoing (or as to which such person has the right
to direct the disposition) for a period of 90 days after the date of this
Agreement, directly or indirectly, except with the prior written consent of the
Representative.

               (k) The Company shall apply the net proceeds of its sale of the
Units as set forth in the Prospectus and shall file such reports with the
Commission with respect to the sale of the Units and the application of the
proceeds therefrom as may be required in accordance with Rule 463 under the Act.

               (l) The Company shall not invest, or otherwise use the proceeds
received by the Company from its sale of the Units in such a manner as would
require the Company to register as an investment company under the Investment
Company Act of 1940, as amended (the "1940 Act").

               (m) The Company will maintain a transfer agent and, if necessary
under the jurisdiction of incorporation of the Company, a registrar for the
Common Stock, and shall comply with the provisions of the Warrant Agreement with
respect to the appointment and maintenance of a Warrant Agent for the Warrants.

               (n) The Company will not take, directly or indirectly, any action
designed to cause or result in, or that has constituted or might reasonably be
expected to constitute, the stabilization or manipulation of the price of any
securities of the Company.

         5. Costs and Expenses.

               (a) The Representative shall be entitled to reimbursement from
the Company, for itself alone and not as Representative of the Underwriters, to
a non-accountable expense allowance equal to 3.0% of the aggregate initial
public offering price of the Firm Units and any Option Units purchased by the
Underwriters. The Representative shall be entitled to withhold this allowance on
the Closing Date related to the purchase of the Firm Units or the Option Units,
as the case may be.

               (b) In addition to the payment described in Paragraph (a) of this
Section 5, the Company will pay all costs, expenses and fees incident to the
performance of the obligations of the Company under this Agreement, including,
without limiting the generality of the foregoing, the following: accounting fees
of the Company; the fees and disbursements of counsel for the Company; the cost
of printing and delivering to, or as requested by, the Underwriters copies of
the Registration Statement, Preliminary Prospectuses, the Prospectus, this
Agreement, the AMEX listing application, the costs of due diligence
investigation of the principals of the Company, the Blue Sky Survey and any
supplements or amendments thereto; the filing fees of the Commission; the filing
fees and expenses (including any fees and disbursements of counsel for the
Underwriters) incident to securing the required review by the NASD Regulation,
Inc. of the underwriting terms and arrangements; the AMEX listing fee; and the
expenses, including the fees and disbursements of counsel for the Underwriters,
incurred in connection with the qualification of the Units under state
securities or Blue Sky laws. Any transfer taxes imposed on the sale of the Units
to the several Underwriters will be paid by the Company. The Company agrees to
pay all costs and expenses of the Underwriters, including the fees and
disbursements of

                                       13
<PAGE>

counsel for the Underwriters, incident to the offer and sale of directed Units
by the Underwriters to employees and persons having business relationships with
the Company. The Company shall not, however, be required to pay for any of the
Underwriters' expenses (other than those related to qualification under NASD
regulation and state securities or Blue Sky laws) except that, if this Agreement
shall not be consummated, then the Company shall reimburse the several
Underwriters for accountable out-of-pocket expenses, including fees and
disbursements of counsel, reasonably incurred in connection with investigating,
marketing and proposing to market the Units or in contemplation of performing
their obligations hereunder; but the Company shall not in any event be liable to
any of the several Underwriters for damages on account of loss of anticipated
profits from the sale by them of the Units.

         6. Conditions of Obligations of the Underwriters. The several
obligations of the Underwriters to purchase the Firm Units on the Closing Date
and the Option Units, if any, on the Option Closing Date are subject to the
accuracy, as of the Closing Date or the Option Closing Date, as the case may be,
of the representations and warranties of the Company contained herein, and to
the performance by the Company of their covenants and obligations hereunder and
to the following additional conditions:

               (a) The Registration Statement and all post-effective amendments
thereto shall have become effective and any and all filings required by Rule 424
and Rule 430A of the Rules and Regulations shall have been made, and any request
of the Commission for additional information (to be included in the Registration
Statement or otherwise) shall have been disclosed to the Representative and
complied with to their reasonable satisfaction. No stop order suspending the
effectiveness of the Registration Statement, as amended from time to time, shall
have been issued and no proceedings for that purpose shall have been taken or,
to the knowledge of the Company, shall be contemplated by the Commission and no
injunction, restraining order, or order of any nature by a Federal or state
court of competent jurisdiction shall have been issued as of the Closing Date
which would prevent the issuance of the Units.

The Representative shall have received on the Closing Date or the Option Closing
Date, as the case may be, the opinion of Morse, Zelnick, Rose & Lander LLP,
counsel for the Company, dated the Closing Date or the Option Closing Date, as
the case may be, addressed to the Underwriters (and stating that it may be
relied upon by counsel to the Underwriters) to the effect that:

                    (i) The Company has been duly organized and is validly
existing as a corporation in good standing under the laws of the State of
Delaware, with corporate power and authority to own or lease its properties and
conduct its business as described in the Registration Statement.

                    (ii) Each Subsidiary has been duly organized and is validly
existing as a business entity in good standing under the laws of its
jurisdiction of formation with all requisite power and authority under the laws
governing such entities to own or lease its properties and conduct its business
as described in the Registration Statement.

                    (iii) The Company and each Subsidiary is duly qualified to
transact business in all jurisdictions in which the conduct of its business
requires such qualification, or in

                                       14
<PAGE>

which the failure to qualify would have a material adverse effect upon the
business of the Company.

                    (iv) The Company has authorized and outstanding capital
stock as set forth under the caption "Capitalization" in the Prospectus; the
outstanding shares of Common Stock have been duly authorized and validly issued
and are fully paid and non-assessable; all of the securities of the Company
conform to the description thereof contained in the Prospectus; the certificates
for the Common Stock and the Warrants are in due and proper form; no preemptive
rights of shareholders exist with respect to any of the Common Stock or the
issuance or sale thereof pursuant to any applicable statute or the provisions of
the Company's Articles of Incorporation or Bylaws or, to such counsel's best
knowledge, pursuant to any contractual obligation. The Company's ownership
interest in each Subsidiary is, in all material respects, as described in the
Registration Statement.

                    (v) Except as described in or contemplated by the
Prospectus, to the knowledge of such counsel, there are no outstanding
securities of the Company convertible or exchangeable into or evidencing the
right to purchase or subscribe for any shares of capital stock of the Company
and there are no outstanding or authorized options, warrants or rights of any
character obligating the Company to issue any shares of its capital stock or any
securities convertible or exchangeable into or evidencing the right to purchase
or subscribe for any shares of such stock; and except as described in the
Prospectus, to the knowledge of such counsel, no holder of any securities of the
Company or any other person has the right, contractual or otherwise, which has
not been satisfied or effectively waived, to cause the Company to sell or
otherwise issue to them, or to permit them to underwrite the sale of, any of the
Units or the right to have any Common Stock or other securities of the Company
included in the Registration Statement or the right, as a result of the filing
of the Registration Statement, to require registration under the Act of any
shares of Common Stock or other securities of the Company.

                    (vi) The Warrant Agreement and the Warrants have been duly
authorized by the Company. When duly executed, authenticated, issued and
delivered as contemplated in the Registration Statement and the Warrant
Agreement, the Warrant Agreement and the Warrants will constitute legally
binding obligations of the Company, enforceable against it in accordance with
their terms and, in the case of the Warrants, entitled to the benefits of the
Warrant Agreement subject, as to enforcement, to bankruptcy, insolvency,
reorganization and other laws of general applicability relating to or affecting
creditors' rights and to general equity principles.

                    (vii) The Warrants are exercisable to purchase Common Stock
in accordance with the terms of the Warrant Agreement; the shares of Common
Stock initially issuable upon exercise of the Warrants (including Warrants
comprising the Option Units and Warrants issuable on exercise of the
Representative's Warrants) have been duly authorized and reserved for issuance
upon such conversion or exercise, as the case may be, and, when issued upon such
conversion or exercise in accordance with the terms of the Warrant Agreement
will be validly issued, fully paid and nonassessable.

                    (viii) The Representative's Warrants have been duly
authorized by the Company. When duly executed, issued and delivered as
contemplated in the Registration

                                       15
<PAGE>

Statement, the Representative's Warrants will constitute the legally binding
obligation of the Company, enforceable against it in accordance with its terms
subject, as to enforcement, to bankruptcy, insolvency, reorganization and other
laws of general applicability relating to or affecting creditors' rights and to
general equity principles.

                    (ix) The Registration Statement has become effective under
the Act and, to the best of the knowledge of such counsel, no stop order
proceedings with respect thereto have been instituted or are pending or
threatened under the Act.

                    (x) The Registration Statement, the Prospectus and each
amendment or supplement thereto comply as to form in all material respects with
the requirements of the Act and the applicable rules and regulations thereunder
(except that such counsel need express no opinion as to the financial statements
and related schedules therein).

                    (xi) The statements under the captions "Business-Patents and
Intellectual Property," "Business-Government Regulation," "Shares Eligible for
Future Sale," "Description of Securities" and _______________________ in the
Prospectus and in Items __ and __ of the Registration Statement, insofar as such
statements constitute a summary of documents referred to therein or matters of
law, fairly summarize in all material respects the information called for with
respect to such documents and matters.

                    (xii) Such counsel does not know of any contracts or
documents required to be filed as exhibits to the Registration Statement or
described in the Registration Statement or the Prospectus which are not so filed
or described as required, and such contracts and documents as are summarized in
the Registration Statement or the Prospectus are fairly summarized in all
material respects.

                    (xiii) Such counsel knows of no material legal or
governmental proceedings pending or threatened against the Company or any
Subsidiary.

                    (xiv) The execution and delivery of this Agreement and the
consummation of the transactions herein contemplated do not and will not
conflict with or result in a breach of any of the terms or provisions of, or
constitute a default under, the Certificate of Incorporation or Bylaws of the
Company, as amended, or any agreement or instrument known to such counsel to
which the Company is a party or by which the Company may be bound.

                    (xv) Each of this Agreement and the Warrant Agreement has
been duly authorized, executed and delivered by the Company.

                    (xvi) No approval, consent, order, authorization,
designation, declaration or filing by or with any regulatory, administrative or
other governmental body is necessary in connection with the execution and
delivery of this Agreement and the consummation of the transactions herein
contemplated (other than as may be required by the NASD, as to which such
counsel need express no opinion) except such as have been obtained or made.

                    (xvii) The Company is not, and will not become, as a result
of the consummation of the transactions contemplated by this Agreement, and
application of the net

                                       16
<PAGE>

proceeds therefrom as described in the Prospectus, required to register as an
investment company under the 1940 Act.

In rendering such opinion, such counsel may rely as to matters governed by the
laws of states other than Oregon, or federal laws on local counsel in such
jurisdictions, provided that in each case such counsel shall state that they
believe that they and the Underwriters are justified in relying on such other
counsel. In addition to the matters set forth above, the opinion of Morse,
Zelnick, Rose & Lander LLP shall also include a statement to the effect that
nothing has come to the attention of such counsel that has caused them to
believe that (i) the Registration Statement, at the time it became effective
under the Act (but after giving effect to any modifications incorporated therein
pursuant to Rule 430A under the Act) and as of the Closing Date or the Option
Closing Date, as the case may be, contained an untrue statement of a material
fact or omitted to state a material fact required to be stated therein or
necessary to make the statements therein not misleading, and (ii) the
Prospectus, or any supplement thereto, on the date it was filed pursuant to the
Rules and Regulations and as of the Closing Date or the Option Closing Date, as
the case may be, contained an untrue statement of a material fact or omitted to
state a material fact necessary in order to make the statements, in the light of
the circumstances under which they are made, not misleading (except that such
counsel need express no view as to financial statements, schedules and
statistical information therein).

               (b) The Representative shall have received from Holland & Knight
LLP, counsel for the Underwriters, an opinion dated the Closing Date or the
Option Closing Date, as the case may be, substantially to the effect specified
in subparagraphs (ix) and (x) of Paragraph (b) of this Section 6. In rendering
such opinion Holland & Knight LLP may rely as to all matters governed other than
by the laws of the State of Oregon or Federal laws on the opinion of counsel
referred to in Paragraph (b) of this Section 6. In addition to the matters set
forth above, such opinion shall also include a statement to the effect that
nothing has come to the attention of such counsel that has caused them to
believe that (i) the Registration Statement, or any amendment thereto, as of the
time it became effective under the Act (but after giving effect to any
modifications incorporated therein pursuant to Rule 430A under the Act) and as
of the Closing Date or the Option Closing Date, as the case may be, contained an
untrue statement of a material fact or omitted to state a material fact required
to be stated therein or necessary to make the statements therein not misleading,
and (ii) the Prospectus, or any supplement thereto, on the date it was filed
pursuant to the Rules and Regulations and as of the Closing Date or the Option
Closing Date, as the case may be, contained an untrue statement of a material
fact or omitted to state a material fact necessary in order to make the
statements, in the light of the circumstances under which they are made, not
misleading (except that such counsel need express no view as to financial
statements, schedules and statistical information therein). With respect to such
statement, Holland & Knight LLP may state that their belief is based upon the
procedures set forth therein, but is without independent check and verification.

               (c) The Representative shall have received at or prior to the
Closing Date from Holland & Knight LLP a memorandum or summary, in form and
substance satisfactory to the Representative, with respect to the qualification
for offering and sale by the Underwriters of the Units under the state
securities or Blue Sky laws of such jurisdictions as the Representative may
reasonably have designated to the Company.

                                       17
<PAGE>

               (d) The Representative, on behalf of the several Underwriters,
shall have received, on each of the dates hereof, the Closing Date and the
Option Closing Date, as the case may be, a letter dated the date hereof, the
Closing Date or the Option Closing Date, as the case may be, in form and
substance satisfactory to the Representative, of J.H. Cohn LLP confirming that
they are independent public accountants within the meaning of the Act and the
applicable published Rules and Regulations thereunder and stating that in their
opinion the financial statements and schedules examined by them and included in
the Registration Statement comply in form in all material respects with the
applicable accounting requirements of the Act and the related published Rules
and Regulations and containing such other statements and information as is
ordinarily included in accountants' "comfort letters" to Underwriters with
respect to the financial statements and certain financial and statistical
information contained in the Registration Statement and Prospectus.

               (e) The Representative shall have received on the Closing Date or
the Option Closing Date, as the case may be, a certificate or certificates of
the Chief Executive Officer and the Chief Financial Officer of the Company to
the effect that, as of the Closing Date or the Option Closing Date, as the case
may be, each of them severally represents as follows:

                    (i) The Registration Statement has become effective under
the Act and no stop order suspending the effectiveness of the Registration
Statement has been issued, and no proceedings for such purpose have been taken
or are, to his or her knowledge, contemplated by the Commission;

                    (ii) The representations and warranties of the Company
contained in Section 1 hereof are true and correct as of the Closing Date or the
Option Closing Date, as the case may be;

                    (iii) All filings required to have been made pursuant to
Rules 424 or 430A under the Act have been made;

                    (iv) He or she has carefully examined the Registration
Statement and the Prospectus and, in his or her opinion, as of the effective
date of the Registration Statement, the statements contained in the Registration
Statement were true and correct, and such Registration Statement and Prospectus
did not omit to state a material fact required to be stated therein or necessary
in order to make the statements therein not misleading, and since the effective
date of the Registration Statement, no event has occurred which should have been
set forth in a supplement to or an amendment of the Prospectus which has not
been so set forth in such supplement or amendment; and

                    (v) Since the respective dates as of which information is
given in the Registration Statement and Prospectus, there has not been any
material adverse change or any development involving a prospective material
adverse change in or affecting the condition, financial or otherwise, of the
Company or the earnings, business, management, properties, assets, rights,
operations, condition (financial or otherwise) or prospects of the Company,
whether or not arising in the ordinary course of business.

                                       18
<PAGE>

               (f) The Company shall have furnished to the Representative such
further certificates and documents confirming the representations and
warranties, covenants and conditions contained herein and related matters as the
Representative may reasonably have requested.

               (g) The Common Stock and the Warrants have been approved for
listing upon notice of issuance of the Units on AMEX.

               (h) The Lock-up Agreements described in Section 4(j) are in full
force and effect.

         The opinions and certificates mentioned in this Agreement shall be
deemed to be in compliance with the provisions hereof only if they are in all
material respects satisfactory to the Representative and to Holland & Knight
LLP, counsel for the Underwriters.

         If any of the conditions hereinabove provided for in this Section 6
shall not have been fulfilled when and as required by this Agreement to be
fulfilled, the obligations of the Underwriters hereunder may be terminated by
the Representative by notifying the Company of such termination in writing or by
telegram at or prior to the Closing Date or the Option Closing Date, as the case
may be.

         In such event, the Company and the Underwriters shall not be under any
obligation to each other (except to the extent provided in Sections 5 and 8
hereof).

         7. Conditions of the Obligations of the Company. The obligations of the
Company to sell and deliver the portion of the Units required to be delivered as
and when specified in this Agreement are subject to the conditions that at the
Closing Date or the Option Closing Date, as the case may be, no stop order
suspending the effectiveness of the Registration Statement shall have been
issued and in effect or proceedings therefor initiated or threatened.

         8. Indemnification.

               (a) The Company agrees to indemnify and hold harmless each
Underwriter and each person, if any, who controls any Underwriter within the
meaning of the Act, against any losses, claims, damages or liabilities to which
such Underwriter or any such controlling person may become subject under the Act
or otherwise, insofar as such losses, claims, damages or liabilities (or actions
or proceedings in respect thereof) arise out of or are based upon (i) any untrue
statement or alleged untrue statement of any material fact contained in the
Registration Statement, any Preliminary Prospectus, the Prospectus or any
amendment or supplement thereto, or (ii) the omission or alleged omission to
state therein a material fact required to be stated therein or necessary to make
the statements therein not misleading; and will reimburse each Underwriter and
each such controlling person upon demand for any legal or other expenses
reasonably incurred by such Underwriter or such controlling person in connection
with investigating or defending any such loss, claim, damage or liability,
action or proceeding or in responding to a subpoena or governmental inquiry
related to the offering of the Units, whether or not such Underwriter or
controlling person is a party to any action or proceeding; provided, however,
that the Company will not be liable in any such case to the extent that any such
loss, claim, damage or liability arises out of or is based upon an untrue
statement or alleged untrue

                                       19
<PAGE>

statement, or omission or alleged omission made in the Registration Statement,
any Preliminary Prospectus, the Prospectus, or such amendment or supplement, in
reliance upon and in conformity with written information furnished to the
Company by or through the Representative specifically for use in the preparation
thereof. This indemnity agreement will be in addition to any liability which the
Company may otherwise have.

               (b) Each Underwriter severally and not jointly will indemnify and
hold harmless the Company, each of its directors, each of its officers who have
signed the Registration Statement and each person, if any, who controls the
Company within the meaning of the Act, against any losses, claims, damages or
liabilities to which the Company or any such director, officer or controlling
person may become subject under the Act or otherwise, insofar as such losses,
claims, damages or liabilities (or actions or proceedings in respect thereof)
arise out of or are based upon (i) any untrue statement or alleged untrue
statement of any material fact contained in the Registration Statement, any
Preliminary Prospectus, the Prospectus or any amendment or supplement thereto,
or (ii) the omission or the alleged omission to state therein a material fact
required to be stated therein or necessary to make the statements therein, in
the light of the circumstances under which they were made, not misleading; and
will reimburse any legal or other expenses reasonably incurred by the Company or
any such director, officer or controlling person in connection with
investigating or defending any such loss, claim, damage, liability, action or
proceeding; provided, however, that each Underwriter will be liable in each case
to the extent, but only to the extent, that such untrue statement or alleged
untrue statement or omission or alleged omission has been made in the
Registration Statement, any Preliminary Prospectus, the Prospectus or such
amendment or supplement, in reliance upon and in conformity with written
information furnished to the Company by or through the Representative
specifically for use in the preparation thereof. This indemnity agreement will
be in addition to any liability which such Underwriter may otherwise have.

               (c) In case any proceeding (including any governmental
investigation) shall be instituted involving any person in respect of which
indemnity may be sought pursuant to this Section 8, such person (the
"indemnified party") shall promptly notify the person against whom such
indemnity may be sought (the "indemnifying party") in writing. No
indemnification provided for in Section 8(a) or (b) shall be available to any
party who shall fail to give notice as provided in this Section 8(c) if the
party to whom notice was not given was unaware of the proceeding to which such
notice would have related and was materially prejudiced by the failure to give
such notice, but the failure to give such notice shall not relieve the
indemnifying party or parties from any liability which it or they may have to
the indemnified party for contribution or otherwise than on account of the
provisions of Section 8(a) or (b). In case any such proceeding shall be brought
against any indemnified party and it shall notify the indemnifying party of the
commencement thereof, the indemnifying party shall be entitled to participate
therein and, to the extent that it shall wish, jointly with any other
indemnifying party similarly notified, to assume the defense thereof, with
counsel satisfactory to such indemnified party and shall pay as incurred the
fees and disbursements of such counsel related to such proceeding. In any such
proceeding, any indemnified party shall have the right to retain its own counsel
at its own expense. Notwithstanding the foregoing, the indemnifying party shall
pay as incurred (or within 30 days of presentation) the fees and expenses of the
counsel retained by the indemnified party in the event (i) the indemnifying
party and the indemnified party shall have mutually agreed to the retention of
such counsel, (ii) the named parties to any such proceeding (including any

                                       20
<PAGE>

impleaded parties) include both the indemnifying party and the indemnified party
and representation of both parties by the same counsel would be inappropriate
due to actual or potential differing interests between them or (iii) the
indemnifying party shall have failed to assume the defense and employ counsel
acceptable to the indemnified party within a reasonable period of time after
notice of commencement of the action. It is understood that the indemnifying
party shall not, in connection with any proceeding or related proceedings in the
same jurisdiction, be liable for the reasonable fees and expenses of more than
one separate firm for all such indemnified parties. Such firm shall be
designated in writing by you in the case of parties indemnified pursuant to
Section 8(a) and by the Company in the case of parties indemnified pursuant to
Section 8(b). The indemnifying party shall not be liable for any settlement of
any proceeding effected without its written consent but if settled with such
consent or if there be a final judgment for the plaintiff, the indemnifying
party agrees to indemnify the indemnified party from and against any loss or
liability by reason of such settlement or judgment. In addition, the
indemnifying party will not, without the prior written consent of the
indemnified party, settle or compromise or consent to the entry of any judgment
in any pending or threatened claim, action or proceeding of which
indemnification may be sought hereunder (whether or not any indemnified party is
an actual or potential party to such claim, action or proceeding) unless such
settlement, compromise or consent includes an unconditional release of each
indemnified party from all liability arising out of such claim, action or
proceeding.

               (d) If the indemnification provided for in this Section 8 is
unavailable to or insufficient to hold harmless an indemnified party under
Section 8(a) or (b) above in respect of any losses, claims, damages or
liabilities (or actions or proceedings in respect thereof) referred to therein,
then each indemnifying party shall contribute to the amount paid or payable by
such indemnified party as a result of such losses, claims, damages or
liabilities (or actions or proceedings in respect thereof) in such proportion as
is appropriate to reflect the relative benefits received by the Company on the
one hand and the Underwriters on the other from the offering of the Units. If,
however, the allocation provided by the immediately preceding sentence is not
permitted by applicable law then each indemnifying party shall contribute to
such amount paid or payable by such indemnified party in such proportion as is
appropriate to reflect not only such relative benefits but also the relative
fault of the Company on the one hand and the Underwriters on the other in
connection with the statements or omissions which resulted in such losses,
claims, damages or liabilities, (or actions or proceedings in respect thereof),
as well as any other relevant equitable considerations. The relative benefits
received by the Company on the one hand and the Underwriters on the other shall
be deemed to be in the same proportion as the total net proceeds from the
offering (before deducting expenses) received by the Company bears to the total
underwriting discounts and commissions received by the Underwriters, in each
case as set forth in the table on the cover page of the Prospectus. The relative
fault shall be determined by reference to, among other things, whether the
untrue or alleged untrue statement of a material fact or the omission or alleged
omission to state a material fact relates to information supplied by the Company
on the one hand or the Underwriters on the other and the parties' relative
intent, knowledge, access to information and opportunity to correct or prevent
such statement or omission.

         The Company and the Underwriters agree that it would not be just and
equitable if contributions pursuant to this Section 8(d) were determined by pro
rata allocation (even if the Underwriters were treated as one entity for such
purpose) or by any other method of allocation

                                       21
<PAGE>

which does not take account of the equitable considerations referred to above in
this Section 8(d). The amount paid or payable by an indemnified party as a
result of the losses, claims, damages or liabilities (or actions or proceedings
in respect thereof) referred to above in this Section 8(d) shall be deemed to
include any legal or other expenses reasonably incurred by such indemnified
party in connection with investigating or defending any such action or claim.
Notwithstanding the provisions of this subsection (d), (i) no Underwriter shall
be required to contribute any amount in excess of the underwriting discounts and
commissions applicable to the Units purchased by such Underwriter, and (ii) no
person guilty of fraudulent misrepresentation (within the meaning of Section
11(f) of the Act) shall be entitled to contribution from any person who was not
guilty of such fraudulent misrepresentation. The Underwriters' obligations in
this Section 8(d) to contribute are several in proportion to their respective
underwriting obligations and not joint.

               (e) In any proceeding relating to the Registration Statement, any
Preliminary Prospectus, the Prospectus or any supplement or amendment thereto,
each party against whom contribution may be sought under this Section 8 hereby
consents to the jurisdiction of any court having jurisdiction over any other
contributing party, agrees that process issuing from such court may be served
upon him or it by any other contributing party and consents to the service of
such process and agrees that any other contributing party may join him or it as
an additional defendant in any such proceeding in which such other contributing
party is a party.

               (f) Any losses, claims, damages, liabilities or expenses for
which an indemnified party is entitled to indemnification or contribution under
this Section 8 shall be paid by the indemnifying party to the indemnified party
as such losses, claims, damages, liabilities or expenses are incurred. The
indemnity and contribution agreements contained in this Section 8 and the
representations and warranties of the Company set forth in this Agreement shall
remain operative and in full force and effect, regardless of (i) any
investigation made by or on behalf of any Underwriter or any person controlling
any Underwriter, the Company, its directors or officers or any persons
controlling the Company, (ii) acceptance of any Units and payment therefor
hereunder, and (iii) any termination of this Agreement. A successor to any
Underwriter, or to the Company, its directors or officers, or any person
controlling the Company, shall be entitled to the benefits of the indemnity,
contribution and reimbursement agreements contained in this Section 8.

         9. Default by Underwriters. If on the Closing Date or the Option
Closing Date, as the case may be, any Underwriter shall fail to purchase and pay
for the portion of the Units which such Underwriter has agreed to purchase and
pay for on such date (otherwise than by reason of any default on the part of the
Company), you, as Representative of the Underwriters, shall use reasonable
efforts to procure within 36 hours thereafter one or more of the other
Underwriters, or any others, to purchase from the Company such amounts as may be
agreed upon and upon the terms set forth herein, the Firm Units or Option Units,
as the case may be, which the defaulting Underwriter or Underwriters failed to
purchase. If during such 36 hours you, as such Representative, shall not have
procured such other Underwriters, or any others, to purchase the Firm Units or
Option Units, as the case may be, agreed to be purchased by the defaulting
Underwriter or Underwriters, then (a) if the aggregate number of Units with
respect to which such default shall occur does not exceed 10% of the Firm Units
or Option Units, as the case may be, covered hereby, the other Underwriters
shall be obligated, severally, in proportion

                                       22
<PAGE>

to the respective numbers of Firm Units or Option Units, as the case may be,
which they are obligated to purchase hereunder, to purchase the Firm Units or
Option Units, as the case may be, which such defaulting Underwriter or
Underwriters failed to purchase, or (b) if the aggregate number of Firm Units or
Option Units, as the case may be, with respect to which such default shall occur
exceeds 10% of the Firm Units or Option Units, as the case may be, covered
hereby, the Company or you as the Representative of the Underwriters will have
the right, by written notice given within the next 36-hour period to the parties
to this Agreement, to terminate this Agreement without liability on the part of
the non-defaulting Underwriters or of the Company except to the extent provided
in Section 8 hereof. In the event of a default by any Underwriter or
Underwriters, as set forth in this Section 9, the Closing Date or Option Closing
Date, as the case may be, may be postponed for such period, not exceeding seven
days, as you, as Representative, may determine in order that the required
changes in the Registration Statement or in the Prospectus or in any other
documents or arrangements may be effected. The term "Underwriter" includes any
person substituted for a defaulting Underwriter. Any action taken under this
Section 9 shall not relieve any defaulting Underwriter from liability in respect
of any default of such Underwriter under this Agreement.

         10. Notices.

         All communications hereunder shall be in writing and, except as
otherwise provided herein, will be mailed, delivered, telecopied or telegraphed
and confirmed as follows:

                  if to the Underwriters, to

                           Paulson Investment Company, Inc.
                           811 SW Naito Parkway, Suite 200
                           Portland, Oregon 97204
                           Attention: Chester L.F. Paulson

                           with a copy, which shall not constitute notice, to

                           Holland & Knight LLP
                           111 SW Fifth Avenue, Suite 2300
                           Portland, Oregon 97204
                           Attention: Mark A. von Bergen

                  if to the Company, to

                           Milestone Scientific Inc.
                           220 South Orange Avenue
                           Livingston, New Jersey 07039
                           Attention: Leonard Osser

                           with copy, which shall not constitute notice, to

                           Morse, Zelnick, Rose & Lander LLP
                           405 Park Avenue

                                       23
<PAGE>

                           New York, New York  10022
                           Attention: Stephen A. Zelnick

         11. Termination. This Agreement may be terminated by you by notice to
the Company as follows:

               (a) at any time prior to the earlier of (i) the time the Units
are released by you for sale by notice to the Underwriters, or (ii) 11:30 a.m.
on the first business day following the date of this Agreement;

               (b) at any time prior to the Closing Date if any of the following
has occurred: (i) since the respective dates as of which information is given in
the Registration Statement and the Prospectus, any material adverse change or
any development involving a prospective material adverse change in or affecting
the condition, financial or otherwise, of the Company, the earnings, business,
management, properties, assets, rights, operations, condition (financial or
otherwise) or prospects of the Company, whether or not arising in the ordinary
course of business, (ii) any outbreak or escalation of hostilities or
declaration of war or national emergency or other national or international
calamity or crisis or change in economic or political conditions if the effect
of such outbreak, escalation, declaration, emergency, calamity, crisis or change
on the financial markets of the United States would, in your reasonable
judgment, make it impracticable to market the Units or to enforce contracts for
the sale of the Units, (iii) the Dow Jones Industrial Average shall have fallen
by 15 percent or more from its closing price on the day immediately preceding
the date that the Registration Statement is declared effective by the
Commission, (iv) suspension of trading in securities generally on the New York
Stock Exchange or AMEX or limitation on prices (other than limitations on hours
or numbers of days of trading) for securities on either such Exchange, (v) the
enactment, publication, decree or other promulgation of any statute, regulation,
rule or order of any court or other governmental authority which in your opinion
materially and adversely affects or may materially and adversely affect the
business or operations of the Company, (vi) declaration of a banking moratorium
by United States or New York State authorities, (vii) any downgrading in the
rating of the Company's debt securities by any "nationally recognized
statistical rating organization" (as defined for purposes of Rule 436(g) under
the Exchange Act); (viii) the suspension of trading of the Common Stock or the
Warrants by the Commission or AMEX, or (ix) the taking of any action by any
governmental body or agency in respect of its monetary or fiscal affairs which
in your reasonable opinion has a material adverse effect on the securities
markets in the United States; or

               (c) as provided in Sections 6 and 9 of this Agreement.

         12. Successors. This Agreement has been and is made solely for the
benefit of the Underwriters, the Company and their respective successors,
executors, administrators, heirs and assigns, and the officers, directors and
controlling persons referred to herein, and no other person will have any right
or obligation hereunder. No purchaser of any of the Units from any Underwriter
shall be deemed a successor or assign merely because of such purchase.

         13. Information Provided by Underwriters. The Company and the
Underwriters acknowledge and agree that the only information furnished or to be
furnished by any

                                       24
<PAGE>

Underwriter to the Company for inclusion in the Prospectus or the Registration
Statement consists of the information set forth in the last paragraph on the
front cover page (insofar as such information relates to the Underwriters),
legends required by Item 502(b) of Regulation S-B under the Act and the
information under the caption "Underwriting" in the Prospectus.

         14. Miscellaneous. The reimbursement, indemnification and contribution
agreements contained in this Agreement and the representations, warranties and
covenants in this Agreement shall remain in full force and effect regardless of
(a) any termination of this Agreement, (b) any investigation made by or on
behalf of any Underwriter or controlling person thereof, or by or on behalf of
the Company or its directors or officers and (c) delivery of and payment for the
Units under this Agreement.

         This Agreement may be executed in two or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute
one and the same instrument.


         This Agreement shall be governed by, and construed in accordance with,
the laws of the State of Oregon. All disputes relating to this Underwriting
Agreement shall be adjudicated before a court located in Multnomah County,
Oregon to the exclusion of all other courts that might have jurisdiction.


      (Remainder of page intentionally left blank; signature page follows)





                                       25
<PAGE>

         If the foregoing letter is in accordance with your understanding of our
agreement, please sign and return to us the enclosed duplicates hereof,
whereupon it will become a binding agreement among the Company and the several
Underwriters in accordance with its terms.

                                       Very truly yours,

                                       MILESTONE SCIENTIFIC INC.


                                       By:
                                          ---------------------------------
                                            Name:
                                            Title:


         The foregoing Underwriting Agreement is hereby confirmed and accepted
as of the date first above written.

                                       PAULSON INVESTMENT COMPANY, INC.
                                       As Representative of the several
                                       Underwriters listed on Schedule I


                                       By:
                                          ---------------------------------
                                            Name:
                                            Title:





                                       26
<PAGE>

                                   SCHEDULE I

                            Schedule of Underwriters

                                                      Number of Firm Units
                 Underwriter                           to Be Purchased
- -----------------------------------------------  -------------------------------
       Paulson Investment Company, Inc.
            S.W. Bach & Company

                  Total






</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.5
<SEQUENCE>4
<FILENAME>file003.txt
<DESCRIPTION>CERTIFICATE OF AMENDMENT
<TEXT>
<PAGE>


                           CERTIFICATE OF AMENDMENT OF

                        THE CERTIFICATE OF INCORPORATION

                                       OF

                           MILESTONE SCIENTIFIC, INC.

        (PURSUANT TO SECTION 242 OF THE DELAWARE GENERAL CORPORATION LAW)

                          ----------------------------


It is hereby certified that:

1.   The name of the corporation is Milestone Scientific Inc (the
     "Corporation").

2.   The Certificate of Incorporation of the Corporation was filed by the
     Department of State on August 17, 1989 (under the name "U.S. Opportunity
     Search, Inc.") and subsequent amendments thereto were filed on July 13,
     1995, December 6, 1996 and, December 17, 1997.

3.   The Certificate of Incorporation of the Corporation is hereby amended to
     increase the total number of shares of common stock and to add a new class
     of preferred stock, which the Corporation shall have authority to issue.

4.   To accomplish the foregoing amendments, a Article FOURTH of the Certificate
     of Incorporation is amended to read in its entirety as follows:


          "FOURTH: The total number of shares which this corporation shall have
          authority to issue is 55,000,000 shares, consisting of (i) 50,000,000
          shares of common stock, $.001 par value per share (the "Common Stock")
          and (ii) 5,000,000 shares of preferred stock, $.001 par value per
          share (the "Preferred Stock"). The Board of Directors, in the exercise
          of its discretion, is authorized to issue the undesignated Preferred
          Stock in one or more series, to determine the powers, preferences and
          rights, and qualifications, limitations or restrictions, granted to or
          imposed upon any wholly unissued series of undesignated Preferred
          Stock, and to fix the number of shares constituting any series and the
          designation of such series, without any further vote or action by the
          stockholders."


<PAGE>



5.   The Amendments herein certified have been duly adopted in accordance with
     the provisions of Section 242 of the Delaware General Corporation Law.

6.   This Certificate of Amendment shall become effective upon the filing hereof
     in the Office of the Secretary of State of the State of Delaware.


Executed on this 24th day of July 2003




                                        /s/ Leonard Osser
                                        -----------------
                                        Leonard Osser
                                        President and Chief Executive Officer












</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.6
<SEQUENCE>5
<FILENAME>file004.txt
<DESCRIPTION>CERTIFICATE OF AMENDMENT
<TEXT>
<PAGE>

                           CERTIFICATE OF AMENDMENT OF

                        THE CERTIFICATE OF INCORPORATION

                                       OF

                            MILESTONE SCIENTIFIC INC.

        (PURSUANT TO SECTION 242 OF THE DELAWARE GENERAL CORPORATION LAW)

                          ----------------------------

     It is hereby certified that:

     1.   The name of the corporation is Milestone Scientific Inc (the
          "Corporation").

     2.   The Certificate of Incorporation of the Corporation was filed by the
          Department of State on August 17, 1989 (under the name "U.S.
          Opportunity Search, Inc.") and subsequent amendments thereto were
          filed on July 13, 1995, December 6, 1996, December 17, 1997 and July
          23, 2003.

     3.   The Certificate of Incorporation of the Corporation is hereby amended
          to effect a one-for-three reverse split of the Corporation's issued
          and outstanding and treasury shares of common stock, without changing
          the par value per share.

     4.   To accomplish the foregoing amendment, Article FOURTH of the
          Certificate of Incorporation is amended to include the following at
          the end of the existing provision:

            "Every 3 shares of the Corporation's common stock, par value $.001
            per share (the "Old Common Stock"), issued and outstanding or held
            in the treasury on the filing hereof, will be automatically
            converted into one share of common stock, par value $.001 per share,
            of the Corporation (the "New Common Stock").

            Notwithstanding the immediately preceding sentence, no fractional
            shares of New Common Stock shall be issued to the holders of record
            of Old Common Stock in connection with the foregoing reverse split
            of shares of Old Common Stock. In lieu thereof, the aggregate of all
            fractional shares otherwise issuable to the holders of record of Old
            Common Stock shall be issued to the Corporation's transfer agent, as
            agent for, the accounts of all holders of record of Old Common Stock
            otherwise entitled to have a fraction of a share issued to them. The
            sale of all of the fractional interests will be effected by the
            transfer agent as soon as practicable after the filing hereof on the
            basis of prevailing market prices of the New Common Stock at the
            time of sale. After such sale and upon the surrender of the
            stockholders' stock certificates, the transfer agent will pay to
            such holders of record their pro rata share of the net proceeds
            derived from the sale of the fractional interests.

            Each stock certificate that, immediately prior to the filing hereof,
            represented shares of Old Common Stock shall, from and after the
            filing

<PAGE>

            hereof, automatically and without the necessity of presenting the
            same for exchange, represent that number of whole shares of New
            Common Stock into which the shares of Old Common Stock represented
            by such certificate shall have been convertible (as well as the
            right to receive cash in lieu of any fractional shares of New Common
            Stock as set forth above), provided, however, that each holder of
            record of a certificate that represented shares of Old Common Stock
            shall receive, upon surrender of such certificate, a new certificate
            representing the number of whole shares of New Common Stock into
            which the shares of Old Common Stock represented by such certificate
            shall have been convertible, as well as any cash in lieu of
            fractional shares of New Common Stock to which such holder may be
            entitled pursuant to the immediately preceding paragraph."

     5.   This Amendment has been duly adopted in accordance with the provisions
          of Section 242 of the Delaware General Corporation Law.

     6.   This Certificate of Amendment shall become effective upon the filing
          hereof in the Office of the Secretary of State of the State of
          Delaware.


Executed on this 7th day of January, 2004



                                          -----------------
                                          Leonard Osser
                                          Chairman and Chief Executive Officer


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.7
<SEQUENCE>6
<FILENAME>file005.txt
<DESCRIPTION>CERTIFICATE OF DESIGNATION
<TEXT>
<PAGE>

                           CERTIFICATE OF DESIGNATIONS
                                       OF

                          CERTIFICATE OF INCORPORATION
                                       OF

                            MILESTONE SCIENTIFIC INC.


         Milestone Scientific Inc., a Delaware corporation (the "Corporation"),
acting pursuant to Section 151 of the Delaware General Corporation Law, hereby
submits the following Certificate of Designation of Series and Determination of
Rights and Preferences of its Series A Preferred Stock.

         FIRST:  The name of the Corporation is Milestone Scientific Inc.

         SECOND: This Certificate of Designations shall be effective as of
January 15, 2004.

         THIRD: WHEREAS, the Certificate of Incorporation of the Corporation
authorizes the issuance of Preferred Stock consisting of 5,000,000 shares, par
value $.001 per share, issuable from time to time in one or more series; and

                WHEREAS, the Board of Directors of the Corporation is
authorized, subject to limitations prescribed by law and by the provisions of
Article FOURTH of the Corporation's amended Certificate of Incorporation to
determine the powers, preferences and rights, and qualifications, limitations or
restrictions, granted to or imposed upon any wholly unissued series of
undesignated Preferred Stock, and to fix the number of shares constituting any
series and the designation of such series, without any further vote or action by
the stockholders; and

                WHEREAS, it is the desire of the Board of Directors to establish
and fix the number of shares to be included in a new series of Preferred Stock
and the designations, rights, preferences and limitations of the shares of such
new series; and

                WHEREAS, by a vote of the Board of Directors of the Corporation
at a meeting on October 8, 2003, the following resolutions were duly adopted:

                RESOLVED, that the Corporation shall issue 8% Series A Preferred
          Stock to Mr. Richard Hayden, in satisfaction of $25,365 of principal
          and accrued interest under his 6%/12% Senior Secured Promissory Note,
          which may be convertible into common stock, at his option, at the
          average closing price of the Corporation's common stock during all the
          trading days beginning September 30 and ending October 29, under terms
          included in the board's resolutions dated September 22, 3003.

<PAGE>

                RESOLVED, that the Corporation shall file a Certificate of
          Designations with the Secretary of State, designating the
          above-mentioned terms to the Series A Preferred Stock and that the
          officers of this Corporation, at the time in office, are, and each of
          them acting singly is, hereby authorized and directed, in the name and
          on behalf of the Corporation, to take any and all action, pay all
          required fees and execute such instruments or other documents which
          they may deem necessary or desirable to file such Certificate of
          Designations.

                NOW, THEREFORE, BE IT RESOLVED that pursuant to Article FOURTH
of the Corporation's Amended Certificate of Incorporation, there is hereby
designated a new Series A Preferred Stock of the Corporation, par value $.001
per share, to have the designations, rights, preferences, powers, restrictions
and limitations set forth in a supplement to Article FOURTH of the Corporation's
Certificate of Incorporation as follows:


                      SERIES A CONVERTIBLE PREFERRED STOCK

1.   Designations, Par Value and Number. 25,356 shares of authorized Series A
     Preferred Stock of the Corporation are hereby designated as Series A
     Preferred Stock ("Series A Preferred", having a par value of $0.001 per
     share. In accordance with the terms hereof, each share of Series A
     Preferred shall have the same relative rights as and be identical in all
     respects with each other share of Series A Preferred.

2.   Dividends.

     (a)  Dividends on each issued and outstanding share of the Series A
          Preferred shall accrue on a daily basis at a rate of 8% per annum on
          the amount of the Series A Liquidation Preference (defined below) from
          and including November 1, 2003 until and including the first to occur
          of (i) the date on which the Series A Liquidation Preference of such
          share is paid to the holder thereof in connection with a Liquidation
          Event or (ii) the date on which such share of Series A Preferred is
          converted into shares of Common Stock hereunder. Such dividends shall
          accrue whether or not they have been declared and whether or not there
          are profits, surplus or other funds of the Corporation legally
          available for the payment of dividends and shall be payable, at the
          option of the Corporation, either in cash or common stock. Dividends
          shall be payable on January 10 of each year.

     (b)  Participation in Dividends on Common Stock. In the event that the
          Corporation declares or pays a dividend or makes any distribution on
          its Common Stock, the holders of the outstanding shares of Series A
          Preferred shall be entitled to receive such dividend under the same
          terms and amounts as though the Series A Preferred had already been
          converted to Common Stock.

                                       -2-

<PAGE>

3.   Voting Rights.

     The holders of the Series A Preferred shall be entitled to notice of all
     stockholders meetings in accordance with the Bylaws and, except as
     otherwise provided herein or required by applicable law, the holders of the
     Series A Preferred shall be entitled to vote on all matters submitted to
     the stockholders for a vote, voting as a single class with the Common and
     other securities that vote with the Common, with the holders of Series A
     Preferred entitled to one vote for each share of Series A Preferred held as
     of the record date for such vote or, if no record date is specified, as of
     the date of such vote.

4.   Liquidation, Dissolution, etc.

     Liquidation Event. Upon any liquidation (whether in connection with a sale
     of all or substantially all of the assets of the Corporation or otherwise),
     dissolution or winding up of the Corporation (whether voluntary or
     involuntary) (a "Liquidation Event"):

     (a)  Each holder of Series A Preferred shares shall be entitled to receive,
          prior and in preference to any distribution or payment made to holders
          of common stock an amount of $1.00 (the "Liquidation Preference") per
          each Series A Preferred share held by such holder, in cash, plus all
          accrued and unpaid dividends on such shares of Series A Preferred.

     (b)  After payment to the holders of the Series A Preferred of the amounts
          set forth in Section 4(a), an amount of $1.00 per each share of Common
          Stock will be paid to the holders of the Common Stock and then, the
          entire remaining assets and funds of the Corporation or merger
          consideration legally available for distribution, if any, shall be
          distributed pro rata among the shares of Common Stock and the shares
          of Series A Preferred as if those had been converted into Common
          Stock.

5.   Conversion.

     (a)  Each share of Series A Preferred shall be convertible into 0.5192 of
          Common Stock, subject to adjustments for such stock splits, including
          reverse stock splits, stock dividends and other capital changes
          occurring after January 1, 2004, at any time and from time to time,
          beginning six months after the closing of a public offering for which
          a registration statement was filed with the SEC on November 10, 2003
          or, if such registration statement is withdrawn, then upon its
          withdrawal.

     (b)  If not converted earlier, all shares of Series A Preferred shall
          automatically convert into 0.5192 of Common Stock (the "Conversion
          Ratio"), subject to adjustments for such stock splits, including
          reverse stock splits, stock dividends and other capital changes
          occurring after January 1, 2004, on November 1, 2005.

     (c)  Each conversion of Series A Preferred shall be deemed to have been
          effected as of the close of business on the date on which the
          certificate or certificates representing the Series A Preferred to be
          converted have been surrendered for conversion at the principal office
          of the Corporation (any such date being referred to as a "Conversion
          Date"). At the time any such conversion has been effected, the rights
          of the holder of the shares of

                                      -3-

<PAGE>

          Series A Preferred converted as a holder of Series A Preferred shall
          cease and the person or persons in whose name or names any certificate
          or certificates for shares of Common Stock are to be issued upon such
          conversion shall be deemed to have become the holder or holders of
          record of the shares of Common Stock represented thereby.

          (i)   As soon as possible after a conversion has been effected, the
                Corporation shall, or (if applicable) use its best efforts to
                cause its transfer agent to, deliver to the converting holder:

                (1)  certificates representing the number of shares of Common
                     Stock issuable by reason of such conversion in such name or
                     names and such denomination or denominations as the
                     converting holder has specified; and

                (2)  a certificate representing any shares of Series A Preferred
                     which were represented by the certificate or certificates
                     delivered to the Corporation in connection with such
                     conversion but which were not converted.

          (ii)  The issuance of certificates for shares of Common Stock, upon
                conversion of Series A Preferred, shall be made without charge
                to the holders of such Series A Preferred or Common Stock and
                any issuance tax in respect thereof or other cost in connection
                with such conversion and the related issuance of shares of
                Common Stock shall be incurred by the Corporation in connection
                with such conversion and the related issuance of shares of
                Common Stock. Upon conversion of each share of Series A
                Preferred, the Corporation shall take all such actions as are
                necessary in order to insure that the Common Stock issuable with
                respect to such conversion shall be validly issued, fully paid
                and nonassessable, free and clear of all taxes, liens, charges
                and encumbrances with respect to the issuance thereof.

          (iii) If any fractional interest in a share of Common would, except
                for the provisions of this subparagraph, be delivered upon any
                conversion of the Series A Preferred, the Corporation, in lieu
                of delivering the fractional share therefor, may pay an amount
                to the holder thereof equal to the market price of such
                fractional interest as of the date of conversion. The
                determination as to whether or not to make any cash payment in
                lieu of the issuance of fractional shares shall be based upon
                the total number of shares of Series A Preferred being converted
                at any one time by the holder thereof, not upon each share of
                Series A Preferred being converted.

          (d)   Effect of Certain Events on Conversion Ratio.

          (i)  Subdivisions or Combinations of Common. If the Corporation at any
          time beginning January 1, 2004, subdivides (by any stock split, stock
          dividend, recapitalization or otherwise) its outstanding shares of
          Common Stock into a greater number of shares, the Series A Conversion
          Ratio prior to such subdivision shall be increased proportionately,
          and if the Corporation at any time beginning January 1, 2004, combines
          (by reverse stock split or otherwise) one or more classes of its
          outstanding shares of Common into a smaller number of shares, the
          Series A Conversion Ratio in effect immediately prior to such
          combination shall be reduced proportionately.

                                      -4-

<PAGE>

         (ii) Recapitalization, Reorganization, Reclassification, Consolidation,
         Merger or Sale. Any recapitalization, reorganization, reclassification,
         consolidation, merger, sale of all or substantially all of the
         Corporation's assets or other transaction, in each case which is
         effected in such a manner that the holders of Common Stock are entitled
         to receive (either directly or upon subsequent liquidation) stock,
         securities or assets with respect to or in exchange for Common Stock,
         and which does not otherwise qualify as a Liquidation Event, is
         referred to herein as an "Organic Change." Prior to the consummation of
         any Organic Change, the Corporation shall make appropriate provisions
         (in form and substance reasonably satisfactory to the holders of a
         majority of the Series A Preferred then outstanding) to insure that
         each of the holders of Series A Preferred shall thereafter have the
         right to acquire and receive, in lieu of or in addition to (as the case
         may be) the shares of Common Stock immediately theretofore acquirable
         and receivable upon the conversion of such holder's Series A Preferred,
         such shares of stock, securities or assets as such holder would have
         received in connection with such Organic Change if such holder had
         converted its Series A Preferred immediately prior to such Organic
         Change.

     (e) Notices.

         (i) Immediately upon any adjustment of the Series A Conversion Ratio,
         the Corporation shall give written notice thereof to all holders of
         Series A Preferred, setting forth in reasonable detail and certifying
         the calculation of such adjustment.

         (ii) The Corporation shall give written notice to all holders of Series
         A Preferred at least ten (10) days prior to the date on which the
         Corporation closes its books or takes a record (A) with respect to any
         dividend or distribution upon Common, (B) with respect to any pro rata
         subscription offer to holders of Common or (C) for determining rights
         to vote with respect to any Liquidation Event, Organic Change,
         dissolution or liquidation.

         (iii)The Corporation shall also give written notice to the holders of
         Series A Preferred at least ten (10) days prior to the date on which
         any Organic Change or Liquidation Event shall take place.

6.   General.

     (a) Upon receipt of evidence reasonably satisfactory to the Corporation (an
         affidavit of the registered holder shall be satisfactory) of the
         ownership and the loss, theft, destruction or mutilation of any
         certificate evidencing shares of Common Stock or Series A Preferred,
         and in the case of any such loss, theft or destruction, upon receipt of
         indemnity reasonably satisfactory to the Corporation (provided that if
         the holder is a financial institution or other institutional investor
         its own agreement shall be satisfactory), or, in the case of any such
         mutilation upon surrender of such certificate, the Corporation shall
         (at its expense) execute and deliver in lieu of such certificate a new
         certificate of like kind representing the number of shares of such
         class represented by such lost, stolen, destroyed or mutilated
         certificate and dated the date of such lost, stolen, destroyed or
         mutilated certificate, and dividends shall accrue on the Common Stock
         or Series A Preferred represented by such new certificate from the date
         to which dividends have been fully paid on such lost, stolen, destroyed
         or mutilated certificate.

                                      -5-

<PAGE>

     (b) Except as otherwise expressly provided hereunder, all notices referred
         to herein shall be in writing and shall be delivered by registered or
         certified mail, return receipt requested and postage prepaid, by
         reputable overnight courier service, charges prepaid or by personal
         delivery, and shall be deemed to have been given (i) three (3) business
         days after being sent by registered or certified mail, (ii) one (1)
         business day after being deposited with such an overnight courier
         service, and (iii) upon delivery, if by personal delivery, if mailed or
         delivered (A) to the Corporation, at its principal executive offices,
         or (B) to any stockholder, at such holder's address as it appears in
         the stock records of the Corporation (unless otherwise indicated by any
         such holder).

         IN WITNESS WHEREOF, the undersigned has executed this Certificate this
15th day of January, 2004.



                               MILESTONE SCIENTIFIC INC.


                               By: /s/ Leonard Osser
                                   -----------------------------
                                   Name: Leonard Osser
                                   Title:  Chairman and Chief Executive Officer





                                      -6-



</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>7
<FILENAME>file006.txt
<DESCRIPTION>UNIT CERTIFICATE
<TEXT>
<PAGE>


                                UNIT CERTIFICATE

                                      FRONT

1. Logo: MILESTONE SCIENTIFIC  (Same as Common Stock Certificate.)

2. Certificate Number: Should have the prefix:  "U"

3. CUSIP NO.: "____________."

4. Centered below the Logo:

                ORGANIZED UNDER THE LAWS OF THE STATE OF delaware
               EACH UNIT CONSISTING OF TWO SHARES OF COMMON STOCK,
              AND ONE WARRANT TO PURCHASE ONE SHARE OF COMMON STOCK

5. In the shaded area:

"THIS CERTIFIES THAT __________________________"

6. Below the shaded area:

"or registered assigns (the "Registered Holder") is the owner of the number of
Units specified above. Each Unit ("Unit") consists of two (2) shares of common
stock, $.001 par value (the "Common Stock"), of Milestone Scientific Inc. (the
"Company") and one (1) redeemable warrant (the "Warrant") to purchase one share
of Common Stock for $_____________ per share (subject to adjustment) until 5:00
p.m. Eastern Time ______________ 2009. On or prior to the Separation Time (as
defined below), the securities evidenced by this certificate cannot be traded
separately. Each Unit will automatically separate into two shares of Common
Stock and one Warrant as of the close of business on ______________, 2004 (the
"Separation Time"). The Common Stock and the Warrants comprising the Units shall
be separately tradable commencing on the first day after the Separation Time on
which the principal exchange on which the Company's stock trades is open for
trading. The Warrants comprising part of the Units are issued under and pursuant
to a certain Warrant Agreement dated as of ______________, 2004 (the "Warrant
Agreement"), between the Company and Continental Stock Transfer & Trust Company,
as Warrant Agent (the "Warrant Agent"), and are subject to the terms and
provisions contained therein and on the face of the certificates covered
thereby, to all of which terms and provisions the holder of this Unit
Certificate consents by acceptance hereof. The Warrant Agreement provides for
adjustment in the number of shares of Common Stock to be delivered upon the
exercise of the Warrant evidenced hereby and to the exercise price of such
Warrant in certain events therein set forth.

     Copies of the Warrant Agreement are available for inspection at the stock
transfer office of the Warrant Agent or may be obtained upon written request
addressed to the Company at 220 South Orange Avenue, Livingston, NJ 07039,
Attention: Chief Financial Officer.

     This Unit Certificate is not valid unless countersigned by the Transfer
Agent and Registrar of the Company."

7. Signatures: Same as Common Stock Certificate, including Transfer Agent.

8. Corporate Seal: Same as Common Stock Certificate.


<PAGE>


BACK

MILESTONE SCIENTIFIC INC.

     The Registered Holder hereby is entitled, at any time, to exchange the
Units represented by this Unit Certificate for Common Stock Certificate(s)
representing two shares of Common Stock, for each Unit represented by this Unit
Certificate and one Warrant Certificate representing one Warrant, for each Unit
represented by this Unit Certificate, upon surrender of this Unit Certificate to
the Transfer Agent and Registrar together with any documentation required by
such agent.

     REFERENCE IS MADE TO THE WARRANT AGREEMENT REFERRED TO ON THE FACE HEREOF,
AND THE PROVISIONS OF SUCH WARRANT AGREEMENT SHALL FOR ALL PURPOSES HAVE THE
SAME EFFECT AS THOUGH FULLY SET FORTH ON THE FACE OF THIS CERTIFICATE. COPIES OF
THE WARRANT AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST FROM THE TRANSFER
AGENT AND REGISTRAR, CONTINENTAL stock transfer & trust company.

     The following abbreviations, when used in the inscription on the face of
this certificate, shall be construed as though they were written out in full
according to applicable laws or regulations.

     TEN COM  as tenants in common
     TEN ENT  as tenants by the entireties
     JT TEN   as joint tenants with rights of survivorship and not as tenants
              in common
     COM PROP as community property

UNIF GIFT MIN ACT          _________________     Custodian      _______________
                           (Cust)                              (minor)
                           under Uniform Gifts to Minors Act

                           __________________________________________
                                               (State)

UNIF TRF MIN ACT           ________________      Custodian      _______________
                           (Cust)                              (minor)
                           under Uniform Gifts to Minors Act 3

                           __________________________________________
                                              (State)

                               FORM OF ASSIGNMENT
                       (TO BE SIGNED ONLY UPON ASSIGNMENT)

FOR VALUE RECEIVED, the undersigned Registered Holder

(------------------------)
(Please insert social security or other identification number of Registered
 Holder)

hereby sells, assigns and transfers unto
______________________________________________________________________________
               (Please Print Name and Address including Zip Code)

Units evidenced by the within Unit Certificate, and irrevocably constitutes and
appoints ______________________________________________________________________
attorney to transfer this Unit Certificate on the books of Milestone Scientific
Inc. with the full power of substitution in the premises.

Dated:   __________________, ________
Signature: __________________________________
(Signature must conform in all respects to the name of Registered Holder as
specified on the face of this Unit Certificate in every particular, without
alteration or any change whatsoever, and the signature must be guaranteed in the
usual manner.)

Signatures Guaranteed:

- ----------------------------------
The signatures should be guaranteed by an eligible institution (banks,
stockbrokers, savings and loan association and credit unions with membership in
an approved signature medallion program), pursuant to S.E.C. Rule 17Ad-15.







</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>8
<FILENAME>file007.txt
<DESCRIPTION>FORM OF WARRANT AGREEMENT
<TEXT>
<PAGE>





                              WARRANT AGREEMENT



                                   BETWEEN



                          MILESTONE SCIENTIFIC INC.

                                     AND

                  CONTINENTAL STOCK TRANSFER & TRUST COMPANY



                       DATED AS OF ___________ __, 2004



<PAGE>


                              WARRANT AGREEMENT

      This Agreement, dated as of ____________ __, 2004, is between Milestone
Scientific Inc., a Delaware corporation (the "Company") and Continental Stock
Transfer & Trust Company _____________, a ______________, (the "Warrant
Agent").

      The Company, at or about the time that it is entering into this
Agreement, proposes to issue and sell to public investors up to 1,200,000
Units (together with the additional units issuable as provided herein, the
"Units").  Each Unit consists of two shares of Common Stock, $0.001 par
value, of the Company and one warrant (collectively, the "Warrants").  Each
Warrant is exercisable to purchase one share of Common Stock upon the terms
and conditions and subject to adjustment in certain circumstances, all as set
forth in this Agreement.  The Company also purposes to grant the
Representative of the Underwriters of the public offering an option to
purchase 180,000 additional Units to cover over-allotments, if any.

      The Company proposes to issue to the Representative of the Underwriters
in the public offering of Units referred to above warrants to purchase up to
100,000 additional Units.

      The Company wishes to retain the Warrant Agent to act on behalf of the
Company, and the Warrant Agent is willing so to act, in connection with the
issuance, transfer, exchange and replacement of the certificates evidencing
the Warrants to be issued under this Agreement (the "Warrant Certificates")
and the exercise of the Warrants;

      The Company and the Warrant Agent wish to enter into this Agreement to
set forth the terms and conditions of the Warrants and the rights of the
holders thereof ("Warrantholders") and to set forth the respective rights and
obligations of the Company and the Warrant Agent.  Each Warrantholder is an
intended beneficiary of this Agreement with respect to the rights of
Warrantholders herein.

      NOW, THEREFORE, in consideration of the premises and the mutual
agreements herein set forth, the parties hereto agree as follows:

      1.    Appointment of Warrant Agent.  The Company appoints the Warrant
Agent to act as agent for the Company in accordance with the instructions in
this Agreement and the Warrant Agent accepts such appointment.

      2.    Date, Denomination and Execution of Warrant Certificates.

     (a) The Warrant Certificates (and the Form of Election to Purchase and the
Form of Assignment to be printed on the reverse thereof) shall be in registered
form only and shall be substantially of the tenor and purport recited in Exhibit
A hereto, and may have such letters, numbers or other marks of identification or
designation and such legends, summaries or endorsements printed, lithographed or
engraved thereon as the Company may deem appropriate and as are not inconsistent
with the provisions of this Agreement, or as may be required to comply with any
law, or with any rule or regulation made pursuant thereto, or with any rule or
regulation of any stock exchange on which the Common Stock or the Warrants may
be listed or any automated quotation system, or to conform to usage. Each
Warrant Certificate shall entitle the registered holder thereof, subject to the
provisions of this Agreement and of the Warrant



                                       1


<PAGE>


Certificate, to purchase, on or after ____________, 2004 and on or before the
close of business on _________, 2009 (the "Expiration Date"), one fully paid and
non-assessable share of Common Stock for each Warrant evidenced by such Warrant
Certificate for $_____. The exercise price of the Warrants (the "Exercise
Price") is subject to adjustments as provided in Section 6 hereof. Each Warrant
Certificate issued as a part of a Unit offered to the public as described in the
recitals, above, shall be dated _____________, 2004; each other Warrant
Certificate shall be dated the date on which the Warrant Agent receives valid
issuance instructions from the Company or a transferring holder of a Warrant
Certificate or, if such instructions specify another date, such other date.

     (b) For purposes of this Agreement, the term "close of business" on any
given date shall mean 5:00 p.m., Eastern time, on such date; provided, however,
that if such date is not a business day, it shall mean 5:00 p.m., Eastern time,
on the next succeeding business day. For purposes of this Agreement, the term
"business day" shall mean any day other than a Saturday, Sunday, or a day on
which banking institutions in New York, New York or in the State in which the
Warrant Agent maintains the principal office in which it conducts business
related to the Warrants are authorized or obligated by law to be closed.

     (c) Each Warrant Certificate shall be executed on behalf of the Company by
the Chairman of the Board or its President or a Vice President, either manually
or by facsimile signature printed thereon, and have affixed thereto the
Company's seal or a facsimile thereof which shall be attested by the Secretary
or an Assistant Secretary of the Company, either manually or by facsimile
signature. Each Warrant Certificate shall be manually countersigned by the
Warrant Agent and shall not be valid for any purpose unless so countersigned. In
case any officer of the Company who shall have signed any Warrant Certificate
shall cease to be such officer of the Company before countersignature by the
Warrant Agent and issue and delivery thereof by the Company, such Warrant
Certificate, nevertheless, may be countersigned by the Warrant Agent, issued and
delivered with the same force and effect as though the person who signed such
Warrant Certificate had not ceased to be such officer of the Company.

   3. Subsequent Issue of Warrant Certificates. Subsequent to their original
issuance, no Warrant Certificates shall be reissued except (i) Warrant
Certificates issued upon transfer thereof in accordance with Section 4 hereof,
(ii) Warrant Certificates issued upon any combination, split-up or exchange of
Warrant Certificates pursuant to Section 4 hereof, (iii) Warrant Certificates
issued in replacement of mutilated, destroyed, lost or stolen Warrant
Certificates pursuant to Section 5 hereof, (iv) Warrant Certificates issued upon
the partial exercise of Warrant Certificates pursuant to Section 7 hereof, and
(v) Warrant Certificates issued to reflect any adjustment or change in the
Exercise Price or the number or kind of shares purchasable thereunder pursuant
to Section 22 hereof. The Warrant Agent is hereby irrevocably authorized to
countersign and deliver, in accordance with the provisions of said Sections 4,
5, 7 and 22, the new Warrant Certificates required for purposes thereof, and the
Company, whenever required by the Warrant Agent, will supply the Warrant Agent
with Warrant Certificates duly executed on behalf of the Company for such
purposes.

                                       2
<PAGE>

   4.    Transfers and Exchanges of Warrant Certificates.

     (a) The Warrant Agent will keep or cause to be kept books for registration
of ownership and transfer of the Warrant Certificates issued hereunder. Such
registers shall show the names and addresses of the respective holders of the
Warrant Certificates and the kind and number of Warrants evidenced by each such
Warrant Certificate.

     (b) The Warrant Agent shall, from time to time, register the transfer of
any outstanding Warrants upon the books to be maintained by the Warrant Agent
for that purpose, upon surrender of the Warrant Certificate evidencing such
Warrants, with the Form of Assignment duly filled in and executed with such
signature guaranteed by a banking institution or NASD member and such supporting
documentation as the Warrant Agent or the Company may reasonably require, to the
Warrant Agent at its stock transfer office in New York, New York at any time on
or before the Expiration Date of such Warrant, and upon payment to the Warrant
Agent for the account of the Company of an amount equal to any applicable
transfer tax. Payment of the amount of such tax may be made in cash, or by
certified or official bank check, payable in lawful money of the United States
of America to the order of the Company.

     (c) Upon receipt of a Warrant Certificate, with the Form of Assignment duly
filled in and executed, accompanied by payment of an amount equal to any
applicable transfer tax, the Warrant Agent shall promptly cancel the surrendered
Warrant Certificate and countersign and deliver to the transferee a new Warrant
Certificate for the number of full Warrants transferred to such transferee;
provided, however, that in case the registered holder of any Warrant Certificate
shall elect to transfer fewer than all of the Warrants evidenced by such Warrant
Certificate, the Warrant Agent in addition shall promptly countersign and
deliver to such registered holder a new Warrant Certificate or Certificates for
the number of full Warrants not so transferred.

     (d) Any Warrant Certificate or Certificates may be exchanged at the option
of the holder thereof for another Warrant Certificate or Certificates of
different denominations, of like tenor and representing in the aggregate the
same kind and number of Warrants, upon surrender of such Warrant Certificate or
Certificates, with the Form of Assignment duly filled in and executed, to the
Warrant Agent, at any time or from time to time after the close of business on
the date hereof and prior to the close of business on the Expiration Date
relating to such Warrant. The Warrant Agent shall promptly cancel the
surrendered Warrant Certificate and deliver the new Warrant Certificate pursuant
to the provisions of this Section.

   5. Mutilated, Destroyed, Lost or Stolen Warrant Certificates. Upon receipt by
the Company and the Warrant Agent of evidence reasonably satisfactory to them of
the loss, theft, destruction or mutilation of any Warrant Certificate, and in
the case of loss, theft or destruction, of indemnity or security reasonably
satisfactory to them, and reimbursement to them of all reasonable expenses
incidental thereto, and, in the case of mutilation, upon surrender and
cancellation of the Warrant Certificate, the Warrant Agent shall countersign and
deliver a new Warrant Certificate of like tenor for the same kind and number of
Warrants.

   6. Adjustments of Number and Kind of Shares Purchasable and Exercise Price.
The number and kind of securities or other property purchasable upon exercise of
a Warrant shall be


                                       3
<PAGE>

subject to adjustment from time to time upon the occurrence, after the date
hereof, of any of the following events:

     (a) In case the Company shall (1) pay a dividend in, or make a distribution
of, shares of capital stock on its outstanding Common Stock, (2) subdivide its
outstanding shares of Common Stock into a greater number of such shares or (3)
combine its outstanding shares of Common Stock into a smaller number of such
shares, the total number of shares of Common Stock purchasable upon the exercise
of each Warrant outstanding immediately prior thereto shall be adjusted so that
the holder of any Warrant Certificate thereafter surrendered for exercise shall
be entitled to receive at the same aggregate Exercise Price the number of shares
of capital stock (of one or more classes) which such holder would have owned or
have been entitled to receive immediately following the happening of any of the
events described above had such Warrant been exercised in full immediately prior
to the record date with respect to such event. Any adjustment made pursuant to
this Subsection shall, in the case of a stock dividend or distribution, become
effective as of the record date therefor and, in the case of a subdivision or
combination, be made as of the effective date thereof. If, as a result of an
adjustment made pursuant to this Subsection, the holder of any Warrant
Certificate thereafter surrendered for exercise shall become entitled to receive
shares of two or more classes of capital stock of the Company, the Board of
Directors of the Company (whose determination shall be conclusive and shall be
evidenced by a Board resolution filed with the Warrant Agent) shall determine
the allocation of the adjusted Exercise Price between or among shares of such
classes of capital stock.

     (b) In the event of a capital reorganization or a reclassification of the
Common Stock (except as provided in Subsection (a) above or Subsection (e)
below), any Warrantholder, upon exercise of Warrants, shall be entitled to
receive, in substitution for the Common Stock to which he would have become
entitled upon exercise immediately prior to such reorganization or
reclassification, the shares (of any class or classes) or other securities or
property of the Company (or cash) that he would have been entitled to receive at
the same aggregate Exercise Price upon such reorganization or reclassification
if such Warrants had been exercised immediately prior to the record date with
respect to such event; and in any such case, appropriate provision (as
determined by the Board of Directors of the Company, whose determination shall
be conclusive and shall be evidenced by a certified Board resolution filed with
the Warrant Agent) shall be made for the application of this Section 6 with
respect to the rights and interests thereafter of the Warrantholders (including
but not limited to the allocation of the Exercise Price between or among shares
of classes of capital stock), to the end that this Section 6 (including the
adjustments of the number of shares of Common Stock or other securities
purchasable and the Exercise Price thereof) shall thereafter be reflected, as
nearly as reasonably practicable, in all subsequent exercises of the Warrants
for any shares or securities or other property (or cash) thereafter deliverable
upon the exercise of the Warrants.

     (c) Whenever the number of shares of Common Stock or other securities
purchasable upon exercise of a Warrant is adjusted as provided in this Section
6, the Company will promptly file with the Warrant Agent a certificate signed by
a Chairman or co-Chairman of the Board or the President or a Vice President of
the Company and by the Treasurer or an Assistant Treasurer or the Secretary or
an Assistant Secretary of the Company setting forth the number and kind of
securities or other property purchasable upon exercise of a Warrant, as so
adjusted, stating that such adjustments in the number or kind of shares or other
securities or


                                       4

<PAGE>


property conform to the requirements of this Section 6, and setting forth a
brief statement of the facts accounting for such adjustments. Promptly after
receipt of such certificate, the Company, or the Warrant Agent at the Company's
request, will deliver, by first-class, postage prepaid mail, a brief summary
thereof (to be supplied by the Company) to the registered holders of the
outstanding Warrant Certificates; provided, however, that failure to file or to
give any notice required under this Subsection, or any defect therein, shall not
affect the legality or validity of any such adjustments under this Section 6;
and provided, further, that, where appropriate, such notice may be given in
advance and included as part of the notice required to be given pursuant to
Section 12 hereof.

     (d) In case of any consolidation of the Company with, or merger of the
Company into, another corporation (other than a consolidation or merger which
does not result in any reclassification or change of the outstanding Common
Stock), or in case of any sale or conveyance to another corporation of the
property of the Company as an entirety or substantially as an entirety, the
corporation formed by such consolidation or merger or the corporation which
shall have acquired such assets, as the case may be, shall execute and deliver
to the Warrant Agent a supplemental warrant agreement providing that the holder
of each Warrant then outstanding shall have the right thereafter (until the
expiration of such Warrant) to receive, upon exercise of such Warrant, solely
the kind and amount of shares of stock and other securities and property (or
cash) receivable upon such consolidation, merger, sale or transfer by a holder
of the number of shares of Common Stock of the Company for which such Warrant
might have been exercised immediately prior to such consolidation, merger, sale
or transfer. Such supplemental warrant agreement shall provide for adjustments
which shall be as nearly equivalent as may be practicable to the adjustments
provided in this Section. The above provision of this Subsection shall similarly
apply to successive consolidations, mergers, sales or transfers.

   The Warrant Agent shall not be under any responsibility to determine the
correctness of any provision contained in any such supplemental warrant
agreement relating to either the kind or amount of shares of stock or securities
or property (or cash) purchasable by holders of Warrant Certificates upon the
exercise of their Warrants after any such consolidation, merger, sale or
transfer or of any adjustment to be made with respect thereto, but subject to
the provisions of Section 20 hereof, may accept as conclusive evidence of the
correctness of any such provisions, and shall be protected in relying upon, a
certificate of a firm of independent certified public accountants (who may be
the accountants regularly employed by the Company) with respect thereto.

     (e) Irrespective of any adjustments in the number or kind of shares
issuable upon exercise of Warrants, Warrant Certificates theretofore or
thereafter issued may continue to express the same price and number and kind of
shares as are stated in the similar Warrant Certificates initially issuable
pursuant to this Warrant Agreement.

     (f) The Company may retain a firm of independent public accountants of
recognized standing, which may be the firm regularly retained by the Company,
selected by the Audit Committee of the Board of Directors of the Company, and
not disapproved by the Warrant Agent, to make any computation required under
this Section, and a certificate signed by such firm shall, in the absence of
fraud or gross negligence, be conclusive evidence of the correctness of any
computation made under this Section.

                                       5
<PAGE>

     (g) For the purpose of this Section, the term "Common Stock" shall mean (i)
the Common Stock or (ii) any other class of stock resulting from successive
changes or reclassifications of such Common Stock consisting solely of changes
in par value, or from par value to no par value, or from no par value to par
value. In the event that at any time as a result of an adjustment made pursuant
to this Section, the holder of any Warrant thereafter surrendered for exercise
shall become entitled to receive any shares of capital stock of the Company
other than shares of Common Stock, thereafter the number of such other shares so
receivable upon exercise of any Warrant shall be subject to adjustment from time
to time in a manner and on terms as nearly equivalent as practicable to the
provisions with respect to the Common Stock contained in this Section, and all
other provisions of this Agreement, with respect to the Common Stock, shall
apply on like terms to any such other shares.

     (h) The Company may, from time to time and to the extent permitted by law,
reduce the Exercise Price of the Warrants by any amount for a period of not less
than 20 days. If the Company so reduces the Exercise Price of such Warrants, it
will give not less than 15 days' notice of such decrease, which notice may be in
the form of a press release, and shall take such other steps as may be required
under applicable law in connection with any offers or sales of securities at the
reduced price.

   7. Exercise and Redemption of Warrants. Unless the Warrants have been
redeemed as provided in this Section 7, the registered holder of any Warrant
Certificate may exercise the Warrants evidenced thereby, in whole at any time or
in part from time to time at or prior to the close of business, on the
Expiration Date relating to such Warrant, subject to the provisions of Section
9, at which time the Warrant Certificates shall be and become wholly void and of
no value. Warrants may be exercised by their holders or redeemed by the Company
as follows:

     (a) Exercise of Warrants shall be accomplished upon surrender of the
Warrant Certificate evidencing such Warrants, with the Form of Election to
Purchase on the reverse side thereof duly filled in and executed, to the Warrant
Agent at its stock transfer office in New York, New York, together with payment
to the Company of the Exercise Price (as of the date of such surrender) of the
Warrants then being exercised and an amount equal to any applicable transfer tax
and, if requested by the Company, any other taxes or governmental charges which
the Company may be required by law to collect in respect of such exercise.
Payment of the Exercise Price and other amounts may be made by wire transfer of
good funds, or by certified or bank cashier's check, payable in lawful money of
the United States of America to the order of the Company. No adjustment shall be
made for any cash dividends, whether paid or declared, on any securities
issuable upon exercise of a Warrant.

     (b) Upon receipt of a Warrant Certificate, with the Form of Election to
Purchase duly filled in and executed, accompanied by payment of the Exercise
Price of the Warrants being exercised (and of an amount equal to any applicable
taxes or government charges as aforesaid), the Warrant Agent shall promptly
request from the Transfer Agent with respect to the securities to be issued and
deliver to or upon the order of the registered holder of such Warrant
Certificate, in such name or names as such registered holder may designate, a
certificate or certificates for the number of full shares of the securities to
be purchased, together with cash made available by the Company pursuant to
Section 8 hereof in respect of any fraction of a share of such securities
otherwise issuable upon such exercise. If the Warrant is then exercisable to



                                       6

<PAGE>


purchase property other than securities, the Warrant Agent shall take
appropriate steps to cause such property to be delivered to or upon the order of
the registered holder of such Warrant Certificate. In addition, if it is
required by law and upon instruction by the Company, the Warrant Agent will
deliver to each Warrantholder a prospectus which complies with the provisions of
Section 9 of the Securities Act of 1933, as amended, and the Company agrees to
supply Warrant Agent with sufficient number of prospectuses to effectuate that
purpose.

     (c) In case the registered holder of any Warrant Certificate shall exercise
fewer than all of the Warrants evidenced by such Warrant Certificate, the
Warrant Agent shall promptly countersign and deliver to the registered holder of
such Warrant Certificate, or to his duly authorized assigns, a new Warrant
Certificate or Certificates evidencing the number of Warrants that were not so
exercised.

     (d) Each person in whose name any certificate for securities is issued upon
the exercise of Warrants shall for all purposes be deemed to have become the
holder of record of the securities represented thereby as of, and such
certificate shall be dated, the date upon which the Warrant Certificate was duly
surrendered in proper form and payment of the Exercise Price (and of any
applicable taxes or other governmental charges) was made; provided, however,
that if the date of such surrender and payment is a date on which the stock
transfer books of the Company are closed, such person shall be deemed to have
become the record holder of such shares as of, and the certificate for such
shares shall be dated, the next succeeding business day on which the stock
transfer books of the Company are open (whether before, on or after the
Expiration Date relating to such Warrant) and the Warrant Agent shall be under
no duty to deliver the certificate for such shares until such date. The Company
covenants and agrees that it shall not cause its stock transfer books to be
closed for a period of more than 20 consecutive business days except upon
consolidation, merger, sale of all or substantially all of its assets,
dissolution or liquidation or as otherwise provided by law.

     (e) Beginning on ____________, 2004, the Warrants outstanding at the time
of a redemption may be redeemed at the option of the Company, in whole or in
part on a pro-rata basis, by giving not less than 30 days prior notice as
provided in Section 7(f) below, which notice may not be give before, but may be
given at any time after, the closing price of the Common Stock on the principal
exchange on which it is then traded has equaled or exceeded $______ per share on
each of five consecutive trading days that occur subsequent to the date of this
Warrant Agreement. The price at which Warrants may be redeemed (the "Redemption
Price") is $0.25 per Warrant. On and after the redemption date the holders of
record of redeemed Warrants shall be entitled to payment of the Redemption Price
upon surrender of such redeemed Warrants to the Company at the office of the
Warrant Agent designated for that purpose.

     (f) Notice of redemption of Warrants shall be given at least 30 days prior
to the redemption date by mailing, by registered or certified mail, return
receipt requested, a copy of such notice to the Warrant Agent and to all of the
holders of record of Warrants at their respective addresses appearing on the
books or transfer records of the Company or such other address designated in
writing by the holder of record to the Warrant Agent not less than 40 days prior
to the redemption date.

                                       7
<PAGE>

     (g) From and after the redemption date, all rights of the Warrantholders
(except the right to receive the Redemption Price) shall terminate, but only if
(i) no later than one day prior to the redemption date the Company shall have
irrevocably deposited with the Warrant Agent as paying agent a sufficient amount
to pay on the redemption date the Redemption Price for all Warrants called for
redemption and (ii) the notice of redemption shall have stated the name and
address of the Warrant Agent and the intention of the Company to deposit such
amount with the Warrant Agent no later than one day prior to the redemption
date.

     (h) On the Redemption Date, the Warrant Agent shall pay to the holders of
record of redeemed Warrants all monies received by the Warrant Agent for the
redemption of Warrants to which the holders of record of such redeemed Warrants
who shall have surrendered their Warrants are entitled. The Warrant Agent shall
have no obligation to pay for the redemption of the warrants except to the
extent that funds for such payment have been provided to it by the Company.

     (i) Any amounts deposited with the Warrant Agent that are not required for
redemption of Warrants may be withdrawn by the Company. Any amounts deposited
with the Warrant Agent that shall be unclaimed after six months after the
redemption date shall be redelivered back to the Company, and thereafter the
holders of the Warrants called for redemption for which such funds were
deposited shall look solely to the Company for payment. The Company shall be
entitled to the interest, if any, on funds deposited with the Warrant Agent and
the holders of redeemed Warrants shall have no right to any such interest. At
the instruction of the Company, the Warrant agent shall deposit or invest any
and all funds deposited with it by the Company in connection with any redemption
in federally insured, interest bearing accounts with a financial institution or
institutions designated by the Company but shall have no liability with respect
to the performance of any such investments other than, in the case of funds
deposited in accounts maintained by the Warrant Agent, the liability of the
Warrant Agent to its depositors in such accounts, generally.

     (j) If the Company fails to make a sufficient deposit with the Warrant
Agent as provided above, the holder of any Warrants called for redemption may at
the option of the holder (i) by notice to the Company declare the notice of
redemption a nullity as to such holder, or (ii) maintain an action against the
Company for the Redemption Price. If the holder brings such an action, the
Company will pay reasonable attorneys' fees of the holder. If the holder fails
to bring an action against the Company for the Redemption Price within 60 days
after the redemption date, the holder shall be deemed to have elected to declare
the notice of redemption to be a nullity as to such holder and such notice shall
be without any force or effect as to such holder. Except as otherwise
specifically provided in this Paragraph 7(j), a notice of redemption, once
mailed by the Company as provided in Paragraph F, shall be irrevocable.

     (k) The Company may not give a notice of redemption of Warrants under this
Section 7 unless the underlying shares are covered by an effective registration
statement. Additionally, an effective registration statement must be in place
for at least 30 calendar days after mailing of the notice of redemption before
the redemption may be effected. Consequently, if an effective registration
statement covering the underlying shares is in place at the time that the
Company mails its notice of redemption, but, during the notice period, the
registration statement ceases to be in effect (or is suspended), then the notice
period will automatically be extended for


                                       8


<PAGE>


that number of calendar days equal to the number of calendar days of cessation
(or suspension), unless waived in writing by the warrant holder.

     8. Fractional Interests. The Company shall not be required to issue any
Warrant Certificate evidencing a fraction of a Warrant or to issue fractions of
shares of securities on the exercise of the Warrants. If any fraction
(calculated to the nearest one-hundredth) of a Warrant or a share of securities
would, except for the provisions of this Section, be issuable on the exercise of
any Warrant, the Company shall, at its option, either purchase such fraction for
an amount in cash equal to the current value of such fraction computed on the
basis of the closing market price (as quoted on the American Stock Exchange) on
the trading day immediately preceding the day upon which such Warrant
Certificate was surrendered for exercise in accordance with Section 7 hereof or
issue the required fractional Warrant or share. By accepting a Warrant
Certificate, the holder thereof expressly waives any right to receive a Warrant
Certificate evidencing any fraction of a Warrant or to receive any fractional
share of securities upon exercise of a Warrant.

     9. Reservation of Equity Securities. The Company covenants that it will at
all times reserve and keep available, free from any pre-emptive rights, out of
its authorized and unissued equity securities, solely for the purpose of issue
upon exercise of the Warrants, such number of shares of equity securities of the
Company as shall then be issuable upon the exercise of all outstanding Warrants
("Equity Securities"). The Company covenants that all Equity Securities which
shall be so issuable shall, upon such issue, be duly authorized, validly issued,
fully paid and non-assessable.

      The Company covenants that if any equity securities, required to be
reserved for the purpose of issue upon exercise of the Warrants hereunder,
require registration with or approval of any governmental authority under any
federal or state law before such shares may be issued upon exercise of
Warrants, the Company will use all commercially reasonable efforts to cause
such securities to be duly registered, or approved, as the case may be, and,
to the extent practicable, take all such action in anticipation of and prior
to the exercise of the Warrants, including, without limitation, filing any
and all post-effective amendments to the Company's Registration Statement on
Form S-2 (Registration No. 333-110376) necessary to permit a public offering
of the securities underlying the Warrants at any and all times during the
term of this Agreement, provided, however, that in no event shall such
securities be issued, and the Company is authorized to refuse to honor the
exercise of any Warrant, if such exercise would result in the opinion of the
Company's Board of Directors, upon advice of counsel, in the violation of any
law; and provided further that, in the case of a Warrant exercisable solely
for securities listed on a securities exchange or for which there are at
least three independent market makers, in lieu of obtaining such registration
or approval, the Company may elect to redeem Warrants submitted to the
Warrant Agent for exercise for a price equal to the difference between the
aggregate low asked price, or closing price, as the case may be, of the
securities for which such Warrant is exercisable on the date of such
submission and the Exercise Price of such Warrants; in the event of such
redemption, the Company will pay to the holder of such Warrants the
above-described redemption price in cash within 10 business days after
receipt of notice from the Warrant Agent that such Warrants have been
submitted for exercise.

                                       9
<PAGE>

     10. Reduction of Conversion Price Below Par Value. Before taking any action
that would cause an adjustment pursuant to Section 6 hereof reducing the portion
of the Exercise Price required to purchase one share of capital stock below the
then par value (if any) of a share of such capital stock, the Company will use
its best efforts to take any corporate action which, in the opinion of its
counsel, may be necessary in order that the Company may validly and legally
issue fully paid and non-assessable shares of such capital stock.

     11. Payment of Taxes. The Company covenants and agrees that it will pay
when due and payable any and all federal and state documentary, stamp and other
original issue taxes which may be payable in respect of the original issuance of
the Warrant Certificates, or any shares of Common Stock or other securities upon
the exercise of Warrants. The Company shall not, however, be required (a) to pay
any tax which may be payable in respect of any transfer involved in the transfer
and delivery of Warrant Certificates or the issuance or delivery of certificates
for Common Stock or other securities in a name other than that of the registered
holder of the Warrant Certificate surrendered for purchase or (b) to issue or
deliver any certificate for shares of Common Stock or other securities upon the
exercise of any Warrant Certificate until any such tax shall have been paid, all
such tax being payable by the holder of such Warrant Certificate at the time of
surrender.

     12. Notice of Certain Corporate Action. In case the Company after the date
hereof shall propose (a) to offer to the holders of Common Stock, generally,
rights to subscribe to or purchase any additional shares of any class of its
capital stock, any evidences of its indebtedness or assets, or any other rights
or options or (b) to effect any reclassification of Common Stock (other than a
reclassification involving merely the subdivision or combination of outstanding
shares of Common Stock) or any capital reorganization, or any consolidation or
merger to which the Company is a party and for which approval of any
stockholders of the Company is required, or any sale, transfer or other
disposition of its property and assets substantially as an entirety, or the
liquidation, voluntary or involuntary dissolution or winding-up of the Company,
then, in each such case, the Company shall file with the Warrant Agent and the
Company, or the Warrant Agent on its behalf, shall mail (by first-class, postage
prepaid mail) to all registered holders of the Warrant Certificates notice of
such proposed action, which notice shall specify the date on which the books of
the Company shall close or a record be taken for such offer of rights or
options, or the date on which such reclassification, reorganization,
consolidation, merger, sale, transfer, other disposition, liquidation, voluntary
or involuntary dissolution or winding-up shall take place or commence, as the
case may be, and which shall also specify any record date for determination of
holders of Common Stock entitled to vote thereon or participate therein and
shall set forth such facts with respect thereto as shall be reasonably necessary
to indicate any adjustments in the Exercise Price and the number or kind of
shares or other securities purchasable upon exercise of Warrants which will be
required as a result of such action. Such notice shall be filed and mailed in
the case of any action covered by clause (a) above, at least ten days prior to
the record date for determining holders of the Common Stock for purposes of such
action or, if a record is not to be taken, the date as of which the holders of
shares of Common Stock of record are to be entitled to such offering; and, in
the case of any action covered by clause (b) above, at least 20 days prior to
the earlier of the date on which such reclassification, reorganization,
consolidation, merger, sale, transfer, other disposition, liquidation, voluntary
or involuntary dissolution or winding-up is expected to become effective and the
date on which it is expected that holders of shares of Common Stock of record on
such date shall be entitled to


                                       10

<PAGE>


exchange their shares for securities or other property deliverable upon such
reclassification, reorganization, consolidation, merger, sale, transfer, other
disposition, liquidation, voluntary or involuntary dissolution or winding-up.

      Failure to give any such notice or any defect therein shall not affect
the legality or validity of any transaction listed in this Section 12.

   13. Disposition of Proceeds on Exercise of Warrant Certificates, etc. The
Warrant Agent shall account promptly to the Company with respect to Warrants
exercised and concurrently pay to the Company all moneys received by the Warrant
Agent for the purchase of securities or other property through the exercise of
such Warrants.

   The Warrant Agent shall keep copies of this Agreement available for
inspection by Warrantholders during normal business hours at its stock transfer
office. Copies of this Agreement may be obtained upon written request addressed
to the Warrant Agent at its stock transfer office in New York, New York.

   14. Warrantholder Not Deemed a Stockholder. No Warrantholder, as such, shall
be entitled to vote, receive dividends or be deemed the holder of Common Stock
or any other securities of the Company which may at any time be issuable on the
exercise of the Warrants represented thereby for any purpose whatever, nor shall
anything contained herein or in any Warrant Certificate be construed to confer
upon any Warrantholder, as such, any of the rights of a stockholder of the
Company or any right to vote for the election of directors or upon any matter
submitted to stockholders at any meeting thereof, or to give or withhold consent
to any corporate action (whether upon any recapitalization, issuance of stock,
reclassification of stock, change of par value or change of stock to no par
value, consolidation, merger, conveyance or otherwise), or to receive notice of
meetings or other actions affecting stockholders (except as provided in Section
12 hereof), or to receive dividend or subscription rights, or otherwise, until
such Warrant Certificate shall have been exercised in accordance with the
provisions hereof and the receipt of the Exercise Price and any other amounts
payable upon such exercise by the Warrant Agent.

   15. Right of Action. All rights of action in respect to this Agreement are
vested in the respective registered holders of the Warrant Certificates; and any
registered holder of any Warrant Certificate, without the consent of the Warrant
Agent or of any other holder of a Warrant Certificate, may, in his own behalf
for his own benefit, enforce, and may institute and maintain any suit, action or
proceeding against the Company suitable to enforce, or otherwise in respect of,
his right to exercise the Warrants evidenced by such Warrant Certificate, for
the purchase of shares of the Common Stock in the manner provided in the Warrant
Certificate and in this Agreement.

   16. Agreement of Holders of Warrant Certificates. Every holder of a Warrant
Certificate by accepting the same consents and agrees with the Company, the
Warrant Agent and with every other holder of a Warrant Certificate that:

     (a) the Warrant Certificates are transferable on the registry books of the
Warrant Agent only upon the terms and conditions set forth in this Agreement;
and

                                       11

<PAGE>

     (b) the Company and the Warrant Agent may deem and treat the person in
whose name the Warrant Certificate is registered as the absolute owner of the
Warrant (notwithstanding any notation of ownership or other writing thereon made
by anyone other than the Company or the Warrant Agent) for all purposes whatever
and neither the Company nor the Warrant Agent shall be affected by any notice to
the contrary.

     17. Cancellation of Warrant Certificates. In the event that the Company
shall purchase or otherwise acquire any Warrant Certificate or Certificates
after the issuance thereof, such Warrant Certificate or Certificates shall
thereupon be delivered to the Warrant Agent and be canceled by it and retired.
The Warrant Agent shall also cancel any Warrant Certificate delivered to it for
exercise, in whole or in part, or delivered to it for transfer, split-up,
combination or exchange. Warrant Certificates so canceled shall be delivered by
the Warrant Agent to the Company from time to time, or disposed of in accordance
with the instructions of the Company.

     18. Concerning the Warrant Agent. The Company agrees to pay to the Warrant
Agent from time to time, on demand of the Warrant Agent, reasonable compensation
for all services rendered by it hereunder and also its reasonable expenses,
including counsel fees, and other disbursements incurred in the administration
and execution of this Agreement and the exercise and performance of its duties
hereunder. The Company also agrees to indemnify the Warrant Agent for, and to
hold it harmless against, any loss, liability or expense, incurred without gross
negligence, bad faith or willful misconduct on the part of the Warrant Agent,
arising out of or in connection with the acceptance and administration of this
Agreement.

     19. Merger or Consolidation or Change of Name of Warrant Agent. Any
corporation into which the Warrant Agent may be merged or with which it may be
consolidated, or any corporation resulting from any merger or consolidation to
which the Warrant Agent shall be a party, or any corporation succeeding to the
corporate trust business of the Warrant Agent, shall be the successor to the
Warrant Agent hereunder without the execution or filing of any paper or any
further act on the part of any of the parties hereto, provided that such
corporation would be eligible for appointment as a successor warrant agent under
the provisions of Section 21 hereof. In case at the time such successor to the
Warrant Agent shall succeed to the agency created by this Agreement, any of the
Warrant Certificates shall have been countersigned but not delivered, any such
successor to the Warrant Agent may adopt the countersignature of the original
Warrant Agent and deliver such Warrant Certificates so countersigned; and in
case at that time any of the Warrant Certificates shall not have been
countersigned, any successor to the Warrant Agent may countersign such Warrant
Certificates either in the name of the predecessor Warrant Agent or in the name
of the successor Warrant Agent; and in all such cases such Warrant Certificates
shall have the full force provided in the Warrant Certificates and in this
Agreement.

      In case at any time the name of the Warrant Agent shall be changed and
at such time any of the Warrant Certificates shall have been countersigned
but not delivered, the Warrant Agent may adopt the countersignature under its
prior name and deliver Warrant Certificates so countersigned; and in case at
that time any of the Warrant Certificates shall not have been countersigned,
the Warrant Agent may countersign such Warrant Certificates either in its
prior name or in its changed name; and in all such cases such Warrant
Certificates shall have the full force provided in the Warrant Certificates
and in this Agreement.

                                       12
<PAGE>

   20. Duties of Warrant Agent. The Warrant Agent undertakes the duties and
obligations imposed by this Agreement upon the following terms and conditions,
by all of which the Company and the holders of Warrant Certificates, by their
acceptance thereof, shall be bound:

     (a) The Warrant Agent may consult with counsel satisfactory to it (who may
be counsel for the Company), and the opinion of such counsel shall be full and
complete authorization and protection to the Warrant Agent as to any action
taken, suffered or omitted by it in good faith and in accordance with such
opinion; provided, however, that the Warrant Agent shall have exercised
reasonable care in the selection of such counsel. Fees and expenses of such
counsel, to the extent reasonable, shall be paid by the Company.

     (b) Whenever in the performance of its duties under this Agreement, the
Warrant Agent shall deem it necessary or desirable that any fact or matter be
proved or established by the Company prior to taking or suffering any action
hereunder, such fact or matter (unless other evidence in respect thereof be
herein specifically prescribed) may be deemed to be conclusively proved and
established by a certificate signed by a Chairman or co-Chairman of the Board or
the President or a Vice President or the Secretary of the Company and delivered
to the Warrant Agent; and such certificate shall be full authorization to the
Warrant Agent for any action taken or suffered in good faith by it under the
provisions of this Agreement in reliance upon such certificate.

     (c) The Warrant Agent shall be liable hereunder only for its own gross
negligence, bad faith or willful misconduct.

     (d) The Warrant Agent shall not be liable for or by reason of any of the
statements of fact or recitals contained in this Agreement or in the Warrant
Certificates (except its countersignature on the Warrant Certificates and such
statements or recitals as describe the Warrant Agent or action taken or to be
taken by it) or be required to verify the same, but all such statements and
recitals are and shall be deemed to have been made by the Company only.

     (e) The Warrant Agent shall not be under any responsibility in respect of
the validity of this Agreement or the execution and delivery hereof (except the
due execution hereof by the Warrant Agent) or in respect of the validity or
execution of any Warrant Certificate (except its countersignature thereof); nor
shall it be responsible for any breach by the Company of any covenant or
condition contained in this Agreement or in any Warrant Certificate; nor shall
it be responsible for the making of any change in the number of shares of Common
Stock for which a Warrant is exercisable required under the provisions of
Section 6 or responsible for the manner, method or amount of any such change or
the ascertaining of the existence of facts that would require any such
adjustment or change (except with respect to the exercise of Warrant
Certificates after actual notice of any adjustment of the Exercise Price); nor
shall it by any act hereunder be deemed to make any representation or warranty
as to the authorization or reservation of any shares of Common Stock to be
issued pursuant to this Agreement or any Warrant Certificate or as to whether
any shares of Common Stock will, when issued, be validly issued, fully paid and
non-assessable.

                                       13
<PAGE>

     (f) The Warrant Agent shall be under no obligation to institute any action,
suit or legal proceeding or take any other action likely to involve expense
unless the Company or one or more registered holders of Warrant Certificates
shall furnish the Warrant Agent with reasonable security and indemnity for any
costs and expenses which may be incurred. All rights of action under this
Agreement or under any of the Warrants may be enforced by the Warrant Agent
without the possession of any of the Warrants or the production thereof at any
trial or other proceeding relative thereto, and any such action, suit or
proceeding instituted by the Warrant Agent shall be brought in its name as
Warrant Agent, and any recovery of judgment shall be for the ratable benefit of
the registered holders of the Warrant Certificates, as their respective rights
or interests may appear.

     (g) The Warrant Agent and any stockholder, director, officer or employee of
the Warrant Agent may buy, sell or deal in any of the Warrants or other
securities of the Company or become pecuniarily interested in any transaction in
which the Company may be interested, or contract with or lend money to or
otherwise act as fully and freely as though it were not Warrant Agent under this
Agreement. Nothing herein shall preclude the Warrant Agent from acting in any
other capacity for the Company or for any other legal entity.

     (h) The Warrant Agent is hereby authorized and directed to accept
instructions with respect to the performance of its duties hereunder from a
Chairman or co-Chairman of the Board or President or a Vice President or the
Secretary or the Controller of the Company, and to apply to such officers for
advice or instructions in connection with the Warrant Agent's duties, and it
shall not be liable for any action taken or suffered or omitted by it in good
faith in accordance with instructions of any such officer.

     (i) The Warrant Agent will not be responsible for any failure of the
Company to comply with any of the covenants contained in this Agreement or in
the Warrant Certificates to be complied with by the Company.

     (j) The Warrant Agent may execute and exercise any of the rights or powers
hereby vested in it or perform any duty hereunder either itself or by or through
its attorneys, agents or employees and the Warrant Agent shall not be answerable
or accountable for any act, default, neglect or misconduct of any such
attorneys, agents or employees or for any loss to the Company resulting from
such neglect or misconduct; provided, however, that reasonable care shall have
been exercised in the selection and continued employment of such attorneys,
agents and employees.

     (k) The Warrant Agent will not incur any liability or responsibility to the
Company or to any holder of any Warrant Certificate for any action taken, or any
failure to take action, in reliance on any notice, resolution, waiver, consent,
order, certificate, or other paper, document or instrument reasonably believed
by the Warrant Agent to be genuine and to have been signed, sent or presented by
the proper party or parties.

     (l) The Warrant Agent will act hereunder solely as agent of the Company in
a ministerial capacity, and its duties will be determined solely by the
provisions hereof. The Warrant Agent will not be liable for anything which it
may do or refrain from doing in connection with this Agreement except for its
own gross negligence, bad faith or willful conduct.

                                       14
<PAGE>

   21. Change of Warrant Agent. The Warrant Agent may resign and be discharged
from its duties under this Agreement upon 30 days' prior notice in writing
mailed, by registered or certified mail, to the Company. The Company may remove
the Warrant Agent or any successor warrant agent upon 30 days' prior notice in
writing, mailed to the Warrant Agent or successor warrant agent, as the case may
be, by registered or certified mail. If the Warrant Agent shall resign or be
removed or shall otherwise become incapable of acting, the Company shall appoint
a successor to the Warrant Agent and shall, within 15 days following such
appointment, give notice thereof in writing to each registered holder of the
Warrant Certificates. If the Company shall fail to make such appointment within
a period of 15 days after giving notice of such removal or after it has been
notified in writing of such resignation or incapacity by the resigning or
incapacitated Warrant Agent, then the Company agrees to perform the duties of
the Warrant Agent hereunder until a successor Warrant Agent is appointed. After
appointment and execution of a copy of this Agreement in effect at that time,
the successor Warrant Agent shall be vested with the same powers, rights, duties
and responsibilities as if it had been originally named as Warrant Agent without
further act or deed; but the former Warrant Agent shall deliver and transfer to
the successor Warrant Agent, within a reasonable time, any property at the time
held by it hereunder, and execute and deliver any further assurance, conveyance,
act or deed necessary for the purpose. Failure to give any notice provided for
in this Section, however, or any defect therein shall not affect the legality or
validity of the resignation or removal of the Warrant Agent or the appointment
of the successor warrant agent, as the case may be.

   22. Issuance of New Warrant Certificates. Notwithstanding any of the
provisions of this Agreement or the several Warrant Certificates to the
contrary, the Company may, at its option, issue new Warrant Certificates in such
form as may be approved by its Board of Directors to reflect any adjustment or
change in the Exercise Price or the number or kind of shares purchasable under
the several Warrant Certificates made in accordance with the provisions of this
Agreement.

   23. Notices. Notice or demand pursuant to this Agreement to be given or made
on the Company by the Warrant Agent or by the registered holder of any Warrant
Certificate shall be sufficiently given or made if sent by first-class or
registered mail, postage prepaid, addressed (until another address is filed in
writing by the Company with the Warrant Agent) as follows:

    Milestone Scientific Inc.
    220 South Orange Ave.
    Livingston, New Jersey 07039
    Attention:  President

    Subject to the provisions of Section 21, any notice pursuant to this
Agreement to be given or made by the Company or by the holder of any Warrant
Certificate to or on the Warrant Agent shall be sufficiently given or made if
sent by first-class or registered mail, postage prepaid, addressed (until
another address is filed in writing by the Warrant Agent with the Company) as
follows:

      -------------------------

      -------------------------

      -------------------------

                                       15
<PAGE>

   Any notice or demand authorized to be given or made to the registered holder
of any Warrant Certificate under this Agreement shall be sufficiently given or
made if sent by first-class or registered mail, postage prepaid, to the last
address of such holder as it shall appear on the registers maintained by the
Warrant Agent.

   24. Modification of Agreement. The Warrant Agent may, without the consent or
concurrence of the Warrantholders, by supplemental agreement or otherwise,
concur with the Company in making any changes or corrections in this Agreement
that the Warrant Agent shall have been advised by counsel (who may be counsel
for the Company) are necessary or desirable to cure any ambiguity or to correct
any defective or inconsistent provision or clerical omission or mistake or
manifest error herein contained, or to make any other provisions in regard to
matters or questions arising hereunder and which shall not be inconsistent with
the provisions of the Warrant Certificates and which shall not adversely affect
the interests of the Warrantholders. As of the date hereof, this Agreement
contains the entire and only agreement, understanding, representation,
condition, warranty or covenant between the parties hereto with respect to the
matters herein, supersedes any and all other agreements between the parties
hereto relating to such matters, and may be modified or amended only by a
written agreement signed by both parties hereto pursuant to the authority
granted by the first sentence of this Section.

   25. Successors. All the covenants and provisions of this Agreement by or for
the benefit of the Company or the Warrant Agent shall bind and inure to the
benefit of their respective successors and assigns hereunder.

   26. Governing Law. This Agreement and each Warrant Certificate issued
hereunder shall be deemed to be a contract made under the laws of the State of
New York, and for all purposes shall be construed in accordance with the laws of
said State. All disputes relating to this Agreement and each Warrant Certificate
issued hereunder shall be adjudicated in a court located in New York, New York
to the exclusion of all other courts that might have jurisdiction.

   27. Termination. This Agreement shall terminate as of the close of business
on the Expiration Date, or such earlier date upon which all Warrants shall have
been exercised or redeemed, except that the Warrant Agent shall account to the
Company as to all Warrants outstanding and all cash held by it as of the close
of business on the Expiration Date.

   28. Benefits of this Agreement. Nothing in this Agreement or in the Warrant
Certificates shall be construed to give to any person or corporation other than
the Company, the Warrant Agent, and their respective successors and assigns
hereunder and the registered holders of the Warrant Certificates any legal or
equitable right, remedy or claim under this Agreement; but this Agreement shall
be for the sole and exclusive benefit of the Company, the Warrant Agent, their
respective successors and assigns hereunder and the registered holders of the
Warrant Certificates.

   29. Descriptive Headings. The descriptive headings of the several Sections of
this Agreement are inserted for convenience only and shall not control or affect
the meaning or construction of any of the provisions hereof.

                                       16
<PAGE>

   30. Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be an original, but such counterparts shall
together constitute one and the same instrument.


      (Remainder of page intentionally left blank; signature page follows)


                                       17
<PAGE>


      IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed, all as of the day and year first above written.


                                    MILESTONE SCIENTIFIC INC.


                                    By: ______________________________________
                                        Name:
                                        Title:


                                    CONTINENTAL STOCK TRANSFER & TRUST COMPANY


                                    By: ______________________________________
                                        Name:
                                        Title:


                                       18
<PAGE>


                                  Exhibit A


          VOID AFTER 5 P.M. PACIFIC TIME ON _________________, 2009

                      WARRANTS TO PURCHASE COMMON STOCK


No. MSW-_____                                               _________ Warrants


                          Milestone Scientific Inc.

                              CUSIP ___________


THIS CERTIFIES THAT




or registered assigns, is the registered holder of the number of Warrants
("Warrants") set forth above.  Each Warrant, unless and until redeemed by the
Company as provided in the Warrant Agreement, hereinafter more fully
described (the "Warrant Agreement") entitles the holder thereof to purchase
from Milestone Scientific Inc., a corporation incorporated under the laws of
the State of Delaware (the "Company"), subject to the terms and conditions
set forth hereinafter and in the Warrant Agreement, at any time on or after
___________, 2004 and before the close of business on ________, 2009
("Expiration Date"), one fully paid and non-assessable share of Common Stock,
par value $0.001 per share, of the Company ("Common Stock") upon presentation
and surrender of this Warrant Certificate, with the instructions for the
registration and delivery of Common Stock filled in, at the stock transfer
office in New York, New York, of Continental Stock Transfer & Trust Company,
Warrant Agent of the Company ("Warrant Agent") or of its successor warrant
agent or, if there be no successor warrant agent, at the corporate offices of
the Company, and upon payment of the Exercise Price (as defined in the
Warrant Agreement) and any applicable taxes paid either in cash, or by
certified or official bank check, payable in lawful money of the United
States of America to the order of the Company. Each Warrant initially
entitles the holder to purchase one share of Common Stock for $____.  The
number and kind of securities or other property for which the Warrants are
exercisable are subject to adjustment in certain events, such as mergers,
splits, stock dividends, splits and the like, to prevent dilution.  Beginning
on _____________, 2004, the Company may redeem any or all outstanding and
unexercised warrants by giving not less than 30 days prior notice at any time
after the closing price of the Common Stock on the principal exchange on
which it is traded has equaled or exceeded $______ per share on each of five
consecutive trading days subsequent to _________, 2004.  The Redemption Price
is $0.25 per Warrant (subject to adjustment in the event of a stock split,
dividend or the like).  All Warrants not theretofore exercised will expire on
the Expiration Date.

                                       1
<PAGE>

      This Warrant Certificate is subject to all of the terms, provisions and
conditions of the Warrant Agreement, dated as of ________________, 2004,
between the Company and the Warrant Agent, to all of which terms, provisions
and conditions the registered holder of this Warrant Certificate consents by
acceptance hereof.  The Warrant Agreement is incorporated herein by reference
and made a part hereof and reference is made to the Warrant Agreement for a
full description of the rights, limitations of rights, obligations, duties
and immunities of the Warrant Agent, the Company and the holders of the
Warrant Certificates.  Copies of the Warrant Agreement are available for
inspection at the stock transfer office of the Warrant Agent or may be
obtained upon written request addressed to the Company at Milestone
Scientific Inc., 220 South Orange Ave., Livingston, New Jersey 07039,
Attention: President.

      The Company shall not be required upon the exercise of the Warrants
evidenced by this Warrant Certificate to issue fractions of Warrants, Common
Stock or other securities, but shall make adjustment therefor in cash on the
basis of the current market value of any fractional interest as provided in
the Warrant Agreement.

      In certain cases, the sale of securities by the Company upon exercise
of Warrants may violate the securities laws of the United States, certain
states thereof or other jurisdictions.  The Company has agreed to use all
commercially reasonable efforts to cause a registration statement to continue
to be effective during the term of the Warrants with respect to such sales
under the Securities Act of 1933, and to take such action under the laws of
various states as may be required to cause the sale of securities upon
exercise to be lawful.  However, the Company will not be required to honor
the exercise of Warrants if, in the opinion of the Board of Directors, upon
advice of counsel, the sale of securities upon such exercise would be
unlawful.  In certain cases, the Company may, but is not required to,
purchase Warrants submitted for exercise for a cash price equal to the
difference between the market price of the securities obtainable upon such
exercise and the exercise price of such Warrants.

      This Warrant Certificate, with or without other Certificates, upon
surrender to the Warrant Agent, any successor warrant agent or, in the
absence of any successor warrant agent, at the corporate offices of the
Company, may be exchanged for another Warrant Certificate or Certificates
evidencing in the aggregate the same number of Warrants as the Warrant
Certificate or Certificates so surrendered.  If the Warrants evidenced by
this Warrant Certificate shall be exercised in part, the holder hereof shall
be entitled to receive upon surrender hereof another Warrant Certificate or
Certificates evidencing the number of Warrants not so exercised.

      No holder of this Warrant Certificate, as such, shall be entitled to
vote, receive dividends or be deemed the holder of Common Stock or any other
securities of the Company which may at any time be issuable on the exercise
hereof for any purpose whatsoever, nor shall anything contained in the
Warrant Agreement or herein be construed to confer upon the holder of this
Warrant Certificate, as such, any of the rights of a stockholder of the
Company or any right to vote for the election of directors or upon any matter
submitted to stockholders at any meeting thereof or give or withhold consent
to any corporate action (whether upon any matter submitted to stockholders at
any meeting thereof, or give or withhold consent to any merger,
recapitalization, issuance of stock, reclassification of stock, change of par
value or change of stock to no par value, consolidation, conveyance or
otherwise) or to receive notice of meetings or


                                       2


<PAGE>

other actions affecting stockholders (except as provided in the Warrant
Agreement) or to receive dividends or subscription rights or otherwise until the
Warrants evidenced by this Warrant Certificate shall have been exercised and the
Common Stock purchasable upon the exercise thereof shall have become deliverable
as provided in the Warrant Agreement.

      If this Warrant Certificate shall be surrendered for exercise within
any period during which the transfer books for the Company's Common Stock or
other class of stock purchasable upon the exercise of the Warrants evidenced
by this Warrant Certificate are closed for any purpose, the Company shall not
be required to make delivery of certificates for shares purchasable upon such
transfer until the date of the reopening of said transfer books.

      Every holder of this Warrant Certificate by accepting the same consents
and agrees with the Company, the Warrant Agent, and with every other holder
of a Warrant Certificate that:

      (a)  this Warrant Certificate is transferable on the registry books of
the Warrant Agent only upon the terms and conditions set forth in the Warrant
Agreement, and

      (b)  the Company and the Warrant Agent may deem and treat the person in
whose name this Warrant Certificate is registered as the absolute owner
hereof (notwithstanding any notation of ownership or other writing thereon
made by anyone other than the Company or the Warrant Agent) for all purposes
whatsoever and neither the Company nor the Warrant Agent shall be affected by
any notice to the contrary.  The Company shall not be required to issue or
deliver any certificate for shares of Common Stock or other securities upon
the exercise of Warrants evidenced by this Warrant Certificate until any tax
which may be payable in respect thereof by the holder of this Warrant
Certificate pursuant to the Warrant Agreement shall have been paid, such tax
being payable by the holder of this Warrant Certificate at the time of
surrender.

      This Warrant Certificate shall not be valid or obligatory for any
purpose until it shall have been countersigned by the Warrant Agent.



     (Remainder of page intentionally left blank; signature page follows)

                                       3

<PAGE>


      WITNESS the facsimile signatures of the proper officers of the Company
and its corporate seal.

Dated: _______________

                                    MILESTONE SCIENTIFIC INC.


                                    By: ______________________________________
                                        Name:
                                        Title:



                                    Attest:
                                    -----------------------------------
                                           Secretary

Countersigned:

Continental Stock Transfer & Trust Company
Warrant Agent and Registrar
17 Battery Place
New York, NY  10004


By: ______________________________________
    Authorized Officer



                                       4



</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>9
<FILENAME>file008.txt
<DESCRIPTION>FORM OF REPRESENTATIVE'S WARRANT
<TEXT>
<PAGE>





                      THIS WARRANT HAS NOT BEEN REGISTERED
                        UNDER THE SECURITIES ACT OF 1933
                             AND IS NOT TRANSFERABLE
                            EXCEPT AS PROVIDED HEREIN

                            MILESTONE SCIENTIFIC INC.

                                PURCHASE WARRANT

                                   Issued to:

                        PAULSON INVESTMENT COMPANY, INC.

                             Exercisable to Purchase

                                  120,000 Units


                                       of


                            MILESTONE SCIENTIFIC INC.












                          Void after ____________, 2009





<PAGE>

         This is to certify that, for value received and subject to the terms
and conditions set forth below, the Warrantholder (hereinafter defined) is
entitled to purchase, and the Company promises and agrees to sell and issue to
the Warrantholder, at any time on or after _____________, 2005 and on or before
____________, 2009, up to 120,000 Units (hereinafter defined) at the Exercise
Price (hereinafter defined).

         This Warrant Certificate is issued subject to the following terms and
conditions:

         1. Definitions of Certain Terms. Except as may be otherwise clearly
required by the context, the following terms have the following meanings:

               (a) "Act" means the Securities Act of 1933, as amended.

               (b) "Cashless Exercise" means an exercise of Warrants in which,
in lieu of payment of the Exercise Price, the Holder elects to receive a lesser
number of Securities such that the value of the Securities that such Holder
would otherwise have been entitled to receive but has agreed not to receive, as
determined by the closing price of such Securities on the date of exercise or,
if such date is not a trading day, on the next prior trading day, is equal to
the Exercise Price with respect to such exercise. A Holder may only elect a
Cashless Exercise if Securities issuable by the Company on such exercise are
publicly traded securities.

               (c) "Closing Date" means the date on which the Offering is
closed.

               (d) "Commission" means the Securities and Exchange Commission.

               (e) "Common Stock" means the common stock, par value $0.001, of
the Company.

               (f) "Company" means Milestone Scientific Inc., a Delaware
corporation.

               (g) "Company's Expenses" means any and all expenses payable by
the Company or the Warrantholder in connection with an offering described in
Section 6 hereof, except Warrantholder's Expenses.

               (h) "Effective Date" means the date on which the Registration
Statement is declared effective by the Commission.

               (i) "Exercise Price" means the price at which the Warrantholder
may purchase one Unit upon exercise of Warrants as determined from time to time
pursuant to the provisions hereof. The initial Exercise Price is $________ per
Unit.

               (j) "Offering" means the public offering of Units made pursuant
to the Registration Statement.

               (k) "Participating Underwriter" means any underwriter
participating in the sale of the Securities pursuant to a registration under
Section 6 of this Warrant Certificate.

<PAGE>

               (l) "Registration Statement" means the Company's registration
statement (File No. 333 - 110376) as amended on the Closing Date.

               (m) "Rules and Regulations" means the rules and regulations of
the Commission adopted under the Act.

               (n) "Securities" means the securities obtained or obtainable upon
exercise of the Warrants and the securities obtained or obtainable upon
exercise, exchange, or conversion the Warrants and any underlying securities.

               (o) "Unit" means two shares of Common Stock and one Unit Warrant.

               (p) "Unit Warrant" means a warrant to purchase one share of
Common Stock issued pursuant to the Warrant Agreement.

               (q) "Warrant Agreement" means that certain Warrant Agreement,
dated as of ______________, 2004, by and between the Company and Continental
Stock Transfer & Trust Company relating to the issuance of Unit Warrants.

               (r) "Warrant Certificate" means a certificate evidencing the
Warrant.

               (s) "Warrantholder" means a record holder of the Warrant or
Securities. The initial Warrantholder is Paulson Investment Company, Inc.

               (t) "Warrantholder's Expenses" means the sum of (i) the aggregate
amount of cash payments made to an underwriter, underwriting syndicate, or agent
in connection with an offering described in Section 6 hereof multiplied by a
fraction the numerator of which is the aggregate sales price of the Securities
sold by such underwriter, underwriting syndicate, or agent in such offering and
the denominator of which is the aggregate sales price of all of the securities
sold by such underwriter, underwriting syndicate, or agent in such offering and
(ii) all out-of-pocket expenses of the Warrantholder, except for the fees and
disbursements of one firm retained as legal counsel for the Warrantholder that
will be paid by the Company.

               (u) "Warrant" means the warrant evidenced by this certificate,
any similar certificate issued in connection with the Offering, or any
certificate obtained upon transfer or partial exercise of the Warrant evidenced
by any such certificate.

         2. Exercise of Warrant. All or any part of the Warrant represented by
this Warrant Certificate may be exercised commencing on the first anniversary of
the Effective Date and ending at 5 p.m. Pacific Time on the fifth anniversary of
the Effective Date by surrendering this Warrant Certificate, together with
appropriate instructions, duly executed by the Warrantholder or by its duly
authorized attorney, at the office of the Company at Milestone Scientific Inc.,
220 South Orange Ave., Livingston, New Jersey 07039, Attention: President; or at
such other office or agency as the Company may designate. The date on which such
instructions are received by the Company shall be the date of exercise. If the
Holder has elected a Cashless Exercise, such instructions shall so state. Upon
receipt of notice of exercise, the Company shall immediately instruct its
transfer agent to prepare certificates for the Securities to be received by the
Warrantholder upon completion of the Warrant exercise. When such certificates
are prepared,

<PAGE>

the Company shall notify the Warrantholder and deliver such certificates to the
Warrantholder or as per the Warrantholder's instructions immediately upon
payment in full by the Warrantholder, in lawful money of the United States, of
the Exercise Price payable with respect to the Securities being purchased, if
any. If the Warrantholder shall represent and warrant that all applicable
registration and prospectus delivery requirements for their sale have been
complied with upon sale of the Securities received upon exercise of the Warrant,
such certificates shall not bear a legend with respect to the Securities Act of
1933, as amended.

         If fewer than all the Securities purchasable under the Warrant are
purchased, the Company will, upon such partial exercise, execute and deliver to
the Warrantholder a new Warrant Certificate (dated the date hereof), in form and
tenor similar to this Warrant Certificate, evidencing that portion of the
Warrant not exercised. The Securities to be obtained on exercise of the Warrant
will be deemed to have been issued, and any person exercising the Warrants will
be deemed to have become a holder of record of those Securities, as of the date
of the payment of the Exercise Price.

         3. Adjustments in Certain Events. The number, class, and price of
Securities for which this Warrant Certificate may be exercised are subject to
adjustment from time to time upon the happening of certain events as follows:

               (a) If the outstanding shares of the Company's Common Stock are
divided into a greater number of shares or a dividend in stock is paid on the
Common Stock, the number of shares of Common Stock for which the Warrant is then
exercisable will be proportionately increased and the Exercise Price will be
proportionately reduced; and, conversely, if the outstanding shares of Common
Stock are combined into a smaller number of shares of Common Stock, the number
of shares of Common Stock for which the Warrant is then exercisable will be
proportionately reduced and the Exercise Price will be proportionately
increased. The increases and reductions provided for in this Section 3(a) will
be made with the intent and, as nearly as practicable, the effect that neither
the percentage of the total equity of the Company obtainable on exercise of the
Warrants nor the price payable for such percentage upon such exercise will be
affected by any event described in this Section 3(a).

               (b) In case of any change in the Common Stock through merger,
consolidation, reclassification, reorganization, partial or complete
liquidation, purchase of substantially all the assets of the Company, or other
change in the capital structure of the Company, then, as a condition of such
change, lawful and adequate provision will be made so that the holder of this
Warrant Certificate will have the right thereafter to receive upon the exercise
of the Warrant the kind and amount of shares of stock or other securities or
property to which he would have been entitled if, immediately prior to such
event, he had held the number of shares of Common Stock obtainable upon the
exercise of the Warrant. In any such case, appropriate adjustment will be made
in the application of the provisions set forth herein with respect to the rights
and interest thereafter of the Warrantholder, to the end that the provisions set
forth herein will thereafter be applicable, as nearly as reasonably may be, in
relation to any shares of stock or other property thereafter deliverable upon
the exercise of the Warrant. The Company will not permit any change in its
capital structure to occur unless the issuer of the shares of stock or other
securities to be received by the holder of this Warrant Certificate, if not the
Company, agrees to be bound by and comply with the provisions of this Warrant
Certificate.

<PAGE>

               (c) When any adjustment is required to be made in the number of
shares of Common Stock, other securities, or the property purchasable upon
exercise of the Warrant, the Company will promptly determine the new number of
such shares or other securities or property purchasable upon exercise of the
Warrant and (i) prepare and retain on file a statement describing in reasonable
detail the method used in arriving at the new number of such shares or other
securities or property purchasable upon exercise of the Warrant and (ii) cause a
copy of such statement to be mailed to the Warrantholder within thirty (30) days
after the date of the event giving rise to the adjustment.

               (d) No fractional shares of Common Stock or other securities will
be issued in connection with the exercise of the Warrant, but the Company will
pay, in lieu of fractional shares, a cash payment therefor on the basis of the
mean between the bid and asked prices of the Common Stock in the
over-the-counter market or the last sale price of the Common Stock on the
principal exchange or other trading facility on which the Common Stock is traded
on the day immediately prior to exercise.

               (e) If securities of the Company or securities of any subsidiary
of the Company are distributed pro rata to holders of Common Stock, such number
of securities will be distributed to the Warrantholder or its assignee upon
exercise of its rights hereunder as such Warrantholder or assignee would have
been entitled to if this Warrant Certificate had been exercised prior to the
record date for such distribution. The provisions with respect to adjustment of
the Common Stock provided in this Section 3 will also apply to the securities to
which the Warrantholder or its assignee is entitled under this Section 3(e).

               (f) Notwithstanding anything herein to the contrary, there will
be no adjustment made hereunder on account of the sale by the Company of the
Common Stock or other Securities purchasable upon exercise of the Warrant.

               (g) If, immediately prior to any exercise of Warrants, there
shall be outstanding no securities of a class or series that, but for the
provisions of this Section 3, would be issuable upon such exercise (the
"Formerly Issuable Securities"), then, upon such exercise, and in lieu of the
Formerly Issuable Securities, the Company shall issue that number and kind of
other securities or property for which the Formerly Issuable Securities were
most recently exercisable or into which the Formerly Issuable Securities were
most recently convertible, as the case may be.

         4. Reservation of Securities. The Company agrees that the number of
shares of Common Stock or other Securities sufficient to provide for the
exercise of the Warrant upon the basis set forth above will at all times during
the term of the Warrant be reserved for exercise.

         5. Validity of Securities. All Securities delivered upon the exercise
of the Warrant will be duly and validly issued in accordance with their terms,
and the Company will pay all documentary and transfer taxes, if any, in respect
of the original issuance thereof upon exercise of the Warrant.

<PAGE>

         6. Registration of Securities Issuable on Exercise of Warrant
Certificate.

               (a) The Company will register the Securities with the Commission
pursuant to the Act so as to allow the unrestricted sale of the Securities to
the public from time to time commencing on the first anniversary of the
Effective Date and ending at 5:00 p.m. Pacific Time on the fifth anniversary of
the Effective Date (the "Registration Period"). The Company will also file such
applications and other documents necessary to permit the sale of the Securities
to the public during the Registration Period in those states in which the Units
were qualified for sale in the Offering or such other states as the Company and
the Warrantholder agree to. In order to comply with the provisions of this
Section 6(a), the Company is not required to file more than one registration
statement. No registration right of any kind, "piggyback" or otherwise, will
last longer than five years from the Effective Date.

               (b) The Company will pay all of the Company's Expenses and each
Warrantholder will pay its pro rata share of the Warrantholder's Expenses
relating to the registration, offer, and sale of the Securities.

               (c) Except as specifically provided herein, the manner and
conduct of the registration, including the contents of the registration, will be
entirely in the control and at the discretion of the Company. The Company will
file such post-effective amendments and supplements as may be necessary to
maintain the currency of the registration statement during the period of its
use. In addition, if the Warrantholder participating in the registration is
advised by counsel that the registration statement, in their opinion, is
deficient in any material respect, the Company will use its best efforts to
cause the registration statement to be amended to eliminate the concerns raised.

               (d) The Company will furnish to the Warrantholder the number of
copies of a prospectus, including a preliminary prospectus, in conformity with
the requirements of the Act, and such other documents as it may reasonably
request in order to facilitate the disposition of Securities owned by it.

               (e) The Company will, at the request of Warrantholders holding at
least 50 percent of the then outstanding Warrants, (i) furnish an opinion of the
counsel representing the Company for the purposes of the registration pursuant
to this Section 6, addressed to the Warrantholders and any Participating
Underwriter, (ii) furnish an appropriate letter from the independent public
accountants of the Company, addressed to the Warrantholders and any
Participating Underwriter, and (iii) make representations and warranties to the
Warrantholders and any Participating Underwriter. A request pursuant to this
subsection (e) may be made on three occasions. The documents required to be
delivered pursuant to this subsection (e) will be dated within ten days of the
request and will be, in form and substance, equivalent to similar documents
furnished to the underwriters in connection with the Offering, with such changes
as may be appropriate in light of changed circumstances.

         7. Indemnification in Connection with Registration.

               (a) If any of the Securities are registered, the Company will
indemnify and hold harmless each selling Warrantholder, any person who controls
any selling Warrantholder

<PAGE>

within the meaning of the Act, and any Participating Underwriter against any
losses, claims, damages, or liabilities, joint or several, to which any
Warrantholder, controlling person, or Participating Underwriter may be subject
under the Act or otherwise; and it will reimburse each Warrantholder, each
controlling person, and each Participating Underwriter for any legal or other
expenses reasonably incurred by the Warrantholder, controlling person, or
Participating Underwriter in connection with investigating or defending any such
loss, claim, damage, liability, or action, insofar as such losses, claims,
damages, or liabilities, joint or several (or actions in respect thereof), arise
out of or are based upon any untrue statement or alleged untrue statement of any
material fact contained, on the effective date thereof, in any such registration
statement or any preliminary prospectus or final prospectus, or any amendment or
supplement thereto, or arise out of or are based upon the omission or alleged
omission to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading; provided, however, that
the Company will not be liable in any case to the extent that any loss, claim,
damage, or liability arises out of or is based upon any untrue statement or
alleged untrue statement or omission or alleged omission made in any
registration statement, preliminary prospectus, final prospectus, or any
amendment or supplement thereto, in reliance upon and in conformity with written
information furnished by a Warrantholder for use in the preparation thereof. The
indemnity agreement contained in this subparagraph (a) will not apply to amounts
paid to any claimant in settlement of any suit or claim unless such payment is
first approved by the Company, such approval not to be unreasonably withheld.

               (b) Each selling Warrantholder, as a condition of the Company's
registration obligation, will indemnify and hold harmless the Company, each of
its directors, each of its officers who have signed any registration statement
or other filing or any amendment or supplement thereto, and any person who
controls the Company within the meaning of the Act, against any losses, claims,
damages, or liabilities to which the Company or any such director, officer, or
controlling person may become subject under the Act or otherwise, and will
reimburse any legal or other expenses reasonably incurred by the Company or any
such director, officer, or controlling person in connection with investigating
or defending any such loss, claim, damage, liability, or action, insofar as such
losses, claims, damages, or liabilities (or actions in respect thereof) arise
out of or are based upon any untrue or alleged untrue statement of any material
fact contained in said registration statement, any preliminary or final
prospectus, or other filing, or any amendment or supplement thereto, or arise
out of or are based upon the omission or the alleged omission to state therein a
material fact required to be stated therein or necessary to make the statements
therein not misleading, but only to the extent that such untrue statement or
alleged untrue statement or omission or alleged omission was made in said
registration statement, preliminary or final prospectus, or other filing, or
amendment or supplement, in reliance upon and in conformity with written
information furnished by such Warrantholder for use in the preparation thereof;
provided, however, that the indemnity agreement contained in this subparagraph
(b) will not apply to amounts paid to any claimant in settlement of any suit or
claim unless such payment is first approved by the Warrantholder, such approval
not to be unreasonably withheld.

               (c) Promptly after receipt by an indemnified party under
subparagraphs (a) or (b) above of notice of the commencement of any action, such
indemnified party will, if a claim in respect thereof is to be made against an
indemnifying party, notify the indemnifying party of the commencement thereof;
but the omission to notify the indemnifying party will not relieve it

<PAGE>

from any liability that it may have to any indemnified party otherwise than
under subparagraphs (a) and (b).

               (d) If any such action is brought against any indemnified party
and it notifies an indemnifying party of the commencement thereof, the
indemnifying party will be entitled to participate in, and, to the extent that
it may wish, jointly with any other indemnifying party similarly notified, to
assume the defense thereof, with counsel satisfactory to such indemnified party;
and after notice from the indemnifying party to such indemnified party of its
election to assume the defense thereof, the indemnifying party will not be
liable to such indemnified party for any legal or other expenses subsequently
incurred by such indemnified party in connection with the defense thereof other
than reasonable costs of investigation.

         8. Restrictions on Transfer. This Warrant Certificate and the Warrant
may not be sold, transferred, assigned or hypothecated for a one-year period
after the Effective Date except to underwriters of the Offering or to
individuals who are either a partner or an officer of such an underwriter or by
will or by operation of law. The Warrant may be divided or combined, upon
request to the Company by the Warrantholder, into a certificate or certificates
evidencing the same aggregate number of Warrants.

         9. No Rights as a Shareholder. Except as otherwise provided herein, the
Warrantholder will not, by virtue of ownership of the Warrant, be entitled to
any rights of a shareholder of the Company but will, upon written request to the
Company, be entitled to receive such quarterly or annual reports as the Company
distributes to its shareholders.

         10. Notice. Any notices required or permitted to be given hereunder
will be in writing and may be served personally or by mail; and if served will
be addressed as follows:

         If to the Company:

                  Milestone Scientific Inc.
                  220 South Orange Ave.
                  Livingston, New Jersey 07039
                  Attention: President

         If to the Warrantholder:

                  At the address furnished
                  by the Warrantholder to the
                  Company for the purpose of
                  notice.

         Any notice so given by mail will be deemed effectively given 48 hours
after mailing when deposited in the United States mail, registered or certified
mail, return receipt requested, postage prepaid and addressed as specified
above. Any party may by written notice to the other specify a different address
for notice purposes.

<PAGE>

         11. Applicable Law. This Warrant Certificate will be governed by and
construed in accordance with the laws of the State of Oregon, without reference
to conflict of laws principles thereunder. All disputes relating to this Warrant
Certificate shall be tried before the courts of Oregon located in Multnomah
County, Oregon to the exclusion of all other courts that might have
jurisdiction.

         Dated as of            , 2004
                    ------------

                                              MILESTONE SCIENTIFIC INC.


                                              By:
                                                 ---------------------------
                                                 Name:
                                                 Title:


         Agreed and Accepted as of              , 2004
                                   -------------

                                              PAULSON INVESTMENT COMPANY, INC.


                                              By:
                                                 ---------------------------
                                                  Name:
                                                  Title:








</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>10
<FILENAME>file009.txt
<DESCRIPTION>LETTER FROM MORSE, ZELNICK, ROSE & LANDER LLP
<TEXT>
<PAGE>




                   [MORSE, ZELNICK, ROSE & LANDER LETTERHEAD]

                          MORSE, ZELNICK, ROSE & LANDER
                         A LIMITED LIABILITY PARTNERSHIP

                                 450 PARK AVENUE
                          NEW YORK, NEW YORK 10022-2605
                                  212-838-1177
                                FAX. 212-838-9190




                                 March 29, 2002
                                                            WRITER'S DIRECT LINE
                                                                  (212) 838-8040




Mr. Thomas Stuckey
Milestone Scientific, Inc.
220 South Orange Avenue
Livingston, New Jersey 07039


Dear Tom:

     This will confirm that we have agreed to defer payment of the current
balance of fees due us for legal services rendered through February 28, 2002
($320,866.01) until January 2, 2003, except out of the proceeds of new equity
financings, provide that Milestone pays us $2,500 per month in reduction of this
accumulated balance.




                                                     Very truly yours,



                                                     Stephen A. Zelnick


cc: Mr. Leonard Osser








</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.27
<SEQUENCE>11
<FILENAME>file010.txt
<DESCRIPTION>MZRL LETTER
<TEXT>
<PAGE>


                          MORSE, ZELNICK, ROSE & LANDER
                         A LIMITED LIABILITY PARTNERSHIP

                                 405 PARK AVENUE
                          NEW YORK, NEW YORK 10022-4405
                                  212-838-1177
                               FAX - 212-838-9190


                                                            WRITER'S DIRECT LINE
                                                                  (212) 838-8040



                                 April 15, 2003

Mr. Thomas Stuckey
Milestone Scientific, Inc.
220 South Orange Avenue
Livingston, New Jersey 07039

Dear Tom:

         This will confirm that we have agreed to defer payment of an additional
$160,000 in fees due to us until January 2, 2005, except for payments out of
future profits or the net proceeds of equity financings.

         This will further inform that the $160,000 balance of the amount
deferred last year until January 2, 2003 (after giving effect to a $90,000
payment in restricted shares of Common Stock), is now deferred until January 2,
2005 except for payments out of future profits or the net proceeds of equity
financings, provided that it does not impact operations.


                                                              Very truly yours,




                                                              Stephen A. Zelnick

SAZ/ds



</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.28
<SEQUENCE>12
<FILENAME>file011.txt
<DESCRIPTION>LINE OF CREDIT
<TEXT>
<PAGE>








                                 April 15, 2003
                                                                  (212) 838-8040

Mr. K. Tucker Andersen
61 Above All Road
Warren, CT 06754

                         New Line of Credit for $900,000
                                       and
                     Extension of Maturity Date on $500,000
                         Owed Under 2001 Line of Credit


Dear Tucker:

     This will confirm that you have opened a new line of credit for Milestone
Scientific Inc., in the aggregate amount of $900,000. Borrowings under line will
bear interest at the rate of 8% per annum and will be evidenced by a promissory
note in usual form. Monies may be drawn by Milestone under the line upon 10
days' written notice to you from either Milestone's Chief Executive Officer or
Chief Financial Officer. The line will expire and borrowings under the line and
interest thereon will be payable in cash on January 2, 2005.

     This will also confirm that you have agreed to further extend the payment
date of the $500,000 owed under the Line of Credit dated January 29, 2001, which
is not now payable in stock at Milestone's election, from December 31, 2003
until January 2, 2005.

     This letter replaces and cancels the commitment in our earlier letter dated
April 8, 2003 which you countersigned.

     If this conforms with your understanding with Milestone please countersign
and return the copy of this letter.

                                                     Very truly yours

                                                     Stephen A. Zelnick
Accepted and agreed to
this 15th day of April, 2003

/s/ K. Tucker Andersen
- ----------------------
K. Tucker Andersen








</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.29
<SEQUENCE>13
<FILENAME>file012.txt
<DESCRIPTION>AGREEMENT WITH DAVINCI SYSTEMS
<TEXT>
<PAGE>




                             [Milestone Letterhead]


July 30, 2003

Alan A. Creamer, CEO
Da Vinci Systems, Inc.
9885 Mesa Rim Road
Suite 216
San Diego, CA 92121


Dear Alan:

     This will confirm the agreement under which we will support your
development of a whitening system head (the "Product") and you will grant us
distribution rights to the Product and all pastes, gels or other disposables or
consumables ("Ancillary Products") and to your "Nova Cordless Curing Light" (the
"Curing Light", see Paragraph 3).

     1. We will reimburse you for the development cost of the Product, up to an
aggregate of $25,500, as follows: $7,000 for the conceptual design and prototype
engineering and $18,500 for the development of CAD files, tooling and
proto-typing. You will bear any costs in excess of these amounts. If, at any
time, you cease work on the development project or if development is not
completed within 28 days of approval of Phase 1 (Conceptual Design and
Engineering) or by October 1, 2003,at the latest, then we shall have the option
to assume control of the development project at our expense. If we assume
control of the development project, you shall cooperate fully with us and shall
turn over to us all work previously completed, including the results of any
tests or submissions to focus groups. Any costs we incur, in excess of $25,500,
shall be credited against our obligations to pay for future units of Product,
Ancillary Products and the Curing Light.

     2. We shall be the exclusive worldwide distributor for the Product and
those Ancillary Products, if any, made exclusively for use with the Product. You
shall meet our requirements for Product and such Ancillary Products, including
related packaging, at a price per unit found in the attached Exhibit A. The
prices found in Exhibit A represent the maximum transfer price. Any reductions
from the product cost will be shared equally between Da Vinci and Milestone. All
orders will be filled within 30 days of a Purchase Order accompanied by a 50%
deposit. The remaining balance is to be paid net 30 days, F.O.B. manufacturer.
In connection with our activities as a distributor, you hereby grant us, a
limited, exclusive worldwide license, to use your intellectual property,
including any patents, in connection with the marketing and sale of the Product
and any Ancillary Products made exclusively for use with the Product.

     3. We shall also be a non-exclusive worldwide distributor of (i) Ancillary
Products not made exclusively for use with the Product and (ii) the Curing
Light. The

<PAGE>

Ancillary Products and the Curing Light shall be provided as attached
in Exhibit A, provided that such price shall not be higher than the lowest price
at which such products are provided to other distributors or dealers. The prices
found in Exhibit A represent the maximum transfer price. Any reductions from the
product cost will be shared equally between Da Vinci and Milestone. All orders
shall be filled within 30 days of a Purchase Order accompanied by a 50% deposit.
The remaining balance is to be paid net 30 days, F.O.B. manufacturer.

     4. You will prepare and submit to us, within 15 days after the end of each
calendar quarter, a report setting forth the fully loaded manufacturing costs
for all products sold to us in the previous quarter, broken down by types of
products and a calculation of the prices due and/or collected on such products
for such period (the "Report"). The Report shall be certified by an officer of
Da Vinci to be true and correct. We shall have the right to audit your books and
records, to the extent necessary to determine compliance with this Section and
Sections 2 and 3, during normal business hours and upon reasonable notice. In
the event the audit reveals any discrepancies, the price paid for products shall
be retroactively readjusted to reflect the audit results and if the discrepancy
is more than 15% of your cost, you shall reimburse us for the cost of the audit.

     5. We shall have the right to use our own trademarks or brand names on the
Product and any Ancillary Product and you shall mark each unit and any packaging
utilized in connection therewith with such mark or marks as we direct.

     6. You will, at our reasonable request, provide us with reasonable
quantities of samples of the Product and Ancillary Products for the purpose of
performing quality control procedures and tests. We shall have the right to
inspect, not more than once every quarter, any of your manufacturing facilities
pertaining to the Product or Ancillary Products during regular business hours
and upon reasonable notice.

     7. You represent and warrant that all Product and Ancillary Product units
produced by you shall comply with all federal, state and local laws, ordinances,
rules, regulations and orders and shall be manufactured in accordance with the
FDA's GMP standards and comparable regulations of the European Community. You
further represent and warrant that all Product and Ancillary Product units
produced by you shall be of merchantable quality and free from defects. You
shall keep your manufacturing and packaging records and data for the Products in
accordance with G.M.P standards. We shall have access to such information upon
reasonable notice during business hours and we shall be entitled to make copies
thereof at our cost.

     8. You shall defend and indemnify us and hold us harmless against all
damages, claims, costs and expenses (including reasonable attorneys' fees)
arising out of or resulting from any product liability claims relating to
products produced by you. The obligation for indemnification set forth above
shall be contingent upon giving you timely notice of any claim or loss. You
shall carry and keep in force throughout the term of this Agreement
Comprehensive General Liability Insurance, including Products Liability

<PAGE>

combined single limit in the amount of [$2,000,000], naming us as an additional
insured party:

     9. All data, inventions, discoveries, product designs, know-how, formulae,
studies, reports, documents, publications, software, computer programs, source
codes and the like relating to the Products or Ancillary Products, as well as
concepts and thoughts, shall be your sole and exclusive property.

     10. You shall disclose to us any intellectual property relating to the
Product or Ancillary Products and assist us in applying for, maintaining, or
otherwise securing legal protection for the same. We agree to execute any
papers, documents or letters necessary to vest title in these materials in your
name. You shall take all appropriate action to defend the intellectual property
and any patents issued with respect thereto.

     11. In the event of any dispute between us, we agree that it shall be
resolved through arbitration in New York under the regulations of the American
Arbitration Association, within ninety (90) days following termination of this
Agreement. Any award rendered shall be final and conclusive upon the parties.
This Agreement shall be construed under the laws of the State of New York.

     12. At all times during the term of this Agreement, we shall act as
independent contractor, and neither the making of this Agreement nor the
performance of any of the provisions hereof shall be construed to make us your
agent or legal representative of Da Vinci for any purpose, nor shall this
Agreement be deemed to establish a joint venture or partnership. Neither of us
shall have the power or authority to bind or obligate the other party in any way
by any of its acts.

     13. All notices or other communications required or permitted to be given
hereunder shall be in writing and shall be valid and sufficient if dispatched by
registered mail, postage prepaid, addressed to the address indicated in this
Agreement or to such other address as the addressee shall have theretofore
furnished to the addressor as indicated below


<PAGE>



     14. This agreement represents the entire agreement between the parties and
may not be changed, amended or modified except by a writing signed by both
parties.

                                                 Very truly yours,

                                                 MILESTONE SCIENTIFIC INC.


                                                 by: /s/ Leonard Osser
                                                     -----------------------
                                                          Leonard Osser, CEO
Accepted and agreed to the
30th day of July 2003

DA VINCI SYSTEMS, INC.

By: Alan A. Creamer
    ---------------
    Alan A. Creamer, CEO














</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.30
<SEQUENCE>14
<FILENAME>file013.txt
<DESCRIPTION>AGREEMENT WITH MARK HOCHMAN
<TEXT>
<PAGE>



                            TECHNOLOGY SALE AGREEMENT

         TECHNOLOGY SALE AGREEMENT made as of the 9th day of April, 1998,
between MILESTONE SCIENTIFIC, INC., a Delaware corporation ("Milestone"), and
CLAUDIA HOCHMAN and MARK HOCHMAN (collectively the "Sellers").

         WHEREAS, the Sellers have developed the technology, know-how and other
intellectual property underlying their invention of (i) a "Pressure/Force
Computer Controlled Drug Delivery System", (ii) a "Universal Syringe Holder
Enhancement" consisting a unique Disposable Syringe and a Unique Syringe Holder
and (iii) a Non-deflecting, Non-clogging Single Use Disposable Hypodermic Needle
(collectively the Intellectual Property) for use as a separate drug delivery or
aspiration system or as an adjunct to Milestone's computer controlled anesthesia
system known as "The Wand TM"; and

         WHEREAS, the Sellers desire to sell to Milestone and Milestone desire
to purchase from Sellers all their rights in and to the Intellectual Property on
the terms hereinafter set forth.

         NOW, THEREFORE, in consideration of the sales transaction and the
agreements set forth below, the parties have entered into the following
transaction and agreements:

         1. Sale of Intellectual Rights. Sellers by this instrument do hereby
sell, transfer and assign to Milestone, all of their rights in and to the
Intellectual Property, including any and all inventions, patent applications and
other indicia evidencing or embodying their proprietary rights therein and agree
to turn over and deliver to Milestone all documentation relating to the
Intellectual Property.



<PAGE>


         2. Obtaining Patents. The Sellers agree that they will use their best
efforts in cooperation with, and at the request of, Milestone to obtain United
States and worldwide patent rights to the Intellectual Property and any
improvements thereon or thereto, which together with all patents and patent
applications are collectively referred to as the "Proprietary Rights". The
expense for preparing and filing appropriate patent applications and if
commercially reasonable, obtaining foreign patents in such jurisdiction as
appropriate, shall be borne by Milestone. Sellers shall assign all rights in and
to all patent applications, patents and other Proprietary Rights developed after
the date hereof to Milestone.

         3. Further Documentation. The Sellers shall from time to time at the
request of Milestone execute and deliver to Milestone such further documentation
as requested by Milestone to more effectively transfer and assign the
Proprietary Rights to Milestone and to otherwise give effect to this Agreement.

         4. Issuance of Options. Milestone agrees that if one or more patents
issues with respect to any pending or future patent application relating to the
Proprietary Rights, Milestone will, as soon as practicably thereafter, issue to
Sellers three year options to purchase an aggregate of 25,000 shares of
Milestone Common Stock at an exercise price per share equal to the fair market
value of a share on the date of grant.

         5. Purchase Price. (a) As consideration for the Sellers transfer of the
Property Rights, including their agreements to cooperate with Milestone in
prosecuting patent applications with respect thereto and to transfer and assign
any and all Proprietary Rights, Milestone shall pay

                                       2

<PAGE>

to the Sellers an amount equal to five (5%) percent of a portion of the "Net
Sales", as defined below, of those products sold by Milestone (the "Products")
which embody the Proprietary Rights as follows:

          (A)  if the Proprietary Rights used in the Products include any
               Proprietary Rights that are patented, royalties will be
               calculated on that portion of the Net Sales of all Products which
               use or embody the Proprietary Rights which bears the same
               relationship to total Net Sales of such Products as the cost of
               all patented elements using or embodying the Proprietary Rights
               bear to the total cost of all patented elements of such Products.



                                                 ILLUSTRATION 5A-1
         ASSUMPTIONS:

1.   Some portion of the Proprietary Rights are patented

2.   Net Sales of all Products which use such proprietary rights are $100,000.

3.   Other elements of the Products embody patents not included within the
     Proprietary Rights.

4.   The cost of all patented elements using the Proprietary Rights are $200 per
     unit of Product.

5.   The cost of other patented elements of the Product are $300 per unit

     THEN Royalties shall be calculated as follows:






                                       3
<PAGE>


<TABLE>
<S>              <C>      <C>                                      <C>    <C>
                          Cost of elements embodying
                 x         the Proprietary Rights                          Royalty Rate
                          ------------------------------
   Net Sales                 Cost of elements embodying               x
                               the Proprietary Rights
                                               +
                                 Cost of all patented elements

$100,000         x                    $200                            x        5%
                                    -----------
                                      $200+$300


                                      $40,000 x 5% Royalty Rate = $2,000
</TABLE>


                                ILLUSTRATION 5A-2

ASSUMPTIONS

Same as above except that other elements not covered by patents, e.g. other
patents have expired or Proprietary Rights are used in a "stand alone" Product.

<TABLE>
<S>              <C>      <C>                                      <C>    <C>

                          Cost of elements embodying
                 x         the Proprietary Rights                            Royalty Rate
                          -----------------------------
   Net Sales               Cost of elements embodying                x
                             the Proprietary Rights
                                               +
                                 Cost of all patented elements


$100,000         x                   $ 200                           x           5%
                                    -----------
                                     $ 200


                                     $100,00 x 5% Royalty Rate = $5,000
</TABLE>




               (B)  if the Proprietary Rights used in the Products are not
                    patented, royalties on such Products will be calculated on
                    that portion of the Net Sales of such Products which bears
                    the same relationship to total Net Sales of the Products as
                    any increase in the selling price of such Products
                    instituted after the incorporation of the Proprietary Rights
                    therein bears to the sales price of such Products
                    immediately preceding such incorporation.


                                       4
<PAGE>


                                ILLUSTRATION 5 B

         ASSUMPTIONS:

1.   Net Sales of the Product equal $100,000

2.   Selling price per unit prior to use of Proprietary Rights was $1,000

3.   The selling price per unit after incorporation of the proprietary rights is
     $1,500

4.   X equals portion of Net sales on which royalties will be paid

               THEN Royalties will be calculated as follows:

<TABLE>

<S>                      <C>           <C>                <C>                        <C>       <C>
Portion of
Net Sales on                                                      Increase in                   Sales price
which                     :            Net Sales           =      sales price         :         prior to
Royalties are                                                                                   increase
payable

        X                 :         $100,000               =              $500        :           $1,000

                                               1,000 X = $50,000,000
                                                X = $50,000
                                            $50,000 x 5% Royalty Rate = $2,500
</TABLE>



                    (C)  if Milestone sells all or part of the Proprietary
                         Rights or license others to use all or any portion of
                         such rights in the production by other parties of their
                         products, Sellers shall be entitled to receive
                         royalties calculated as provided in (A) and (B) above
                         except that the consideration received by Milestone
                         from any such sale or license shall be treated as the
                         "Net Sales", and the products produced by third parties
                         shall be treated as if they were Products of Milestone.

         (b) Milestone shall within 45 days after the end of each calendar
quarter pay Sellers the amount of purchase price owing to them for the quarter.
Such payment shall be accompanied by statements showing the basis used in
calculating the royalties for such period. Allocations of costs required under
(A) and (B), determinations under (C) above with respect to


                                       5
<PAGE>

whether and how much non patented proprietary rights contributed to an increase
in the price of the product as well as determinations under (C) which shall be
based on such information as Milestone can obtain from its licensee or
purchaser, shall be determined by Milestone and Milestone's good faith
determinations with respect thereto shall be conclusive and binding on the
parties.

         (c) For purposes of this section 5 Net Sales shall mean gross sales
less returns, discounts and allowances. Purchase price payments for any
quarterly period shall be adjusted in subsequent quarters to take into account
returns and allowances occurring in these later periods. If by reason of (d)
below payments are payable for only a portion of a quarterly period, Sellers
shall be entitled to a payment in the amount they would have received if they
were entitled to royalties for the full quarterly period multiplied by a
fraction in which the numerator shall be the number of days in which they are
entitled to royalties and the denominator shall be 90.

         (d) Payments shall be made hereunder only until the expiration of the
last patent covering any portion of the Proprietary Rights or if no patent
issues until the expiration of 10 years from the date hereof; provided, however
that if no patent has issued and a Milestone Product incorporating the
Proprietary Rights faces substantial competition from other products using
similar technology the payment hereunder shall be appropriately adjusted by
Milestone to eliminate the competitive disadvantage.

         6. Sellers Warranty. Sellers jointly and severally represent and
warrant to Milestone that they have not sold, assigned, transferred or
encumbered the Proprietary Rights or any interest thereon to any third party.


                                       6
<PAGE>

         7. Indemnification. Milestone shall defend, at its own cost and
expense, any infringement suits that may be brought against Sellers or Milestone
on account of the manufacture, production, use or marketing of the Proprietary
Information by Milestone or its licensees. Milestone shall indemnify and save
harmless Sellers against any and all such patent infringement suits and any
claims, costs, expenses and damages which may be incurred by Sellers therein or
in settlement thereof. When information is brought to Milestone's attention
indicating that others are unlawfully infringing on its rights with respect to
the Proprietary Information, Milestone shall take all steps and commence such
legal action which, in the judgment of Milestone, are (a) necessary to protect
Milestone's rights thereto and (b) consistent with Milestone's then business and
financial condition. Seller shall cooperate with Milestone in the prosecution of
any such action or litigation.

         8. Governing Law. This Agreement shall be construed and interpreted
according to the laws of the State of New York.

         9. Severability. In case any provision of this Agreement shall be
invalid, illegal or unenforceable, the validity, legality and enforceability of
the remaining provisions shall not in any way be affected or impaired thereby.

         10. Notice. All notices required or permitted to be delivered pursuant
hereto shall be in writing and shall be deemed to have been given upon personal
delivery or two (2) days after deposit in the United States mail by registered
or certified mail, first class postage prepaid, with return receipt requested,
addressed as follows:




                                       7
<PAGE>


         If to Milestone:
                                    Milestone Scientific, Inc.
                                    220 South Orange Avenue
                                    Livingston, New Jersey 07039
                                    Attn: Leonard Osser

         With a copy to:            Morse, Zelnick, Rose & Lander
                                    450 Park Avenue
                                    New York, NY 10022
                                    Attn: Stephen A. Zelnick

         If to Sellers:             Claudia Hochman, D.D.S
                                    Mark Hochman, D.D.S.
                                    26 Meadow Woods Road
                                    Great Neck, New York 11020

or to such other addresses as may from time to time be designated by the parties
by like notice.

         11. Binding Effect. This Agreement shall be binding upon and inure to
the benefit of each of the parties hereto and their respective successors,
assigns and/or legal representatives.

         12. Headings. The descriptive headings used and inserted in this
Agreement are for convenience only and shall not be deemed to affect the meaning
or construction of any provisions hereof.

         13. Entire Agreement. This Agreement and any documents or agreements
executed by the parties simultaneously herewith constitute the entire
understanding and agreement of the parties hereto with respect to the sale of
the rights described herein and supersede all other prior


                                       8
<PAGE>

agreements or understandings, written or oral, between the parties with respect
thereto. This Agreement may not be amended except by a writing signed by
Milestone and the Sellers.

         IN WITNESS WHEREOF, the parties hereto have executed this Memorandum of
Sale and Agreement as of the day and year first above written.

                                            MILESTONE SCIENTIFIC, INC.
                                            By: /s/ Leonard Osser
                                                -----------------
                                                 Leonard Osser, CEO

                                                 /s/ Claudia Hochman
                                                 -------------------
                                                 Claudia Hochman, D.D.S.

                                                 /s/ Mark Hochman
                                                 ----------------
                                                 Mark Hochman, D.D.S.






                                       9

<PAGE>


                  AMENDMENT TO TECHNOLOGY SALE AGREEMENT

         WHEREAS, MILESTONE SCIENTIFIC, INC., a Delaware corporation
("Milestone"), and CLAUDIA HOCHMAN and MARK HOCHMAN (collectively the "Sellers")
entered into a "Technology Sale Agreement" made as of the 9th of April, 1998,
governing Sellers sale to Milestone of their invention of (i) a "Pressure/Force
Computer Controlled Drug Delivery System", (ii) a "Universal Syringe Holder
Enhancement" consisting a unique Disposable Syringe and a Unique Syringe Holder
and (iii) a Non-deflecting, Non-clogging Single Use Disposable Hypodermic Needle
for use as a separate drug delivery or aspiration system or as an adjunct to
Milestone's computer controlled anesthesia system known as "The Wand TM"; and

         WHEREAS, the Sellers also invented a Self-retracting Needle Hand Piece
and Syringe With Self-retracting Needle (Reg #29,876) for use as a separate drug
delivery or aspiration system or as an adjunct to Milestone's computer
controlled anesthesia system known as "The Wand TM"; and

         WHEREAS, the sellers also invented an Anti-Deflection/ Force
Penetrating Reduction Rotating Needle Handpiece and Syringe devices for use as a
separate drug delivery or aspiration system or as an adjunct to Milestone's
computer controlled anesthesia system known as "The Wand(TM)";

         WHEREAS, subject to the conditions contained in the Technology Sale
Agreement made as of the 9th of April, 1998, Sellers desire to sell and
Milestone desires to purchase the Anti-Deflection/ Force Penetrating Reduction
Rotating Needle Handpiece, Anti-


<PAGE>

Deflection/ Force Penetrating Reduction Rotating Needle Syringe,
Anti-Deflection/ Force Penetrating Reduction Rotating Needle Dental Syringe,
Self-retracting Needle Handpiece and Syringe with and Self-retracting Needle
(Reg #29,876).

         WHEREAS, Sellers and Milestone desire to amend the Technology Sale
Agreement made as of the 9th of April, 1998, so that the sale by Seller to
Milestone of the Anti-Deflection/ Force Penetrating Reduction Rotating Needle
Handpiece, Anti-Deflection/ Force Penetrating Reduction Rotating Needle Syringe,
Anti-Deflection/ Force Penetrating Reduction Rotating Needle Dental Syringe,
Self-retracting Needle Handpiece, Syringe With Self-retracting Needle be
governed by the terms of the Technology Sale Agreement;

         NOW, THEREFORE, for good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, the definition of "Intellectual
Property" under the Technology Sale Agreement made as of the 9th of April, 1998,
is hereby amended to include the Anti-Deflection/ Force Penetrating Reduction
Rotating Needle Handpiece Device, Anti-Deflection/ Force Penetrating Reduction
Rotating Needle Syringe, Anti-Deflection/ Force Penetrating Reduction Rotating
Needle Dental Syringe, Self-Retracting Needle Handpiece and Syringe With
Self-retracting Needle in addition to (i) a "Pressure/Force Computer Controlled
Drug Delivery System", (ii) a "Universal Syringe Holder Enhancement" consisting
a unique Disposable Syringe and a Unique Syringe Holder and (iii) a
Non-deflecting, Non-clogging Single Use Disposable Hypodermic Needle.

         IN WITNESS WHEREOF, the parties hereto have executed this Amendment to
Technology Sale Agreement as of the day and year first above written.


<PAGE>

                                            MILESTONE SCIENTIFIC, INC.

         By: /s/ Leonard Osser                       12/16/99
             --- -------------                       --------
               Leonard Osser, CEO                    Date


         /s/ Claudia Hochman                         12/16/99
                                                     --------
         Claudia Hochman, D.D.S.                     Date


         /s/ Mark Hochman                            12/16/99
                                                     --------
         Mark Hochman, D.D.S.                        Date





<PAGE>


                               SECOND AMENDMENT TO
                            TECHNOLOGY SALE AGREEMENT


         THIS SECOND AMENDMENT, is dated this 28th day of November 2001 (the
"Second Amendment") by and between MILESTONE SCIENTIFIC INC., a Delaware
corporation, ("Milestone") and CLAUDIA HOCHMAN and MARK HOCHMAN (collectively
the "Sellers").

         WHEREAS, Milestone and Sellers entered into a "Technology Sale
Agreement" dated the 9th of April, 1998 (the "Agreement"), governing Sellers'
sale to Milestone of their invention of (i) a "Pressure/Force Computer
Controlled Drug Delivery System", (ii) a "Universal Syringe Holder Enhancement"
consisting a unique Disposable Syringe and a Unique Syringe Holder, and (iii) a
Non-deflecting, Non-clogging Single Use Disposable Hypodermic Needle for use as
a separate drug delivery or aspiration system or as an adjunct to Milestone's
computer controlled anesthesia system known as "The Wand TM"; and

         WHEREAS, in June 1999, Milestone and Sellers entered an "Amendment to
the Technology Sale Agreement" (the "First Amendment") that amended the
Agreement to include in the definition of "Intellectual Property" under the
Agreement a Self-Retracting Needle Hand Piece and Syringe with Self-Retracting
Needle (Reg. # 29,876) for use as a separate drug delivery or aspiration system
or as an adjunct to Milestone's computer controlled anesthesia system known as
"The Wand TM"; and

         WHEREAS, the Sellers also have invented a Local Anesthetic and Delivery
Injection Unit with Automated Rate Control; and

<PAGE>

         WHEREAS, subject to the conditions contained in the Technology Sale
Agreement, Sellers desire to sell and Milestone desires to purchase the Local
Anesthetic and Delivery Injection Unit with Automated Rate Control; and

         WHEREAS, Sellers and Milestone desire to amend further the Technology
Sale Agreement so that the sale by Seller to Milestone of the Local Anesthetic
and Delivery Injection Unit with Automated Rate Control be governed by its
terms;

         NOW, THEREFORE, for good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the definition of "Intellectual
Property" in the Agreement, as amended by the First Amendment, is hereby amended
further to include the Local Anesthetic and Delivery Injection Unit with
Automated Rate Control in addition to (i) a "Pressure/Force Computer Controlled
Drug Delivery System", (ii) a "Universal Syringe Holder Enhancement" consisting
a unique Disposable Syringe and a Unique Syringe Holder, (iii) a Non-deflecting,
Non-clogging Single Use Disposable Hypodermic Needle, and (iv) a Self-Retracting
Needle Hand Piece and Syringe with Self-Retracting Needle (Reg. # 29,876) for
use as a separate drug delivery or aspiration system or as an adjunct to
Milestone's computer controlled anesthesia system known as "The Wand TM".







                                       2
<PAGE>


         IN WITNESS WHEREOF, the parties hereto have executed this Second
Amendment as of the day and year first above written.

                                            MILESTONE SCIENTIFIC, INC.

                                            By: /s/ Leonard Osser
                                                -----------------
                                                     Leonard Osser, CEO


                                                /s/ Claudia Hochman
                                                --- ---------------
                                                    Claudia Hochman, D.D.S.


                                                /s/ Mark Hochman
                                                ----------------
                                                    Mark Hochman, D.D.S.











                                       3
<PAGE>




                  THIRD AMENDMENT TO TECHNOLOGY SALE AGREEMENT

         THIRD AMENDMENT TO TECHNOLOGY SALE AGREEMENT, dated October 10, 2002,
between MILESTONE SCIENTIFIC INC., a Delaware corporation ("Milestone") and
CLAUDIA HOCHMAN and MARK HOCHMAN (collectively the "Sellers").

                                   WITNESSETH

         WHEREAS, Milestone and Sellers entered into a Technology Sale Agreement
dated April 9, 1998, as amended on December 16, 1999 and November 28, 2001,
governing Sellers' sale to Milestone of their inventions, of (i) a
"Pressure/Force Computer Controlled Drug Delivery System", (ii) a "Universal
Syringe Holder Enhancement" consisting of a unique Disposable Syringe and a
Unique Syringe Holder, (iii) a Non-deflecting, Non-clogging Single Use
Disposable Hypodermic Needle for use as a separate drug delivery or aspiration
system or as an adjunct to Milestone's computer controlled anesthesia system
known as "The CompuMed/Wand(TM)", (iv) a Hand-piece For Injection Device With A
Retractable And Rotating Needle (U.S. Patent No. 6,428,517 B1), Anti-Deflection
/ Force Reduction Rotating Needle Handpiece device, Anti-Deflection/Force
Reduction Rotating Syringe (Reg No. 29,876), for use as separate drug delivery
or aspiration system or as an adjunct to Milestone's computer controlled
anesthesia system known as "The CompuMed/Wand(TM)", and (v) a Local Anesthetic
and Delivery Injection Unit with Automated Rate Control;

         WHEREAS, the Sellers have now invented a Safety IV Catheter Infusion
Device (U.S. Utility Patent App. Serial No. 10/174,246) ("IV Catheter") for use
as a

<PAGE>

separate drug delivery catheter device or as an adjunct to Milestone's existing
technologies;

         WHEREAS, subject to the conditions contained in the Technology Sale
Agreement, Sellers desire to sell and Milestone desires to purchase the IV
Catheter ; and

         WHEREAS, Sellers and Milestone desire to further amend the Technology
Sale Agreement to allow for the sale of the IV Catheter to be governed by the
terms of the Technology Sale Agreement and to effect such additional terms and
provisions that the parties deem necessary all as are set forth below.

         NOW, THEREFORE, for good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, the Technology Sale Agreement as
previously amended is hereby further amended as follows:

         1. The definition of "Intellectual Property" shall include new
subpoints (vi) and (vii) set forth below:

          "(vi) the Safety IV Catheter Infusion Device (U.S. Utility Patent
          Application Serial No. 10/174,246); and (vii) any and all other patent
          submissions, past, present and future, that bear the name of one or
          both of the Sellers, including all divisional patents, primary patents
          and secondary patents."

         2. Section 4 shall be amended to read as follows:

          "4. Issuance of Options. Milestone agrees that for each future patent
          issued, relating to the Proprietary Rights, Milestone will, as soon as
          practicable thereafter, issue to Sellers, five year options to
          purchase an aggregate of 25,000 shares of Milestone Common Stock at an
          exercise price per share equal to the fair market value of a share on
          the date of grant."

                                       2

<PAGE>




         3. Section 11 shall be amended to read as follows:

          "11. Binding Effect. This Technology Sale Agreement shall be binding
          upon and inure to the benefit of each of the parties hereto and their
          respective successors, assigns and/or legal representatives. In the
          event that the obligations under this Technology Sale Agreement, do
          not, for any reason, automatically survive a sale or transfer of all
          or a significant part of Milestone's business or assets to a third
          party (the "Transferee"), Milestone shall cause the Transferee to
          assume all of Milestone's obligations under this Technology Sale
          Agreement, as amended from time to time. If the undertaking of these
          obligations, whether by way of automatic survival or by way of
          assumption, in their entirety or in part, is impossible, impracticable
          or of significantly different economic impact on Sellers, Milestone
          shall use its best efforts to cause the Transferee to provide the
          Sellers with alternatives that are essentially equivalent in value to
          the existing obligations of Milestone under this Technology Sale
          Agreement, as amended."

         IN WITNESS WHEREOF, the parties hereto have executed this Third
Amendment to the Technology Sale Agreement as of the day and year first above
written;


MILESTONE SCIENTIFIC, INC.


By: /s/ Leonard Osser
    -----------------
    Leonard Osser, CEO





By: /s/ Mark N. Hochman
    -------------------
    Mark N. Hochman, DDS



By: /s/ Claudia B. Hochman
    ----------------------
      Claudia B. Hochman, DDS



                                       3

<PAGE>




                  FOURTH AMENDMENT TO TECHNOLOGY SALE AGREEMENT

FOURTH AMENDMENT TO TECHNOLOGY SALE AGREEMENT, dated as of December 19, 2003,
between MILESTONE SCIENTIFIC, INC., a Delaware corporation ("Milestone") and
MARK HOCHMAN and CLAUDIA HOCHMAN (collectively the "Sellers").


                                   WITNESSETH

WHEREAS, Milestone and Sellers entered into a Technology Sale Agreement dated
April 9, 1998, as amended on December 16, 1999, November 28, 2001 and October
10, 2002, governing Sellers' sale to Milestone of their inventions, of (i) a
"Pressure/Force Computer Controlled Drug Delivery System", (ii) a "Universal
syringe Holder Enhancement" (iii) a non-deflecting, non-clogging single use
disposable hypodermic needle, (iv) a Handpiece for Injection Device with a
retractable rotating needle (US Patent No. 6,428,517 B1), Anti-deflection/force
penetration reduction rotating syringe (US Patent No. 6,428,517), for use as a
separate drug delivery or aspiration system or as an adjunct to Milestone's
computer controlled anesthesia system known as "The CompuDent/CompuMed/Wand(TM),
(v) a Local Anesthetic and Delivery Injection Unit with Automated Rate Control
(US Patent No. 6,652,482 B2), and (vi) Safety IV Catheter Infusion Device (US
Utility Patent App 10/174,246).


NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged, the Technology Sale Agreement as previously
amended is hereby further amended as follows:

1.   Section 5 shall be amended to include the following language at the end of
     subsection 5(a):

     "Notwithstanding the general consideration structure set forth above, the
     following shall exclusively govern the consideration payable to Sellers
     with regard to U.S. Patents No. 6,652,482 B2, 6,428,517 and 6,200,289 B2:

     (i) As consideration for US Patent No. 6,652,482 B2 embodying defined newly
     essential elements to the technology, defining additional elements of the
     system, and providing longevity for inclusive and comprehensive patent
     coverage to previous and current Products including The Wand w/ Cruise,
     WandPlus(TM), CompuDent(TM) and CompuMed(TM):

     A.   Milestone shall pay to Sellers an amount equal to 0.025 (2.5%) of the
          Net Sales of those products, previously and currently sold by
          Milestone, which embody the Proprietary Rights of US Patent No.
          6,652,482 B2. The products that have embodied this technology,
          previously and currently, are The Wand w/ Cruise, WandPlus(TM),
          CompuDent(TM), CompuMed. Payments shall be made hereunder only until
          the expiration of the US Patent No. 6,652,482 B2.

                                  Page 1 of 3

<PAGE>

     B.   The sellers, in good faith, hereby voluntarily agree to defer all
          payments due to them for past and future sales of products embodying
          the technology underlying US Patent No. 6,652,482 B2 until the earlier
          of January 15, 2004 or such time that Milestone achieves positive net
          income, as will be reflected in its quarterly or annual financial
          statements. Milestone agrees not to delay payments further without
          obtaining written consent from Sellers.


ASSUMPTIONS AND EXAMPLES:

     1.   Proprietary Rights are patented, US Patent No. 6,652,482 B2.

     2.   The Product which embodies technology underlying such Proprietary
          Rights is sold for $660.00 per unit.

     3.   Number of units sold is 10 units.

     4.   There were no discounts, returns or allowances.

     5.   Net Sales of all Products which use such Proprietary rights are
          $6600.00

THEN Royalties shall be calculated as follows:


                  Price per Unit      x    No. of Units   x   Royalty Rate

                  $660.00             x         10        x      0.025

                         $6,600.00    x    0.025  Royalty Rate  =  $165.00

- - or -

                  Net Sales    x    Royalty Rate  =  Royalty

                  $6,600       x        2.5%      =  $165.00



     (ii) As consideration for U.S. Patent No. 6,428,517 "Hand-Piece For
     Injection Device With A Retractable And Rotating Needle" and U.S. Patent
     No. 6,200,289 B2 "Pressure/Force Computer Controlled Drug Delivery System",
     Milestone shall pay to the Sellers an amount equal to 0.05 (5%) of the Net
     Sales of those products sold by Milestone, which embody the Proprietary
     Rights underlying in the above-mentioned patents, except that for products
     using the technology covered by Patent No. 6428,517 royalties shall be paid
     only on those products produced from a six cavity or greater mold. The
     products that have embodied these Proprietary Rights are the
     SafetyWand(TM), The Wand-PDL Drive Unit device and the CompuFlo(TM).


                                  Page 2 of 3

<PAGE>



ASSUMPTIONS AND EXAMPLES:

     1.   Proprietary Rights are patented under US Patent No. 6,428,517 or U.S.
          Patent No. 6,200,289 B2.

     2.   The Product which embodies technology underlying such Proprietary
          Rights is sold for $2.00 per unit.

     3.   Number of Units Sold are 10 units.

     4.   There were no discounts, returns or allowances.

     5.   Net Sales of all Products which embody such Proprietary rights are
          $20.00

THEN Royalties shall be calculated as follows:

                  Price per Unit      x    No. of Units   x   Royalty Rate

                  $2.00               x         100       x       0.05

                          $200.00     x    0.5  Royalty Rate  =  $10.00

- - or -

                  Net Sales    x   Royalty Rate  =  Royalty

                  $200.00      x        5%       =   $10.00"




IN WITNESS WHEREOF, the parties hereto have executed this Fourth Amendment to
the Technology Sale Agreement as of the day and year first above written.


MILESTONE SCIENTIFIC, INC.


By: /s/ Leonard Osser
    -----------------
    Leonard Osser, CEO


SELLERS:

By: /s/ Mark Hochman
    ----------------
    Mark Hochman, DDS

By: /s/ Claudia Hochman
    -------------------
    Claudia Hochman, DDS



                                  Page 3 of 3






</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>15
<FILENAME>file014.txt
<DESCRIPTION>AGREEMENT WITH STRIDER
<TEXT>
<PAGE>






                             [Milestone Letterhead]


September 3, 2003

Strider
106 Hart Road
Gaithersburg, MD 20878


Attn: Richard Brown


Dear Richard:

     This will confirm our agreement to pay you commissions for any future sales
made by us of products purchased from Da Vinci Systems ("Da Vinci") including
the "Nova Cordless Curing Light" (the "Products").

     1. In consideration for your assistance in reaching a distribution
agreement between Da Vinci and us, we hereby agree to pay you the following
commissions:

          1.1  We will pay 2% of net sales (less returns, discounts and
               allowances) on all Products purchased from Da Vinci and resold by
               us directly, or indirectly to dentists, hygienists or other
               health care professionals providing dental services
               ("Professional Dental Market"), including sales through
               distributors, agents or wholesale suppliers.

          1.2  We will pay 5% of net sales (less returns, discounts and
               allowances) on all Products purchased from Da Vinci and resold by
               us directly, or indirectly for use in any other market other than
               the Professional Dental Market, including sales through
               distributors, agents or wholesale suppliers.

     2. In consideration for your assistance in financing the final development
of the whitening head product with Da Vinci and us, we hereby agree to pay you
the following:

          2.1  We will pay an additional 2% of net sales on Products purchased
               from Da Vinci and resold by us directly, or indirectly to
               dentists, hygienists or other health care professionals providing
               dental services and 5% of net sales on all Products purchased
               from Da Vinci and resold by us directly, or indirectly for use in
               any other market other than the Professional Dental Market until
               such time as a total amount of $25,500 is attained.


<PAGE>

     Payments will be made within 30 days following the end of each calendar
quarter, with respect to all revenues collected by us from Product sales during
the previous calendar quarter.

     3. The term of this agreement shall be for seven years beginning on the
date hereof.

     4. All notices or other communications given with respect to this agreement
shall be in writing and shall be valid and sufficient if dispatched by
registered mail, postage prepaid, addressed to the address indicated in this
Agreement or to such other address as the addressee shall have theretofore
furnished to the addressor as indicated below.

     5. This agreement represents the entire agreement between the parties and
may not be changed, amended or modified except by a writing signed by both
parties.

     6. In the event of any dispute between us, we agree that it shall be
resolved through arbitration in New York under the regulations of the American
Arbitration Association, within ninety (90) days following termination of this
agreement. Any award rendered shall be final and conclusive upon the parties.
This agreement shall be construed under the laws of the State of New York.



                                                Very truly yours,

                                                MILESTONE SCIENTIFIC INC.


                                                by: Leonard Osser
                                                    -------------
                                                    Leonard Osser, CEO


Accepted and agreed to the
8th day of September 2003


Strider

by: /s/ Richard Brown
    -----------------
         Richard Brown








</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>16
<FILENAME>file015.txt
<DESCRIPTION>AGREEMENT WITH LEN OSSR AND K. TUCKER ANDERSEN
<TEXT>
<PAGE>



         AGREEMENT, dated as of October 9, 2003 among Milestone Scientific Inc.
(the "Company"), a Delaware corporation with its principal place of business at
Livingston Corporate Park, 220 South Orange Avenue, Livingston, New Jersey, on
the one hand and Leonard Osser ("Osser"), an individual having an address at 101
John Dietz Road, Callicoon Center, New York 12724 and K. Tucker Andersen
("Andersen" and together with Osser, the "Creditors"), an individual with an
address at c/o Cumberland Partners, 1114 Avenue of the Americas, New York, New
York 10036.

                              W I T N E S S E T H:

         WHEREAS, Osser is the chief executive officer as well as a principal
shareholder of the Company; and

         WHEREAS, Schedule A-1 annexed hereto sets forth in detail the amounts
owed by the Company to Osser as deferred compensation and for money borrowed
(the "Osser Indebtedness"); and

         WHEREAS, Andersen is a principal shareholder of the Company; and

         WHEREAS, Schedule A-2 annexed hereto sets forth in detail the amounts
owed by the Company to Andersen for money borrowed (the "Andersen
Indebtedness"): and

         WHEREAS, the Company has entered into a Letter of Intent, dated
September 23, 2003, with Paulson Investment Company, Inc. ("Paulson"), pursuant
to which Paulson has agreed to act as underwriter in connection with a
registered public offering to be undertaken by the Company (the "Public
Offering"); and

         WHEREAS, the Company has reached an agreement in principal with certain
investors (the "Investors") who will lend $400,000 to the Company before it
files a registration statement with the United States Securities and Exchange
Commission (the "SEC") covering the securities to be sold in the Public
Offering.

         NOW, THEREFORE, in consideration of the premises set forth above and
the agreements, covenants, representations and warranties set forth below and
for other good and valuable consideration, the sufficiency of which is hereby
acknowledge, the parties hereto hereby agree as follows:

         1. Satisfaction of Debt.

          (a) On the Satisfaction Date (as defined below), the Company shall
transfer to Andersen the following:

               (i) cash in an amount equal to 40% of the accrued interest
(through the Satisfaction Date) on the Andersen Indebtedness; and

               (ii) securities (as more particularly described below in
paragraph (c) of this Section 1) of the Company having a value equal to the
equal to the sum of (x) the principal

<PAGE>

amount of the Andersen Indebtedness and (y) 60% of the accrued interest (through
the Satisfaction Date) on the Andersen Indebtedness.

          (b) On the Satisfaction Date, the Company shall transfer to Osser the
following:

               (i) cash in an amount equal to 40% of the sum of the (x) deferred
compensation portion of the Osser Indebtedness (as set forth on Schedule A-1)
and (y) accrued interest (through the Satisfaction Date) on the Osser
Indebtedness; and

               (ii) securities (as more particularly described below in
paragraph (c) of this Section 1) of the Company having a value equal to the
equal to the sum of (x) the principal amount of the Osser Indebtedness and (y)
60% of the accrued interest (through the Satisfaction Date) on the Osser
Indebtedness and (z) 60% of the deferred compensation portion of the Osser
Indebtedness.

          (c) The securities of the Company to be issued to Andersen and Osser
pursuant to paragraphs (a)(ii) and (b)(ii), respectively, of this Section 1
shall be identical in all material respects to the securities sold by the
Company in the Public Offering. For purposes of calculating the value of such
securities, they shall be deemed to have a value equal to the public offering
price as set forth in the final prospectus, filed under Rule 424(b) promulgated
by the SEC under the Securities Act of 1933, as amended (the "Act") in
connection with the Public Offering (the "Final Prospectus").

          (d) The Satisfaction Date shall be the date that is the later of (i)
the effective date of the Public Offering (i.e., the date of the Final
Prospectus) and (ii) January 2, 2004.

         2. REPRESENTATIONS AND WARRANTIES OF THE CREDITORS. Each Creditor,
solely for himself and not with respect to the other Creditor, represents and
warrants to the Company that:

          (a) INVESTMENT PURPOSE. He is acquiring the securities described in
Section 1 hereof and any and all other securities of the Company underlying or
covered by such securities and any securities issuable upon exercise of any
rights to purchase or to convert such securities or any securities underlying
such securities (collectively, the "Securities") for his own account and not
with a present view towards the public sale or distribution thereof, except
pursuant to sales registered or exempted from registration under the Act;
provided, however, that by making the representations herein, subject to any
agreement to the contrary contemplated hereby, he does not agree to hold any of
the Securities for any minimum or other specific term and reserves the right to
dispose of the Securities at any time in accordance with or pursuant to a
registration statement or an exemption under the Act.

          (b) ACCREDITED INVESTOR STATUS. He is an "accredited investor" as that
term is defined in Rule 501(a) of Regulation D (an "Accredited Investor").

          (c) RELIANCE ON EXEMPTIONS. He understands that the Securities are
being issued to him in reliance upon specific exemptions from the registration
requirements of United States federal and state securities laws and that the
Company is relying upon the truth and

                                       2
<PAGE>

accuracy of, and his compliance with, the representations, warranties,
agreements, acknowledgments and understandings set forth herein in order to
determine the availability of such exemptions and his eligibility to acquire the
Securities.

          (d) INFORMATION. He, or his advisors, if any, has been furnished with
all materials relating to the business, finances and operations of the Company
and materials relating to the offer and sale of the Securities that he has or
they have requested. He, or his advisors, if any, has been afforded the
opportunity to ask questions of the Company. Neither such inquiries nor any
other due diligence investigation conducted by him or any of his advisors shall
modify, amend or affect his right to rely on the Company's representations and
warranties contained in Section 3 below. He understands that his investment in
the Securities involves a significant degree of risk.

          (e) GOVERNMENTAL REVIEW. He understands that no United States federal
or state agency or any other government or governmental agency has passed upon
or made any recommendation or endorsement of the Securities.

          (f) TRANSFER OR RE-SALE. He understands that (i) except as set forth
in Section 4(b) below, the sale or re-sale of the Securities has not been is not
and will not being registered under the Act or any applicable state securities
laws, and the Securities may not be transferred unless (a) the Securities are
sold pursuant to an effective registration statement under the Act, (b) he has
delivered to the Company an opinion of counsel (which opinion shall be in form,
substance and scope customary for opinions of counsel in comparable
transactions) to the effect that the Securities to be sold or transferred may be
sold or transferred pursuant to an exemption from such registration, (c) the
Securities are sold or transferred to an "affiliate" (as defined in Rule 144
promulgated under the Act (or a successor rule) ("Rule 144")) who agrees to sell
or otherwise transfer the Securities only in accordance with this Section 2(f)
and who is an Accredited Investor, or (d) the Securities are sold pursuant to
Rule 144; (ii) any sale of Securities made in reliance on Rule 144 may be made
only in accordance with the terms of said Rule and further, if said Rule is not
applicable, any re-sale of such Securities under circumstances in which the
seller (or the person through whom the sale is made) may be deemed to be an
underwriter (as that term is defined in the Act) may require compliance with
some other exemption under the Act or the rules and regulations of the SEC
thereunder; and (iii) other than as set forth in Section 4(b) below), neither
the Company nor any other person is under any obligation to register such
Securities under the Act or any state securities laws or to comply with the
terms and conditions of any exemption thereunder.

          (g) LEGENDS. He understands that, until such time as the Securities
have been registered under the Act or otherwise may be sold pursuant to Rule 144
without any restriction as to the number of securities as of a particular date
that can then be immediately sold, the certificates evidencing the Securities
shall bear a restrictive legend in substantially the following form (and a
stop-transfer order may be placed against transfer of the certificates for such
Securities):

          "The securities represented by this certificate have not been
          registered under the Securities Act of 1933, as amended. The
          securities may not be sold, transferred or assigned in the absence of

                                       3
<PAGE>

          an effective registration statement for the securities under said Act,
          or an opinion of counsel, in form, substance and scope customary for
          opinions of counsel in comparable transactions, that registration is
          not required under said Act or unless sold pursuant to Rule 144 under
          said Act."

         The legend set forth above shall be removed and the Company shall
issue a certificate without such legend to the holder of any Security upon which
it is stamped, if, unless otherwise required by applicable state securities
laws, (a) such Security is registered for sale under an effective registration
statement filed under the Act or otherwise may be sold pursuant to Rule 144
without any restriction as to the number of securities as of a particular date
that can then be immediately sold, or (b) such holder provides the Company with
an opinion of counsel, in form, substance and scope customary for opinions of
counsel in comparable transactions, to the effect that a public sale or transfer
of such Security may be made without registration under the Act, including
pursuant to the provisions of Rule 144 and such sale or transfer is effected.
The Creditor agrees to sell all Securities, including those represented by a
certificate(s) from which the legend has been removed, in compliance with
applicable prospectus delivery requirements, if any. This paragraph (g) shall
apply separately with respect to each security included in the definition of
Securities.

          (h) AUTHORIZATION; ENFORCEMENT. This Agreement has been duly executed
and delivered by or on behalf of the Creditor, and constitutes, and upon
execution and delivery by the Creditor will constitute, a valid and binding
agreement of the Creditor enforceable in accordance with its terms.

          (i) RESIDENCY. He is a resident of New York State.

          3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company
represents and warrants to the Creditors that:

          (a) ORGANIZATION AND QUALIFICATION. The Company and each of its
Subsidiaries (as defined below), if any, is a corporation duly organized,
validly existing and in good standing under the laws of the jurisdiction in
which it is incorporated, with full power and authority (corporate and other) to
own, lease, use and operate its properties and to carry on its business as and
where now owned, leased, used, operated and conducted. The Company and each of
its Subsidiaries is duly qualified as a foreign corporation to do business and
is in good standing in every jurisdiction in which its ownership or use of
property or the nature of the business conducted by it makes such qualification
necessary except where the failure to be so qualified or in good standing would
not have a Material Adverse Effect. "Material Adverse Effect" means any material
adverse effect on the business, operations, assets, financial condition or
prospects of the Company or its Subsidiaries, if any, taken as a whole, or on
the transactions contemplated hereby or by the agreements or instruments to be
entered into in connection herewith. "Subsidiaries" means any corporation or
other organization, whether incorporated or unincorporated, in which the Company
owns, directly or indirectly, any equity or other ownership interest.

                                       4
<PAGE>

          (b) AUTHORIZATION; ENFORCEMENT. (i) The Company has all requisite
corporate power and authority to enter into and perform and to consummate the
transactions contemplated hereby and to issue the Securities, in accordance with
the terms hereof, (ii) the execution and delivery of this Agreement by the
Company and the consummation by it of the transactions contemplated hereby
(including without limitation, the issuance of the Securities) have been duly
authorized by the Company's board of directors (the "Board") and no further
consent or authorization of the Company, the Board, or its stockholders is
required, (iii) this Agreement has been duly executed and delivered by the
Company, and (iv) this Agreement constitutes, and upon its execution and
delivery by the Company, will constitute a legal, valid and binding obligation
of the Company enforceable against the Company in accordance with its terms.

          (c) ISSUANCE OF SHARES. Any shares of the Company's common stock, par
value $ .001 per share (the "Common Stock") issuable upon the exercise of any
rights set forth in any of the Securities are (or shall be as of the
Satisfaction Date) duly authorized and reserved for issuance and, upon issuance
in accordance with the terms of the Securities to which they relate will be
validly issued, fully paid and non-assessable, and free from all taxes, liens,
claims and encumbrances with respect to the issue thereof and shall not be
subject to preemptive rights or other similar rights of stockholders of the
Company and will not impose personal liability upon the holder thereof.

          (d) NO CONFLICTS. The execution, delivery and performance of this
Agreement by the Company and the consummation by the Company of the transactions
contemplated hereby will not (i) conflict with or result in a violation of any
provision of the Certificate of Incorporation or Bylaws of the Company or (ii)
violate or conflict with, or result in a breach of any provision of, or
constitute a default (or an event which with notice or lapse of time or both
could become a default) under, or give to others any rights of termination,
amendment, acceleration or cancellation of, any agreement, indenture, patent,
patent license or instrument to which the Company or any of its Subsidiaries is
a party, or (iii) result in a violation of any law, rule, regulation, order,
judgment or decree (including federal and state securities laws and regulations
and regulations of any self-regulatory organizations to which the Company or its
securities are subject) applicable to the Company or any of its Subsidiaries or
by which any property or asset of the Company or any of its Subsidiaries is
bound or affected (except for such conflicts, defaults, terminations,
amendments, accelerations, cancellations and violations as would not,
individually or in the aggregate, have a Material Adverse Effect). Neither the
Company nor any of its Subsidiaries is in violation of its Certificate of
Incorporation, Bylaws or other organizational documents and neither the Company
nor any of its Subsidiaries is in default (and no event has occurred which with
notice or lapse of time or both could put the Company or any of its Subsidiaries
in default) under, and neither the Company nor any of its Subsidiaries has taken
any action or failed to take any action that would give to others any rights of
termination, amendment, acceleration or cancellation of, any agreement,
indenture or instrument to which the Company or any of its Subsidiaries is a
party or by which any property or assets of the Company or any of its
Subsidiaries is bound or affected, except for possible defaults as would not,
individually or in the aggregate, have a Material Adverse Effect. The businesses
of the Company and its Subsidiaries, if any, are not being conducted, and shall
not be conducted so long as the Creditors owns any of the Securities, in
violation of any law, ordinance or regulation of any governmental entity where
such violation would have a Material Adverse Effect. Except


                                       5
<PAGE>

as specifically contemplated by this Agreement and as required under the Act and
any applicable state securities laws, the Company is not required to obtain any
consent, authorization or order of, or make any filing or registration with, any
court, governmental agency, regulatory agency, self regulatory organization or
stock market or any third party in order for it to execute, deliver or perform
any of its obligations under this Agreement. Except as disclosed in Schedule
3(f), all consents, authorizations, orders, filings and registrations which the
Company is required to obtain pursuant to the preceding sentence have been
obtained or effected on or prior to the date hereof. The Company is not in
violation of the listing requirements of the American Stock Exchange.

          (e) ACKNOWLEDGMENT REGARDING SECURITIES. The Company acknowledges and
agrees that each Creditor is acting solely in the capacity of an arm's length
purchaser with respect to this Agreement and the transactions contemplated
hereby. The Company further acknowledges that neither Creditor is acting as a
financial advisor or fiduciary of the Company (or in any similar capacity) with
respect to this Agreement and the transactions contemplated hereby and any
statement made by a Creditor or any of its respective representatives or agents
in connection with this Agreement and the transactions contemplated hereby is
not advice or a recommendation and is merely incidental to his acquisition of
the Securities. The Company further represents to the Creditors that its
decision to enter into this Agreement has been based solely on the independent
evaluation by the Company and its representatives.

         4. COVENANTS.

          (a) FORM D; BLUE SKY LAWS. The Company agrees to file a Form D with
respect to the Securities as required under Regulation D and to provide a copy
thereof to the Creditors promptly after such filing. The Company shall, on or
before the Satisfaction Date, take such action as the Company shall reasonably
determine is necessary to qualify the Securities for sale to the Creditors
pursuant to this Agreement under applicable securities or "blue sky" laws of the
states of the United States (or to obtain an exemption from such qualification),
and shall provide evidence of any such action so taken to the Creditor on or
prior to the Satisfaction Date.

          (b) REGISTRATION RIGHTS. The Company will use its commercially
reasonable best efforts to file with the SEC a registration statement covering
the resale of the Common Stock included in the Securities within 30 days of the
effective date (as described in Section 1(d)) of the Public Offering and to
cause such registration statement to be effective as promptly as possible
thereafter. The Creditors hereby covenant and agree to provide the Company with
such information as the Company shall need about the Creditors and their
proposed plan of distribution in order to file such resale registration
statement.

          (c) RESERVATION OF SHARES. The Company shall at all times have
authorized, and reserved for the purpose of issuance, a sufficient number of
shares of Common Stock to provide for the full conversion or exercise of the
outstanding Securities. The Company will promptly take all corporate action
necessary to authorize and reserve a sufficient number of shares, including,
without limitation, calling a special meeting of stockholders to authorize
additional shares to meet the Company's obligations under this Section 4(c), in
the case of an insufficient number of authorized shares, and using its best
efforts to obtain stockholder approval of an increase in such authorized number
of shares.


                                       6
<PAGE>

          (d) LOCK-UP AGREEMENT. Each Creditor agrees that he will execute a
lock-up agreement with Paulson (the "Paulson Lock-Up Agreement") for a period
not to exceed one hundred and eighty (180) days from the effective date (as
described in Section 1(d)) of the Public Offering; provided, however, in no
event shall the Paulson Lock-Up Agreement be more restrictive than that offered
to any of the Company's officers, directors or holders of five percent (5%) or
more of the outstanding shares of the Company's Common Stock. In addition, if
Paulson consents to any less restrictive modification or waiver of the terms of
any such agreement with one or more of the Company's officers, directors or
holders of five percent (5%) or more of the outstanding shares of the Company's
Common Stock, then the Paulson Lock-Up Agreement shall be similarly modified or
waived.

          (e) INTERCREDITOR AGREEMENT. Each Creditor agrees that, upon request,
he shall execute and deliver an agreement with the Investors, pursuant to which
the Creditors shall agree that (a) notwithstanding the order in which any UCC
financing statements would have filed, the lien to be given to the Investors to
secure their loan to the Company shall be senior and superior to the lien
granted to the Creditors to secure their respective indebtedness, (b) so long as
the loan from the Investors remains outstanding, the Creditors will not accept
any payments from the Company with respect to the Osser Indebtedness or the
Andersen Indebtedness, (c) the Creditors will not commence any action to collect
their debt or enforce their security interest until the Investors have been in
full and (d) such other terms and conditions as may be customary in agreements
of this type among creditors.

         5. GOVERNING LAW; MISCELLANEOUS.

          (a) GOVERNING LAW. THIS AGREEMENT SHALL BE ENFORCED, GOVERNED BY AND
CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO
AGREEMENTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE, WITHOUT REGARD
TO THE PRINCIPLES OF CONFLICT OF LAWS. THE PARTIES HERETO HEREBY SUBMIT TO THE
EXCLUSIVE JURISDICTION OF THE UNITED STATES FEDERAL COURTS LOCATED IN NEW YORK,
NEW YORK WITH RESPECT TO ANY DISPUTE ARISING UNDER THIS AGREEMENT, THE
AGREEMENTS ENTERED INTO IN CONNECTION HEREWITH OR THE TRANSACTIONS CONTEMPLATED
HEREBY OR THEREBY. THE PARTIES HERETO IRREVOCABLY WAIVE THE DEFENSE OF AN
INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH SUIT OR PROCEEDING. THEY FURTHER
AGREE THAT SERVICE OF PROCESS UPON A PARTY MAILED BY FIRST CLASS MAIL SHALL BE
DEEMED IN EVERY RESPECT EFFECTIVE SERVICE OF PROCESS UPON THE PARTY IN ANY SUCH
SUIT OR PROCEEDING. NOTHING HEREIN SHALL AFFECT A PARTY'S RIGHT TO SERVE PROCESS
IN ANY OTHER MANNER PERMITTED BY LAW. THE PARTIES AGREE THAT A FINAL
NON-APPEALABLE JUDGMENT IN ANY SUCH SUIT OR PROCEEDING SHALL BE CONCLUSIVE AND
MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON SUCH JUDGMENT OR IN ANY OTHER
LAWFUL MANNER. THE PARTY THAT DOES NOT PREVAIL IN ANY DISPUTE ARISING UNDER THIS
AGREEMENT SHALL BE RESPONSIBLE FOR ALL FEES AND EXPENSES, INCLUDING ATTORNEYS'
FEES, INCURRED BY THE PREVAILING PARTY IN CONNECTION WITH SUCH DISPUTE.


                                       7
<PAGE>

          (b) COUNTERPARTS; SIGNATURES BY FACSIMILE. This Agreement may be
executed in one or more counterparts, each of which shall be deemed an original
but all of which shall constitute one and the same agreement and shall become
effective when counterparts have been signed by each party and delivered to the
other party. This Agreement, once executed by a party, may be delivered to the
other party hereto by facsimile transmission of a copy of this Agreement bearing
the signature of the party so delivering this Agreement.

          (c) HEADINGS. The headings of this Agreement are for convenience of
reference only and shall not form part of, or affect the interpretation of, this
Agreement.

          (d) SEVERABILITY. In the event that any provision of this Agreement is
invalid or enforceable under any applicable statute or rule of law, then such
provision shall be deemed inoperative to the extent that it may conflict
therewith and shall be deemed modified to conform with such statute or rule of
law. Any provision hereof which may prove invalid or unenforceable under any law
shall not affect the validity or enforceability of any other provision hereof.

          (e) ENTIRE AGREEMENT; AMENDMENTS. This Agreement and the instruments
referenced herein contain the entire understanding of the parties with respect
to the matters covered herein and therein and, except as specifically set forth
herein or therein, neither the Company nor the Buyer makes any representation,
warranty, covenant or undertaking with respect to such matters. No provision of
this Agreement may be waived or amended other than by an instrument in writing
signed by the party to be charged with enforcement.

          (f) NOTICES. Any notices required or permitted to be given under the
terms of this Agreement shall be sent by certified or registered mail (return
receipt requested) or delivered personally or by courier (including a recognized
overnight delivery service) or by facsimile and shall be effective five days
after being placed in the mail, if mailed by regular United States mail, or upon
receipt, if delivered personally or by courier (including a recognized overnight
delivery service) or by facsimile, in each case addressed to a party. The
addresses for such communications shall be:

         If to the Company:

                  Milestone Scientific Inc.
                  Livingston Corporate Park
                  220 South Orange Avenue
                  Livingston, New Jersey 07039
                  Attention: Chief Financial Officer
                  Telephone: 973-535-2717
                  Facsimile: 973-535-2829


                                       8
<PAGE>

         With copy to:

                  Morse, Zelnick, Rose & Lander, LLP
                  405 Park Avenue, Suite 1401
                  New York, New York 10022
                  Attention:  Stephen A. Zelnick, Esq.
                  Telephone:  212-838-8040
                  Facsimile:  212-838-9190

         If to the Creditors:

                  Mr. K. Tucker Andersen
                  c/o Cumberland Partners
                  1114 Avenue of the Americas
                  New York, New York 10036
                  Telephone:  212-536-9703
                  Facsimile:  212-575-2007

                  Mr. Leonard Osser
                  101 John Dietz Road
                  Callicoon Center, New York 12724
                  Telephone:  845-482-3792
                  Facsimile:  212-717-5684

Each party shall provide notice to the other party of any change in address.

          (g) SUCCESSORS AND ASSIGNS. This Agreement shall be binding upon and
inure to the benefit of the parties and their successors and assigns. Except as
may otherwise be permitted by Section 2(f) hereof, no party hereto may assign
this Agreement or any rights or obligations hereunder without the prior written
consent of the other parties.

          (h) THIRD PARTY BENEFICIARIES. This Agreement is intended for the
benefit of the parties hereto and their respective permitted successors and
assigns, and is not for the benefit of, nor may any other person enforce any
provision hereof.

          (i) SURVIVAL. The representations and warranties of the Company and
the agreements and covenants set forth herein shall survive until the
Satisfaction Date.

          (j) FURTHER ASSURANCES. Each party shall do and perform, or cause to
be done and performed, all such further acts and things, and shall execute and
deliver all such other agreements, certificates, instruments and documents, as
the other party may reasonably request in order to carry out the intent and
accomplish the purposes of this Agreement and the consummation of the
transactions contemplated hereby.

          (k) NO STRICT CONSTRUCTION. The language used in this Agreement will
be deemed to be the language chosen by the parties to express their mutual
intent, and no rules of strict construction will be applied against any party.


                                       9
<PAGE>

         IN WITNESS WHEREOF, the parties hereto have caused this Agreement to
be duly executed as of the date first above written.

                                               MILESTONE SCIENTIFIC INC.


                                               By: /s/ Thomas M. Stuckey
                                                   ---------------------
                                                   Thomas M. Stuckey
                                                   Chief Financial Officer



                                               /s/ K. TUCKER ANDERSEN
                                               ----------------------
                                               K. TUCKER ANDERSEN




                                               LEONARD OSSER
                                               -------------
                                               LEONARD OSSER












                                       10








</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>17
<FILENAME>file016.txt
<DESCRIPTION>AGREEMENT WITH MORSE, ZELNICK, ROSE & LANDER
<TEXT>
<PAGE>



         AGREEMENT, dated as of December 22, 2003 between Milestone Scientific
Inc. (the "Company"), a Delaware corporation with its principal place of
business at Livingston Corporate Park, 220 South Orange Avenue, Livingston, New
Jersey, and Morse, Zelnick, Rose & Lander, LLP, a law firm and a creditor of the
Company having an address at 405Park Avenue, New York, NY 10022 ("MZRL" or the
"Creditor."

                              W I T N E S S E T H:

         WHEREAS, the Company is indebted to MZRL for legal services rendered
during the past 3 years in an amount in excess of $500,000; and

         WHEREAS, MZRL has agreed to accept in satisfaction of $200,000 of the
indebtedness of the Company to it, units valued at their initial offering price
pursuant to the letter of intent dated September 23, 2003 with Paulson
Investment Company, Inc. and the Company for a $6 million public offering (the
"Public Offering").

         NOW, THEREFORE, in consideration of the premises set forth above and
the agreements, covenants, representations and warranties set forth below and
for other good and valuable consideration, the sufficiency of which is hereby
acknowledge, the parties hereto hereby agree as follows:

         1. Satisfaction of Debt.

          (a) On the Satisfaction Date (as defined below), the Company shall
issue to MZRL securities (as more particularly described below in paragraph (c)
of this Section 1) of the Company having a value equal to $200,000.

          (b) The securities of the Company to be issued to MZRL pursuant to
paragraphs (a) of this Section 1 shall be identical in all material respects to
the securities sold by the Company in the Public Offering. For purposes of
calculating the value of such securities, they shall be deemed to have a value
equal to the public offering price as set forth in the final prospectus, filed
under Rule 424(b) promulgated by the SEC under the Securities Act of 1933, as
amended (the "Act") in connection with the Public Offering (the "Final
Prospectus").

          (c) The Satisfaction Date shall be 10 days after the closing of the
Public Offering.

         2. REPRESENTATIONS AND WARRANTIES OF THE CREDITORS. The Creditor
represents and warrants to the Company that:

          (a) INVESTMENT PURPOSE. It is acquiring the securities described in
Section 1 hereof and any and all other securities of the Company underlying or
covered by such securities and any securities issuable upon exercise of any
rights to purchase or to convert such securities or any securities underlying
such securities (collectively, the "Securities") for its own account and not
with a present view towards the public sale or distribution thereof, except
pursuant to sales registered or exempted from registration under the Act;
provided, however, that by making



<PAGE>

the representations herein, subject to any agreement to the contrary
contemplated hereby, he does not agree to hold any of the Securities for any
minimum or other specific term and reserves the right to dispose of the
Securities at any time in accordance with or pursuant to a registration
statement or an exemption under the Act.

          (b) ACCREDITED INVESTOR STATUS. It is an "accredited investor" as that
term is defined in Rule 501(a) of Regulation D (an "Accredited Investor").

          (c) RELIANCE ON EXEMPTIONS. It understands that the Securities are
being issued to it in reliance upon specific exemptions from the registration
requirements of United States federal and state securities laws and that the
Company is relying upon the truth and accuracy of, and its compliance with, the
representations, warranties, agreements, acknowledgments and understandings set
forth herein in order to determine the availability of such exemptions and its
eligibility to acquire the Securities.

          (d) INFORMATION. It, or its advisors, if any, has been furnished with
all materials relating to the business, finances and operations of the Company
and materials relating to the offer and sale of the Securities that he has or
they have requested. It, or its advisors, if any, has been afforded the
opportunity to ask questions of the Company. Neither such inquiries nor any
other due diligence investigation conducted by him or any of its advisors shall
modify, amend or affect its right to rely on the Company's representations and
warranties contained in Section 3 below. It understands that its investment in
the Securities involves a significant degree of risk.

          (e) GOVERNMENTAL REVIEW. It understands that no United States federal
or state agency or any other government or governmental agency has passed upon
or made any recommendation or endorsement of the Securities.

          (f) TRANSFER OR RE-SALE. It understands that (i) except as set forth
in Section 4(b) below, the sale or re-sale of the Securities has not been is not
and will not being registered under the Act or any applicable state securities
laws, and the Securities may not be transferred unless (a) the Securities are
sold pursuant to an effective registration statement under the Act, (b) he has
delivered to the Company an opinion of counsel (which opinion shall be in form,
substance and scope customary for opinions of counsel in comparable
transactions) to the effect that the Securities to be sold or transferred may be
sold or transferred pursuant to an exemption from such registration, (c) the
Securities are sold or transferred to an "affiliate" (as defined in Rule 144
promulgated under the Act (or a successor rule) ("Rule 144")) who agrees to sell
or otherwise transfer the Securities only in accordance with this Section 2(f)
and who is an Accredited Investor, or (d) the Securities are sold pursuant to
Rule 144; (ii) any sale of Securities made in reliance on Rule 144 may be made
only in accordance with the terms of said Rule and further, if said Rule is not
applicable, any re-sale of such Securities under circumstances in which the
seller (or the person through whom the sale is made) may be deemed to be an
underwriter (as that term is defined in the Act) may require compliance with
some other exemption under the Act or the rules and regulations of the SEC
thereunder; and (iii) other than as set forth in Section 4(b) below), neither
the Company nor any other person is under any obligation to register such
Securities under the Act or any state securities laws or to comply with the
terms and conditions of any exemption thereunder.

                                       2
<PAGE>

          (g) LEGENDS. It understands that, until such time as the Securities
have been registered under the Act or otherwise may be sold pursuant to Rule 144
without any restriction as to the number of securities as of a particular date
that can then be immediately sold, the certificates evidencing the Securities
shall bear a restrictive legend in substantially the following form (and a
stop-transfer order may be placed against transfer of the certificates for such
Securities):

          "The securities represented by this certificate have not been
          registered under the Securities Act of 1933, as amended. The
          securities may not be sold, transferred or assigned in the absence of
          an effective registration statement for the securities under said Act,
          or an opinion of counsel, in form, substance and scope customary for
          opinions of counsel in comparable transactions, that registration is
          not required under said Act or unless sold pursuant to Rule 144 under
          said Act."

         The legend set forth above shall be removed and the Company shall
issue a certificate without such legend to the holder of any Security upon which
it is stamped, if, unless otherwise required by applicable state securities
laws, (a) such Security is registered for sale under an effective registration
statement filed under the Act or otherwise may be sold pursuant to Rule 144
without any restriction as to the number of securities as of a particular date
that can then be immediately sold, or (b) such holder provides the Company with
an opinion of counsel, in form, substance and scope customary for opinions of
counsel in comparable transactions, to the effect that a public sale or transfer
of such Security may be made without registration under the Act, including
pursuant to the provisions of Rule 144 and such sale or transfer is effected.
The Creditor agrees to sell all Securities, including those represented by a
certificate(s) from which the legend has been removed, in compliance with
applicable prospectus delivery requirements, if any. This paragraph (g) shall
apply separately with respect to each security included in the definition of
Securities.

          (h) AUTHORIZATION; ENFORCEMENT. This Agreement has been duly executed
and delivered by or on behalf of the Creditor, and constitutes, and upon
execution and delivery by the Creditor will constitute, a valid and binding
agreement of the Creditor enforceable in accordance with its terms.

          (i) RESIDENCY. It is a resident of New York State.

         3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company
represents and warrants to the Creditors that:

          (a) ORGANIZATION AND QUALIFICATION. The Company and each of its
Subsidiaries (as defined below), if any, is a corporation duly organized,
validly existing and in good standing under the laws of the jurisdiction in
which it is incorporated, with full power and authority (corporate and other) to
own, lease, use and operate its properties and to carry on its business as and
where now owned, leased, used, operated and conducted. The Company and each of
its Subsidiaries is duly qualified as a foreign corporation to do business and
is in good standing in every jurisdiction in which its ownership or use of
property or the nature of the


                                       3
<PAGE>

business conducted by it makes such qualification necessary except where the
failure to be so qualified or in good standing would not have a Material Adverse
Effect. "Material Adverse Effect" means any material adverse effect on the
business, operations, assets, financial condition or prospects of the Company or
its Subsidiaries, if any, taken as a whole, or on the transactions contemplated
hereby or by the agreements or instruments to be entered into in connection
herewith. "Subsidiaries" means any corporation or other organization, whether
incorporated or unincorporated, in which the Company owns, directly or
indirectly, any equity or other ownership interest.

          (b) AUTHORIZATION; ENFORCEMENT. (i) The Company has all requisite
corporate power and authority to enter into and perform and to consummate the
transactions contemplated hereby and to issue the Securities, in accordance with
the terms hereof, (ii) the execution and delivery of this Agreement by the
Company and the consummation by it of the transactions contemplated hereby
(including without limitation, the issuance of the Securities) have been duly
authorized by the Company's board of directors (the "Board") and no further
consent or authorization of the Company, the Board, or its stockholders is
required, (iii) this Agreement has been duly executed and delivered by the
Company, and (iv) this Agreement constitutes, and upon its execution and
delivery by the Company, will constitute a legal, valid and binding obligation
of the Company enforceable against the Company in accordance with its terms.

          (c) ISSUANCE OF SHARES. Any shares of the Company's common stock, par
value $ .001 per share (the "Common Stock") issuable upon the exercise of any
rights set forth in any of the Securities are (or shall be as of the
Satisfaction Date) duly authorized and reserved for issuance and, upon issuance
in accordance with the terms of the Securities to which they relate will be
validly issued, fully paid and non-assessable, and free from all taxes, liens,
claims and encumbrances with respect to the issue thereof and shall not be
subject to preemptive rights or other similar rights of stockholders of the
Company and will not impose personal liability upon the holder thereof.

          (d) NO CONFLICTS. The execution, delivery and performance of this
Agreement by the Company and the consummation by the Company of the transactions
contemplated hereby will not (i) conflict with or result in a violation of any
provision of the Certificate of Incorporation or Bylaws of the Company or (ii)
violate or conflict with, or result in a breach of any provision of, or
constitute a default (or an event which with notice or lapse of time or both
could become a default) under, or give to others any rights of termination,
amendment, acceleration or cancellation of, any agreement, indenture, patent,
patent license or instrument to which the Company or any of its Subsidiaries is
a party, or (iii) result in a violation of any law, rule, regulation, order,
judgment or decree (including federal and state securities laws and regulations
and regulations of any self-regulatory organizations to which the Company or its
securities are subject) applicable to the Company or any of its Subsidiaries or
by which any property or asset of the Company or any of its Subsidiaries is
bound or affected (except for such conflicts, defaults, terminations,
amendments, accelerations, cancellations and violations as would not,
individually or in the aggregate, have a Material Adverse Effect). Neither the
Company nor any of its Subsidiaries is in violation of its Certificate of
Incorporation, Bylaws or other organizational documents and neither the Company
nor any of its Subsidiaries is in default (and no event has occurred which with
notice or lapse of time or both could put the Company or


                                       4
<PAGE>

any of its Subsidiaries in default) under, and neither the Company nor any of
its Subsidiaries has taken any action or failed to take any action that would
give to others any rights of termination, amendment, acceleration or
cancellation of, any agreement, indenture or instrument to which the Company or
any of its Subsidiaries is a party or by which any property or assets of the
Company or any of its Subsidiaries is bound or affected, except for possible
defaults as would not, individually or in the aggregate, have a Material Adverse
Effect. The businesses of the Company and its Subsidiaries, if any, are not
being conducted, and shall not be conducted so long as the Creditors owns any of
the Securities, in violation of any law, ordinance or regulation of any
governmental entity where such violation would have a Material Adverse Effect.
Except as specifically contemplated by this Agreement and as required under the
Act and any applicable state securities laws, the Company is not required to
obtain any consent, authorization or order of, or make any filing or
registration with, any court, governmental agency, regulatory agency, self
regulatory organization or stock market or any third party in order for it to
execute, deliver or perform any of its obligations under this Agreement. Except
as disclosed in Schedule 3(f), all consents, authorizations, orders, filings and
registrations which the Company is required to obtain pursuant to the preceding
sentence have been obtained or effected on or prior to the date hereof. The
Company is not in violation of the listing requirements of the American Stock
Exchange.

          (e) ACKNOWLEDGMENT REGARDING SECURITIES. The Company acknowledges and
agrees that each Creditor is acting solely in the capacity of an arm's length
purchaser with respect to this Agreement and the transactions contemplated
hereby. The Company further acknowledges that neither Creditor is acting as a
financial advisor or fiduciary of the Company (or in any similar capacity) with
respect to this Agreement and the transactions contemplated hereby and any
statement made by a Creditor or any of its respective representatives or agents
in connection with this Agreement and the transactions contemplated hereby is
not advice or a recommendation and is merely incidental to its acquisition of
the Securities. The Company further represents to the Creditors that its
decision to enter into this Agreement has been based solely on the independent
evaluation by the Company and its representatives.

         4. COVENANTS.

          (a) FORM D; BLUE SKY LAWS. The Company agrees to file a Form D with
respect to the Securities as required under Regulation D and to provide a copy
thereof to the Creditors promptly after such filing. The Company shall, on or
before the Satisfaction Date, take such action as the Company shall reasonably
determine is necessary to qualify the Securities for sale to the Creditors
pursuant to this Agreement under applicable securities or "blue sky" laws of the
states of the United States (or to obtain an exemption from such qualification),
and shall provide evidence of any such action so taken to the Creditor on or
prior to the Satisfaction Date.

          (b) REGISTRATION RIGHTS. The Company will use its commercially
reasonable best efforts to file with the SEC a registration statement covering
the resale of the Common Stock included in the Securities within 30 days of the
effective date of the Public Offering and to cause such registration statement
to be effective as promptly as possible thereafter. The Creditors hereby
covenant and agree to provide the Company with such information as the Company
shall need about the Creditors and their proposed plan of distribution in order
to file such resale registration statement.


                                       5
<PAGE>

          (c) RESERVATION OF SHARES. The Company shall at all times have
authorized, and reserved for the purpose of issuance, a sufficient number of
shares of Common Stock to provide for the full conversion or exercise of the
outstanding Securities. The Company will promptly take all corporate action
necessary to authorize and reserve a sufficient number of shares, including,
without limitation, calling a special meeting of stockholders to authorize
additional shares to meet the Company's obligations under this Section 4(c), in
the case of an insufficient number of authorized shares, and using its best
efforts to obtain stockholder approval of an increase in such authorized number
of shares.

         5. GOVERNING LAW; MISCELLANEOUS.

          (a) GOVERNING LAW. THIS AGREEMENT SHALL BE ENFORCED, GOVERNED BY AND
CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO
AGREEMENTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE, WITHOUT REGARD
TO THE PRINCIPLES OF CONFLICT OF LAWS. THE PARTIES HERETO HEREBY SUBMIT TO THE
EXCLUSIVE JURISDICTION OF THE UNITED STATES FEDERAL COURTS LOCATED IN NEW YORK,
NEW YORK WITH RESPECT TO ANY DISPUTE ARISING UNDER THIS AGREEMENT, THE
AGREEMENTS ENTERED INTO IN CONNECTION HEREWITH OR THE TRANSACTIONS CONTEMPLATED
HEREBY OR THEREBY. THE PARTIES HERETO IRREVOCABLY WAIVE THE DEFENSE OF AN
INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH SUIT OR PROCEEDING. THEY FURTHER
AGREE THAT SERVICE OF PROCESS UPON A PARTY MAILED BY FIRST CLASS MAIL SHALL BE
DEEMED IN EVERY RESPECT EFFECTIVE SERVICE OF PROCESS UPON THE PARTY IN ANY SUCH
SUIT OR PROCEEDING. NOTHING HEREIN SHALL AFFECT A PARTY'S RIGHT TO SERVE PROCESS
IN ANY OTHER MANNER PERMITTED BY LAW. THE PARTIES AGREE THAT A FINAL
NON-APPEALABLE JUDGMENT IN ANY SUCH SUIT OR PROCEEDING SHALL BE CONCLUSIVE AND
MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON SUCH JUDGMENT OR IN ANY OTHER
LAWFUL MANNER. THE PARTY THAT DOES NOT PREVAIL IN ANY DISPUTE ARISING UNDER THIS
AGREEMENT SHALL BE RESPONSIBLE FOR ALL FEES AND EXPENSES, INCLUDING ATTORNEYS'
FEES, INCURRED BY THE PREVAILING PARTY IN CONNECTION WITH SUCH DISPUTE.

          (b) COUNTERPARTS; SIGNATURES BY FACSIMILE. This Agreement may be
executed in one or more counterparts, each of which shall be deemed an original
but all of which shall constitute one and the same agreement and shall become
effective when counterparts have been signed by each party and delivered to the
other party. This Agreement, once executed by a party, may be delivered to the
other party hereto by facsimile transmission of a copy of this Agreement bearing
the signature of the party so delivering this Agreement.

          (c) HEADINGS. The headings of this Agreement are for convenience of
reference only and shall not form part of, or affect the interpretation of, this
Agreement.

          (d) SEVERABILITY. In the event that any provision of this Agreement is
invalid or enforceable under any applicable statute or rule of law, then such
provision shall be deemed inoperative to the extent that it may conflict
therewith and shall be deemed modified to conform


                                       6
<PAGE>

with such statute or rule of law. Any provision hereof which may prove invalid
or unenforceable under any law shall not affect the validity or enforceability
of any other provision hereof.

          (e) ENTIRE AGREEMENT; AMENDMENTS. This Agreement and the instruments
referenced herein contain the entire understanding of the parties with respect
to the matters covered herein and therein and, except as specifically set forth
herein or therein, neither the Company nor the Buyer makes any representation,
warranty, covenant or undertaking with respect to such matters. No provision of
this Agreement may be waived or amended other than by an instrument in writing
signed by the party to be charged with enforcement.

          (f) NOTICES. Any notices required or permitted to be given under the
terms of this Agreement shall be sent by certified or registered mail (return
receipt requested) or delivered personally or by courier (including a recognized
overnight delivery service) or by facsimile and shall be effective five days
after being placed in the mail, if mailed by regular United States mail, or upon
receipt, if delivered personally or by courier (including a recognized overnight
delivery service) or by facsimile, in each case addressed to a party. The
addresses for such communications shall be:

         If to the Company:

                  Milestone Scientific Inc.
                  Livingston Corporate Park
                  220 South Orange Avenue
                  Livingston, New Jersey 07039
                  Attention: Chief Financial Officer
                  Telephone: 973-535-2717
                  Facsimile: 973-535-2829

         If to MZRL:

                  Morse, Zelnick, Rose & Lander, LLP
                  405 Park Avenue, Suite 1401
                  New York, New York 10022
                  Attention: Stephen A. Zelnick, Esq.
                  Telephone: 212-838-8040
                  Facsimile: 212-838-9190

Each party shall provide notice to the other party of any change in address.

          (g) SUCCESSORS AND ASSIGNS. This Agreement shall be binding upon and
inure to the benefit of the parties and their successors and assigns. Except as
may otherwise be permitted by Section 2(f) hereof, no party hereto may assign
this Agreement or any rights or obligations hereunder without the prior written
consent of the other parties.

          (h) THIRD PARTY BENEFICIARIES. This Agreement is intended for the
benefit of the parties hereto and their respective permitted successors and
assigns, and is not for the benefit of, nor may any other person enforce any
provision hereof.

                                       7
<PAGE>

          (i) SURVIVAL. The representations and warranties of the Company and
the agreements and covenants set forth herein shall survive until the
Satisfaction Date.

          (j) FURTHER ASSURANCES. Each party shall do and perform, or cause to
be done and performed, all such further acts and things, and shall execute and
deliver all such other agreements, certificates, instruments and documents, as
the other party may reasonably request in order to carry out the intent and
accomplish the purposes of this Agreement and the consummation of the
transactions contemplated hereby.

          (k) NO STRICT CONSTRUCTION. The language used in this Agreement will
be deemed to be the language chosen by the parties to express their mutual
intent, and no rules of strict construction will be applied against any party.


          IN WITNESS WHEREOF, the parties hereto have caused this Agreement to
be duly executed as of the date first above written.

                                    MILESTONE SCIENTIFIC INC.


                                    by: Leonard Osser
                                        -------------
                                        Leonard Osser, CEO


                                    MORSE, ZELNICK, ROSE & LANDER




                                    by: Stephen A. Zelnick
                                        ------------------
                                         Stephen A. Zelnick, General Partner









</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.34
<SEQUENCE>18
<FILENAME>file017.txt
<DESCRIPTION>EMPLOYMENT AGREEMENT WITH LEONARD OSSER
<TEXT>
<PAGE>

                              EMPLOYMENT AGREEMENT

         EMPLOYMENT AGREEMENT dated as of December 20, 2003 between LEONARD
OSSER (the "EXECUTIVE") and MILESTONE SCIENTIFIC INC. (The "COMPANY").

         WHEREAS, the Company presently employs the Executive as its Chief
Executive Officer; and

         WHEREAS, the Company desires to continue to retain the Executive and
the Executive desires to continue to work for the Company; and

         WHEREAS, the Company and the Executive desire to provide for the terms
and conditions of the future employment of the Executive by the Company.

         NOW, THEREFORE, in consideration of the premises and covenants herein
contained, the parties hereto agree as follows:

         1. TERM OF AGREEMENT. Subject to the terms and conditions hereof, the
Company employs the Executive and the Executive accepts such employment for the
five year period commencing January 1, 2004 and ending December 31, 2008, unless
extended or terminated as provided in Sections 2 and 7, respectively (the
"EMPLOYMENT TERM").

         2. RENEWAL. The Employment Term shall be extended for successive
one-year periods unless prior to December 1 of any year, either party notifies
the other that he or it chooses not to extend the Employment Term. By way of
example, if neither party makes an election prior to December 1, 2004 then the
Employment Term shall automatically be extended by one additional year to
December 31, 2009.

         3. DUTIES AND RESPONSIBILITIES. During the Employment Term, the
Executive shall serve as the Chief Executive Officer of the Company and as the
holder of such other senior executive positions consistent therewith as the
Board may determine. He shall report to, and be subject to, the direction of the
Company's Board of Directors with such duties and responsibilities as are
commensurate with his title and position. The Executive shall work on a full
time basis and shall devote his time, energy and attention to the business of
the Company.

<PAGE>

         4. COMPENSATION.

         (A) BASIC COMPENSATION. In payment for services to be rendered by the
Executive hereunder, the Executive shall be entitled to Basic Compensation
during the Employment Term consisting of the cash component and stock component
described below less any withholding required by law.

         (i)   The cash component shall consist of $150,000 payable monthly or
               on such more frequent schedule as the Company may elect.

         (ii)  The stock component shall consist of a stock allotment for the
               benefit of the Executive at the end of each year during the
               Employment Term (the "Annual Allotment") consisting of such
               number of shares of the Company's Common Stock (the "Shares") as
               provided in (A) below which Shares shall be issuable as provided
               in (B) below.

               (A)  The Annual Allotment for each year shall be such number of
                    Shares which, when valued at their average closing price on
                    the American Stock Exchange or on such other exchange on
                    which such Shares are then traded during the first fifteen
                    (15) trading days of the last full month of each year during
                    the Employment Term, shall equal $150,000 provided that in
                    the event that the last year during the Employment Term is
                    less than twelve (12) full months the number of shares
                    included in that year's Annual Allotment shall be based on a
                    value of $150,000 multiplied by a fraction the numerator of
                    which shall be the number of full months the Executive was
                    employed during such year and the denominator of which shall
                    be twelve (12).

               (B)  The aggregate number of Shares included in the Annual
                    Allotments shall be issued and delivered to the Executive
                    within fifteen (15) days after the expiration of the
                    Employment Term.

                                       2
<PAGE>

               (C)  The Executive acknowledges that the Shares issuable under
                    this Section 4(a) and the Bonus Shares issuable under
                    Section 4(b) will be taken by him for investment and not for
                    distribution thereof and will not be sold or otherwise
                    disposed of in violation of the Securities Act of 1933 as
                    amended and the rules and regulations promulgated
                    thereunder.

         (b) BONUS. Executive shall be entitled to a bonus not to exceed
$300,000 each year during the Employment Term based on the Company achieving
certain threshold operating targets established by its Board of Directors for
each year during the Employment Term. For calendar year 2004 the bonus shall be
awarded based on meeting the following thresholds:


<TABLE>
<CAPTION>
                                     Target                                                  Bonus Amount
- --------------------------------------------------------------------------------------     ------------------
<S>                                                                                            <C>
If the Company achieves break even cash flow operations (Cash Flow Bonus)                      $150,000

If the Company achieves net revenues of $6,250,000 (Net Revenue Bonus)                         $100,000

If the Company  achieves  break even earnings  determined in accordance  with general
accounting principles (Earnings Bonus)                                                         $ 50,000
</TABLE>

For purposes of this Agreement, operating cash flow shall mean cash flow from
operations adjusted for financial transactions plus accounts receivable
increases and less accounts payable increases. The Cash Flow Bonus and Earnings
Bonus shall be payable only to the extent that payment thereof will not reduce
operating cash flow or earnings as the case may be below break even. The
aggregate bonus earned by Executive in any year will be payable one-half (1/2)
in cash payable at the expiration of the year and one-half (1/2) by an allotment
of Shares (the "Bonus Shares") determined (based on a valuation equal to
one-half (1/2) of the Bonus Amount for such year) as provided in Section
4(a)(ii)(A) at the end of such year and issuable within 15 days after the
expiration of the Employment Term.


                                       3
<PAGE>

         (c) OPTIONS. If in any year the Executive receives an allotment of
Bonus Shares under Section 3(b) above, he shall also be entitled to receive
options to purchase two times the number of Bonus Shares included in the
allotment. The options shall be issued at the same time that the Bonus Shares
are allotted and shall be exercisable at a purchase price equal to the same
price per share used in determining the number of Bonus Shares allotted, or 110%
of that price if the Executive is the owner of 10% or more of the Company's
outstanding shares. Such options shall have a five (5) year duration and shall
vest and become exercisable to the extent of one-third (1/3) of the options
granted at the expiration of each of the first three (3) years from the date of
grant. The vested options shall be exercisable only while Executive is employed
by the Company or within thirty (30) days after any termination of employment.
The options shall contain anti-dilution protection in the event of stock
dividends and splits and such other provisions as are customary in option grants
of this kind.

         5. EXPENSES. During the Employment Term, the Executive shall be
entitled to receive prompt reimbursement for all reasonable expenses incurred by
him (in accordance with the policies and procedures established from time to
time by the Board of Directors of the Company) in performing services hereunder,
provided that such expenses are incurred and accounted for in accordance with
the policies and procedures established by the Company.

         6. OTHER BENEFITS. The Executive shall be entitled to the following
additional benefits:

         (A) Four weeks of paid vacation during each year of the term.

         (B) Paid holidays in accordance with the Company's usual holiday
schedule plus eight additional paid holiday, or personal days, to be taken at
such time as the Executive determines.

         (C) Such major medical, family health and dental coverage benefits and
long-term disability group plan coverage generally available to the Company's
officers. To the extent the Executive qualifies, the Executive may participate
in, or benefit under, any employee benefit plan, arrangement or perquisite made
available by the Company to its key executives.

         (D) The Company shall reimburse the Executive for such ordinary and
necessary business related expenses as shall be incurred by the Executive in the
course of the performance of his duties under this Agreement.


                                       4
<PAGE>

         (e) A monthly car allowance in the amount of the monthly rental cost of
a domestic luxury sedan or its equivalent plus expenses for business use.

         7. TERMINATION. The Executive's employment hereunder may be terminated
under the following circumstances:

         (A) The Company shall have the right to terminate the employment of the
Executive under this Agreement for disability in the event the Executive suffers
an injury, or physical or mental illness or incapacity of such character as to
substantially disable him from performing his duties hereunder for a period of
more than one hundred eighty (180) consecutive days upon the Company giving at
last thirty (30) days written notice of termination; provided, however, that if
the Executive is eligible to receive disability payments pursuant to a
disability insurance policy or policies paid for by the Company, the Executive
shall assign such benefits to the Company for all periods as to which he is
receiving payment under this Agreement.

         (B) This Agreement shall terminate upon the death of Executive.

         (C) The Company may terminate this Agreement at any time because of (i)
Executive's material breach of any term of this Agreement or (ii) the willful
engaging by the Executive in misconduct which is materially injurious to the
Company, monetarily or otherwise; provided, in each case, however, that the
Company shall not terminate this Agreement pursuant to this Section 7(c) unless
the Company shall first have delivered to the Executive a notice which
specifically identifies such breach or misconduct, specifies reasonable
corrective action and the Executive shall not have cured the breach or corrected
the misconduct within fifteen (15) days after receipt of such notice.

         (D) The Executive may terminate his employment for "Good Reason" on
five days written notice if:

         (i)   he is assigned, without his express written consent, any duties
               inconsistent with his positions, duties, responsibilities,
               authority and status with the Company as of the date hereof, or a
               change in his reporting responsibilities or titles as in effect
               as of the date hereof, except in connection with the termination
               of his employment by him without Good Reason; or

                                       5
<PAGE>

         (ii)  his compensation is reduced or

         (iii) any purchaser or purchasers of substantially all of the business
               or assets of the Company do not agree, at or prior to the closing
               of any such transaction, by agreement in form and substance
               satisfactory to the Executive to perform this Agreement in the
               same manner and to the same extent that the Company would be
               required to perform if no sale was consummated.

         8. NONDISCLOSURE; NONCOMPETITION.

         (A) The Executive agrees not to use or disclose, either while in the
Company's employ or at any time thereafter, except with the prior written
consent of the Board of Directors, any trade secrets, proprietary information,
or other information that the Company considers confidential relating to
processes, suppliers (including but not limited to a list or lists of
suppliers), customers (including but not limited to a list or lists of
customers), compositions, improvements, inventions, operations, processing,
marketing, distributing, selling, cost and pricing data, or master files
utilized by the Company, not presently generally known to the public, and which
is, obtained or acquired by the Executive while in the employ of the Company.

         (B) During the Employment Term and for a period of two years
thereafter, the Executive shall not, directly or indirectly; (i) in any manner,
engage in any business which competes with any business conducted by the Company
(including any subsidiary) and will not directly or indirectly own, manage,
operate, join, control or participate in the ownership, management, operation or
control of, or be employed by or connected in any manner with any corporation,
firm or business that is so engaged (provided, however, that nothing herein
shall prohibit the Executive from owning not more than three percent (3%) of the
outstanding stock of any publicly held corporation), (ii) persuade or attempt to
persuade any employee of the Company to leave the employ of the Company or to
become employed by any other entity, or (iii) persuade or attempt to persuade
any current client or former client with leaving, or to reduce the amount of
business it does or intends or anticipates doing with the Company.

         (C) During his employment with the Company, and for two years
thereafter, the Executive shall not take any action which might divert from the
Company any opportunity learned about by him

                                       6
<PAGE>

during his employment with the Company (including without limitation during the
Employment Term) which would be within the scope of any of the businesses then
engaged in or planned to be engaged in by the Company.

         (D) In the event that this Agreement shall be terminated, then
notwithstanding such termination, the obligations of Executive pursuant to this
Section 8 of this Agreement shall survive such termination.

         9. SUCCESSORS; BINDING AGREEMENT.

         (A) The Company shall require any purchaser or purchasers of the
Company or any purchaser or purchasers of substantially all of the business or
assets of the Company, by agreement in form and substance satisfactory to the
Executive, to assume and agree to perform this Agreement in the same manner and
to the same extent that the Company would be required to perform it if no such
purchase had taken place. As used in this Agreement, "Company" shall mean the
Company as hereinbefore defined and any successor to its business or assets
which executes and delivers the agreement provided for in this Section 9(a) or
which otherwise becomes bound by all the terms and provisions of this Agreement
by operation of law.

         (B) This agreement shall inure to the benefit of and be enforceable by
the Executive's personal or legal representatives, executors, administrators,
successors, heirs, distributees, devisees and legatees. If the Executive should
die while any amount would still be payable hereunder if the Executive had
continued to live, all such amounts, unless otherwise provided herein, shall be
paid in accordance with the terms of this Agreement to your devisee, legatee or
other designee or, if there be no such designee, to the Executive's estate.

         10. AMENDMENT; WAIVER. No provisions of this Agreement may be modified,
supplemented, waived or discharged unless such waiver, modification or discharge
is agreed to in writing signed by the Executive and the Company. No waiver by
either party hereto at any time of any breach by the other party hereto of, or
compliance with, any condition or provision of this Agreement to be performed by
such other party shall be deemed a waiver of similar or dissimilar provisions or
conditions at the same or at any prior or subsequent time. No agreements or
representations, oral or

                                       7
<PAGE>

otherwise, express of implied, with respect to the subject matter hereof have
been made by either party which are not set forth expressly in this Agreement.

         11. APPLICABLE LAW. The validity, interpretation, construction and
performance of this Agreement shall be governed by the laws of the State of New
Jersey without regard to its conflict of laws principles.

         12. SEVERABILITY OF COVENANTS. In the event that any provision of this
Agreement, including any sentence, clause or part hereof, shall be deemed
contrary to law or invalid or unenforceable in any respect by a court of
competent jurisdiction, the remaining provisions shall not be affected, but
shall remain in full force and effect and any invalid and enforceable provisions
shall be deemed, without further action on the part of the undersigned,
modified, amended and limited solely to the extent necessary to render the same
valid and enforceable.

         13. REMEDIES.

         (A) In the event of a breach or threatened breach of any of the
Executive's covenants under Section 8, the Executive acknowledges that the
Company will not have an adequate remedy at law. Accordingly, in the event of
any such breach or threatened breach, the Company will be entitled to such
equitable and injunctive relief as may be available to restrain the Executive
from the violation of the provisions thereof.

         (B) Nothing herein shall be construed as prohibiting the Company, on
the one hand, and the Executive, on the other hand, from pursuing any remedies
available at law or in equity for any breach or threatened breach of the
provisions of this Agreement by the other party, including the recovery of
damages.

         (C) If the Executive terminates his employment for a Good Reason (as
defined above in Section 7(d)) then the Executive will suffer damages which will
be difficult to calculate. Consequently, the Executive shall be entitled by way
of liquidated damages, and not as a penalty, to receive a lump sum payment in an
amount equal to the amount of the compensation payments that, but for his
termination of employment, would have been payable to the Executive under
Section 4(a) for the remainder of the Employment Term. Such payment shall be
made by the Company to the

                                       8
<PAGE>

Executive within fifteen (15) days following his termination of employment. The
Executive shall not be required to mitigate the amount of any payment received
pursuant to this paragraph nor shall the amount payable under this paragraphbe
reduced by any compensation earned by the Executive after the date of his
termination of employment.

         14. NOTICES. Any notice, request, instruction or other document to be
given hereunder by any party to the other party shall be in writing and shall be
deemed to have been duly given when delivered personally or five (5) days after
dispatch by registered or certified mail, postage prepaid, return receipt
requested, to the party to whom the same is so given or made:

         If to the Company
            addressed to:           Milestone Scientific Inc.
                                            220 South Orange Avenue
                                            Livingston Corporate Park
                                            Livingston, New Jersey 07039

         with a copy to:            Morse, Zelnick, Rose & Lander, LLP
                                            405 Park Avenue
                                            New York, New York 10022

                                            -----------------

         If to the Executive
            addressed to:           Mr. Leonard Osser
                                    110 East 71st Street
                                            New York, NY 10021

or to such other address as the one party shall specify to the other party in
writing.

         15. ENTIRE AGREEMENT. This Agreement sets forth the entire agreement of
the parties hereto in respect of the subject matter contained herein and
supersedes all prior agreements, promises, covenants, arrangements,
communications, representations or warranties, whether oral or written, by any
officer, employee or representative of any party hereto; and any prior agreement
of the parties hereto in respect of the subject matter contained herein is
hereby terminated and canceled. IN WITNESS WHEREOF, the parties have executed
this Agreement on the date and year first above written.

                                    MILESTONE SCIENTIFIC INC.

                                    BY: /s/ Stuart Wildhorn
                                        --------------------------------------
                                            STUART WILDHORN, PRESIDENT


                                        /s/ Leonard Osser
                                        --------------------------------------
                                            LEONARD OSSER


                                       9


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>19
<FILENAME>file018.txt
<DESCRIPTION>CONSENT
<TEXT>
<PAGE>
                                                                    Exhibit 23.1




                    CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS

   We consent to the inclusion in this Amendment No. 2 to the registration
   statement on Form S-2 (File No. 333-110376) of our report dated April 1,
   2003, except for Notes B and H which are as of April 15, 2003 and Note Q
   which is as of January 6, 2004, on our audits of the consolidated financial
   statements of Milestone Scientific, Inc. and Subsidiaries as of December 31,
   2002 and for the years ended December 31, 2002 and 2001. We also consent to
   the references to our Firm under the captions "Experts" and "Selected
   Consolidated Financial Data".




                                                               /s/ J.H. Cohn LLP

Roseland, New Jersey
January 27, 2004


</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
